Metasubstituted thiazolidinones, their manufacture and use as a drug

Abstract

This invention involves thiazolidinone of general formula (I) and its creation and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.

Description

The invention concerns thiazolidinones, their manufacture and use as polo-like kinase (PLK) inhibitors for treating various diseases.

Tumor cells set themselves apart through their uninhibited cell-cycle process. On the one hand, it is based on the loss of control proteins like RB, p16, p21, p53 etc. as well as the activation of so-called cell-cycle process accelerators, the cyclin-dependant kinases (CDK's). CDK's are a recognized anti-tumor target-protein in pharmacy. In addition to the CDK's, new cell-cycle regulating serine/threonine-kinases, so-called ‘polo-like kinases’ were described that are involved not only in regulating cell-cycles but also in coordinating with other processes during mitosis and cytokinesis (formation of the spindle apparatus, chromosome separation). Consequently, this protein class represents an interesting point of contact for the therapeutic intervention of proliferative diseases like cancer (Descombes and Nigg. Embo j, 17; 1328ff, 1998; Glover et al. Genes Dev 12, 3777ff, 1998).

A high expression rate of PLK-1 was found in ‘non-small cell lung’-cancer (Wolf et al. Oncogene, 14, 543ff, 1997), in melanomas (Strebhardt et al. JAMA, 283, 479ff, 2000), in ‘squamous cell carcinomas’ (Knecht et al. Cancer Res, 59, 2794ff, 1999) and in ‘esophageal carcinomas’ (Tokumitsu et al. Int J Oncol 15, 687ff, 1999). A correlation of high expression rate was shown in tumor patients with a poor prognosis for sundry tumors (Strebhardt et al. JAMA, 283, 479ff, 2000, Knecht et al. Cancer Res, 59, 2794ff, 1999 and Tokumitsu et al. Int J Oncol 15, 687ff, 1999).

Constitutive expression of PLK-1 in NIH-3t3-cells resulted in malignant transformation (increased proliferation, soft-agar growth, colony formation, and tumor development in naked mice (Smith et al. Biochem Biophys Res Comm, 234, 397ff., 1997).

Microinjections of PLK-1-antibodies into HeLa-cells resulted in defective mitosis (Lane et al.; Journal Cell Biol, 135, 1701ff, 1996).

Using a ‘20-mer’ antisense oligo the expression of PLK-1 in a549-cells could be inhibited and their ability to survive stopped. A clear anti-tumor-effect could also be demonstrated in naked mice (Mundt et al., Biochem Biophys Res Comm, 269, 377ff., 2000).

Microinjecting anti-PLK-antibodies into nonimmortalized human hs68-cells exhibited, in contrast to HeLa cells, significantly higher fraction of cells, which remained in a growth arrest on G2 and exhibited far fewer indications of defective mitosis (Lane et al.; Journal Cell Biol, 135, 1701ff, 1996).

In contrast to tumor cells, antisense-oligo-molecules did not inhibit the growth and viability of primary human mesangial cells (Mundt et al., Biochem Biophys Res Comm, 269, 377ff., 2000).

Until now, besides PLK-1, three other polo-kinases that are mitogenic response-induced and that perform their function in the G1 phase of the cell cycle, have been documented in mammals. They are the so-called PRK/PLK-3 (the human homologue of the mouse FNK=fibroblast growth factor induced kinase; Wiest et al, Genes, Chromosomes & Cancer, 32: 384ff, 2001), SNK/PLK-2 (serum induced kinase, Liby et al., DNA Sequence, 11, 527-33, 2001) and SAK/PLK4 (Fode et al., Proc.Natl.Acad.Sci.U.S.A., 91, 6388ff; 1994).

The inhibition of PLK-1 and the other kinases of the polo-family, like PLK-2, PLK-3 and PLK-4 therefore represent a promising approach for treating a variety of diseases.

The sequence identity within the PLK-domains of the polo-family lies between 40 and 60%, such that sometimes the inhibitors of one kinase will interact with one or several other kinases of that family. But depending on the structure of the inhibitor, the effect can also occur selectively or preferably on only kinase of the polo family.

International application WO 03/093249 discloses thiazolidinone compounds that inhibit kinases of the polo family.

The task of the present compound is to furnish improved compounds, improved particularly in the inhibition of polo-like kinases as compared to prior art and/or to provide compounds that inhibit kinases, in particular polo-like kinases or that have better physicochemical properties as compared to compounds disclosed in prior art.

First Embodiment of the Present Invention

In a first embodiment of the present invention it was found in claim 1 that compounds of the general formula I,

• • in which
  • T¹, T²
  • and T³ independently represent —CH═ or —N═ and T² can also represent (—CF)═,
  • U represents —CR⁴═ or —N═,
  • R¹ represents C₁-C₃-alkyl or cyclopropyl optionally mono- or polysubstituted identically or differently with halogen,
  • R² represents C₁-C₃-alkyl, C₃-C₄-alkenyl, C₃-C₄-alkinyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or halogen, or hydroxyl, ethyl at least monosubstituted with methyl,
  • R³ represents K, L or M or R¹⁵,
  • K represents C₁-C₃-alkyl or C₂-C₄-alkenyl optionally mono- or polysubstituted, identically or differently, with X,
  • X represents halogen, hydroxyl or the group —OR⁶, —NR¹⁰R¹¹ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group 13 (CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl,
  • L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R⁸, —O—(CH₂)_n—(CO)—R^{15 or}—O—(CH₂)_n—(CO)—O—R⁸,
  • M represents the group —NH—R⁹, —NH—(CO)—OH, —NH—(CO)—O—R⁹or —NR¹²—(CO)—R¹⁶,
  • R⁴ represents hydrogen, cyanogen or halogen or represents methyl optionally mono- or polysubstituted, identically or differently, with halogen,
  • R⁵ represents C₁-C₄-alkyl, phenyl or —NR¹²R¹³,
  • R⁶ represents —SO₂—R¹⁴,
  • R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with —NR¹²R¹³ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen,
  • R⁸ represents C₁-C₃-alkyl, C₃-C₄-alkenyl or C₃-C₄-alkinyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or halogen,
  • R⁹ represents C₁-C₅-alkyl, C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R^{14 or}—O—(SO₂)—R¹⁴, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can optionally be interrupted in the ring by one or several —(CO)— or —SO— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl,
  • R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl, —(CH₂)_n-aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,
  • R¹² and R¹³ independently represent hydrogen or C₁-C₄-alkyl,
  • R¹⁴ represents C₁-C₃-alkyl or aryl
  • R¹⁵ represents C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₃-alkyl or —(CH₂)_n-aryl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur, and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,
  • R¹⁶ represents hydrogen or C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴ or C₁-C₄-alkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)-R¹⁴ or —O—(SO₂)—R¹⁴ or represents methyl optionally mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl or heteroaryl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl,
    • or represents C₁-C₄-alkyl mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl, or represents C₂-C₄-alkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxy-C₁-C₄-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the following group, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, and
• n is 1-4,
  • and their solvates, hydrates, diastereomers, enantiomers and salts, are improved compounds where the inhibition of polo-like kinases is concerned.

Another variation of the first embodiment of the present invention are compounds of the general formula I in claim 2, as described in claim 1, in which the following mean

• • R³ represents K, L or M,
  • X represents halogen, hydroxyl or the group —OR⁶, —NR¹⁰R¹¹ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl,
  • L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R⁸, or —O—(CH₂)_n—(CO)—O—R⁸,
  • R⁹ represents C₁-C₄-alkyl, C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can optionally be interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl,
  • R¹⁶ represents hydrogen or C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴ or C₁-C₄-alkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴ or represents methyl optionally mono- or polysubstituted, identically or differently, with C₂-C¹⁰-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, or C₁-C₄-alkyl mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl, or C₂-C₄-alkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxy-C₁-C₄-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the following group, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl, and
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another object according to this first embodiment of the present invention are also compounds of the general formula I in claim 3, as described in claim 1 or 2, in which the following mean

• • R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with —NR¹²R¹³ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,
  • R⁹ represents C₁-C₅-alkyl, C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹², wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can optionally be interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl, or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl,
  • R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl, or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, and C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,
  • R¹⁴ represents C₁-C₃-alkyl or phenyl and
  • n is 1-4,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another variation of the first embodiment of the present invention are compounds of the general formula I in claim 4, as described in any of claims 1 through 3, in which the following mean

• • R¹ represents methyl, ethyl, isopropyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with halogen,
  • R² represents methyl, ethyl, allyl, propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or halogen or for hydroxyethyl at least monosubstituted with methyl,
  • X represents halogen, hydroxyl or the group —OR⁶, —NR¹⁰R¹¹ or azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, or phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl or C₁-C₃-alkylthiol,
  • R⁴ represents hydrogen or halogen or methyl optionally mono- or polysubstituted, identically or differently, with halogen,
  • R⁵ represents methyl, ethyl, tert.-butyl, phenyl or —NH₂,
  • R⁶ represents —SO₂-methyl,
  • R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with —N(C₁-C₃-alkyl )₂, pyrrolidinyl, morpholinyl or piperidinyl,
  • R⁸ represents methyl, ethyl, allyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or halogen,
  • R⁹ represents methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—C₁-C₃-alkyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl or C₁-C₃-alkoxyl, or with the group —(CO)—R⁵, —(CO)—O—R⁵, —(SO₂)—R¹⁴, —N(CH₃)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, methylthiol or phenyl,
  • R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, pyrrolidinyl, phenyl or pyridinyl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl,
  • R¹² and R¹³ independently represent hydrogen or methyl, ethyl, or isopropyl,
  • R¹⁴ represents C₁-C₄-alkyl or phenyl and
  • n is 1 or 2,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another object of the present invention according to this embodiment are also compounds of the general formula I in claim 5, as described in any of claims 1 through 4, in which the following mean

• • U represents —CH═, —CF═, —C(CH₃)═OR —N═,
  • R¹ represents methyl, ethyl, isopropyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with fluorine,
  • R² represents methyl, ethyl, allyl, propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or fluorine or for hydroxyethyl at least monosubstituted with methyl,
  • K represents methyl, ethyl or ethenyl optionally mono- or polysubstituted, identically or differently, with X,
  • X represents halogen, hydroxyl or the group —O—SO₂-methyl or pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl or with methyl optionally mono- or polysubstituted, identically or differently, with halogen,
  • L represents the group —O—R⁷, —O—(CH₂)—(CO)—NH—R⁸ or —O—(CH₂)—(CO)—O—R⁸,
  • M represents the group —N H—R⁹, —NH—(CO)—R¹⁶, —NH—(CO)—O—R⁹ or —N(CH₃)—(CO)—R¹⁶,
  • R⁷ represents ethyl optionally mono- or polysubstituted, identically or differently, with —N(C₁-C₃-ALKYL)₂, pyrrolidinyl, morpholinyl or piperidinyl,
  • R⁸ represents methyl, ethyl, allyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or fluorine and
  • R⁹ represents methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —N(C₁-C₃-alkyl)₂, —O—(CO)—(C₁-C₃-alkyl) or —O—(SO₂)—C₁-C₃-alkyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or with the group —(CO)—C₁-C₄-alkyl, —(CO)—O—C₁-C₄-alkyl, —(SO₂)—C₁-C₃-alkyl, —(SO₂)-phenyl, —N(C₁-C₃-alkyl)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another object of the invention according to this embodiment are also compounds of the general formula I in claim 6, as described in any of claims 1 through 5, in which

• • R¹ represents ethyl,
  • X represents iodine, hydroxyl or the group —O—SO₂-methyl or pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl or with methyl optionally mono- or polysubstituted, identically or differently, with halogen,
  • R⁷ represents ethyl optionally mono- or polysubstituted, identically or differently, with —N(CH₃)₂, pyrrolidinyl, morpholinyl or piperidinyl,
  • R⁹ represents methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with methoxyl, ethoxyl, butoxy-ethoxyl, methoxy-ethoxyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, cyanogen, cyclopropyl, chlorine, fluorine, hydroxyl or with the group —N(CH₃)₂, —N(CH₃)(C₂H₅), —O—(CO)—(CH₃) OR —O—(SO₂)-methyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl themselves can be optionally mono- or polysubstituted, identically or differently, with fluorine, or with the group —(CO)—CH₃, —(CO)—C₂H₅, —(CO)—C(CH₃)₃, —(CO)—O—C(CH₃)₃, —(SO₂)—CH₃, —(SO₂)-phenyl, —N(CH₃)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with fluorine, hydroxyl or methylthiol,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another object of the first embodiment of this invention are also compounds of the general formula I in claim 7, as described in any of claims 1 through 6, in which the following means

• • R¹⁶ represents C₁-C₄-alkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴ or methyl optionally mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen or C₁-C₃-alkoxyl,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another object of the first embodiment of this invention are also compounds of the general formula I in claim 8, as described in claim 7, in which the following means

• • R¹⁶ represents C₁-C₄-alkyl optionally mono- or polysubstituted, identically or differently, with the group —NR¹⁰R¹¹, or methyl optionally mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen or C₁-C₃-alkoxyl,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which K

represents C₁-C₃-alkyl or C₂-C₄-alkenyl optionally mono- or polysubstituted, identically or differently, with X.

Another object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which K represents C₁-C₃-alkyl or C₂-C₄-alkenyl mono- or polysubstituted, identically or differently, with X.

Another preferred object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which K stands methyl, ethyl or ethenyl optionally mono- or polysubstituted, identically or differently, with X.

Another object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R⁸, —O—(CH₂)_n—(CO)—R¹⁵or —O—(CH₂)_n—(CO)—O—R⁸.

Another object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R⁸or —O—(CH₂)_n—(CO)—O—R⁸.

Another preferred object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which L represents the group —O—R⁷, —O—(CH₂)—(CO)—NH—R⁸, or —O—(CH₂)—(CO)—O—R⁸.

Another object of this first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which R⁵ represents C₁-C₄-alkyl, phenyl or —NR²R¹³.

Another preferred object of this first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which R⁵ represents methyl, ethyl, tert.-butyl, phenyl or —NH₂.

Another object of the first embodiment of the present invention are compounds of the general formula I, as described in claims 1 through 8, in which R¹⁶ represents hydrogen or C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R or —O—(SO₂)—R¹⁴ or C₁-C₄-alkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴ or represents methyl optionally mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl or heteroaryl, but preferably without heteroaryl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, but preferably without —(C═S)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen, C₁-C₃-alkyl, but preferably without C₁-C₃-alkyl, or with C₁-C₃-alkoxyl,

• • or represents C₁-C₄-alkyl mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl, or represents C₂-C₄-alkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxy-C₁-C₄-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the following group, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, but preferably without —(C═S)— or —SO₂—groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen , C₁-C₃-alkyl, but preferably without C₁-C₃-alkyl, or with C₁-C₃-alkoxy.

Another preferred object of the first embodiment of the present invention is compounds of the general formula I, as described in any of claims 1 through 8, in which R¹⁶ represents C¹-C₄-alkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴ or methyl optionally mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl or heteroaryl, but preferably without heteroaryl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, but preferably without —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen, with C₁-C₃-alkyl, but preferably without C₁-C₃-alkyl, or with C₁-C₃-alkoxy.

Another preferred object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which R¹⁶ represents C₁-C₄-alkyl mono- or polysubstituted, identically or differently, with the group —NR¹⁰R¹¹ or methyl optionally mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl or heteroaryl, but preferably without heteroaryl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, but preferably without —(C═S)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R , —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen, with C₁-C₃-alkyl, but preferably without C₁-C₃-alkyl or C₁-C₃-alkoxy.

Another preferred object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8, in which R¹⁶ represents methyl optionally mono- or polysubstituted, identically or differently, with the group —NR¹⁰R¹¹, C₂-C₁₀-heterocycloalkyl, imidazolyl or benzimidazolyl, but preferably without imidazolyl or benzimidazolyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, but preferably without —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, phenyl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the phenyl itself can be optionally mono- or polysubstituted, identically or differently with halogen, with C₁-C₃-alkyl, but preferably without C₁-C₃-alkyl or with C₁-C₃-alkoxy.

Another preferred object of the first embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 8 in which R¹⁶ represents methyl optionally mono- or polysubstituted, identically or differently, with pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl, imidazolyl or benzimidazolyl, but preferably without imidazolyl or benzimidazolyl, or with the group —NR¹⁰R¹¹, wherein pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl or with the group —(CO)—R⁵, —(CO)—O—R⁵, —(SO₂)—R¹⁴, —N(CH₃)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, methylthiol or phenyl, wherein the phenyl itself can be optionally mono- or polysubstituted, identically or differently with halogen, with C₁-C₃-alkyl, but preferably without C₁-C₃-alkyl or with C₁-C₃-alkoxy.

Second Embodiment of the Present Invention

In a second embodiment of the present invention it was found that compounds of the general formula I in claim 9, as described in claim 1, in which

• • K represents C₁-C₃-alkyl mono- or polysubstitued, identically or differently, with P or C₂-C₄-alkenyl mono- or polysubstituted, identically or differently, with X,
  • P represents the group —OR⁶, —NR¹⁸R¹⁹, C₂-C₅-heterocycloalkyl or C₆-C₁₀ heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀ heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl itself can be mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or optionally with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl,
  • L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R⁸, —O—(CH₂)_n—(CO)—R¹⁵ or —O—(CH₂)_n—(CO)—O—R⁸,
  • R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with C₆-C₁₀-heterocycloalkyl, wherein the C₆-C₁₀-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, or for C₁-C₃-Alkyl mono- or polysubstituted, identically or differently, with C₂-C₅-Heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be mono- or polysubstituted, identically or differently, with halogen, aryl or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen,
  • R¹⁶ represents hydrogen, C₂-C₄-alkenyl, cyclopropyl, C₂-C5-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl or a methyl substituted with heteroaryl or C₁-C₄-alkenyl, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl or C₆-C₁₀-heterocycloalkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl or with the group —NR¹⁸R¹⁹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀-heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴—NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen or C₁-C₃-alkoxyl,
  • R¹⁷ represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen or cyanogen or C₃-C₄-alkenyl or C₃-C₄-alkinyl optionally mono- or polysubstituted, identically or differently, with halogen, cyclopropyl or cyanogen,
  • R¹⁸ and R¹⁹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl, —(CH₂)_n-aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring, wherein
    • either R¹⁸ or R¹⁹ represents a C₂-C₁₀-heterocycloalkyl, —(CH₂)_n-aryl, or a heteroaryl, or a C₂-C₁₀-heterocycloalkyl, —(CH₂)_n-aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, C₁-C₃-alkoxyl, or a C₁-C₅-alkyl mono- or polysubstituted, identically or differently, with C₁-C₃-alkoxyl, or an aryl mono- or polysubstituted, identically or differently, with C₁-C₃-alkyl, C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts solve the task of the present invention.

Another variation of the second embodiment of the present invention are compounds of the general formula I in claim 10, as described in claim 9,

in which

• • T, T²
  • and T³ independently represent —CH═ or —N═
  • R³ is K, L or M,
  • P represents the group —OR⁶, —NR¹⁸R¹⁹, C₂-C₅-heterocycloalkyl or C₆-C₁₀ heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀ heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or optionally with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl,
  • L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R¹⁷, or —O—(CH₂)_n—(CO)—R⁸,
  • R⁹ represents C₁-C₄-alkyl, C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃ alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen or C₁-C₃-alkoxyl,
  • R¹⁶ represents hydrogen, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl or a methyl substituted with heteroaryl or C₁-C₄-alkenyl, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl or C₆-C₁₀-heterocycloalkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl or with the group —NR¹⁸R¹⁹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀-heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴—NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen or C₁-C₃-alkoxyl,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another variation of the second embodiment of the present invention are compounds of the general formula I in claim 22, as described in claim 9, in which

• • P represents the group —OR⁶, —NR¹⁸R¹⁹, C₂-C₅-heterocycloalkyl or C₆-C₁₀ heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀ heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or With the group —(CO)—R⁵, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or optionally with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl,
  • R⁵ represents C₁-C₄-alkyl or phenyl,
  • R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with C₆-C₁₀-heterocycloalkyl, wherein the C₆-C₁₀-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, or C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with C₂-C₅-heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the C₂-C₅-heterocycloalkyl ring itself can be polysubstituted, identically or differently, with halogen or aryl or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen,
  • R¹⁶ represents hydrogen, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl or a methyl substituted with heteroaryl or C₁-C₄-alkenyl, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl or C₆-C₁₀-heterocycloalkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl or with the group —NR¹⁸R¹⁹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)-R⁴, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀-heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself can be polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxy or the ring of the C₂-C₅-heterocycloalkyl is monosubstituted with halogen, cyanogen, hydroxyl, aryl, wherein in this case the aryl itself is mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxy or the ring of the C₂-C₅-heterocycloalkyl is mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or phenyl, and the ring of the C₆-C₁₀-heterocycloalkyl can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxy.
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another variation of the second embodiment of the present invention are compounds of the general formula I in claim 23, as described in claim 10, in which

• • P represents the group —OR⁶, —NR¹⁸R¹⁹, C₂-C₅-heterocycloalkyl or C₆-C₁₀ heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀ heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or optionally with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl,
  • R⁵ represents C₁-C₄-alkyl or phenyl,
  • R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with C₆-C₁₀-heterocycloalkyl, wherein the C₆-C₁₀-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, or
    • C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with C₂-C₅-heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the C₂-C₅-heterocycloalkyl ring itself can be polysubstituted, identically or differently, with halogen or aryl or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen,
  • R¹⁶ represents hydrogen, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl or C₁-C₄-alkenyl, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl or C₆-C₁₀-heterocycloalkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl or with the group —NR¹⁸R¹⁹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀-heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen or C₁-C₃-alkoxy or the ring of the C2-C₅-heterocycloalkyl is monosubstituted with —(CO)—O—R¹², —(CO)—R⁵ or aryl, wherein in this case the aryl itself is mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl or the ring of the C₂-C₅-heterocycloalkyl is mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkylthiol or phenyl, and the ring of the C₆-C₁₀-heterocycloalkyl can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxy,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another variation of the second embodiment of the present invention are compounds of the general formula I in claim 24, as described in any of claims 9, 10, 22 or 23, in which P represents the group —OR⁶, —NR¹⁸R¹⁹ or azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves are mono- or polysubstituted, identically or differently with halogen, hydroxyl, phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with the group -(CO)-R⁵ or mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkylthiol,

as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another variation of the second embodiment of the present invention are compounds of the general formula I in claim 25, as described in any of claims 9, 10, 22, 23 or 24, in which R¹⁸ and R¹⁹ independently represent C₁-C₅-alkyl, pyrrolidinyl, phenyl or pyridinyl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, wherein either R¹⁸ and R¹⁹ represent pyrrolidinyl or pyridinyl or a pyrrolidinyl or pyridinyl mono- or polysubstituted, identically or differently with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl.

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which K represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with P or C₂-C₄-alkenyl mono- or polysubstituted, identically or differently, with X,

Another preferred object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which K represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with P,

Another object of the second embodiment of the present invention is compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which P represents the group —OR⁶, —NR¹⁸R¹⁹, C₂-C₅-heterocycloalkyl or C₆-C₁₀ heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀ heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, but preferably without —(C═S)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl itself can be mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or optionally with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl,

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which P represents the group —OR⁶, —NR¹⁸R¹⁹, C₂-C₅-heterocycloalkyl or C₆-C₁₀ heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀ heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, but preferably without —(C═S)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkylthiol or the ring of the C₂-C₁₅-heterocycloalkyl itself can be monosubstituted with the group —(CO)—R⁵, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl itself can be mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or optionally with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxy.

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which P represents the group —OR⁶, —NR¹⁸R¹⁹ or azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves are mono- or polysubstituted, identically or differently with halogen, hydroxyl, phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with the group —(CO)—R⁵ or mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkylthiol.

In a preferred variation, the pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves are polysubstituted identically or differently with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵ or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkylthiol or monosubstituted with the group —(CO)—R⁵, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxy.

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25 , in which L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R¹⁷, —O—(CH₂)_n—(CO)—R¹⁵ or —O—(CH₂)_n—(CO)—O—R⁸. Preferably, L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R¹⁷ or —O—(CH₂)_n—(CO)—O—R⁸ .

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R⁵ represents C₁-C₄-alkyl, phenyl or —NR¹²R¹³.

Another object of this second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R⁵ represents C₁-C₄-alkyl or phenyl.

Another preferred object of this second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R⁵ stands methyl, ethyl, tert.-butyl, or phenyl.

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with C₆-C₁₀-heterocycloalkyl, wherein the C₆-C₁₀-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, or

• • C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with C₂-C₅-heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself is mono- or polysubstituted, identically or differently, with halogen or aryl or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen.

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with C₆-C₁₀-heterocycloalkyl, wherein the C₆-C₁₀-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, or

• • C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with C₂-C₅heterocycloalkyl, wherein the C₂-C₅-heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the C₂-C₅-heterocycloalkyl ring itself is mono- or polysubstituted, identically or differently, with halogen or aryl or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen.

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R¹⁶ represents hydrogen, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl or a methyl substituted with heteroaryl, but preferably a methyl not substituted with heteroaryl or C₁-C₄-alkenyl, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl or C₆-C₁₀-heterocycloalkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl or with the group —NR¹⁸R¹⁹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀-heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— but preferably without —(C═S)— or with —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen, with halogen, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen or C₁-C₃-alkoxy, but preferably without C₁-C₃-alkyl, or with C₁-C₃-alkoxyl, and the ring of the C₆-C₁₀-heterocycloalkyl can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)-R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl,

Another preferred object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R¹⁶ represents hydrogen, but preferably not hydrogen, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl or a methyl substituted with heteroaryl, but preferably for a methyl not substituted with heteroaryl, or C₁-C₄-alkenyl, C₂-C₄-alkenyl, cyclopropyl, C₂-C₅-heterocycloalkyl or C₆-C₁₀-heterocycloalkyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₂-C₅-heterocycloalkyl, C₆-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl or with the group —NR¹⁸R¹⁹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the C₂-C₅-heterocycloalkyl and the C₆-C₁₀-heterocycloalkyl contain at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— but preferably without —(C═S)—, or with —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring of the C₂-C₅-heterocycloalkyl itself is polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, wherein in this case the aryl can be optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl but preferably without C₁-C₃ alkyl, or with C₁-C₃-alkoxy or the ring of the C₂-C₅-heterocycloalkyl is monosubstituted with —(CO)—O—R¹², —(CO)—R⁵, or aryl, wherein in this case the aryl itself is mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, but preferably without C₁-C₃-alkyl, or with C₁-C₃-alkoxy or the ring of the of the C₂-C₅-heterocycloalkyl is substituted with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkylthiol or phenyl and the ring of the C₆-C₁₀-heterocycloalkyl can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl,

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R¹⁷ represents C₁-C³-alkyl mono- or polysubstituted, identically or differently, with halogen or cyanogen or C³-C⁴-alkenyl or C³-C⁴-alkinyl optionally mono- or polysubstituted, identically or differently, with halogen, cyclopropyl or cyanogen.

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R¹⁸ and R¹⁹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl, —(C₂)_n-aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring, wherein

• • either R¹⁸ or R¹⁹ represents a C₂-C₁₀-heterocycloalkyl, —(CH₂)_n-aryl, or a heteroaryl, or a C₂-C₁₀-heterocycloalkyl, —(CH₂)_n-aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, C₁-C₃-alkoxyl, or a C₁-C₅-alkyl mono- or polysubstituted, identically or differently, with C₁-C₃-alkoxyl, or an aryl mono- or polysubstituted, identically or differently, with C₁-C₃-alkyl, C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R¹⁸ and R¹⁹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl, —(C₂)_n-aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring, wherein either R¹⁸ or R¹⁹ represents a C₂-C₁₀-heterocycloalkyl or a heteroaryl, or C₂-C₁₀-heterocycloalkyl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring.

Another object of the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 9, 10, 22, 23, 24 or 25, in which R¹⁸ and R¹⁹ independently represent C₁-C₅-alkyl, pyrrolidinyl, phenyl or pyridinyl optionally mono- or polysubstituted, identically or differently with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, wherein,

• • either R¹⁸ or R¹⁹ represent pyrrolidinyl or pyridinyl or a pyrrolidinyl or pyridinyl mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxy. Third Embodiment of the Present Invention

The task of the present compound in the third embodiment is to furnish improved compounds, improved particularly in the inhibition of polo-like kinases as compared to prior art and/or to provide compounds that have better physicochemical properties as compared to compounds disclosed in prior art.

In a third embodiment of the present invention it was found in claim 11, as described in claim 1 and/or 2, that compounds of the general formula I, in which the following mean

• • R³ represents K or L,
  • K represents C₁-C₃-alkyl mono- or polysubstitued, identically or differently, with X, where by the C₁-C₃-alkyl can be mono- or polysubstituted, identically or differently with hydroxyl or halogen,
  • X represents NR¹⁰R¹¹ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with cyanogen, halogen or C₁-C₃-alkoxyl,
  • L represents the group —O—R⁷,
  • R⁷ represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with —NR¹²R¹³ or C₂-C₁₀-heterocycloalkyl and the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen.
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts solve the task of the present invention especially well.

Another variation of the third embodiment of the present invention are compounds of the general formula I in claim 12, as described in claim 11, in which

X represents —N(C₁-C₃-alkyl)₂ or azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves are mono- or polysubstituted, identically or differently with halogen, hydroxyl, phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with the group —(CO)—R⁵ or mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkylthiol.

• • R⁷ represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with —N(C₁-C₃-alkyl)₂ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring.
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Another object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which R³ represents K or L.

Another object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which K represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with X, wherein the C₁-C₃-alkyl can be optionally mono- or polysubstituted, identically or differently, with hydroxyl or halogen,

Another preferred object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which K represents C₁-C₃-alkyl monosubstituted with X, wherein the C₁-C₃-alkyl can be optionally mono- or polysubstituted, identically or differently, with hydroxyl or halogen. Preferably, the C₁-C₃-alkyl is only substituted with X.

Another object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which L represents the group —O—R⁷.

Another object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which X represents NR¹⁰R¹¹ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur, and in a preferred variation contains at least one nitrogen, and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with cyanogen, halogen or C₁-C₃-alkoxyl,

Another preferred object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which X represents azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves are mono- or polysubstituted, identically or differently with halogen, hydroxyl, phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl, or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with the group —(CO)—R⁵ or mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkylthiol.

In a preferred variation, X represents unsubstituted azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl [sic].

Another preferred object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which X represents pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl or with methyl optionally mono- or polysubstituted, identically or differently, with halogen. In a preferred variation the pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl are not substituted.

Another object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which R⁷ represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with —NR 2R¹³ or C₂-C₁₀-heterocycloalkyl and the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur, and in a preferred variation contains at least one nitrogen, and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen.

Another object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which R⁷ represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with —NR¹²R¹³, preferably —N(C₁-C₃-alkyl)₂ or C₂-C₁₀-heterocycloalkyl, but preferably only C₁-C₃-alkyl, [sic: substituted with] C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and in a preferred variation contains at least one nitrogen and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring.

Another preferred object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which R⁷ represents C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with —N(C₁-C₃-alkyl)₂, pyrrolidinyl, morpholinyl or piperidinyl.

Another preferred object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which R⁷ represents ethyl optionally mono- or polysubstituted, identically or differently, with —N(C₁-C₃-alkyl)2, pyrrolidinyl, morpholinyl or piperidinyl.

Another preferred object of the third embodiment of the present invention are compounds of the general formula I, as described in any of claims 11 or 12, in which R⁷ represents ethyl optionally mono- or polysubstituted, identically or differently, with —N(CH₃)₂, pyrrolidinyl, morpholinyl or piperidinyl.

Fourth Embodiment of the Present Invention

The task of the present compound in the third embodiment is to furnish improved compounds, improved particularly in the inhibition of polo-like kinases as compared to prior art and/or to provide compounds that have better physicochemical properties as compared to compounds disclosed in prior art.

In a fourth embodiment of the present invention it was found in claim 13, as described in claim 1 and/or 2, that compounds of the general formula I, in which the following mean

• • R³ represents M,
  • M represents the group —NR¹²—(CO)—R¹⁹,
  • R¹⁶ represents methyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, heteroaryl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the methyl itself can be optionally mono- or polysubstituted, identically or differently, with C¹ to C₃-alkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups in the ring and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts, solve the task of the present invention especially well.

Especially well suited to solve the task of the present invention according to this fourth embodiment therefore are compounds of the general formula I for which R³ represents M, M represents the group —NR¹²—(CO)—R¹⁶ and R¹⁶ represents methyl, wherein the methyl in turn is substituted at least with C₂-C₁₀-heterocycloalkyl, heteroaryl or with the group —NR¹⁰R¹¹ and the heterocycloalkyl and the heteroaryl contain at least one nitrogen.

Another variation of the fourth embodiment of the present invention are compounds of the general formula I in claim 14, as described in claim 13, in which

• • R¹⁶ represents methyl mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl, heteroaryl, or with the group —NR¹⁰R¹¹, wherein the methyl itself can be optionally mono- or polysubstituted, identically or differently, with C₁to C₃-alkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl,
  • as well as their solvates, hydrates, diastereomers, enantiomers and salts.

An object of the fourth embodiment of the present invention are compounds of the general formula I, as described in any of claims 13 or 14, in which R³ represents M.

Another object of the fourth embodiment of the present invention are compounds of the general formula I, as described in any of claims 13 or 14, in which M represents the group —NR —(CO)—R¹⁶.

Another object of the fourth embodiment of the present invention are compounds of the general formula I, as described in one of claims 13 or 14, in which for R¹⁶ represents methyl mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, heteroaryl, preferably without heteroaryl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the methyl itself can be optionally mono- or polysubstituted, identically or differently, with C₁ to C₃-alkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and in a preferred variation contains at least one nitrogen, and can be optionally interrupted by one or several —(CO)—, —(C═S)—, preferably without —(C═S)—, or with —SO₂— groups in the ring and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, preferably without C₁-C₃-alkyl, or C₁-C₃-alkoxyl,

Another object of the fourth embodiment of the present invention are compounds of the general formula I, as described in one of claims 13 or 14, in which for R¹⁶ represents methyl mono- or polysubstituted, identically or differently, with C₂-C₁₀-heterocycloalkyl, heteroaryl, preferably without heteroaryl, or with the group —NR¹⁰R¹¹, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and in a preferred variation contains at least one nitrogen, and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)—, preferably without —(C═S)—, or with —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, - NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, preferably without C₁-C₃-alkyl, or C₁-C₃-alkoxy. In a preferred variation the ring of the heterocycloalkyl is not substituted.

Another preferred object of the fourth embodiment of the present invention are compounds of the general formula I, as described in one of claims 13 or 14, in which R¹⁶ represents methyl mono- or polysubstituted, identically or differently, with pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl, imidazolyl or benzimidazolyl, preferably without imidazolyl or benzimidazolyl, or with the group —NR¹⁰R¹¹, wherein pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl, or with the group —(CO)—R⁵, —(CO)—O—R⁵, —(SO₂)—R¹⁴, —N(CH₃)₂ or substituted with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, methylthiol or phenyl, wherein the phenyl itself can be optionally mono- or or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, preferably without C₁-C₃-alkyl or with C₁-C₃-alkoxy. In a preferred variation the pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, or the octahydroisochinolinyl are not substituted.

Fifth Embodiment of the Present Invention

In a fifth embodiment of the present invention it was found that compounds of the general formula I, in which the following mean

• T¹, T²
• and T³ independently represent —CH═ or —N═,
• U represents —CR⁴═ or —N═,
• R¹ represents C₁-C₃-alkyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with halogen,
• R² represents C₁-C₃-alkyl, C₃-C₄-alkenyl, C₃-C₄-alkinyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or halogen or for hydroxyethyl at least monosubstituted with methyl,
• R³ represents K, L or M,
• K represents C₁-C₃-alkyl or C₂-C₄-alkenyl optionally mono- or polysubstituted, identically or differently, with X,
• X represents halogen, hydroxyl or the group —OR⁶, —NR¹⁰R¹¹ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl,
• L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH-R⁸or —O—(CH₂)_n—(CO)—O—R⁸,
• M represents the group —NH—R⁹, —NH—(CO)—O—R⁹ or —NR¹²—(CO)—R⁹,
• R⁴ represents hydrogen, cyanogen or halogen or represents methyl optionally mono- or polysubstituted, identically or differently, with halogen,
• R⁵ represents C₁-C₄-alkyl, phenyl or —NR¹²R¹³,
• R⁶ represents —SO₂—R¹⁴,
• R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with —NR¹²R¹³ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen,
• R⁸ represents C₁-C₃-alkyl, C₃-C₄-alkenyl or C₃-C₄-alkinyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or halogen,
• R⁹ represents hydrogen or C₁-C₄-alkyl, C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently with halogen, or C₁-C₃-alkoxyl,
• R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl, —(CH₂)_n-aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,
• R¹² and R¹³ independently represent hydrogen or C₁-C₄-alkyl,
• R¹⁴ represents C₁-C₃-alkyl or aryl and
• n is 1-4, as well as their solvates, hydrates, diastereomers, enantiomers and salts with the exception of:
• 2-[5-[1-(3-amino-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-yl idene]-2-cyano-n-ethyl-acetamide,
• 2-cyano-n-ethyl-2-[3-ethyl-5-[1-{3-[2-(2-methoxy-ethoxy)-acetylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide,
• 2-cyano-2-[5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-n-ethyl-acetamide,
• 2-cyano-n-ethyl-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,
• 2-cyano-2-[5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-n-(2-hydroxy-1,1-dimethyl-ethyl)-acetamide,
• 2-cyano-2-[5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-n-prop-2-ynyl-acetamide,
• 2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-n-prop -2-ynyl-acetamide,
• 2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-n-(2,2,2-trifluoro-ethyl)-acetamide,
• 2-cyano-n-cyclopropylmethyl-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,
• n-allyl-2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,
• 2-cyano-2-[5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-n-methyl-acetamide
• 2-cyano-2-[5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-n-((s)-2-hydroxy-1-methyl-ethyl)-acetamide
• 2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-n-(2-methyl-allyl)-acetamide
• 2-cyano-2-[3-ethyl-4-oxo-5-[l -[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-n-(2-methoxy-1-methyl-ethyl)-acetamide
• 2-cyano-2-[3-ethyl4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-n-(2-hydroxy-propyl)-acetamide
• 2-cyano-n-cyclopropyl-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide
• 2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-n-(2-methoxy-ethyl)-acetamide
• 2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-n-propyl-acetamide
• 2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-n-(2-hydroxy-1-methyl-ethyl)-acetamide
• 2-cyano-n-(cyano-dimethyl-methyl)-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide represent improved compounds, where the inhibition of polo-like kinases is concerned, that inhibit polo-like kinases in the nanomolecular range.

In particular those compounds of the general formula I are preferred in which

• T¹, T²
• and T³ independently represent —CH═ or —N═,
• U represents —CR⁴═ or —N═,
• R¹ represents C₁-C₃-alkyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with halogen,
• R² represents C₁-C₃-alkyl, C₃-C₄-alkenyl, C₃-C₄-alkinyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or halogen or for hydroxyethyl at least monosubstituted with methyl,
• R³ represents K, L or M,
• K represents C₁-C₃-alkyl or C₂-C₄-alkenyl optionally mono- or polysubstituted, identically or differently, with X,
• X represents halogen, hydroxyl or the group —OR⁶, —NR¹⁰R¹¹ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxyl,
• L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R⁸ or —O—(CH₂)_n—(CO)—O—R⁸,
• M represents the group —NH—R⁹, —NH—(CO)—O—R⁹ or —NR¹²—(CO)—R⁹,
• R⁴ represents hydrogen, cyanogen or halogen or represents methyl optionally mono- or polysubstituted, identically or differently, with halogen,
• R⁵ represents C₁-C₄-alkyl, phenyl or —NR¹²R¹³,
• R⁵ represents —SO₂—R¹⁴,
• R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with —NR¹²R¹³ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,
• R⁸ represents C₁-C₃-alkyl, C₃-C₄-alkenyl or C₃-C₄-alkinyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or halogen,
• R⁹ represents hydrogen or C₁-C₄-alkyl, C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R^-or —O—(SO₂)—R¹⁴, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl, or with the —(CO)—R⁵, —(CO)—O—R¹², —(SO₂)—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl,
• R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl, or heteroaryl optionally mono- or polysubstituted, identically or-differently, with halogen, C₁-C₃-alkyl, C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,
• R¹² and R¹³ independently represent hydrogen or C₁-C₄-alkyl,
• R¹⁴ represents C₁-C₃-alkyl or aryl and
• n is 1-4, as well as their solvates, hydrates, diastereomers, enantiomers and salts.

The following compounds of the general formula I are also preferred, in which

• T¹, T²
• and T³ independently represent —CH═ or —N═,
• U represents —CR⁴═ or —N═,
• R¹ represents methyl, ethyl, isopropyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with halogen,
• R² represents methyl, ethyl, allyl, propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or halogen or hydroxyethyl at least monosubstituted with methyl,
• R³ represents K, L or M,
• K represents C₁-C₃-alkyl or C₂-C₄-alkenyl optionally mono- or polysubstituted, identically or differently, with X,
• X represents halogen, hydroxyl or the group —OR⁶, —NR¹⁰R¹¹ or azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves are mono- or polysubstituted, identically or differently with halogen, hydroxyl, phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl, or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkylthiol,
• L represents the group —O—R⁷, —O—(CH₂)_n—(CO)—NH—R⁸ or —O—(CH₂)_n—(CO)—O—R⁸,
• M represents the group —NH—R⁹, —NH—(CO)—R⁹, —NH—(CO)—O—R⁹ or —NR¹²—(CO)—R⁹,
• R⁴ represents hydrogen or halogen or methyl optionally mono- or polysubstituted, identically or differently, with halogen,
• R⁵ represents methyl, ethyl, tert.-butyl, phenyl or —NH₂,
• R⁶ represents —SO₂-methyl,
• R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with —N(C₁-C₃-alkyl)₂, pyrrolidinyl, morpholinyl or piperidinyl,
• R³ represents methyl, ethyl, allyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or halogen,
• R⁹ represents hydrogen or methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)- C₁-C₃-alkyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl or C₁-C₃-alkoxyl, or with the group —(CO)—R⁵, —(CO)—O—R⁵, —(SO₂)—R¹⁴, —N(CH₃)₂— or methyl or ethyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, methylthiol or phenyl,
• R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, pyrrolidinyl, phenyl or pyridinyl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl, or C₁-C₃-alkoxyl,
• R¹² and R¹³ independently represent hydrogen or methyl, ethyl, isopropyl,
• R¹⁴ represents C₁-C₄-alkyl or phenyl and
• n is 1 or 2, as well as their solvates, hydrates, diastereomers, enantiomers and salts.

The following compounds of the general formula I are also preferred, in which

• T¹, T²
• and T³ independently represent —CH═ or —N═,
• U represents —CH═, —CF═, —C(CH₃)═ or —N═,
• R¹ represents methyl, ethyl, isopropyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with fluorine,
• R² represents methyl, ethyl, allyl, propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or fluorine or hydroxyethyl at least monosubstituted with methyl,
• R³ represents K, L or M,
• K represents methyl, ethyl or ethenyl optionally mono- or polysubstituted, identically or differently, with X,
• X represents halogen, hydroxyl or the group —O—SO₂-methyl or R⁶, —NR¹⁰R¹¹ or pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl, or with methyl optionally mono- or polysubstituted, identically or differently, with halogen,
• L represents the group —O—R⁷, —O—(CH₂)—(CO)—NH—R⁸ or —O—(CH₂)—(CO)——O—R⁸,
• M represents the group —NH₂ —NH—R⁹, —NH—(CO)—R⁹, —NH—(CO)—O—R⁹ or —N(CH₃)—(CO)-R⁹,
• R⁷ represents ethyl optionally mono- or polysubstituted, identically or differently, with —N(C₁-C₃-alkyl)₂, pyrrolidinyl, morpholinyl or piperidinyl,
• R⁸ represents methyl, ethyl, allyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or fluorine,
• R⁹ represents hydrogen or methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —N(C₁-C₃-alkyl)₂, —O—(CO)—(C₁-C₃-alkyl) or —O—(SO₂)—C₁-C₃-alkyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or with the group —(CO)—C₁-C₄-alkyl, —(CO)—O—C₁-C₄-alkyl, —(SO₂)—C₁-C₃-alkyl, —(SO₂)-phenyl, —N(C₁-C₃-alkyl)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Those compounds of the general formula I are in turn also preferred, in which the following mean

• T¹, T²
• and T³ independently represent —CH═ or —N═,
• U represents —CH═, —CF═, —C(CH₃)═ or —N═,
• R¹ represents ethyl,
• R² represents methyl, ethyl, allyl, propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or fluorine or hydroxyethyl at least monosubstituted with methyl,
• R³ represents K, L or M,
• K represents methyl, ethyl or ethenyl optionally mono- or polysubstituted, identically or differently, with X,
• X represents iodine, hydroxyl or the group —O—SO₂-methyl or pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl, or with methyl optionally mono- or polysubstituted, identically or differently, with halogen,
• L represents the group —O—R⁷, —O—(CH₂)—(CO)—NH—R⁸ or —O—(CH₂)—(CO)—O—R⁸,
• M represents the group —NH₂ —NH—R⁹, —NH—(CO)—R⁹, —NH—(CO)—O—R⁹, —N(CH₃)—(CO)—R⁹ or —N(CH₃)—R⁹,
• R⁷ represents ethyl optionally mono- or polysubstituted, identically or differently, with —N(CH₃)₂, pyrrolidinyl, morpholinyl or piperidinyl,
• R⁸ represents methyl, ethyl, allyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or fluorine,
• R⁹ represents methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with methoxy, ethoxy, butoxy-ethoxy, methoxy-ethoxy, pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, cyanogen, cyclopropyl, halogen, hydroxyl or the group —N(CH₃)₂, —N(CH₃)(C₂H₅), —O—(CO)—(CH₃) or —O—(SO₂)-methyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, themselves can be optionally mono- or polysubstituted, identically or differently, with fluorine or with the group —(CO)—CH₃, —(CO)—C₂H₅, —(CO)—C(CH₃)₃, —(CO)—O—C(CH₃)₃, —(SO₂)—CH₃, —(SO₂)-phenyl, —N(CH₃)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with fluorine, hydroxyl or methylthiol, as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Moreover, preferred among those are those compounds of the general formula I, in which the following mean

• T¹, T²
• and T³ independently represent —CH═ or —N═ and T2 can also represent (—CF)═ and at least one substituent of T¹, T² or T³ represents —N═,
• U represents —CH═,
• R¹ represents ethyl,
• R² represents methyl, ethyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen or fluorine or hydroxyethyl at least monosubstituted with methyl,
• R³ represents M,
• M represents the group —NH—(CO)—R⁹,
• R⁹ represents methyl or tert.-butyl optionally substituted with methoxy-ethoxy, as well as their solvates, hydrates, diastereomers, enantiomers and salts.

Other preferred compounds of the general formula I are those in which

• T¹, T²
• and T³ represent —CH═,
• U represents —N═,
• R¹ represents ethyl,
• R² represents methyl, ethyl, propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen or fluorine or for hydroxyethyl at least monosubstituted with methyl,
• R³ represents M,
• M represents the group —NH—R⁹,
• R⁹ represents ethyl, as well as their solvates, hydrates, diastereomers, enantiomers or salts.

The compounds of the general formula 11 are likewise objects of the invention in which

• R¹ and R² have the meanings set forth in general formula I, as well as their solvates, hydrates, diastereomers, enantiomers and salts as intermediate products. The Following Implementations Pertain to the First and the Second Embodiment of the Invention Similarly:

Another object of the first and the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which R³ represents K, L or M or R¹⁵ and preferably in which R³ represents K, L or M.

Another object of the first and the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which X represents halogen, hydroxyl or the group —OR⁶, —NR¹⁰R¹¹ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— but preferably without —(C═S)—, or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen or C₁-C₃-alkoxy.

Another preferred object of the first and second embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which X represents halogen, hydroxyl or the group —OR⁶, —NR¹⁰R¹¹ or azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or phenyl, which themselves can be optionally mono- or polysubstituted, identically or differently with halogen or C₁-C₃-alkoxyl, or with the group —(CO)—R⁵, —NR¹²R¹³ or with C₁-C₃-alkoxy optionally mono- or polysubstituted, identically or differently, with cyanogen, halogen, hydroxyl, or C₁-C₃-alkylthiol.

Another preferred object of the first and second embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which X represents halogen, hydroxyl or the group —O—SO₂-methyl or pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently with halogen, hydroxyl, phenyl or methyl optionally mono- or polysubstituted, identically or differently, with halogen.

Another preferred object of the first and second embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which X represents iodine, hydroxyl or the group —O—SO₂-methyl or pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, wherein pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently with halogen, hydroxyl, phenyl or with methyl optionally mono- or polysubstituted, identically or differently, with halogen.

Another object of the first and the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which M represents the group —NH—R⁹, —NH—(CO)—OH, —NH—(CO)—O—R⁹ or —NR¹²—(CO)—R¹⁶.

Another preferred object of the first and the second embodiment of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which M represents the group —NH—R⁹, —NH—(CO)—R¹⁶, —NH—(CO)—O—R⁹ or —N(CH₃)—(CO)—R¹⁶.

Another object of the first and second embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which R⁷ represents C₁-C₃-alkoxy optionally mono- or polysubstituted, identically or differently, with —NR¹²R¹³ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, aryl or with the group —(CO)—R⁵, or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen.

Another object of the first and second embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with —NR¹²R¹³ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring.

Another preferred object of the first and second embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 10, in which R⁷ represents C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with —N(C₁-C₃-alkyl )₂, pyrrolidinyl, morpholinyl or piperidinyl.

Another preferred object of the first and second embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁷ represents ethyl optionally mono- or polysubstituted, identically or differently, with —N(C₁-C₃-alkyl)₂, pyrrolidinyl, morpholinyl or piperidinyl.

Another preferred object of the first and second embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁷ represents ethyl optionally mono- or polysubstituted, identically or differently, with —N(CH₃)₂, pyrrolidinyl, morpholinyl or piperidinyl.

The Following Implementations Pertain to the Third and Fourth Embodiments of the Invention Similarly:

Another object of the third and fourth embodiments of the present invention are compounds of the general formula I, as described in any of claims 11 through 14, in which R⁵ represents C₁-C₄-alkyl, phenyl or —NR¹²R¹³.

Another preferred object of the third and fourth embodiments of the present invention are compounds of the general formula I, as described in any of claims 11 through 14, in which R⁵ stands or methyl, ethyl, tert.-butyl, phenyl or —NH₂.

The Following Implementations Pertain to the First Four Embodiments of the Invention Similarly:

An object of the present invention as described in the first four embodiments are compounds of the general formula I, as described in any of claims 1 through 14, in which T¹, T² and T³ independently represent —CH═ or —N═ and T² can also represent (—CF)═.

An object of the present invention as described in the first four embodiments are compounds of the general formula I, as described in any of claims 1 through 14, in which T¹, T² and T³ independently represent —CH═ or —N═.

Another object of the present invention as described in the first four embodiments are compounds of the general formula I, as described in any of claims 1 through 14, in which U represents —CR⁴═ or —N═.

Another preferred object of the present invention as described in the first four embodiments are compounds of the general formula I, as described in any of claims 1 through 14, in which U represents —CH═, —CF═, —C(CH₃)═ or —N═.

Another object of the present invention as described in the first four embodiments are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹ represents C₁-C₃-alkyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with halogen,

Another object of the present invention as described in the first four embodiments are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹ represents methyl, ethyl, isopropyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with halogen.

Another preferred object of the present invention as described in the first four embodiments are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹ represents methyl, ethyl, isopropyl, or cyclopropyl optionally mono- or polysubstituted, identically or differently, with fluorine.

Another preferred object of the present invention as described in the first four embodiments are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹ represents ethyl.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R² represents C₁-C₃-alkyl, C₃-C₄-alkenyl, C₃-C₄-alkinyl or cyclopropyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or halogen or for hydroxyethyl at least monosubstituted with methyl.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R² represents methyl, ethyl, allyl, or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or halogen or hydroxyethyl at least monosubstituted with methyl.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R² represents methyl, ethyl, allyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl, ethinyl or fluorine or hydroxyethyl at least monosubstituted with methyl.

An object of the invention as described in the first four embodiments are compounds of the general formula (I), as described in any of claims 1 through 14, in which N represents 1 through 4. Another object of the present invention as per the first four embodiments are compounds of the general formula (I), as described in any of claims 1 through 14, in which N means 1 through 3. Another object of the present invention as per the first four embodiments are compounds of the general formula (I), as described in any of claims 1 through 14, in which N represents 1 through 2. Another object of the present invention as per the first four embodiments are compounds of the general formula (I), as described in any of claims 1 through 14, in which N represents 1.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁴ represents hydrogen, cyanogen or halogen or methyl optionally mono- or polysubstituted, identically or differently, with halogen.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁴ represents hydrogen or halogen, or methyl optionally mono- or polysubstituted, identically or differently, with halogen.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R represents —SO₂—R¹⁴.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁶ represents —SO₂-methyl.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁸ stands C₁-C₃-alkyl, C₃-C₄-alkenyl or C₃-C₄-alkinyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or halogen.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁸ represents methyl, ethyl, allyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or halogen.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁸ represents methyl, ethyl, allyl or propargyl optionally mono- or polysubstituted, identically or differently, with cyanogen, cyclopropyl or fluorine.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁹ represents C₁-C₅-alkyl, preferably C₁-C₄-alkyl, C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹⁴, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —SO₂—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxy.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁹ represents C₁-C₅-alkyl, preferably C₁-C₄-alkyl, C₂-C₄-alkenyl, cyclopropyl or C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, C₂-C₁₀-heterocycloalkyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹¹, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—R¹², wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently, with halogen, cyanogen, hydroxyl, aryl or with the group —(CO)—R⁵, —(CO)—O—R¹², —SO₂—R¹⁴, —NR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, C₁-C₃-alkylthiol or phenyl.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁹ represents methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —NR¹⁰R¹⁴, —O—(CO)—R⁵, —(SO₂)—R¹⁴ or —O—(SO₂)—C₁-C₃-alkyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, phenyl or C₁-C₃-alkoxyl, or with the group —(CO)—R⁵, —(CO)—O—R⁵, —(SO₂)—R¹⁴, —N(CH₃)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, methylthiol or phenyl.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims through 14, in which R⁹ represents methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with C₁-C₄-alkoxyl, C₁-C₄-alkoxy-C₁-C₄-alkoxyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, cyanogen, cyclopropyl, halogen, hydroxyl or with the group —N(C₁-C₃-alkyl)₂, —O—(CO)—₁-C₃-alkyl) or —O—(SO₂)—C₁-C₃-alkyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl themselves can be optionally mono- or polysubstituted, identically or differently, with halogen or with the group —(CO)—C₁-C₄-alkyl, —(CO)—O—C₁-C₄-alkyl, —(SO₂)—C₁-C₃-alkyl, —(SO₂)-phenyl, —N(C₁-C₃-alkyl)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl or C₁-C₃-alkylthiol.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R⁹ represents methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl optionally mono- or polysubstituted, identically or differently, with methoxy, ethoxy, butoxy-ethoxy, methoxy-ethoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, cyanogen, cyclopropyl, chlorine, fluorine, hydroxyl or with the group —N(CH₃)₂, —N(CH₃)(C₂H₅), —O—(CO)—(CH₃) or —O—(SO₂)-methyl, wherein pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl themselves can be optionally mono- or polysubstituted, identically or differently, with fluorine, or with the group —(CO)—CH₃, —(CO)—C₂H₅, —(CO)—C(CH₃)₃,—(CO)—O—C(CH₃)₃, —(SO₂)—CH₃, —(SO₂)-phenyl, —N(CH₃)₂ or with methyl or ethyl optionally mono- or polysubstituted, identically or differently, with fluorine, hydroxyl or methylthiol.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl, —(CH₂)_n-aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring,

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, C₂-C₁₀-heterocycloalkyl, aryl or heteroaryl optionally mono- or polysubstituted, identically or differently, with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹⁰ and R¹¹ independently represent C₁-C₅-alkyl, pyrrolidinyl, phenyl or pyridinyl optionally mono- or polysubstituted, identically or differently with halogen, C₁-C₃-alkyl or C₁-C₃-alkoxy.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹² and R¹³ independently represent hydrogen or C₁-C₄-alkyl.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹² and R¹³ independently represent hydrogen or methyl, ethyl, or isopropyl.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹⁴ represents C₁-C₃-alkyl or aryl.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹⁴ represents C₁-C₃-alkyl or phenyl.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹⁴ represents C₁-C₄-alkyl or phenyl.

Another object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R represents a C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₃-alkyl or —(CH₂)_n-aryl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the following group, oxygen or sulfur, and can be optionally interrupted in the ring by one or several —(CO)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring.

Another preferred object of the first four embodiments of the present invention are compounds of the general formula I, as described in any of claims 1 through 14, in which R¹⁵ represents a C₂-C₁₀-heterocycloalkyl optionally mono- or polysubstituted, identically or differently, with C₁-C₃-alkyl or —(CH₂)_n-phenyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the following group, oxygen or sulfur.

Another object of the first four embodiments of the present invention are compounds of the general formula II or IV in claim 15,

• • in which
  • R¹, R², R³, U, T¹, T² and R³ have the meaning shown in the general formula I, as described in any of claims 1 through 14, as well as their solvates, hydrates, diastereomers, enantiomers and salts as intermediate products for producing compounds of the general formula (I).

Another object of the first four embodiments of the present invention are compounds of the general formula II as per claim 15 in claim 16 with the following formulas:

• 2-cyanogen-n-ethyl-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide, 2-cyanogen-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-n-(2,2,2-trifluoro-ethyl)-acetamide,
• 2-cyanogen-2-[3-ethyl-4-oxo-thiazolid in-(2-(E or Z))-ylidene]-n-prop-2-ynyl-acetamide or 2-cyanogen-n-cyanogenmethyl-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide
• 2-cyanogen-n-(2 ,2-difluoro-ethyl)-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide
• 2-cyanogen-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-n-(2-hydroxy-1,1-dimethyl-ethyl)-acetamide
• 2-cyanogen-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-n-(2-fluoro-ethyl )-acetamide as well as their solvates, hydrates, diastereomers, enantiomers and salts as intermediate products for producing compounds of the general formula (I).

Another object of the first four embodiments of the present invention are compounds in claim 17 of the general formulas (II) or (IV) as described in claim 15 or compounds as described in claim 16 for use as intermediate products for producing compounds of the general formula (I).

Another object of the first four embodiments of the present invention are the use of the compounds of the general formulas (II) or (IV) in claim 18 as described in claim 15 or compounds as described in claim 16 as intermediate products for producing compounds of the general formula (I).

Another object of the first four embodiments of the present invention is drugs in claim 19 that contain at least one compound described in any of claims 1 through 14.

Another object of the first four embodiments of the present invention is the use of compounds of the general formula I in claim 20, as described in any of claims 1 through 14, for producing a drug.

Another object of the first four embodiments of the present invention are compounds in claim 21 described in any of claims 1 through 14 or the drug described in claim 19 with suitable formulation substances and carrier substances.

Another object of the first four embodiments of the present invention is a method in claim 22 for producing compounds of the general formula I, wherein compounds of the general formula II are heated with compounds of the general formula III, in which

• R³, U, T¹, T² and T³ have the same meaning as R³, U, T¹, T² and T³ described in any of claims 1 through 14, in a formic acid orthoester with three identical or different alkoxy- or aryloxy residues optionally bridged or substituted with halogen and optionally a polar solvent, or compounds of the general formula IV in which
• R¹, R³, U, T¹, T² and T³ have the same meaning as R¹, R³, U, T¹, T² and T³ as described in any of claims 1 through 14, are converted with an allyl acceptor and a catalyst in an aprotic solvent and, after completion of a first partial reaction with a coupling reagent, a base and R²—NH₂, wherein R² has the same meaning as R² as set forth in any of claims 1 through 14, converted in an aprotic solvent into compounds of the general formula I.

Another object of the first four embodiments of the present invention is a method in claim 23, according to claim 22, wherein for producing the compounds of the general formula II, compounds of the general formula V, in which

• R¹ has the same meaning as R¹ as described in any of claims 1 through 14, are converted with an allyl acceptor and a catalyst in an aprotic solvent and, after completion of a first partial reaction, converted with a coupling reagent, a base and R²—NH₂, wherein R² has the same meaning as R² as described in any of claims 1 through 14, and with an aprotic solvent into the compounds of the general formula I.

Understood under formic acid orthoester with three identical or different alkoxy residues optionally bridged or substituted with halogen, as described in either of claims 22 or 23, is preferably a triethylorthoformiate. Other formic acid orthoesters that fall under this definition are known to people skilled in the field.

Polar solvents suitable for performing the method described in claim 22 are C₁ through C₅ alcohols or diols like e.g. glycol, preferably C₁ through C₅ alcohols and especially preferably ethanol or 1-propanol. If there is an excess of formic acid orthoester on hand, no polar solvent is needed to perform the reaction of the compounds of the general formula II with compounds of the general formula III to the compounds of the general formula I.

For reacting the compounds of the general formula II with compounds of the general formula III to the compounds with the general formula I as described in claim 22, they must be heated up. In a preferred variation, the reaction is supposed to occur at, at least, 70° C., more preferably between 70° C. and 150° C. and even more preferably between 100° C. and 150° C. The reaction can also be performed at higher temperatures, but then—as anyone skilled in the field knows—a higher-boiling solvent or pressure vessel should be used. In a preferred variation of the invention the heating reaction is performed for 2 to 24 hours.

“Catalysts” employable for the methods described in any of claims 22 or 23 are known to people skilled in the field. The use of a palladium catalyst is preferable.

“Aprotic solvents” employable for performing the methods of claims 22 or 23 are known to people skilled in the field. Tetrahydrofurane and dichloromethane are suitable aprotic solvents that are preferably used. In the coupling reaction (2^nd partial reaction) of claims 22 or 23, dimethylformamide can preferably also be used as an aprotic solvent. People skilled in the field also know, however, that other aprotic solvents like e.g. dimethylacetamide (DMA) and n-methylpyrrolidone (NMP) can also be used to perform the methods of claims 22 or 23.

Understood to be preferable allyl acceptors according to the present invention and according to claims 22 or 23 are 1,3-dimethylbarbituric acid, barbituric acid and/or a silane. People skilled in the field also are also aware of other allyl acceptors that can be used to perform the production method described.

“Coupling reagents” employable for performing the methods of claim 22 or 23 are known to people skilled in the field. Preferably used coupling reagents are O-(BENZOTRIAZOL-1-YL)-N,N,N′,N′-TETRAMETHYLURONIUM TETRAFLUOROBORATE (TBTU) and/or O-(7-AZABENZOTRIAZOL-1-YL)-N,N,N′,N′-TETRAMETHYLURONIUM HEXAFLUORO-PHOSPHATES (HATU).

“Bases” employable for performing the methods of claims 22 or 23 are known to people skilled in the field. Preferably used bases are triethylamine, Hunig's base or sodiumhydrogencarbonate.

The reactions of compounds of the general formula IV to the compounds of the general formula I described in claim 22 and of compounds of the general formula V to compounds of the general formula II as described in claim 23, are preferably performed at a temperature of 0° C. to 50° C. and even more preferably at ambient temperature.

The Following Implementations Pertain Similarly to all Embodiments of the Invention

Understood under alkyl is any straight-chained or branched alkyl residue, like e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. butyl, tert. butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl and decyl.

Understood under alkoxyl is any straight-chained or branched alkoxyl residue, like e.g. methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec. butyloxy, pentyloxy, isopentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy or decyloxy. Preferred in the present invention, however, are C₁-C₆-alkoxy groups, especially preferred are C₁-C₃-alkoxyl groups and especially preferred is a methoxyl group.

The alkenyl substituents are respectively straight-chained or branched, wherein e.g. the following residues are intended: vinyl, propen-1-yl, propen-2-yl, but-1-en-1-yl, but-1-en-2-yl, but-2-en-1-yl, but-2-en-2-yl, 2-methyl-prop-2-en-1-yl, 2-methyl-prop-1-en-1-yl, but -1-en-3-yl, but-3-en-1-yl, allyl.

Understood under alkinyl is any straight-chained or branched alkinyl residue that contains 2-6, preferably 2-4 C-atoms. The following residues are given as examples: acetylene, propin-1-yl, propin-3-yl (propargyl), but-1-in-1-yl, but-1-in-4-yl, but-2-in-1-yl, but-1-in-3-yl, etc.

C₂-C₁₀-heterocycloalkyl represents an alkyl ring comprising 2-10 carbon atoms, preferably 3 to 10 carbon atoms and especially preferably 5 to 6 carbon atoms, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group oxygen, sulfur or nitrogen and can be optionally interrupted in the ring by one or several —(CO)—, —(CS)— or —SO²— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted or annealed identically or differently.

Examples mentioned of heterocycloalkyls are: oxiranyl, oxethanyl, dioxolanyl, dithianyl, dioxanyl, aziridinyl, azetidinyl, tetrahydrofuraneyl, tetrahydropyranyl, tetrahydrooxazolyl, tetrahydrothiazolyl, tetrahydroisochinolinyl, octahydroisochinolinyl, tetrahydrochinolinyl, octahydrochinolinyl, tetrahydroimidazolonyl, pyrazolidinyl, pyrrolidinyl, pyrolidonyl, piperidinyl, piperazinyl, piperazinonyl, n-methylpyrolidinyl, 2-hydroxymethylpyrolidinyl, 3-hydroxypyrolidinyl, n-methylpiperazinyl, n-acetylpiperazinyl, n-methylsulfonylpiperazinyl, 4-hydroxypiperidinyl, 4-aminocarbonylpiperidinyl, 2-hydroxyethylpiperidinyl, 4-hydroxymethylpiperidinyl, imidazolidinyl, tetrahydroimidazolonyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, trithianyl, tetrahydrotriazinthionyl, triazinthionyl, chinuclidinyl, nortropinyl, etc. or rings of the aforementioned, which are benzocondensed, like e.g. benzopyrrolidinyl, benzomorpholinyl, etc.

Substituents on the heterocycloalkylring can be e.g.: cyanogen, halogen, hydroxyl, C₁-C₆-alkyl, C₁-C₆-alkoxyl, C₁-C₆-alkoxyalkyl, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, aryl or C₁-C₆-alkyl optionally mono- or polysubstituted, identically or differently with halogen, hydroxyl or C₁-C₆-alkylthiol, or with the group —(CO)—C₁-C₆-alkyl, —(CO)—O—C₁-C₆-alkyl, —(SO₂)—C₁-C₆-alkyl, —(SO₂)-phenyl, —NH₂, —N(C₁-C₆-alkyl)₂, —NH(C₁-C₆-alkyl) etc.

Understood under cycloalkyl are monocyclic alkyl rings like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, but also bicyclic rings or tricyclic rings like e.g. adamantanyl. The cycloalkyl may also be optionally benzocondensed, like e.g. (tetralin)yl, etc.

Understood under halogen are fluorine, chlorine, bromine or iodine respectively.

The heteroaryl residue comprises 5-16 ring atoms, preferably 5 to 10 ring atoms and especially preferably 5 to 7 ring atoms, and, instead of carbon, contain one or several, identical or different, heteroatoms, like oxygen, nitrogen or sulfur in the ring, and can be mono-, bi- or tricyclic, and can also be benzocondensed.

Examples mentioned are:

Thienyl, furanyl, pyrroidinylyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, etc. and benzoderivates thereof, like e.g. benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc. and benzoderivates thereof, like e.g. chinolyl, isochinolyl, etc.; or oxepinyl, azocinyl, indolizinyl, indolyl, indolinyl, isoindolyl, indazolyl, benzimidazolyl, purinyl, etc. and benzoderivates thereof; or chinolinyl, isochinolinyl, cinnolinyl, phthalazinyl, chinazolinyl, chinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, xanthenyl, tetralinyl etc.

Especially preferred heteroaryl residues are e.g. 5-ring heteroaromates like thiophene, furanyl, oxazolyl, thiazol, imidazolyl and benzoderivates thereof (like e.g. benzimidazolyl) and 6-ring heteroaromates like pyridinyl, pyrimidinyl, triazinyl, chinolinyl, isochinolinyl and benzoderivates thereof.

The aryl residue comprises respectively 3-12 carbon atoms and may be respectively substituted or benzocondensed.

Mentioned as examples: cyclopropenyl, cyclopentadienyl, phenyl, tropyl, cyclooctadienyl, indenyl, naphthyl, azulenyl, biphenyl, fluorenyl, anthracenyl, tetralinyl, tolyl etc.

As it is used in this application, “C₁-C₅” means, e.g. in connection with the definition of “C₁-C₅-alkyl”, an alkyl group with an end number of 1 to 5 carbon atoms, i.e. 1,2,3,4 or 5 carbon atoms. The definition of “C₁-C₅” is further interpreted to include any possible subgroup, like e.g., C₁-C₅, C₂-C₅, C₃-C₅, C₄-C₅, C₁-C₂, C₁-C₃, C₁-C₄, C₁-C₅.

The information of the application regarding the different groups not explicitly listed here is defined in the same way as the “C₁-C₅” groups mentioned as examples above.

Understood under isomers are chemical compounds of the same sum formula but of a different chemical structure. A differentiation is generally made between isomers and stereoisomers.

Constitutional isomers possess the same sum formula, but are set apart, however, by how their atoms or atom groups link. These include functional isomers, position isomers, tautomers or valence isomers.

Stereoisomers have basically the same structure (constitution)—and therefore the same formula as well—but differ through the spatial configuration of the atoms. A differentiation is generally made between configurational isomers and conformational isomers. Configurational isomers are stereoisomers that can only be converted into each other by bond breakage. They include enantiomers, diastereomers and E/Z (cis/trans) isomers.

Enantiomers are stereoisomers that behave like an image to a mirror image and do not exhibit any plane of symmetry. All stereoisomers that are not enantiomers are called diastereomers. E/Z (cis/trans) isomers at double bonds are the special case. Conformational isomers are stereoisomers that can be converted into each other through single bond rotation. For delineating isomery types from each other, see also the IUPAC rules, section E (Pure Appl. Chem. 45, 11-30, 1976).

The inventive compounds of the general formula I also include the possible tautomeric forms and include the E or Z isomers or, if there is a chiral center, the racemates and enantiomers as well. These are understood to include double bond isomers as well.

The compounds of the invention may also be in the form of solvates, particularly hydrates, wherein the compounds of the invention accordingly contain polar solvents, particularly of water, as a structural element of the crystal lattice of the compounds of the invention. The portion of polar solvent, in particular water, can be in stoichiometric or unstoichiometric ratio. For stoichiometric solvates or hydrates, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta-, etc. solvates or hydrates are also mentioned.

If there is an acidic function, physiologically compatible salts of organic and inorganic bases are suitable as salts, like e.g. well-soluble alkali- and earth alkali salts as well as n-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, 1,6-hexadiamine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak-base, 1-amino-2,3,4-butantriol.

If it contains a basic function, the physiologically compatible salts of organic and inorganic acids are suitable, like hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid, maleinic acid, fumaric acid, etc.

The compounds of the invention of the general formula I essentially inhibit polo-like kinases, on which their effect is also based, e.g. against cancer, like solid tumors and leukemia, autoimmune diseases like psoriasis, alopecia, and multiple sclerosis, chemotherapeutically-induced alopecia and mucositis, cardiovascular diseases like stenoses, arterioscleroses and restenoses, infectious diseases, like those brought upon e.g. by unicellular parasites like trypanosoma, toxoplasma or plasmodium, or by fungi, nephrological diseases like e.g. glomerulonephritis, chronic neurodegenerative diseases like Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS-induced dementia and Alzheimer's disease, acute neurodegenerative diseases like cerebral ischemias and neurotraumas, viral infections like e.g. cytomegalus-infections, herpes, hepatitis B and C, and HIV diseases.

An object of the present invention is also the use of the compounds of the general formula II as well as their solvates, hydrates, diastereomers, enantiomers and salts as intermediate products.

To use the inventive compounds of the general formula I as a drug, they are brought into the form of a pharmaceutical preparation that, in addition to the agent for the enteral or parenteral application, contains pharmaceutical, organic or inorganic inert carrier materials, like e.g. water, gelatins, Arabian rubber, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc. The pharmaceutical preparations may be in solid form, e.g. as tablets, dragees, suppositories, capsules or in liquid form, e.g. as solutions, suspensions or emulsions. In addition to that they also contain adjuvants, like preservatives, stabilizers or emulsifiers; salts to change osmotic pressure or buffers.

These pharmaceutical preparations are also an object of the present invention.

Particularly suited for parenteral application are injection solutions or suspensions, especially aqueous solutions of the active compounds in polyhydroxyethoxylated ricinus oil.

Surface-active adjuvants like salts of gallic acids or animal or vegetable phospholipids, but also mixtures thereof, as well as liposomes or their components can also be used as carrier systems.

Suited particularly for oral application are tablets, dragees or capsules with talcum and/or carbon hydrogen carriers or binders, like e.g. lactose, corn or potato starch. Application can also be done in liquid form, like e.g. as a juice with an optionally added sweetener.

The enteral, parenteral and oral applications are also an object of the present invention.

The dosage of these agents can vary depending on the administration path, age and weight of the patient, type and severity of the disease being treated and similar factors. The daily dose is 0.5-1000 mg, preferably 50-200 mg, wherein the dose can be given as a one-time dose or divided into 2 or more daily doses.

Likewise an object of the present invention is the use of the compounds of the general formula I for producing a drug for treating cancer, autoimmune diseases, cardiovascular diseases, chemotherapeutically-induced alopecia and mucositis, infectious diseases, nephrological diseases, chronic and acute neurodegenerative diseases and viral infections, wherein understood under cancer are solid tumors and leukemia, understood under autoimmune diseases are psoriasis, alopecia and multiple sclerosis, understood under cardiovascular diseases are stenoses, arterial scleroses and restenoses, understood under infectious diseases are diseases brought about by unicellular parasites, understood under nephrological diseases are glomerulonephritis, understood under chronic neurodegenerative diseases are Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS-induced dementia and Alzheimer's disease, understood under acute neurodegenerative diseases are cerebral ischemias and neurotraumas, and understood under viral infections are cytomegalus-infections, herpes, hepatitis B or C, and HIV diseases.

Likewise an object of the present invention are drugs for treating the diseases listed above that contain at least one compound of the general formula I as well as drugs with suitable formulation and carrier substances.

The compounds of the invention of general formula I are among other things excellent inhibitors of polo-like kinases, like PLK 1, PLK 2, PLK 3 and PLK 4.

Where the production of the starting compounds is not described, they are known or similar to known compounds or producible according to methods described here. It is also possible to perform all the conversions described here in parallel reactors or by means of combined work methods.

The isomer mixtures can be separated according to standard methods like e.g. crystallization, chromatography or salification into isomers, like e.g. into enantiomers, diastereomers or E/Z isomers as long as the isomers do not stand in equilibrium with each other.

The salts are produced in the standard way by mixing a solution of the compound of formula I with the equivalent amount or an excess of a base or acid that is preferably in solution and separating off the precipitate or preparing the solution in the standard manner. Wherein R¹, R², R³, U, T¹, T² and T³ have the meaning given in general formula I. Spacer =—C₁-C₃-alkyl or —nO. ¹²-(CO)—C₁-C₃-alkyl.

R^X=-No. ¹⁰R¹¹ or C₂-C₁₀-heterocycloalkyl, wherein the heterocycloalkyl contains at least one atom in the ring, identically or differently, from the group nitrogen, oxygen or sulfur and can be optionally interrupted in the ring by one or several —(CO)—, —(C═S)— or —SO₂— groups and optionally one or several double bonds can be contained in the ring and the ring itself can be optionally mono- or polysubstituted, identically or differently with cyanogens, halogen, hydroxyl, aryl or with the group —(CO)—R⁵, —nR¹²R¹³ or with C₁-C₃-alkyl optionally mono- or polysubstituted, identically or differently, with halogen, hydroxyl, or C₁-C₃-alkylthiol, wherein the aryl itself can be optionally mono- or polysubstituted, identically or differently, with halogen or C₁-C₃-alkoxyl.

Wherein U, T¹, T²,T³, R¹, R², R³, R⁹, R¹², R⁵, R¹⁴, R¹³, R¹⁰, and R¹¹ have the meaning given in general formula I.

Wherein U, T¹, T², and T³, have the meaning given in general formula I and R^X has the meaning given in Synthesis Scheme 2.

Wherein U, T¹, T², and T³ have the meaning given in general formula I.

Wherein U, T¹, T², and T³ have the meaning given in general formula I and R^X has the meaning given in Synthesis Scheme 2.

Wherein U, T¹, T², T³, and R⁹ have the meaning given in general formula I.

Wherein U, T¹, T², and T³ have the meaning given in general formula I.

Wherein U, T¹, T², T³, and R⁹ have the meaning given in general formula I.

Wherein U, T¹, T², T³, and R⁹ have the meaning given in general formula I.

Wherein U, T¹, T², and T³ have the meaning given in general formula I and R^X has the meaning shown in Synthesis Scheme 2.

Wherein R⁹ has the meaning given in general formula I.

Wherein U, T¹, T², and T³ have the meaning given in general formula I and R^X has the meaning shown in Synthesis Scheme 2.

Wherein U, T¹, T², T³, R⁹, and R¹² have the meaning given in general formula I.

Wherein U, T¹, T², T³, R⁹ have the meaning given in general formula I.

Wherein U, T¹, T², T³, and R⁹ have the meaning given in general formula I.

1. Synthesis of Aniline Components

Intermediate INT1

1-(2-iodo-ethyl)-3-nitro-benzene

5 g 3-nitrophenyl ethanol, 9.4 g triphenylphosphine and 3.1 g imidazol are dissolved in 250 ml THF, mixed with 9.1 g iodine in portions and stirred for 15 hours at ambient temperature. The reaction mixture is mixed with ammonium chloride solution and extracted with dichloromethane. The organic phase is washed consecutively with sodiumthiosulfate solution and water and dried over sodium sulfate. After purification by chromatography on silica gel, 7.51 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=3.31 (t, 2H); 3.41 (t, 2H); 7.46-7.60 (m, 2H); 8.09 (s, 1H); 8.16 (d, 1 H); ppm.

Intermediate INT2

1-[2-(3-nitro-phenyl)-ethyl]-pyrrolidine

1.88 g of the compound described under INT1) is dissolved in 10 ml dimethylformamide, slowly mixed with 0.85 ml pyrolidine and stirred for 15 hours at ambient temperature. The solution is condensed off in the high vacuum, the residue is incorporated into acetic acid ethylester and washed three times with water. The organic phase is dried over sodium sulfate. After purification by chromatography on silica gel, 350 g of title compound is obtained.

1H-nMR (CDCl3): δ=1.81 (m, 4H); 2.57 (m, 4H); 2.74 (t, 2H); 2.93 (t, 2H); 7.45 (t, 1H); 7.56 (d, 1H); 8.03-8.13 (m, 2H) ppm.

Intermediate INT3

3-(2-pyrrolidin-1-yl-ethyl)-phenylamine

650 mg of the compound described under INT2) is dissolved in 250 ml ethanol and mixed (10%) with 130 mg palladium on carbon. It is stirred for 15 hours in a hydrogen atmosphere at ambient temperature. After filtration over kieselguhr and condensing off the solvent on the rotary evaporator, 540mg of the title compound is obtained.

1H-nMR (DMSO-d6): δ=1.78 (m, 4H); 2.65 (t, 2H); 2.70-2.92 (m, 6H); 4.99 (s, 2H), 6.31-6.45 (m, 3H); 6.92 (t, 1H) ppm.

Intermediate INT4

N-(3-amino-phenyl)-2,2-dimethyl-propionamide

5.0 g of 1,3-diaminobenzol is dissolved in 50 ml dichloromethane and mixed at 0° C. with 24 ml diisopropylethylamine and 10.4 ml pivalic acid anhydride. It is stirred for 2 hours at 0° C. and 18 hours at ambient temperature. The reaction mixture is mixed with semisaturated sodiumhydrogencarbonate solution and extracted with acetic acid ethylester. The organic solution is washed with saturated sodiumchloride solution, dried over sodium sulfate, condensed and after being purified by chromatography on silica gel, 5.7 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=1.20 (s, 9H); 4.98 (s, 2H); 6.24 (d, 1H); 6.70 (d, 1H); 6.83-6.96 (m, 2H) ppm.

Intermediate INT5

1-(2-iodo-ethyl)-3-nitro-benzene

1.5 g of 2-hydroxy-2-methyl-propionic acid is mixed in 50 ml dimethylacetamide at −10° C. with 1.05 ml thionylchloride and stirred for 30 minutes at −10° C. A solution of 2 g 3-nitroaniline is dropped into 10 ml dimethylacetamide at −10° C. and stirred consecutively for one hour at −10° C., one hour at 0° C. and for 15 hours at ambient temperature. The solution is condensed off in the high vacuum, the residue is incorporated into a mixture of acetic acid ethylester and dichloromethane (1:3) and washed twice with semisaturated sodiumhydrogencarbonate solution. The organic phase is dried over sodium sulfate. After being purified by chromatography on silica gel, 2.42 g of title compound is obtained.

1H-nMR (CDCl3): δ=1.49 (s, 6H); 2.35 (s, 1H); 7.50 (t, 1H); 7.98 (d, 2H); 8.49 (s, 1H); 8.98 (s, b, 1H) ppm.

Intermediate INT6

N-(3-amino-phenyl)-2-hydroxy-2-methyl-propionamide

1.92 g of the compound described under INT5) is dissolved in 400 ml ethanol and mixed with 50 mg Raney nickel. It is stirred for 18 hours in a hydrogen atmosphere at ambient temperature. After filtration over kieselguhr and condensing off the solvent on the rotary evaporator, 1.9 g of title compound is obtained.

1H-nMR (CDCl₃): δ=1.51 (s, 6H); 2.68 (s, 1H); 3.71 (s, b, 2H); 6.42 (d, 1H); 7.08 (t, 1H); 7.20 (s, 1H); 8.60 (s, b, 1H) ppm.

Intermediate INT7

2-(2-methoxy-ethoxy)-n-(3-nitro-phenyl)-acetamide

5 g (2-methoxyethoxy)-acetic acid is dissolved in 500 ml tetrahydrofurane. 9.7 ml triethylamine and 5.6 ml isobutylchloroformate is added at 0° C., and it is stirred for 30 minutes at 0° C. 5.0 g of 3-nitroaniline is added and it is stirred for another for 15 hours. The reaction mixture is mixed with semisaturated sodiumhydrogencarbonate solution and extracted with acetic acid ethylester. The organic solution is washed with saturated sodiumchloride solution, dried over sodium sulfate, condensed, and after being purified by chromatography on silica gel, 7.5g of title compound is obtained.

1H-nMR (DMSO-d6): δ=3.30 (s, 3H); 3.53 (m, 2H); 3.70 (m, 2H); 4.04 (s, 1H); 7.62 (t, 1H); 7.93 (d, 1H); 8.02 (d, 1H); 8.69 (s, 1H); 10.20 (s, b, 1H) ppm.

Intermediate INT8

N-(3-amino-phenyl)-2-(2-methoxy-ethoxy)-acetamide

7.5 g of the compound described under INT7) is dissolved in 150 ml ethanol and mixed (10%) with 1.3 g palladium on carbon. It is stirred for 15 hours in a hydrogen atmosphere at ambient temperature. After filtration over kieselguhr and condensing off the solvent on the rotary evaporator, 6.5 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=3.31 (s, 3H); 3.51 (m, 2H); 3.65 (m, 2H); 4.02 (s, 2H); 6.10 (s, 2H); 6.28 (d, 1H); 6.70 (d, 1H); 6.87-6.98 (m, 2H); 9.27 (s, 1H) ppm.

Intermediate INT9

N-(6-amino-pyridin-2-yl)-2,2-dimethyl-propionamide

10 g of 2,6-diaminopyridine is dissolved in 150 ml tetrahydrofurane. 48 ml diisopropylethylamine and 20.8 ml pivalic acid anhydride is added and it is stirred for 15 hours at ambient temperature. The solvent is condensed off on the rotary evaporator. After purification by chromatography on silica gel, 10.6 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=1.20 (s, 9H); 5.72 (s, 2H); 6.07 (d, 1H); 7.18 (d, 1H); 7.33 (t, 1H); 8.93 (s, 1H) ppm.

Intermediate INT10

N-(6-amino-pyridin-2-yl)-2-(2-methoxy-ethoxy)-acetamide

4.9 ml of (2-methoxyethoxy)-acetic acid is dissolved in 500 ml tetrahydrofurane. 9.7 ml triethylamine and 5.6 ml isobutylchloroformate is added at 0° C. and it is stirred for 30 minutes at 0° C. 3.96 g of 2,6-diaminopyridine is added and it is stirred for another 4 hours at ambient temperature. The reaction mixture is mixed with semisaturated sodiumhydrogencarbonate solution and extracted with acetic acid ethylester. The organic solution is washed with saturated sodiumchloride solution, dried over sodium sulfate, condensed and after being purified by chromatography on silica gel, 5.04 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=3.31 (s, 3H); 3.50 (m, 2H); 3.67 (m, 2H); 4.07 (s, 2H); 5.88 s, 2H); 6.19 (d, 1H); 7.21 (d, 1H); 7.36 (t, 1H); 9.13 (s, 1H) ppm.

Intermediate INT11

Ethyl-(4-nitro-1-oxy-pyridin-2-yl)-amine

2.0 g of 2-chloro-4-nitro-pyridine 1-oxide is dissolved in 20 ml ethanol. 11.5 ml triethylamine is added and it is stirred for 4 hours under reflux. The solution is condensed off on the rotary evaporator. After purification by chromatography on silica gel, 1.5 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=1.19 (t, 3H); 3.39 (pentuplet, 2H); 7.39 (dd, 1H); 7.47 (d, 1H); 7.64 (t, 1H); 8.35 (d, 1H) ppm.

Intermediate INT12

4-amino-2-ethylamino-pyridine

800 mg of the compound described under INT11) is dissolved in 50 ml ethanol and mixed with 50 mg Raney nickel. It is hydrated in a 3.5 bar hydrogen atmosphere at ambient temperature. After filtration over kieselguhr and condensing off the solvent on the rotary evaporator, 610 mg of title compound is obtained.

1H-nMR (DMSO-d6): δ=1.09 (t, 3H); 3.11 (m, 2H); 5.48 (s, 2H); 5.52 (d, 1H); 5.71 (t, 1H); 5.78 (dd, 1H); 7.49 (d, 1H) ppm.

Intermediate INT13

2-chloro-n-(3-nitro-phenyl)-acetamide

13.8 g of 3-nitroaniline is dissolved in 500 ml tetrahydrofurane. 30.5 ml triethylamine and 19.4 g chloroformic acid anhydride is added at 0° C. It is stirred for 12 hours at ambient temperature. The reaction mixture is mixed with semisaturated sodiumhydrogencarbonate solution and extracted with acetic acid ethylester. The organic solution is washed with saturated sodium chloride solution, dried over sodium sulfate, condensed and after being purified by chromatography on silica gel, 20.0 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=4.31 (s, 2H); 7.64 (t, 1H); 7.89-8.00 (m, 2H); 8.61 (s, 1H); 10.79 (b, 1H) ppm.

Intermediate INT14

N-(3-nitro-phenyl)-2-piperidin-1-yl-acetamide

2.14 g of the compound described under INT13) is dissolved in 100 ml dimethylformamide. 2.0 ml triethylamine, 248 mg potassium iodide and 1.48 ml piperidine is added. It is stirred for 4 hours at ambient temperature. The reaction mixture is mixed with semisaturated sodiumhydrogencarbonate solution and extracted with acetic acid ethylester. The organic solution is washed with saturated sodium chloride solution, dried over sodium sulfate, condensed and after being purified by chromatography on silica gel, 1.97 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=1.34-1.48 (m, 2H); 1.51-1.63 (m, 4H); 2.5 (m, 4H); 3.12 (s, 2H); 7.60 (t, 1H); 7.91 (d, 1H); 8.02 (d, 1H); 8.70 (s, 1H); 10.18 (s, 1H) ppm.

Intermediate INT15

Acetic acid (3-nitro-phenylcarbamoyl)-methyl ester

5.0 g of the compound described under INT13) is dissolved in 200 ml dimethylformamide. 19.1 g sodiumacetate and 350 mg potassium iodide is added. It is stirred for 24 hours at ambient temperature. The reaction mixture is mixed with water and extracted with acetic acid ethylester. The organic solution is washed three times with semisaturated sodiumchloride solution, dried over sodium sulfate, condensed and after being purified by chromatography on silica gel, 4.7 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=2.14 (s, 3H); 4.70 (s, 2H); 7.62 (t, 1H); 7.87-7.98 (m, 2H); 8.60 (s, 1H); 10.57 (b, 1H) ppm.

Intermediate INT16

4-[2-(2-methyl-5-nitro-phenoxy)-ethyl]-morpholine

A suspension of 10 g 2-methyl-5-nitrophenol, 12 g 4-(2-chlorethyl)-morpholine and 27.1 g potassium carbonate is heated under reflux in 200 ml acetone for 15 hours. The batch is made free of solvent with the vacuum and the residue is incorporated into ethylacetate. It is extracted with NaOH aq. (1n, 3×200ml) and the united organic phases are dried over sodiumcarbonate, the solvent is distilled off on the rotary evaporator and a yield of 62% is obtained (10.9) of 4-[2-(2-methyl-5-nitro-phenoxy)-ethyl]-morpholine.

1H-nMR (300 MHz, CDCl₃): δ=2.30 (s, 3H); 2.61 (m, 4H); 2.86 (m, 2H); 3.71 (m, 4H); 4.20 (m, 2H); 7.22 (d, 1H); 7.68 (d, 1H); 7.75 (dd, 1H) ppm.

Intermediate INT17

4-methyl-3-(2-morpholin-4-yl-ethoxy)-phenylamine

15.9 g of the compound described under INT16) and 2 g palladium on carbon is hydrated in 300 ml methanol at low pressure and ambient temperature. After hydrogen incorporation is completed, it is filtered off from the catalyst and the raw product is freed of solvent on the rotary evaporator. A quantitative yield of title compound is obtained. The raw product is used in the next step without further purification.

1H-nMR (300 MHz, CDCl₃): δ=2.10 (s, 3H); 2.62 (m, 4H); 2.85 (m, 2H); 3.77 (m, 4H), 4.10 (m, 2H); 6.21 (m, 2H); 6.90 (d, 1H) ppm.

The following compounds are produced according to the method described above.

				Educt/
Exam-			Mol. weight/	syn-
ple			MS (ESI)	thesis
no.	Structure and name	1H-nMR	[M + ]+	analogous
INT18		(DMSO-d6, stored over K2CO3): δ =2.06 (t, 1H); 3.55 (m, 2H); 4.60 (s, 1H); 4.91 (s, 2H); 6.25-6.50 (m, 3H); 6.91 (t, 1H) ppm.		3-nitro- phenyl- ethanol/ INT3
INT19		(DMSO-d6): δ =1.20 (s, 9H); 4.93 (s, 2H); 6.29-6.38 (m, 1H); 6.70 (dd, 1H); 6.85 (dd, 1H); 8.77 (s, 1H) ppm.		N-(5- nitro-2- fluoro- phenyl)- 2,2- dimethyl- propion- amide/ INT3
INT20		(DMSO-d6): δ =1.45 (m, 2H); 1.65 (m, 4H); 2.78 (m, 4H); 3.45 (s, 2H); 4.70-6.00 (b, 2H); 6.29 (d, 1H); 6.72 (d, 1H); 6.88-7.00 (m, 2H); 9.80 (s, 1H) ppm.		INT14/ INT3
INT21		(DMSO-d6): δ =1.76 (m, 4H); 2.60 (m, 4H); 3.30 (s, 2H); 7.60 (t, 1H); 7.91 (d, 1H); 8.04 (d, 1H); 8.71 (s, 1H), 10.21 (s, b, 1H) ppm.		INT13/ INT14
INT22		(DMSO-d6): δ =1.85 (m, 4H); 3.00 (m, 4H); 3.71 (s, 2H); 4.70-5.55 (b, 2H); 6.28 (d, 1H); 6.71 (d, 1H); 6.87-6.97 (m, 2H); 9.88 (s, 1H) ppm.		INT21/ INT3
INT23		(DMSO-d6): δ =2.51 (m, 4H); 3.19 (s, 2H); 3.55 (m, 4H); 7.60 (t, 1H); 7.92 (dd, 1H); 8.02 (dd, 1H); 8.79 (t, 1H); 10.25 (s, b, 1H) ppm.		INT13/ INT14
INT24		(DMSO-d6): δ =2.49 (m, 4H); 3.08 (s, 2H); 3.63 (m, 4H); 5.07 (s, 2H); 6.27 (d, 1H); 6.19 (d, 1H); 6.91 (t, 1H); 6.94 (s, 1H); 9.39 (s, 1H) ppm.		INT23/ INT3
INT25			MW: 238.25; MS (ESI) [M + 1]+: 239	3-nitro- aniline/ INT3
INT26			MW: 208.26; MS (ESI) [M + 1]+: 209	INT25/ INT3
INT27		(DMSO-d6): δ =2.11 (s, 3H); 4.60 (s, 2H); 5.08 (s, 2H); 6.28 (d, 1H); 6.67 (d, 1H); 6.83-6.97 (m, 2H); 9.75 (s, 1H) ppm.		INT15/ INT3
INT28			MW: 210.23; MS (ESI) [M + 1]+: 211	3-nitro- phenol/ INT16
INT29			MW: 250.30; MS (ESI) [M + 1]+: 251	3-nitro- phenol/ INT16
INT30			MW: 236.27; MS (ESI) [M + 1]+: 237	3-nitro- phenol/ INT16
INT31			MW: 180.25; MS (ESI) [M + 1]+: 181	INT28/ INT3
INT32			MW: 220.32; MS (ESI) [M + 1]+: 221	INT29/ INT3
INT33			MW: 206.29; MS (ESI) [M + 1]+: 207	INT30/ INT3
INT34			208.218/ 209	3-nitro- anilin/ INT7
INT35			178.236/ 179	INT34/ INT8
INT36			164.208/ 165	INT49/ INT8
INT37			223.233/ 224	INT13/ INT14
INT38			193.250/ 194	INT37/ INT8
INT39			222.245/ 223	3-nitro- anilin/ INT9
INT40			236.272/ 237	INT39/ INT-dK1
INT41			206.290/ 207	INT40/ INT8
INT43			222.245/ 223	INT34/ INT49
INT44			192.263/ 193	INT43/ INT8
INT45			152.197/ 153	INT50/ INT8
INT46			166.224/ 167	INT51/ INT8
INT47			237.260/ 238	INT13/ INT14
INT48			207.277/ 208	INT47/ INT8

Intermediate INT49

N-methyl-n-(3-nitro-phenyl)-acetamide

0.43g of sodiumhydride (60% suspension in mineral oil) is washed in a round-bottomed flask in protective gas with n-hexane (3×) and suspended in a little THF. A solution of 1.3 g 3-nitroacetanilide in 15 ml THF is dripped into that suspension. After the formation of gas has abated, 4.5 ml methyliodide is dripped into the reaction mixture. It is stirred for 2 hours at ambient temperature. The solvent is then distilled off to the greatest extent possible. Any sodium hydride that is left unconverted is broken down by adding a little water. The residue yielded is incorporated into ethylacetate. The organic phase is consecutively washed with water and saturated sodiumchoride solution and dried over magnesium sulfate. The oil yielded after evaporation is purified in silica gel. 1.23 g of title compound was yielded as a light-yellow oil.

¹H-nMR (CDCl₃): δ=1.93 (s, 3H); 3.31 (s, 3H); 7.56-7.64 (m, 2H); 8.0 (s, 1H); 8.18-8.20 (m, 1H) ppm. MS (ESI)[M+1]⁺: 195.

Intermediate INT50

2-(3-nitro-phenylamino)-ethanol

195 mg glycoaldehyde, 195 mg sodium cyanoborohydride and 0.08 ml glacial acetate is added to a solution of 200 mg 3-nitroaniline in 10 ml methanol cooled to 0° C. It is stirred for 5 hours at ambient temperature. For conversion it is mixed with 150 ml sodiumhydrogencarbonate solution and extracted with ethylacetate. The organic phase is washed with saturated sodiumchoride solution and dried over magnesium sulfate. The oil yielded after evaporation is purified on silica gel. 224 mg of title compound was yielded as orange crystals.

¹H-nMR (DMSO-d₆): δ=3.15 (q, 2H); 3.56 (q, 2H); 4.76 (t, 1H); 6.39 (t, 1H); 6.97-6.99 (m, 1H); 7.28-7.34 (m, 3H) ppm. MS (ESI)[M+1]⁺: 183.

Intermediate INT51

N-(2-methoxy-ethyl)-benzen-1,3-diamine

A mixture comprising 5 g 1,3-phenylendiamine, 4.2 ml 2-methoxyethylchloride, 4.9 g sodiumcarbonate (anhydride) and 30 ml water is boiled for 12 hours under reflux. It is then diluted with water (600 ml) and filtered. The filtrate is extracted with ethylacetate. The organic phase is washed consecutively with water and saturated sodiumchoride solution and dried over magnesiumsulfate. The oil yielded after evaporation is purified on silica gel. 1.85 g of title compound was yielded as oil.

1H-nMR (DMSO-d6): δ=3.09 (q, 2H); 3.25 (s, 3H); 3.43 (t, 2H); 4.68 (s, 2H); 5.10 (t, 1H); 5.78-5.81 (m, 3H); 6.69 (t, 1H) ppm. MS (ESI)[M+1]+: 167.

Intermediate INT52

2-(3-nitro-phenyl)-oxirane

10 g of 2-bromo-1-(3-nitro-phenyl)-ethanone is dissolved in 200 ml ethanol, mixed with 1.55 g sodiumborohydride and stirred for 1 hour at ambient temperature. 2.1 g potassium hydroxide is added and it is stirred for another for 15 hours at ambient temperature. 1000 ml acetic acid ethylester is added and washed twice with 300 ml semisaturated ammonium chloride solution and once with 100 ml water. The organic phase is dried over sodium sulfate. After purification by chromatography on silica gel, 7.48 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=2.79 (dd, 1H); 3.19 (dd, 1H); 3.93 (dd, 1H); 7.50 (t, 1H); 7.60 (d, 1H); 8.08-8.16 (m, 2H) ppm.

Intermediate INT53

1-(3-nitro-phenyl)-2-piperidin-1-yl-ethanol

1.68 g of the compound described under INT52 was dissolved in 10 ml tetrahydrofurane and mixed with 1.5 ml piperidine and stirred under reflux for 15 hours. The solvent is distilled off on the rotary evaporator, and after being purified by chromatography on silica gel, 1.4 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=1.40-1.80 (m, 6H); 2.23-2.49 (m, 3H); 2.59 (dd, 1H); 2.71 (b, 2H); 4.35 (b, 1H); 4.80 (dd, 1H); 7.51 (t, 1H); 7.73 (d, 1H); 8.13 (d, 1H); 8.28 (s, 1H) ppm.

Intermediate INT54

1-(3-amino-phenyl)-2-piperidin-1-yl-ethanol

2.0 g of the compound described under INT53 is dissolved in 250 ml ethanol and mixed (10%) with 200 mg palladium on carbon. It is stirred for 15 hours in a hydrogen atmosphere at ambient temperature. After filtration over kieselguhr and condensing off the solvent on the rotary evaporator, 1.76 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=1.40-1.70 (m, 6H); 2.28-2.55 (m, 4H); 2.58-2.77 (m, 2H); 3.65 (b, 2H); 4.63 (dd, 1H); 6.52-6.62 (m, 1H); 6.72 (d,1H); 6.75 (s, 1H); 7.11 (t, 1H) ppm.

Intermediate INT55

1-(3-nitro-phenyl)-2-(4aR,8aS)-octahydro-isoquinolin-2-yl-ethanol (Diastereomersmixture)

5.0 g of the compound described under INT52 is dissolved in 50 ml tetrahydrofurane and mixed with 7.3 g trans-decahydroisochinolin and stirred for 20 hours under reflux. The solvent is distilled off on the rotary evaporator, and after being purified by chromatography on silica gel, 5.75 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=0.72-1.45 (m, 7H); 1.45-1.85 (m, 6H); 1.95-3.20 (m, 5H); 4.43 (b, 1H); 4.75-4.86 (m, 1H); 7.51 (t, 1H); 7.72 (d, 1H); 8.13 (d, 1H); 8.25 (s, 1H) ppm.

Intermediate INT56

Acetic acid (4aR,8aS)-1-(3-nitro-phenyl)-2-octahydro-isoquinolin-2-yl-ethyl ester

5.75 g of the compound described under INT55 is dissolved in 100 ml tetrahydrofurane and mixed at 0° C. with 5.4 ml triethylamine and 3.6 ml acetanehydride and then stirred for 48 hours at ambient temperature. Half the solvent is distilled off on the rotary evaporator, 100 ml semisaturated sodiumhydrogencarbonate solution is added and it is extracted three times with 150 ml dichlormethane each time. The united organic phases are dried over sodium sulfate. After purification by chromatography on silica gel and then recrystallization, 4.07 g of title compound is obtained.

¹H NMR (CDCl₃; main isomer):

δ=0.72-1.05 (m, 3H); 1.06-1.35 (m, 4H); 1.40-1.89 (m, 6H); 2.00-2.22 (m, 4H); 2.55 (dd, 1H); 2.64-2.96 (m, 3H); 5.97 (dd, 1H); 7.51 (t, 1H); 7.68 (d, 1H); 8.14 (d, 1H); 8.22 (s, 1H) ppm.

Intermediate INT57

3-[(4aR,8aS)-2-(octahydro-isoquinolin-2-yl)-ethyl]-phenylamine

4.07 g of the compound described under INT56) is dissolved in 400 ml acetic acid ethylester and 100 ml glacial acetate and mixed (10%) with 400 mg palladium on carbon. It is hydrated for 15 hours under 100 bar hydrogen at ambient temperature. Another 1000 mg palladium on carbon is added (10%) and hydrated for another 15 hours under 100 bar hydrogen at ambient temperature. Half the solvent is distilled off on the rotary evaporator, approx. 1 L of 2 normal sodium hydroxide solution is added until the solution has a pH von 9.5. The solution is consecutively extracted with 300 ml acetic acid ethylester and with 500 ml of a mixture of chloroform and methanol (10:1). The united organic phases are washed with water (100 ml) and saturated table salt solution (100 ml) and dried over sodium sulfate. After filtering and condensing off the solvent on the rotary evaporator, 2.57 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=0.69-1.03 (m, 3H); 1.03-1.33 (m, 4H); 1.39-1.73 (m, 6H); 1.86.2,00 (m, 1H); 2.41-2.53 (m, 2H); 2.61-2.71 (m, 2H); 2.75-2.83 (m, 1H); 2.88-3.00 (m, 1H); 3.37-3.70 (b, 2H); 6.40-6.50 (m, 2H); 6.54 (d, 1H); 7.00 (t, 1H) ppm.

Intermediate INT58

2-chloro-n-(2-fluoro-5-nitro-phenyl)-acetamide

10 g 2-fluoro-5-nitro-phenylamine is dissolved in 330 ml tetrahydrofurane mixed at 0° C. with 19.5 ml triethylamine, 0.5 ml pyridine and 5.6 ml chloracetylchloride and then stirred for 24 hours at ambient temperature. The solvent is distilled off on the rotary evaporator, 1 L of acetic acid ethylester is added and washed with 200 ml semisaturated sodiumhydrogencarbonate solution. The organic phases are dried over sodium sulfate. After purification by chromatography on silica gel, 5.4 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=4.27 (s, 2H); 7.21-7.38 (m, 1H); 7.97-8.31 (m, 1H); 8.66 (s, b, 1H); 9.19-9.32 (m, 1H) ppm.

Intermediate INT59

N-(2-fluoro-5-nitro-phenyl)-2-morpholin-4-yl-acetamide

3.0 g of the compound described under INT58 is dissolved in 50 ml dimethylformamide, mixed with 2.68 ml triethylamine, 330 mg potassium iodide and 1.18 ml 4,4-morpholine and stirred for 15 hours at ambient temperature. The solvent is distilled off on the rotary evaporator, 500 ml acetic acid ethylester is added and then it is washed with 50 ml water and twice with 50 ml semisaturated sodiumhydrogencarbonate solution. The organic phase is dried over sodium sulfate. After purification by chromatography on silica gel, 2.7 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=2.66 (t, 4H); 3.23 (s, 2H); 3.79 (t, 4H); 7.18-7.33 (m, 1H); 7.92-8.05 (m, 1H); 9.27-9.39 (m, 1H); 9.73 (s, b, 1H) ppm.

Intermediate INT60

N-(5-amino-2-fluoro-phenyl)-2-morpholin-4-yl-acetamide

2.7 g of the compound described under INT59 is dissolved in 500 ml ethanol and mixed (10%) with 270 mg palladium on carbon. It is stirred for 15 hours in a hydrogen atmosphere at ambient temperature. After filtration over kieselguhr and condensing off the solvent on the rotary evaporator, 2.4 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=2.62 (t, 4H); 3.15 (s, 2H); 3.35-3.70 (b, 2H); 3.77 (t, 4H); 6.25-6.39 (m, 1H); 6.81-6.95 (m, 1H); 7.70-7.84 (m, 1H); 9.44 (s, b, 1H) ppm.

Intermediate INT61

2-(4,4-difluoro-piperidin-1-yl)-n-(2-fluoro-5-nitro-phenyl)-acetamide

1.41 g of the compound described under INT58 is dissolved in 25 ml dimethylformamide, mixed with 1.26 ml triethylamine, 155 mg potassium iodide and 1.0 g 4,4-difluoropiperidine and stirred for 15 hours at ambient temperature. The solvent is distilled off on the rotary evaporator, 500 ml of a mixture of dichloromethane and methanol (100:1) is added and then it is washed twice each time with 50 ml semisaturated sodiumhydrogencarbonate solution. The organic phase is dried over sodium sulfate. After purification by chromatography on silica gel, 1.1 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=2.00-2.21 (m, 4H); 2.78 (t, 4H); 3.28 (s, 2H); 7.18-7.34 (m, 1H); 7.91-8.52 (m, 1H); 9.25-9.38 (m, 1H); 9.62 (s, b, 1H) ppm.

Intermediate INT62

N-(5-amino-2-fluoro-phenyl)-2-(4,4-difluoro-piperidin-1-yl)-acetamide

1.1 g of the compound described under INT61 is dissolved in 200 ml ethanol and mixed (10%) with 110 mg palladium on carbon. It is stirred for 15 hours in a hydrogen atmosphere at ambient temperature. After filtration over kieselguhr and condensing off the solvent on the rotary evaporator, 0.99 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=1.93-2.20 (m, 4H); 2.73 (t, 4H); 3.20 (s, 2H); 3.60 (b, 2H); 6.24-6.44 (m, 1H); 6.87 (t, 1H); 7.65-7.85 (m, 1H); 9.36 (s, b, 1H) ppm.

Intermediate INT63

(5-bromo-2-chloro-pyrimidin-4-yl)-(2-methoxy-ethyl )-amine

5.0 g 5-bromo-2,4-dichlorpyrimidine is dissolved in 100 ml acetonitrile, mixed with 5.2 ml triethylamine and 1.85 ml 2-methoxyethylamine and stirred for 15 hours at ambient temperature. 100 ml acetic acid ethylester is added and then it is washed twice with 50 ml water and twice with 50 ml saturated sodiumchloride solution. The organic phase is dried over sodium sulfate. After purification by chromatography on silica gel, 4.97 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=3.46 (s, 3H); 3.62 (t, 2H); 3.77 (m, 2H); 5.98 (s, b, 1H); 8.18 (s, 1H) ppm.

Intermediate INT64

5-bromo-n*4*-(2-methoxy-ethyl )-pyrimidine-2,4-diamine

2.97 g of the compound described under INT63 is dissolved in 80 ml methanol. The solution is saturated at 8 bar with ammoniac and the closed autoclave is stirred for 20 hours at 80 ° C. The solvent is distilled off on the rotary evaporator. The residue is mixed with 10 ml methanol, incorporated into 100 ml chloroform and washed twice with 20 ml water. After purification by chromatography on silica gel, 1.4 g of title compound is obtained.

¹H NMR (CDCl₃):

δ=3.39 (s, 3H); 3.54 (t, 2H); 3.61 (m, 2H); 4.82 (s, b, 2H); 5.54 (s, b, 1H); 7.86 (s, 1H) ppm.

Intermediate INT65

N*4*-(2-methoxy-ethyl )-pyrimidine-2,4-diamine

1.1 g of the compound described under INT64 is dissolved in 250 ml ethanol and mixed (10%) with 110 mg palladium on carbon. It is stirred for 15 hours in a hydrogen atmosphere at ambient temperature. After filtration over kieselguhr and condensing off the solvent on the rotary evaporator, 0.99 g of title compound is obtained as HBr salt.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=3.27 (s, 3H); 3.43-3.58 (m, 4H); 6.12 (d, 1H); 7.64 (d, 1H); 7.73 (s, b, 2H); 8.81 (s, b 1 H); 11.57 (s, b, 1 H) ppm.

Intermediate INT66

(R)-2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-3-methyl-butan-1-ol

Analogous to the production of intermediate INT63, the title compound is obtained starting from 5-bromo-2,4-dichlorpyrimidine and (R)-2-amino-3-methyl-butan-1-ol. Mol. weight / MS (ESI) [M+1]⁺: 294.58/ 294; 296 (100%); 298.

Intermediate INT67

(R)-2-(2-amino-5-bromo-pyrimidin-4-ylamino)-3-methyl-butan-1-ol

1.0 g of the compound described under INT66 is dissolved in 100 ml methanol. The solvent is saturated at 8 bar with ammoniac and the closed autoclave is stirred for 20 hours at 80° C. The solvent is distilled off on the rotary evaporator. The residue is mixed with 5 ml methanol, incorporated into 50 ml chloroform and washed twice with 20 ml water. After purification by chromatography on silica gel, 640 mg of title compound is obtained.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=0.90-1.04 (m, 6H); 1.91-2.08 (m, 1H); 3.00 (s, b, 1H); 3.70 (dd, 1H); 3.80 (dd, 1H); 3.95 (m, 1H); 4.89 (s, 2H); 5.33 (d, 1H); 7.89 (s, 1H) ppm.

Intermediate INT68

(6-bromo-pyridin-2-yl)-difluoro-acetic acid ethyl ester

6.75 g 2,6-dibromopyridine is dissolved in 40 ml dimethylsulfoxide. 4.1 g of copper powder and 7.51 g ethylbromodifluoroacetate is added and stirred for 4 hours at 50° C. The reaction mixture is mixed with 200 ml acetic acid ethylester and 200 ml 1.3 molar potassium hydrogenphosphate solution and stirred for 30 minutes at ambient temperature. The solid substance is filtered off, the organic phase is separated off, it is washed three times consecutively with 50 ml semisaturated table salt solution and dried over sodium sulfate. After purification by chromatography on silica gel, 4.1 g of title compound is obtained.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=1.24 (t, 3H); 4.38 (q, 2H); 7.88-7.97 (m, 2H); 8.03 (t, 1H) ppm.

Intermediate INT69

2-(6-bromo-pyridin-2-yl )-2,2-difluoro-ethanol

7.75 g of the compound described under INT68 is dissolved in 130 ml ethanol, mixed at 0° C. with 785 mg sodium borohydride and stirred for 4 hours at ambient temperature. 15 ml of 2 molar salt acid is added subject to the cooling of an ice bath. It is stirred for 10 minutes at ambient temperature and brought up to pH 10 with caustic soda. The reaction mixture is mixed with 500 ml dichloromethane and 100 ml semisaturated table salt solution, the organic phase is separated off and dried over sodium sulfate. After purification by filtration through silica gel, 6.3 g of title compound is obtained.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=3.93 (t, 2H); 5.59 (s, 1H); 7.70 (d, 1H); 7.79 (d, 1H); 7.90 (t, 1H) ppm.

Intermediate INT70

2-bromo-6-[2-(tert-butyl-dimethyl-silanyloxy)-1,1-difluoro-ethyl]-pyridine

6.9 g of the compound described under INT69 is dissolved in 60 ml dimethylformamide, mixed with 3.77 g imidazol and 5.27 g tert.-butyldimethylsilylchloride and stirred for 15 hours at ambient temperature. 300 ml semisaturated sodiumhydrogencarbonate solution is added and extracted three times with 150 ml acetic acid ethylester. The united organic phases are dried over sodium sulfate. After purification by filtration through silica gel, 9.2 g of title compound is obtained.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=−0.07 (s, 6H); 0.70 (s, 9H); 4.16 (t, 2H); 7.72 (d, 1H); 7.80 (d, 1H); 7.91 (t, 1H) ppm.

Intermediate INT71

{6-[2-(tert-butyl-dimethyl-silanyloxy)-1,1-difluoro-ethyl]-pyridin-2-yl}-(2,4-dimethoxy-benzyl)-amine

2.5 g of the compound described under INT70 is dissolved in 25 ml dioxane, mixed with 2.7 ml of 2,4-dimethylbenzlamine, 168 mg palladium acetate, 218 mg BINAP and 950 mg sodium-tert-butylate and stirred for 3 hours at 80° C. 100 ml water is added and extracted three times with 50 ml acetic acid ethylester. The united organic phases are dried over sodium sulfate. After purification by chromatography on silica gel, 2.3 g of title compound is obtained.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=−0.07 (s, 6H); 0.75 (s, 9H); 3.69 (s, 3H); 3.77 (s, 3H); 4.06 (t, 2H); 4.30 (d, 2H); 6.39 (d, 2H); 6.48-6.58 (m, 2H); 6.69 (d, 1H); 6.97 (t, 1H); 7.20 (d, 1H); 7.41 (t, 1H) ppm.

Intermediate INT72

2-[6-(2,4-dimethoxy-benzylamino)-pyridin-2-yl]-2,2-difluoro-ethanol

2.3 g of the compound described under INT71 is dissolved in 100 ml tetrahydrofurane and mixed with 13 ml of a 1 molar solution of tetrabutylammoniumfluoride in tetrahydrofurane and stirred for 1 hour at ambient temperature. 100 ml semisaturated sodiumhydrogencarbonate solution is added and extracted three times with 100 ml acetic acid ethylester. The united organic phases are dried over sodium sulfate. After purification by chromatography on silica gel, 1.42 g of title compound is obtained.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=3.70 (s, 3H); 3.77 (s, 3H); 3.87 (t, 2H); 4.30 (d, 2H); 5.37 (s, b, 1H); 6.41 (d, 1H); 6.50-6.59 (m, 2H); 6.70 (d, 1H); 6.95 (t, 1H); 7.13 (d, 1H); 7.41 (t, 1H) ppm.

Intermediate INT73

Methane sulfonic acid 2-[6-(2,4-dimethoxy-benzylamino)-pyridin-2-yl]-2,2-difluoro-ethyl ester

1.37 g of the compound described under INT72 is dissolved in 100 ml tetrahydrofurane and mixed at 0° C. with 1.47 ml triethylamine and 0.49 ml methanesulfonic acid chloride and then stirred for 2 hours at ambient temperature. 100 ml water is added and extraction with 50 ml acetic acid ethylester occurs. The united organic phases are dried over sodium sulfate. After purification by chromatography on silica gel, 1.56 g of title compound is obtained.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=3.19 (s, 3H); 3.70 (s, 3H); 3.77 (s, 3H); 4.31 (d, 2H); 4.79 (t, 2H); 6.41 (d, 1H); 6.52 (s, 1H); 6.62 (d, 1H); 6.79 (d, 1H); 7.08-7.19 (m, 2H); 7.49 (t, 1H) ppm.

Intermediate INT74

[6-(1,1-difluoro-2-pyrrolidin-1-yl-ethyl)-pyridin-2-yl]-(2,4-dimethoxy-benzyl)-amine

2.0 g of the compound described under INT73 is dissolved in 40 ml dimethylformamide, mixed with 1.38 g potassium carbonate, 120 mg potassium iodide and 2.1 ml pyrolidine and then stirred for 24 hours at 120° C. 200 ml acetic acid ethylester is added and then washed three times with water (50 ml) and three times with 50 ml semisaturated sodiumchloride solution. The organic phase is dried over sodium sulfate. After purification by chromatography on silica gel, 1.35 g of title compound is obtained.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=1.54 (b, 4H); 2.40 (b, 4H); 3.14 (t, 2H); 3.70 (s, 3H); 3.77 (s, 3H); 4.30 (d, 2H); 6.39 (d, 1H); 6.48-6.57 (m, 2H); 6.68 (d, 1H); 7.00 (t, 1H); 7.10 (d, 1H); 7.42 (t, 1H) ppm.

Intermediate INT75

6-(1,1-difluoro-2-pyrrolidin-1-yl-ethyl)-pyridin-2-ylamine

1.34 g of the compound described under INT74 is dissolved in 70 ml dichlormethane, mixed with 14 ml trifluoroacetic acid and stirred for 1 hour at ambient temperature. 50 ml sodiumhydrogencarbonate solution is added and extracted three times with 50 ml dichloromethane. The united organic phases are dried over sodium sulfate. 520 mg of title compound as raw product is yielded and used without purification.

¹H NMR (DMSO-d6, stored over K₂CO₃):

δ=1.58 (b, 4H); 2.49 (b, 4H); 3.14 (t, 3H); 6.15 (s, 2H); 6.46 (d, 1H); 6.69 (d, 1H); 7.42 (t,1 H) ppm.

Intermediate INT76

4-[2-(3-nitro-phenoxy)-acetyl]-piperazine-1-carboxylic acid tert-butylester

3-nitrophenoxyacetic acid (9,3 g, 50 mmol) is dissolved in dimethylacetamide (200 ml) and dripped in at ambient temperature among argon SOCl₂ (7,4 ml, 102 mmol) within 5 minutes. It is stirred for 30 minutes at ambient temperature and then the boc-piperazine (19.1 g, 102 mmol) is added in portions subject to ice cooling. It was stirred for 50 minutes at ambient temperature among argon and then the reaction mixture was poured onto water (500 ml), neutralized with sodiumcarbonate and extracted with ethyl acetate (3×100 ml). The united organic phases were washed with water (3×100 ml), dried over sodium sulfate and the solvent was distilled off in the vacuum. The title compound is obtained in a quantitative yield as black oil, which slowly completely crystallizes. The raw product was used in the next step without further repurification.

¹H-nMR (CDCl₃,): δ=1.49 (s, 9H); 3.42 (m, 4H); 3.50 (m, 4H); 4.82 (s, 2H); 7.32 (dd, 1H); 7.48 (t, 1H); 7.77 (m, 1H); 0.88 (dd, 1H) ppm.

Intermediate INT77

4-[2-(3-amino-phenoxy)-acetyl]-piperazine-1-carboxylic acid tert-butyl ester

22 g (50 mmol) of the compound described under INT76 is dissolved in methanol (600 ml). Pd/C (4 g) is added among argon and hydrated until the hydrogen incorporation is complete. The catalyst is filtered off and the solvent distilled off in the vacuum. The title compound is obtained in the form of a viscous brown oil in a quantitative yield. The raw product is used in the next step without any further purification.

¹H-nMR (CDCl₃,): δ=1.48 (s, 9H); 3.41 (m, 4H); 3.59 (m, 4H); 4.68 (s, 2H); 6.31 (m, 3H); 7.07 (t, 1H) ppm.

Intermediate INT78

3-(3-nitrophenyl)-propionaldehyde

2.81 g Dess-martin periodinanes are added to a solution of 0.80 g 3-(3-nitrophenyl)-1-propanol (ref. J. Med. Chem., 1989, 32, 2104) in 100 ml dichlormethane. It is stirred for 2 hours at ambient temperature. 50 ml 10% sodiumthiosulfate solution and 50 ml saturated sodiumhydrogen carbonate solution is added, it is stirred for 10 minutes at ambient temperature and the dichloromethane is distilled off on the rotary evaporator. The residue is extracted twice with 100 ml acetic acid ethylester, the united organic phases are washed consecutively with 100 ml water and with 100 ml saturated table salt solution and dried over sodium sulfate. After condensing off the solvent on the rotary evaporator, 780 mg of title compound as raw product is yielded, which is further used without further purification.

¹H-nMR (CDCl₃): δ=2.86 (t, 2H); 3.06 (t, 2H); 7.44-7.49 (m, 1H); 7.55 (d, 1H); 8.08 (m, 2H); 9.83 (s, 1H) ppm.

Intermediate INT79

1-[3-(3-nitro-phenyl)-propyl]-piperidine

1.27 ml piperidine and 0.16 g sodium cyanoborohydride is added to a solution of 0.46 g of the compound produced under INT78 in 10 ml methanol. It is stirred for 3 hours at ambient temperature and 50 ml water and 40 ml acetic acid ethylester is added. The phases are separated and the aqueous phase is extracted twice with 40 ml acetic acid ethylester. The united organic phases are washed with 40 ml saturated table salt solution and dried over sodium sulfate. After purification by chromatography on silica gel, 635 mg of title compound is obtained.

¹H-nMR (CDCl₃): δ=1.41-1.48 (m, 2H); 1.57-1.65 (m, 4H); 1.87 (q, 2H); 2.32-2.44 (m, 6H); 2.75 (t, 2H); 7.43 (t, 1H); 7.52 (d, 1H); 8.06 (m, 2H) ppm.

Intermediate INT80

6-fluoro-pyridin-2-ylamine

13 g 2,6-difluorpyridine and 15 ml of a 25% aqueous ammoniumhydroxide solution is stirred for 24 hours at 125° C. in a [sic: elbow pipe]. The reaction mixture is cooled to 0° C. and stirred for 2 hours at that temperature. The resulting solid substance is filtered off and dried at 40° C. in the vacuum. 5.0 g of title compound is obtained.

Mol. weight/MS (ESI) [M+1]⁺: 112.107/113.

¹H NMR (CDCl₃): δ=4.52, (bs, 2H), 6.24 (dd, 1H); 6.35 (dd, 1H); 7.50 (q, 1H) ppm.

Intermediate INT81

(6-fluoro-pyridin-2-yl)-carbamic acid tert-butyl ester

0.5 g of the compound described under INT80 is dissolved in 10 ml tetrahydrofurane, mixed with 10 mg dimethylaminopyridine, 1.57 ml diisopropylethylamine and 0.97 g di-tert-butyldicarbonate and then stirred for 4 hours at ambient temperature. 100 ml acetic acid ethylester is added and it is washed with water (50 ml). The organic phase is dried over sodium sulfate. After purification by chromatography on silica gel, 100 mg of title compound is obtained.

Mol. weight/MS (ESI) [M+1]⁺: 212.226/213.

¹H NMR (CDCl₃): δ=1.54, (s, 9H), 6.56 (dd, 1H); 7.08 (bs, 1H); 7.74 (m, 2H) ppm.

Intermediate INT82

[6-(2-methoxy-ethylamino)-pyridin-2-yl]-carbamic acid tert-butyl ester

1.0 g of the compound described under INT81 and 5.0 ml 2-methoxy-ethylamine is stirred for 48 hours at 80° C. The reaction mixture is vacuum-condensed. The residue is incorporated with 100 ml acetic acid ethylester, and washed consecutively with 50 ml water and with 50 ml saturated table salt solution and dried over sodium sulfate. After purification by chromatography on silica gel, 500 mg of title compound is obtained.

Mol. weight/MS (ESI) [M+1]⁺: 267.331/268.

¹H NMR (CDCl₃): 1.50, (s, 9H); 3.32 (s, 3H); 3.42 (m, 2H); 3.52 (m, 2H); 4.64 (t, 1H); 6.08 (d, 1H); 6.90 (s, 1H); 7.18 (d, 1H); 7.34 (t, 1H) ppm.

Intermediate INT83

N-(2-methoxy-ethyl)-pyridine-2,6-diamine

0.51 g of the compound described under INT82 is dissolved in 5 ml dichloromethane and mixed with 4.0 ml of 4 molar HCl in dioxane. It is stirred for 48 hours at ambient temperature. The solvent is distilled off in the vacuum, the residue is incorporated with 100 ml acetic acid ethylester and washed consecutively with 50 ml of 1 normal sodiumhydrogen carbonate solution, 50 ml water and 50 ml saturated table salt solution and dried over sodium sulfate. After the solvent is distilled off, 300 mg of title compound is obtained.

Mol. weight/MS (ESI) [M+1]⁺: 167.212/168.

¹H NMR (DMSO-d6, supported via K₂CO3): δ=3.36 (s, 3H); 3.42 (m, 2H); 3.54 (m, 2H); 4.16 (s, 2H); 4.60 (s, 1H); 5.80 (m, 2H); 7.18 (t, 1H) ppm.

Intermediate INT84

3,5,6-trifluoro-pyridin-2-ylamine

5.0 g 2,3,5,6-tetrafluoropyridine, 140 ml tetrahydrofurane and 25 ml of 25% aqueous ammonium hydroxide solution is stirred for 48 hours at 60° C. in an [sic: elbow pipe]. The reaction mixture is mixed with 100 ml water and extracted three times with 150 ml diethylether. After drying over sodium sulfate and distilling off the solvent, 3.5 g of title compound as raw product is yielded, which is used without further purification. Mol. weight/MS (ESI) [M+1]⁺: 148.088/149.

The following compounds are produced according to the method described above.

				Educt/
Inter-			Mol. weight/	syn-
mediate			MS (ESI)	thesis
no.	Structure and name	1H-nMR	[M + 1]+	analogous
INT85		(DMSO-d6, stored over K2CO3): δ =2.11 (s, 3H); 2.29 (m, 4H); 2.40 (m, 4H); 2.60 (m, 2H); 3.90 (m; 2H); 4.92 (s, 2H); 6.03 (dd, 1H); 6.10 (m, 2H); 6.82 (m, 1H) ppm.	235.33/ 236	INT86/ INT77
INT86		(CDCl3): δ =2.31 (s, 3H); 2.50 (m, 4H); 2.62 (m, 4H); 2.83 (m, 2H); 4.19 (m, 2H); 7.21 (m, 1H); 7.41 (t, 1H); 7.78 (m, 1H); 7.82 (dd, 1H) ppm.	265.31/ 266	3-nitro- phenol/ INT16
INT87		(CDCl3): δ =0.90 (m, 4H); 1.30 (m, 2H); 1.62 (m, 2H); 2.08 (m, 2H); 2.75 (m, 2H); 2.96 (m, 2H); 3.62 (m, 2H); 4.05 (m, 2H); 6.30 (m, 2H); 7.04 (t, 1H); 8.01 (s, 1H) ppm.	234.34/ 235	INT88/ INT77
INT88		(CDCl3): δ =0.93 (d, 4H); 1.29 (m, 2H); 1.37 (m, 2H); 1.68 (m, 2H); 2.10 (m, 2H); 2.80 (m, 2H); 2.97 (d, 2H); 4.18 (m, 2H); 7.25 (m, 1H); 7.43 (t, 1H); 7.77 (m, 1H); 7.81 (dd, 1H) ppm.	264.33/ 265	3-nitro- phenol/ INT16
INT89		(CDCl3): δ =1.68 (m, 8H); 2.81 (m, 4H); 2.99 (m, 2H); 3.65 (s, 2H); 4.08 (m, 2H); 6.29 (m, 3H); 7.04 (t, 1H) ppm.	234.34/ 235	INT90/ INT77
INT90		(CDCl3): δ =1.61 (m, 4H); 1.72 (m, 4H); 2.82 (m, 4H); 3.03 (m, 2H); 4.20 (m, 2H); 7.28 (m, 1H); 7.41 (m, 1H); 7.75 (d, 1H); 7.81 (d, 1H) ppm.	264.33/ 265	3-nitro- phenol/ INT16
INT91		(CDCl3): δ =1.74-1.86 (m, 6H); 2.42-2.68 (m, 8H); 3.54-3.70 (m, 2H); 6.49-6.54 (m, 2H); 6.60 (d, 1H); 7.07 (t, 1H); ppm.		INT78/ INT79 +INT77
INT92		(CDCl3): δ =1.80 (q, 2H); 2.47 (t, 2H); 2.42-2.50 (m, 4H); 2.55 (t, 2H); 3.45-3.78 (m, 2H); 3.72 (q, 4H); 6.50-6.54 (m, 2H); 6.60 (d, 1H); 7.07 (t, 1H); ppm.		INT78/ INT79 +INT77
INT93		(CDCl3): 1.42 (m, 2H); 1.55-1.64 (m, 4H); 1.82 (q, 2H); 2.30-2.44 (m, 6H); 2.53 (t, 2H); 3.52-3.68 (m, 2H); 6.48-6.53 (m, 2H); 6.60 (d, 1H); 7.06 (t, 1H); ppm.		INT79/ INT77
INT94		(CDCl3): δ =1.75 (q, 2H); 2.33 (t, 6H); 2.47 (t, 2H); 2.60-2.71 (m, 8H); 3.34-3.68 (m, 2H); 6.43 (m, 2H); 6.51 (d, 1H); 7.00 (t, 1H); ppm.		INT78/ INT79 +INT77
INT95		(DMSO-d6, stored over K2CO3): δ =1.62 (q, 2H); 1.81-1.97 (m, 4H); 2.28 (t, 2H); 2.36-2.45 (m, 6H); 4.78-4.94 (s, 2H); 6.26-6.37 (m, 3H); 6.87 (t, 1H); ppm.		INT78/ INT79 +INT77
INT96			251.29/ 252	INT13/ INT14
INT97			221.30/ 222	INT17
INT98			251.29/ 252	INT13/ INT14
INT99			221.30/ 222	INT17
INT100			251.29/ 252	INT13/ INT14
INT101			221.30/ 222	INT17
INT102			267.29/ 268	INT13/ INT14
INT103			237.30/ 238	INT17
INT104			281.31/ 282	INT13/ INT14
INT105			251.33/ 252	INT17
INT106			299.33/ 300	INT13/ INT14
INT107			269.35/ 267	INT17
INT108			265.31/ 266	INT13/ INT14
INT109			235.33/ 236	INT17
INT110			313.36/ 314	INT13/ INT14
INT111			283.38/ 284	INT17
INT112			248.207/ 249	INT84/ INT81
INT113			303.311/ 304	INT112/ INT82
INT114			203.193/ 305	INT113/ INT83
INT115		(CDCl3): δ =1.50, (s, 9H); 3.30 (m, 4H); 3.66 (m, 4H); 6.28 (d, 1H); 6.86 (s, 1H); 7.20 (d, 1H); 7.48(t, 1H) ppm.	279.342/ 280	INT81/ INT82
INT116		(CDCl3): δ =3.40 (m, 4H); 3.74 (m, 4H); 4.20 (s, 2H); 5.90 (d, 1H); 6.00 (d, 1H); 7.22 (t, 1H) ppm.	179.223/ 180	INT115/ INT83
INT117		(CDCl3): δ =1.56, (s, 9H); 2.58 (s, 3H); 2.50 (m, 4H); 3.50 (m, 4H); 6.26 (d, 1H); 6.90 (s, 1H); 7.16 (d, 1H); 7.48 (t, 1H) ppm.	292.384/ 293	INT81/ INT82
INT118		(CDCl3): δ =2.88 (s, 3H); 3.60 (m, 4H); 3.74 (m, 4H); 5.92 (d, 1H); 6.20 (d, 1H); 7.54 (t, 1H) ppm.	192.266/ 193	INT117/ INT83
INT119		(CDCl3): δ =1.46, (s, 9H); 2.42 (s, 6H); 3.22 (m, 2H); 3.34 (m, 2H); 4.70 (t, 1H); 6.06 (d, 1H); 7.14 (d, 1H); 7.36 (t, 1H) ppm.	280.373/ 281	INT81/ INT82
INT120		(DMSO-d6): δ =2.44 (s, 6H); 2.50 (t, 2H); 3.34 (m, 2H); 5.78 (m, 2H); 7.20 (t, 1H) ppm.	180.255/ 181	INT119/ INT83
INT121		(CDCl3): δ =3.46 (m, 4H); 3.94 (m, 4H); 7.66 (s, 1H); 7.72 (dd, 1H); 8.20 (d, 1H) ppm.	225.206/ 226	—/ INT11
INT122		(CDCl3): δ =3.42 (m, 4H); 3.82 (m, 4H); 5.84 (s, 1H); 6.02 (d, 1H); 7.88 (d, 1H) ppm.	179.223/ 180	INT121/ INT12
INT123		(CDCl3): δ =2.36 (s, 3H); 3.40 (m, 4H); 3.74 (m, 4H); 7.22 (dd, 1H); 7.30 (s, 1H); 8.34 (d, 1H) ppm.	238.248/ 239	—/ INT11
INT124		(CDCl3): δ =2.30 (s, 3H); 2.45 (m, 4H); 3.48 (m, 4H); 5.88 (s, 1H); 5.96 (dd, 1H); 7.84 (d, 1H) ppm.	192.266/ 193	INT123/ INT12
INT125		(CDCl3): δ =3.42 (s, 3H); 3.64 (m, 2H); 3.72 (m, 2H); 7.14 (s, 1H); 7.46 (dd, 1H); 7.58 (dd, 1H); 7.26 (d, 1H) ppm.	213.195/ 214	—/ INT11
INT126		(DMSO-d6): δ =3.40 (s, 3H); 3.46 (m, 2H); 3.64 (m, 2H); 5.54 (s, 1H); 5.60 (s, 2H); 5.80 (dd, 1H); 5.88 (t, 1H); 7.44 (d, 1H) ppm.	167.212/ 168	INT125/ INT12

2. Template Synthesis Intermediate INTT1)

cyano-ethylthiocarbamoyl-acetic acid ethylester

4.25 ml ethylisothiocyanate is added to a mixture of 5 g cyanoacetic acid ethylester and 5 ml triethylamine 25° C. Then it is left to stir for 6 hours at 50° C. After that, the reaction mixture is vacuum-condensed. The residue is incorporated into ethanol and poured onto 150 ml of ice cold 1 normal hydrochloric acid. It is left to stir for 3 hours at 25° C. and then the residue is filtered off. The solid substance yielded is washed with water. 7 g of product is yielded.

Mol mass=200.261; MS (ESI): [M+1]⁺=201. Intermediate INTT2) (E or Z)-cyano-(3-ethyl-4-oxo-thiazolidin-2-yliden)-acetic acid ethylester

7.82 g of the compound described under INTT1) is dissolved in 100 ml tetrahydrofurane. A solution of 3.9 ml bromoacetyl chloride is added and left to stir for 8 hours at 25° C. The reaction mixture is then poured onto saturated aqueous sodium hydrogencarbonate. It is left to stir for 1 hour and then extracted with ethylacetate. The organic phase is washed with saturated sodium chloride solution, dried over sodium sulfate and vacuum-condensed. The raw product yielded is recrystallized from a mixture of ethylacetate/diisopropylester. 7.7 g of product is obtained.

1H-nMR (CDCl3): δ=1.36 (6H); 3.70 (2H); 4.32 (4H) ppm.

Intermediate INTT3)

(E or Z)-cyano-(5-(E/Z)-ethoxymethylen-3-ethyl4-oxo-thiazolidin-2-yliden)-acetic acid ethylester

A mixture of 1.54 g of the substance described under INTT2), 2.5 ml triethylorthoformiate and 3.5 ml acetic acid anhydride is boiled for 8 hours under reflux. The reaction mixture is then poured onto ice water. It is left to stir for 3 hours and then the residue is filtered off. The solid substance yielded is washed with water. 1.28 g of product is obtained.

1H-nMR (CDCl3): δ=1.38 (9H); 4.20-4.40 (6H); 7.72 (1H) ppm.

Intermediate INTT4)

(E or Z)-cyano-(3-ethyl-4-oxo-thiazolidin-2-yliden)-acetic acidallylester

A solution of 37.6 ml cyanoacetic acid allylester in 60 ml dimethylformamide is added to a suspension of 12.8 g sodium hydride (60%) at 0° C. It is stirred for 10 minutes at 0° C. and then a solution of 28.0 ml ethylisothiocyanate in 60 ml dimethylformamide is added. It is then stirred for 2 hours at 25° C. A solution of 32 ml bromoacetylchloride in 60 ml dimethylformamide is then added at 0° C. and stirred for 15 hours at 25° C. The reaction mixture is then poured onto saturated sodiumhydrogencarbonate solution. Acetic acid ethylester is used to extract, the organic phase is washed with saturated sodiumchloride solution, dried over sodium sulfate and vacuum-condensed. The raw product is purified by column chromatography on silica gel with a mixture made from hexane/ethylacetate. 33.9 g of product is yielded.

1H-nMR (CDCl3): δ=1.23 (3H); 4.11 (2H); 4.71 (2H); 5.25 (1 H); 5.37 (1H); 5.90-6.04 (1H) ppm.

Intermediate INTT5)

(E or Z)-cyano-(5-(E/Z)-ethoxymethylen-3-ethyl-4-oxo-thiazolidin-2-yliden)-acetic acidallylester

Analogous to intermediate INTT3), 14.8 g of product is yielded from 12.8 g of the compound described under INTT4), 20.9 ml triethylorthoformiate and 29,4 ml acetic acidanhydride.

1H-nMR (CDCl3): δ=1.32-1.45 (6H); 4.23 (2H); 4.38 (2H); 4.73 (2H); 5.29 (1H); 5.41 (1H), 5.92-6.05 (1H); 7.72 (1H) ppm.

Intermediate INTT6)

cyano-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid

5.04 g of the compound described under INTT4) is dissolved in 300 ml tetrahydrofurane. 3,42 g of 1,3-dimethylbarbituric acid and 1.17 g Tetrakis-(triphenylphosphin)-palladium is added. It is stirred for 30 minutes at ambient temperature and the reaction mixture is condensed on the rotary evaporator until dry. The raw product yielded is used without any further purification.

1H-nMR (DMSO-d6, selected signals) δ=1.21 (t, 3H); 3.89 (s, 2H); 4.10 (q, 2H); 13.24 (s, b, 1H) ppm.

Intermediate INTT7)

2-cyano-n-ethyl-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide

Approx. 4.15 g of the compound described under INTT6) (raw product that was yielded from 2.5 g of the compound described under INTT4) is dissolved in 100 ml dimethylformamide. 3.34 g sodiumhydrogencarbonate, 6.0 ml of a solution of ethylamine in tetrahydrofurane (c=2.0 M) and 3.88 g TBTU is added. It is stirred for 3 hours at ambient temperature. The reaction mixture is mixed with water and extracted with acetic acid ethylester. The organic solution is washed with saturated sodium lo chloride solution, dried over sodium sulfate and condensed. After purification by means of recrystillation from ethanol, 1.47 g of title compound is obtained.

1H-nMR (DMSO-d6): δ=1.05 (t, 3H); 1.21 (t, 3H); 3.18 (pentuplet, 2H); 3.70 (s, 2H); 4.10 (q, 2H); 7.81 (t, 1H) ppm.

The following compounds are produced according to the method described above.

				Educt/
				syn-
Example			Mol.	thesis
no.	Structure and name	1H-nMR	weight	analogous
INTT8		(DMSO-d6, stored over K2CO3): δ =1.22 (t, 3H); 3.84 (s, 2H); 3.95 (m, 2H); 4.11 (q, 2H); 8.33 (t, 1H) ppm.	293.27	INTT6/ INTT7
INTT9		(DMSO-d6, stored over K2CO3): δ =1.21 (t, 3H); 3.07 (m, 1H); 3.83 (s, 2H); 3.90 (m, 2H); 4.10 (q, 2H); 8.22 (t, 1H) ppm.	249.29	INTT6/ INTT7
INTT10		(DMSO-d6, stored over K2CO3): δ =1.21 (t, 3H); 3.88 (s, 2H); 4.10 (q, 2H); 4.17 (d, 2H); 8.47 (t, 1H) ppm.	250.28	INTT6/ INTT7
INTT11		(DMSO-d6, stored over K2CO3): δ =1.17 (t, 3H); 3.03 (m, 2H); 3.78 (s, 2H); 4.07 (q, 2H); 6.02 (m, 1H); 8.01 (m, 1H) ppm.	275.27/ 276	INTT6/ INTT7
INTT12		(CDCl3): δ =1.32 (t, 3H); 1.36 (s, 6H); 3.60 (s, 2H); 3.68 (m, 2H); 4.24 (q, 2H); 6.30 (s, 1H) ppm.	283.35/ 284	INTT6/ INTT7
INTT13		(CDCl3): δ =1.32 (t, 3H); 3.62 (s, 2H); 3.64 (m, 2H); 4.35 (q, 2H); 4.50 (m, 2H); 6.63 (s, 1H) ppm.	257.28/ 258	INTT6/ INTT7

3. Synthesis of Ethylester- and Allylether Intermediates Intermediate INTE1

Cyano-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester

740 mg of the compound described under INT3) is dissolved in 50 ml Ethanol. 1.1 g of the compound described under INTT3) is added stirred for 5 hours under reflux. The solvent is condensed off on the rotary evaporator. After purification by chromatography on silica gel, 540 mg of title compound as pH-dependent 5-(E/Z)-isomer mixture is obtained.

1 H-nMR (CDCl3, main isomer): δ=1.38 (t, 3H); 1.42 (t, 3H); 1.83 (m, 4H); 2.60 (m, 4H) 2.72 (m, 2H); 2.86 (m, 2H); 4.31 (q, 2H); 4.43 (q, 2H); 6.87-6.97 (m, 2H); 7.00 (d, 1H); 7.29 (t, 1H); 7.62 (d, 1H); 10.56 (d, 1H) ppm.

Intermediate INTE2

Cyano-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester

1.35 g of the compound described under INT3) is dissolved in 400 ml ethanol. 2.19 g of the compound described under INTT5) is added and stirred for 4 hours under reflux. The solvent is condensed off on the rotary evaporator. After purification by chromatography on silica gel, 2.2 g of title compound as pH-dependent 5-(E/Z)-isomer mixture is obtained.

1H-nMR (DMSO-d6, stored over K₂CO₃, main isomer): δ=1.24 (t, 3H); 1.69 (m, 4H); 2.50 (m, 4H); 2.66 (m, 2H); 2.76 (m, 2H); 4.25 (q, 2H); 4.71 (d, 2H); 5.26 (d, 1H); 5.38 (d, 1H); 5.90-6.08 (m, 1H); 6.96 (d, 1H); 7.12 (d, 1H); 7.22 (s, 1H); 7.26 (t, 1H); 8.22 (s, 1H); 10.53 (s, b, 1H) ppm.

Intermediate INTE3

Cyano-[3-ethyl-5-[1-[3-(2-hydroxy-2-methyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester

1.26 g of the compound described under INT6) is dissolved in 400 ml ethanol. 2.0 g of the compound described under INTT5) is added and stirred for 6 hours under reflux. After cooling, the reaction mixture is filtered and the solid substance yielded is recrystallized from ethanol. 1.4 g of title compound as pH-dependent 5-(E/Z)-isomer mixture is obtained. The solution obtained at filtration is condensed on the rotary evaporator. After purification by chromatography on silica gel, the residue yields another 1.1 g of title compound as pH-dependent 5-(E/Z)-isomer mixture.

1H-nMR (DMSO-d6, stored over K2CO3, main isomer): δ=1.28 (t, 3H); 1.38 (s, 6H); 4.26 (q, 2H); 4.72 (d, 2H); 5.27 (d, 1H); 5.39 (d, 1H); 5.76 (s, 1H); 5.90-6.08 (m, 1H); 6.99 (d, 1H); 7.27 (t, 1H); 7.46 (d, 1H); 7.89 (s, 1H); 8.16 (s, 1H); 9.67 (s, 1H); 10.63 (s, 1H) ppm.

Intermediate INTE4

Cyano-[3-ethyl-5-[1-(2-ethylamino-pyridin-4-ylamino)-meth-(E/Z)-ylidene]4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester

0.94 g of the compound described under INT12) is dissolved in 50 ml 1-propanol. 1.85 g of the compound described under INTT5) is added and it is stirred for 4 hours under reflux. After cooling, the reaction mixture is filtered. After purification by chromatography on silica gel, the solid substance yields 1.48 g of title compound as pH-dependent 5-(E/Z)-isomer mixture.

1 H-nMR (DMSO-d6, stored over K₂CO₃, main isomer): δ=1.13 (t, 3H); 1.26 (t, 3H); 3.24 (pentuplet, 2H); 4.25 (q, 2H); 4.72 (d, 1H); 5.28 (d, 1H); 5.39 (d, 1H); 5.90-6.07 (m, 1H); 6.25 (d, 1H); 6.44 (dd, 1H); 6.49 (t, 1H); 7.85 (d, 1H); 8.13 (s, 1H); 10.47 (s, 1H) ppm.

Intermediate INTE5

Cyano-[5-[1-[6-(2,2-dimethyl-propionylamino)-pyridin-2-ylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester

1.35 g of the compound described under INT9) is dissolved in 50 ml 1-propanol. 2.0 g of the compound described under INTT5) is added and it is stirred for 3 hours under reflux. After cooling, the reaction mixture is filtered and the solid substance yielded is recrystallized from ethanol. 2.47 g of title compound is yielded as pH-dependent 5-(E/Z)-isomer mixture. 1H-nMR (DMSO-d6, stored over K₂CO₃, main isomer): δ=1.20-1.31 (m, 12H); 4.27 (q, 2H); 4.72 (d, 2H); 5.28 (d, 2H); 5.39 (d, 2H); 5.91-6.06 (m, 1H); 6.29 (d, 2H); 7.68-7.80 (m, 2H); 8.86 (s, 1H); 9.71 (s, 1H); 10.94 (s, 1H) ppm.

The following compounds are produced according to the method described above.

Example
no.	Structure and name
INTE6
INTE7
INTE8
INTE9
INTE10
INTE11
INTE12
INTE13
INTE14
INTE15
INTE16
INTE17
INTE18
INTE19
INTE20
INTE21
INTE22
INTE23
INTE24
INTE25
INTE26
INTE27
INTE28
INTE29
INTE30
INTE31
INTE32
INTE33
INTE34
INTE35
INTE36
INTE37
INTE38
INTE39
INTE40
INTE41
INTE42
INTE43
INTE44
INTE45
INTE46
INTE47
INTE48
INTE49
INTE50
INTE51
INTE52
INTE53
INTE54
INTE55
INTE56
INTE57
INTE58
INTE59
INTE60
INTE61
INTE62
INTE63
INTE64
INTE65
INTE66
INTE67
INTE68
INTE69
INTE70
INTE71
INTE72
INTE73
INTE74
INTE75
INTE76
			Mol.	Educt/
			weight/	syn-
	Example		MS (ESI)	thesis
	no.	1H-nMR	[M + 1]+	analogous
	INTE6	(DMSO-d6, stored	454.55/	INTT5/
		over K2CO3, main	455	INTE2
		isomer):
		δ =
		1.19-1.32 (m, 12H);
		4.27 (q, 2H);
		4.72 (d, 2H);
		5.27 (m, 1H);
		5.39 (m, 1H);
		5.91-6.07 (m, 1H),
		6.99 (d, 1H);
		7.28 (t, 1H);
		7.39 (d, 1H);
		7.78 (s, 1H);
		8.13 (d, 1H);
		9.28 (s, 1H);
		10.67 (d, 1H) ppm.
	INTE7	(DMSO-d6, stored	486.55/	INTT5/
		over K2CO3, main	487	INTE2
		isomer):
		δ =
		1.25 (t, 3H);
		3.30 (s, 3H);
		3.55 (m, 2H);
		3.68 (m, 2H);
		4.10 (s, 2H);
		4.26 (q, 2H);
		4.72 (d, 2H);
		5.77 (d, 1H);
		5.89 (d, 1H);
		5.90-6.07 (m, 1H);
		7.03 (m, 1H);
		7.24-7.36 (m, 2H);
		7.78 (s, 1H);
		8.15 (s, 1H);
		9.72 (s, 1H);
		10.69 (s, 1H) ppm.
	INTE8	(DMSO-d6, stored	443.53/	INTT3/
		over K2CO3, main	444	INTE1
		isomer):
		δ =
		1.18-1.32 (m, 15H);
		4.16-4.31 (m, 4H);
		6.80 (d, 1H);
		7.68-7.79 (m, 2H);
		8.86 (s, 1H);
		9.70 (s, 1H);
		10.92 (s, 1H) ppm.
	INTE9	(DMSO-d6, stored	487.53/	INTT5/
		over K2CO3, main	488	INTE2
		isomer):
		δ =
		1.26 (t, 3H);
		3.33 (s, 3H);
		3.52 (m, 2H);
		3.70 (m, 2H);
		4.26 (q, 2H);
		4.71 (d, 1H);
		5.27 (d, 1H);
		5.39 (d, 1H);
		5.92-6.07 (m, 1H);
		6.80 (d, 1H);
		7.70-7.83 (m, 2H);
		8.80 (s, 1H);
		9.97 (s, 1H);
		11.01 (s, 1H) ppm.
	INTE10	(DMSO-d6, stored	475.52/	INTT3/
		ver K2CO3, main	476	INTE1
		isomer):
		δ =
		1.20-1.32 (m, 6H);
		3.32 (s, 3H);
		3.53 (m, 2H);
		3.70 (m, 2H);
		4.25 (s, 2H);
		4.20-4.31 (m, 4H);
		6.82 (d, 1H);
		7.71-8.84 (m, 2H);
		8.74 (s, 1H);
		10.00 (s, 1H);
		10.98 (s, 1H) ppm.
	INTE11	(DMSO-d6, stored	387.46/	INTT3/
		over K2CO3, main	388	INTE1
		isomer):
		δ =
		1.12 (t, 3H);
		1.19-1,32 (m, 6H);
		3.23 (m, 2H);
		4.15-4.31 (m, 4H);
		6.25 (d, 1H);
		6.44 (dd, 1H);
		6.49 (t, 1H);
		7.35 (d, 1H);
		8.11 (s, 1H);
		10.46 (s, 1H) ppm.
	INTE12	(DMSO-d6, stored	385.44/	INTT5/
		over K2CO3, main	386	INTE2
		isomer):
		δ =
		1.15 (t, 3H);
		4.26 (q, 2H);
		4.51 (d, 2H);
		4.72 (d, 2H);
		5.21-5.32 (m, 2H);
		5.39 (d, 1H);
		5.90-6.08 (m, 1H),
		7.04 (d, 1H);
		7.18 (d, 1H);
		7.25-7.38 (m, 2H);
		8.21 (s, 1H);
		10.60 (s, 1H) ppm.
	INTE13	(DMSO-d6, stored	378.84/	INTT3/
		over K2CO3, main	379	INTE1
		isomer):
		δ =
		1.19-1.32 (m, 6H);
		4.19-4.31 (m, 4H);
		7.30 (d, 1H);
		7.44 (s, 1H);
		8.21 (d, 1H);
		8.32 (d, 1H);
		10.67 (s, 1H) ppm.
	INTE14	(DMSO-d6, stored	359.41/	INTT3/
		over K2CO3, main	360	INTE1
		isomer):
		δ =
		1.18-1.31 (m, 6H);
		4.15-4.31 (m, 4H);
		6.09-6.25 (m, 4H);
		7.33 (t, 1H);
		8.77 (s, 1H);
		10.73 (s, 1H) ppm.
	INTE15	(DMSO-d6, stored	547.65/	INTT3/
		over K2CO3, main	548	INTE1
		isomer):
		δ =
		1.33 (m, 6H);
		2.48 (m, 2H);
		2.86 (m, 2H);
		2.93 (m, 4H);
		3.08 (m, 4H);
		4.13-4.30 (m, 4H);
		7.00 (d, 1H);
		7.19 (d, 1H);
		7.28 (t, 1H);
		7.73 (5, 1H);
		8.10 (s, 1H);
		10.40 (s, 1H);
		10.64 (s, 1H) ppm.
	INTE16	(DMSO-d6, stored	399.47/	INTT5/
		over K2CO3, main	400	INTE2
		isomer):
		δ =
		1.25 (t, 3H);
		2.72 (t, 2H);
		3.61 (q, 2H);
		4.24 (q, 2H);
		4.65 (t, 1H);
		4.70 (d, 2H);
		5.27 (d, 1H);
		5.39 (d, 1H);
		5.91-6.08 (m, 1H);
		6.94 (d, 1H);
		7.11 (d, 1H);
		7.18 (s, 1H);
		7.24 (t, 1H);
		8.23 (s, 1H);
		10.55 (s, 1H) ppm.
	INTE17	(DMSO-d6, stored	470.55/	INTT5/
		over K2CO3, main	471	INTE2
		isomer):
		δ =
		1.07 (t, 3H);
		1.26 (t, 3H);
		4.25 (q, 2H);
		4.71 (d, 2H);
		5.28 (d, 1H);
		5.39 (d, 1H);
		5.91-6.08 (m, 1H);
		6.92 (d, 1H);
		7.09 (d, 1H);
		7.21 (t, 1H);
		7.60 (s, 1H);
		8.11 (s, 1H);
		9.48 (s, 1H);
		10.67 (s, 1H) ppm.
	INTE18	1H-nMR (CDCl3,	MW:	INTT5/
		300 MHz) (selected	438.55	INTE2
		peaks) δ = 1.38 (m,	MS
		3H); 1.75 (m, 4H);	(ESI)
		2.48 (m, 4H); 3.59	[M + 1]+:
		(s, 2H); 4.41 (m,	439
		2H); 4.72 (m, 2H);
		5.23 (dd, 1H); 5.39
		(dd, 1H); 5.97 (m,
		1H); 6.97 (dd, 1H);
		7.11 (m, 2H); 7.30
		(m, 1H); 7.68 (s,
		1H); 10.52 (s, 1H).
	INTE19	1H-nMR (CDCl3,	MW:	INTT3/
		300 MHz) (selected	426.54	INTE1
		peaks) δ = 1.38 (m,	MS
		6H); 1.80 (m, 4H);	(ESI)
		2.51 (m, 4H); 3.62	[M + 1]+:
		3H); 4.46 (m, 2H);	427
		6.98 (dd, 1H); 7.10
		(m, 2H); 7.30 (m,
		1H); 7.68 (d, 1H);
		10.58 (d, 1H).
	INTE20	1H-nMR (DMSO-d6,	MW:	INTT5/
		300 MHz) (selected	442.54	INTE2
		peaks)	MS
		δ = 1.29 (m,	(ESI)
		3H); 2.22 (5, 6H);	[M + 1]+:
		2.63 (m, 2H); 4.08	443
		(m, 2H); 4.27 (m,
		2H); 4.71 (d, 2H);
		5.28 (dd, 1H); 5.39
		(dd, 1H); 6.00 (m,
		1H); 6.67 (dd, 1H);
		6.91 (m, 1H); 7.24
		(m, 1H); 8.22 (s,
		1H); 10.48 (s, 1H).
	INTE21	1H-nMR (CDCl3,	MW:	INTT5/
		300 MHz) (selected	484.57
		peaks) δ =	MS
		1.21 (m, 3H); 2.67	(ESI)
		(m, 2H); 3.58 (m,	[M + 1]+:
		4H); 4.09 (m, 2H);	485
		4.21 (m, 2H); 4.70
		(d, 2H); 5.28 (dd,
		1H); 5.40 (dd, 1H);
		6.00 (m, 1H); 6.65
		(dd, 1H); 6.86 (m,
		2H); 7.21 (m, 1H);
		8.16 (s, 1H); 10.39
		(s, 1H).
	INTE22	1H-nMR (CDCl3,	MW:	INTT3/
		300 MHz) (selected	472.56	INTE1
		peaks) δ = 1.36	MS
		(m, 6H); 2.59 (m,	(ESI)
		4H); 2.81 (m, 2H);	[M + 1]+:
		3.73 (m, 4H); 4.11	473
		(m, 2H); 4.30 (m,
		2H); 4.42 (m, 2H);
		6.65 (m, 3H); 7.23
		(m, 1H); 7.58 (d,
		1H); 10.50 (d, 1H).
	INTE23	1H-nMR (DMSO-	MW:	INTT5/
		d6, 300 MHz)	498.56	INTE2
		(selected peaks) δ =	MS
		1.29 (m, 3H);	(ESI)
		3.36 (s, 2H); 3.62	[M + 1]+:
		(m, 4H); 4.28 (m,	499
		2H); 4.71 (d, 2H);
		4.87 (m, 2H); 5.29
		(dd, 1H); 5.40 (dd,
		1H); 6.01 (m, 1H);
		6.68 (dd, 1H); 6.92
		(m, 2H); 7.28 (m,
		1H); 8.20 (d, 1H);
		10.49 (d, 1H).
	INTE24	1H-NMR (DMSO-	MW:	INTT5/
		d6, 300 MHz)	468.58	INTE2
		(selected peaks) δ =	MS
		1.23 (m, 3H);	(ESI)
		1.69 (m, 4H); 2.80	[M + 1]+:
		(m, 2H); 4.08 (m,	469
		2H); 4.26 (m, 2H);
		4.71 (d, 2H); 5.28
		(dd, 1H); 5.40 (dd,
		1H); 6.00 (m, 1H);
		6.68 (dd, 1H); 6.90
		(m, 2H); 7.27 (m,
		1H); 8.27 (s, 1H);
		10.48 (s, 1H).
	INTE25	1H-NMR (DMSO-	MW:	INTT5/
		d6, 300 MHz)	482.60	INTE2
		(selected peaks) δ =	MS
		1.25 (m, 3H);	(ESI)
		1.39 (m, 2H); 1.49	[M + 1]+:
		2H); 4.10 (m, 2H);	483
		4.25 (m, 2H); 4.72
		(d, 2H); 5.28 (dd,
		1H); 5.39 (dd, 1H);
		5.98 (m, 1H); 6.65
		(dd, 1H); 6.90 (m,
		2H); 7.25 (m, 1H);
		8.27 (s, 1H); 10.43
		(s, 1H).
	INTE26	1H-NMR (CDCl3,	MW:	INTT5/
		300 MHz) (selected	498.61	INTE2
		peaks) δ = 1.40 (m,	MS
		3H); 2.19 (s, 3H);	(ESI)
		2.68 (m, 4H); 2.89	[M + 1]+:
		4H); 4.13 (m, 2H);	499
		4.42 (m, 2H); 4.73
		(m, 2H); 5.28 (dd,
		1H); 5.41 (dd, 1H);
		5.99 (m, 1H); 6.55
		(m, 2H); 7.11 (m,
		2H); 8.10 (d, 1H).
	INTE27	(DMSO-d6, stored	428.51/	INTT3/
		via K2CO3, primary	429	INTE1
		isomer):
		δ =
		1.10 (d, 6H);
		1.21-1.28 (m, 6H);
		2.58 (m, 1H);
		4.19-4.25 (m, 4H);
		6.93 (d, 1H);
		7.17-7.25 (m, 2H);
		7.72 (s, 1H);
		8.06 (1H);
		9.87 (s, 1H);
		10.58 (1H) ppm.
	INTE28	(DMSO-d6, stored	440.53/	INTT5/
		via K2CO3, primary	441	INTE2
		isomer):
		δ =
		1.10 (d, 6H);
		1.24 (t, 3H);
		2.58 (m, 1H);
		4.23 (q, 2H),
		4.27 (d, 2H);
		5.23-5.26 (m, 1H);
		5.34-5.39 (m, 1H);
		5.92-6.01 (m, 1H),
		6.95 (d, 1H);
		7.19-7.26 (m, 2H);
		7.74 (s, 1H);
		8.09 (1H);
		9.88 (s, 1H);
		10.62 (1H) ppm.
	INTE29	(DMSO-d6, stored	414.49/	INTT3
		via K2CO3, primary	415	INTE1
		isomer):
		δ =
		1.21-1.27 (2t, 6H);
		1.80 (3H);
		3.15 (3H);
		4.19-4.25 (m, 4H);
		7.01 (d, 1H);
		7.24-7.26 (m, 1H);
		7.35-7.39 (m, 2H);
		8.25 (d, 1H);
		10.51 (1H) ppm.
	INTE30	(DMSO-d6, stored	426.50/	INTT5/
		via K2CO3, primary	427	INTE2
		isomer):
		δ =
		1.24 (t, 3H);
		1.80 (3H);
		3.15 (3H);
		4.24 (q, 2H);
		4.69-4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.34-5.39 (m, 1H);
		5.92-6.02 (m, 1H);
		7.02 (d, 1H);
		7.25-7.27 (m, 1H);
		7.36-7.40 (m, 2H);
		8.27 (1H);
		10.51 (1H) ppm.
	INTE31	(DMSO-d6, stored	443.53/	INTT3/
		via K2CO3, primary	444	INTE1
		isomer):
		δ =
		1.24 (t, 3H);
		1.26 (t, 3H);
		2.28 (s, 6H);
		3.07 (s, 2H);
		4.18-4.25 (m, 4H);
		6.94-6.97 (m, 1H);
		7.23 (t, 1H);
		7.29-7.32 (m, 1H);
		7.77 (1H);
		8.09 (s, 1H);
		9.76 (s, 1H);
		10.58 (1H) ppm.
	INTE32	(DMSO-d6, stored	455.54/	INTT5/
		via K2CO3, primary	456	INTE2
		isomer):
		δ =
		1.24 (t, 3H);
		2.28 (s, 6H);
		3.08 (s, 2H);
		4.24 (q, 2H);
		4.69-4.71 (m, 2H);
		5.23-5.27 (2q, 2H);
		5.92-6.02 (m, 1H);
		6.96-6.99 (m, 1H);
		7.24 (t, 1H);
		7.30-7.33 (m, 1H),
		7.79 (1H);
		8.12 (s, 1H);
		9.78 (s, 1H);
		10.62 (1H) ppm.
	INTE33	(DMSO-d6, stored	456.57/	INTT3/
		via K2CO3, primary	457	INTE1
		isomer):
		δ =
		1.00 (s, 9H);
		1.24 (t, 3H);
		1.26 (t, 3H);
		3.10 (s, 3H);
		4.19-4.26 (m, 4H);
		6.99-7.01 (m, 1H);
		7.28-7.39 (m, 3H);
		8.23 (s, 1H);
		10.49 (s, 1H) ppm.
	INTE34	(DMSO-d6, stored	468.58/	INTT5/
		via K2CO3, primary	467	INTE2
		isomer):
		δ =
		1.00 (s, 9H);
		1.25 (t, 3H);
		3.10 (s, 3H);
		4.23 (q, 2H);
		4.68-4.70 (m, 2H);
		5.22-5.26 (m, 1H);
		5.33-5.39 (m, 1H);
		5.91-6.00 (m, 1H);
		6.98-7.00 (m, 1H);
		7.28-7.38 (m, 3H);
		8.23 (1H);
		10.49 (1H) ppm.
	INTE35	(DMSO-d6, stored	442.54/	INTT3/
		via K2CO3, primary	443	INTE1
		isomer):
		δ =
		0.93 (d, 6H);
		1.22-1.28 (m, 6H);
		2.47 (m, 1H);
		3.14 (s, 3H);
		4.20-4.26 (m, 4H);
		7.00-7.02 (m, 1H);
		7.29-7.42 (m, 3H);
		8.25 (s, 1H);
		10.51 (s, 1H) ppm.
	INTE36	(DMSO-d6, stored	454.55/	INTT5/
		via K2CO3, primary	455	INTE2
		isomer):
		δ =
		0.93 (d, 6H);
		1.25 (t, 3H);
		2.47 (m, 1H);
		3.14 (s, 3H);
		4.25 (q, 2H);
		4.71 (d, 2H);
		5.24-5.27 (m, 1H);
		5.35-5.40 (m, 1H);
		5.93-6.02 (m, 1H);
		7.02 (d, 1H);
		7.29-7.43 (m, 3H);
		8.27 (s, 1H);
		10.54 (s, 1H) ppm.
	INTE37	(DMSO-d6, stored	402.48/	INTT3/
		via K2CO3, primary	403	INTE1
		isomer):
		δ =
		1.21-1.28 (m, 6H);
		3.09 (q, 2H);
		3.54 (q, 2H);
		4.19-4.26 (m, 4H);
		4.70 (t, 1H);
		5.75 (t, 1H);
		6.32-6.35 (m, 1H);
		6.43-6.49 (m, 2H);
		7.02 (t, 1H);
		8.10 (1H);
		10.39 (H) ppm.
	INTE38	(DMSO-d6, stored	416.50/	INTT3/
		via K2CO3, primary	417	INTE2
		isomer):
		δ =
		1.21-1.28 (m, 6H);
		3.19 (q, 2H);
		3.28 (s, 3H);
		3.48 (t, 2H);
		4.19-4.26 (m, 4H);
		5.80 (t, 1H);
		6.33-6.36 (dd, 1H);
		6.44-6.49 (dd, 1H);
		6.51 (m, 1H);
		7.02 (t, 1H);
		8.09-8.11 (m, 1H);
		10.39 (1H) ppm.
	INTE39	(DMSO-d6, stored	428.51/	INTT5/
		via K2CO3, primary	429	INTE2
		isomer):
		δ =
		1.24 (t, 3H);
		3.19 (q, 2H);
		3.28 (s, 3H);
		3.47 (t, 2H);
		4.23 (q, 2H);
		4.68-4.70 (m, 2H);
		5.23-5.26 (m, 1H);
		5.34-5.39 (m, 1H);
		5.80 (t, 1H);
		5.92-6.01 (m, 1H);
		6.32-6.35 (dd, 1H);
		6.43-6.45 (dd, 1H);
		6.49-6.51 (m, 1H);
		7.01 (t, 1H);
		8.10 (1H);
		10.39 (1H) ppm.
	INTE40	(DMSO-d6, stored	457.56/	INTT3/
		via K2CO3, primary	458	INTE1
		isomer):
		δ =
		1.04 (t, 3H);
		1.22-1.28 (m, 6H);
		2.28 (s, 3H);
		3.12 (s, 3H);
		4.20-4.26 (m, 4H);
		6.97-6.99 (m, 1H);
		7.24-7.34 (m, 2H);
		7.78 (s, 1H);
		8.13 (s, 1H);
		8.73 (s, 1H);
		10.61 (s, 1H) ppm.
	INTE41	(DMSO-d6, stored	469.57/	INTT5/
		via K2CO3, primary	470	INTE2
		isomer):
		δ =
		1.04 (t, 3H);
		1.24 (t, 3H);
		2.28 (s, 3H);
		3.12 (s, 3H);
		4.24 (q, 2H);
		4.69-4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.35-5.40 (m, 1H);
		5.92-6.02 (m, 1H);
		6.97-6.99 (m, 1H);
		7.23-7.33 (m, 2H);
		7.78 (1H);
		8.13 (1H);
		9.73	(s, 1H);
		10.62 (s, 1H) ppm.
	INTE42	(DMSO-d6, stored		INTT4 +
		via K2CO3, primary		INT54/5
		isomer):
		δ =
		1.20 (t, 3H);
		2.22-2.44 (m, 6H);
		4.21 (q, 2H);
		4.58-4.74 (m, 3H);
		4.92 (s, b, 1H),
		5.22 (d, 1H);
		5.33 (d, 1H);
		5.84-6.04 (m, 1H);
		6.91-7.11 (m, 2H);
		7.13-7.33 (m, 2H);
		8.20 (s, 1H);
		10.56 (s, b, 1H)
		ppm
	INTE43	(DMSO-d6, stored		INTT5 +
		via K2CO3, primary		INT57/
		isomer):		INTE2
		δ =
		0.72-1.28 (m, 10H);
		1.40-1.69 (m, 6H);
		1.90 (t, 1H);
		2.37-2.50 (m, 2H);
		2.62-2.72 (m, 2H);
		2.76 (d, 2H);
		2.90 (d, 2H);
		4.21 (q, 2H);
		4.67 (d, 2H);
		5.22 (d, 1H);
		5.34 (d, 1H);
		5.88-6.01 (m, 1H);
		6.91 (d, 1H);
		7.08 (d, 1H);
		7.15-7.26 (m, 2H);
		8.19 (s, 1H);
		10.49 (s, b, 1H)
		ppm
	INTE44	(DMSO-d6, stored		INTT5 +
		via K2CO3, primary		INT27/
		isomer):		INTE2
		δ =
		1.20 (t, 3H);
		2.09 (s, 3H);
		4.21 (q, 2H);
		4.56-4.73 (m, 4H);
		5.16-5.44 (dd, 1H);
		5.83-6.06 (m, 1H);
		6.98 (d, 1H),
		7.16 (d, 1H);
		7.25 (t, 1H);
		7.64 (s, 1H);
		8.09 (s, 1H);
		10.11 (s, 1H);
		10.63 (s, 1H)
		ppm
	INTE45	(DMSO-d6, stored		INTT5 +
		via K2CO3, primary		INT24/
		isomer):		INTE2
		δ =
		1.21 (t, 3H);
		2.41-2.58 (m, 4H);
		3.10 (s, 2H);
		3.55-3.68 (m, 4H);
		4.22 (q, 2H);
		4.68 (d, 2H);
		5.22 (dd, 1H);
		5.35 (dd, 1H);
		5.88-6.05 (m, 1H);
		6.91-7.02 (m, 1H);
		7.20-7.34 (m, 2H);
		7.71 (s, 1H);
		8.12 (s, 1H);
		9.78 (s, 1H);
		10.61 (s, b, 1H)
		ppm
	INTE46	(DMSO-d6, stored		INTT5 +
		via K2CO3, primary		INT64/
		isomer):		INTE2
		δ =
		1.20 (t, 3H);
		3.25 (s, 3H);
		3.42-3.65 (m, 4H);
		4.20 (q, 2H);
		4.69 (d, 2H);
		5.22 (d, 1H);
		5.34 (d, 1H);
		5.87-6.03 (m, 1H);
		7.29 (t, 1H);
		8.13 (s, 1H);
		8.57 (s, 1H);
		11.18 (s, 1H)
		ppm
	INTE47	(DMSO-d6, stored		INTT5 +
		via K2CO3, primary		INT67/
		isomer):		INTE4
		δ =
		0.84 (d, 3H);
		0.90 (d, 3H);
		1.20 (t, 3H);
		1.89-2.01 (m, 1H);
		3.49-3.63 (m, 2H);
		4.01 (m, 1H);
		4.20 (q, 2H);
		4.68 (d, 2H);
		4.72 (t, 1H);
		5.22 (d, 1H);
		5.34 (d, 1H);
		5.88-6.01 (m, 1H);
		6.40 (s, b, 1H);
		8.11 (s, 1H);
		8.69 (s, b, 1H);
		11.13 (s, 1H)
		ppm
	INTE48	(DMSO-d6, stored		INTT5 +
		via K2CO3, primary		INT65/
		isomer):		INTE4
		δ =
		1.20 (t, 3H);
		3.26 (s, 3H);
		3.48 (b, 4H);
		4.20 (q, 2H);
		4.69 (d, 2H);
		5.22 (d, 1H);
		5.33 (d, 1H);
		5.87-6.03 (m, 1H);
		6.19 (d, 1H);
		7.70 (s, b, 1H);
		7.81 (s, b, 1H);
		8.69 (s, 1H);
		11.08 (s, b, 1H)
		ppm
	INTE49	(DMSO-d6, stored		INTT5 +
		via K2CO3, primary		INT75/
		isomer):		INTE4
		δ =
		1.22 (t, 3H);
		1.57 (b, 4H);
		2.50 (b, 4H);
		3.18-3.36 (m, 2H);
		4.21 (q, 2H);
		4.69 (d, 2H),
		5.23 (m, 1H);
		5.35 (m, 1H);
		5.84-6.06 (m, 1H);
		7.16 (d, 1H);
		7.32 (d, 1H);
		7.87 (t, 1H);
		8.67 (s, 1H);
		ppm
	INTE50	(DMSO-d6, stored	525.63/	INTE76/
		via K2CO3, primary	526	INTE77
		isomer):
		δ =
		0.99 (t, 3H);
		1.20 (t, 3H);
		2.32 (m, 6H);
		3.41 (m, 4H);
		4.23 (m, 2H);
		4.69 (m, 2H);
		4.82 (s, 2H);
		5.21 (d, 1H);
		5.32 (d, 1H);
		5.97 (m, 1H);
		6.62 (dd, 1H);
		6.86 (s, 1H);
		6.89 (d, 1H);
		7.21 (t, 1H);
		8.18 (s, 1H);
		10.47 (s, 1H) ppm.
	INTE51	(DMSO-d6, stored	511.60/	INTE76/
		via K2CO3, primary	512	INTE77
		isomer):
		δ =
		1.27 (m, 3H);
		2.20 (s, 3H);
		2.29 (m, 2H);
		2.38 (m, 2H);
		3.48 (m, 4H);
		4.28 (m, 2H);
		4.71 (m, 2H);
		4.82 (s, 2H),
		5.29 (d, 1H);
		5.38 (d, 1H);
		6.00 (m, 1H);
		6.68 (dd, 1H);
		6.89 (s, 1H);
		6.92 (d, 1H);
		7.28 (t, 1H);
		8.20 (s, 1H);
		10.51 (s, 1H) ppm.
	INTE52	(DMSO-d6, stored	469.57/	INTT3/
		via K2CO3, primary	470	INTE1
		isomer):
		δ =
		1.02 (t, 6H);
		1.24 (t, 3H);
		1.26 (t, 3H);
		2.61 (q, 4H);
		3.16 (s, 2H);
		4.22 (q, 2H);
		6.99-7.01 (m, 1H);
		7.24-7.34 (m, 2H);
		7.77 (1H);
		8.14 (1H);
		9.71 (s, 1H);
		10.60 (s, 1H) ppm.
	INTE53	(DMSO-d6, stored	483.59/	INTT5/
		via K2CO3, primary	484	INTE2
		isomer):
		δ =
		1.02 (t, 6H);
		1.24 (t, 6H);
		2.60 (q, 4H);
		3.16 (s, 2H);
		4.24 (q, 2H);
		4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.36-5.40 (m, 1H);
		5.93-6.02 (m, 1H);
		6.99-7.01 (m, 1H);
		7.24-7.35 (m, 2H);
		7.78 (1H);
		8.16 (1H);
		9.72 (s, 1H);
		10.64 (s, 1H) ppm.
	INTE54	(DMSO-d6, stored	471.58/	INTT3/
		via K2CO3, primary	472	INTE1
		isomer):
		δ =
		0.87 (t, 3H);
		1.22-1.28 (m, 6H);
		1.45-1.50 (m, 2H);
		2.29 (s, 3H);
		2.40 (t, 2H);
		3.12 (s, 2H);
		4.19-4.26 (m, 4H);
		6.90-6.99 (m, 1H);
		7.24-7.30 (m, 2H);
		7.77 (1H);
		8.12 (1H);
		9.69 (s, 1H);
		10.61 (s, 1H) ppm.
	INTE55	(DMSO-d6, stored	483.59/	INTT5/
		via K2CO3, primary	484	INTE2
		isomer):
		δ =
		0.88 (t, 3H);
		1.24 (t, 3H);
		1.43-1.52 (m, 2H);
		2.29 (s, 3H);
		2.40 (t, 2H);
		3.13 (s, 2H);
		4.24 (q, 2H);
		4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.36-5.40 (m, 1H);
		5.93-6.02 (m, 1H);
		6.99-7.01 (m, 1H);
		7.24-7.31 (m, 2H);
		7.78 (1H);
		8.12-8.15 (1H);
		9.72 (s, 1H);
		10.63-10.66 (1H)
		ppm.
	INTE56	(DMSO-d6, stored	471.58/	INTT3/
		via K2CO3, primary	472	INTE1
		isomer):
		δ =
		1.02 (d, 6H);
		1.22-1.28 (m, 6H);
		2.25 (s, 3H);
		2.84-2.91 (m, 1H);
		3.10 (s, 2H);
		4.19-4.26 (m, 4H);
		4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.36-5.40 (m, 1H);
		5.93-6.02 (m, 1H);
		6.98-7.00 (m, 1H);
		7.24-7.36 (m, 2H);
		7.77 (1H);
		8.14 (1H);
		9.70 (5, 1H);
		10.61 (s, 1H) ppm.
	INTE57	(DMSO-d6, stored	483.59/	INTT5/
		via K2CO3, primary	484	INTE2
		isomer):
		δ =
		1.02 (d, 6H);
		1.24 (t, 3H);
		2.25 (s, 3H);
		2.84-2.91 (m, 1H);
		3.10 (s, 2H);
		4.23 (q, 2H),
		4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.36-5.40 (m, 1H);
		5.93-6.02 (m, 1H);
		6.98-7.00 (m, 1H);
		7.24-7.36 (m, 2H);
		7.77 (1H);
		8.15 (1H);
		9.69 (s, 1H);
		10.63 (s, 1H) ppm.
	INTE58	(DMSO-d6, stored	487.58/	INTT3/
		via K2CO3, primary	488	INTE1
		isomer):
		1.22-1.28 (m, 6H);
		1.45-1.50 (m, 2H);
		2.36 (s, 3H);
		2.64 (t, 1H);
		3.19 (s, 2H);
		3.27 (s, 3H);
		3.46 (t, 1H);
		4.19-4.26 (m, 4H);
		6.98-7.00 (m, 1H);
		7.22-7.29 (m, 2H);
		7.76 (1H);
		8.12 (1H);
		9.79 (s, 1H);
		10.63 (s, 1H) ppm.
	INTE59	(DMSO-d6, stored	499.59/	INTT5/
		via K2CO3, primary	500	INTE2
		isomer):
		δ =
		1.45-1.50 (m, 2H);
		2.36 (s, 3H);
		2.64 (t, 1H);
		3.18 (s, 2H);
		3.27 (s, 3H);
		3.46 (t, 1H);
		4.24 (q, 2H);
		4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.36-5.40 (m, 1H);
		5.93-6.03 (m, 1H);
		6.99-7.01 (m, 1H);
		7.22-7.30 (m, 2H);
		7.77 (1H);
		8.13 (1H);
		9.79 (s, 1H);
		10.65 (s, 1H) ppm.
	INTE60	(DMSO-d6, stored	501.61/	INTT3/
		via K2CO3, primary	502	INTE1
		isomer):
		1.01 (t, 3H);
		1.24 (t, 3H);
		1.26 (t, 3H);
		2.36 (s, 3H);
		2.66 (q, 2H);
		2.72 (t, 2H);
		3.21 (s, 2H);
		3.26 (s, 3H);
		3.44 (t, 1H);
		4.20-4.26 (m, 4H);
		7.00-7.02 (m, 1H);
		7.21-7.30 (m, 2H);
		7.74 (1H);
		8.12-8.14 (1H);
		9.79 (s, 1H);
		10.62-10.64 (1H)
		ppm.
	INTE61	(DMSO-d6, stored	513.62/	INTT5/
		via K2CO3, primary	514	INTE2
		isomer):
		δ =
		1.01 (t, 3H);
		1.24 (t, 3H);
		2.36 (s, 3H);
		2.66 (q, 2H);
		2.72 (t, 2H);
		3.21 (s, 2H);
		3.26 (s, 3H);
		3.44 (t, 1H);
		4.24 (q, 4H);
		4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.35-5.40 (m, 1H);
		5.93-6.02 (m, 1H);
		7.00-7.02 (m, 1H);
		7.21-7.32 (m, 2H);
		7.75 (1H);
		8.13-8.15 (1H);
		9.79 (s, 1H);
		10.65-10.66 (1H)
		ppm.
	INTE62	(DMSO-d6, stored	519.63/	INTT3/
		via K2CO3, primary	520	INTE1
		isomer):
		δ =
		1.22-1.28 (m, 6H);
		1.26 (t, 3H);
		2.27 (s, 3H);
		3.19 (s, 2H);
		3.65 (s, 2H);
		4.19-4.26 (m, 4H);
		6.98-7.00 (m, 1H);
		7.21-7.40 (m, 7H);
		7.78 (1H);
		8.12 (1H);
		9.81 (s, 1H);
		10.63 (1H) ppm.
	INTE63	(DMSO-d6, stored	531.64/	INTT5/
		via K2CO3, primary	532	INTE2
		isomer):
		δ =
		1.24 (t, 3H);
		2.27 (s, 3H);
		3.19 (s, 2H);
		3.65 (s, 2H);
		4.22-4.27 (q, 2H);
		4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.35-5.40 (m, 1H);
		5.93-6.03 (m, 1H);
		6.98-7.00 (m, 1H);
		7.21-7.40 (m, 7H);
		7.78 (1H);
		8.14 (1H);
		9.81 (s, 1H);
		10.66 (1H) ppm.
	INTE64	(DMSO-d6, stored	485.61/	INTT3/
		via K2CO3, primary	486	INTE1
		isomer):
		δ =
		1.09 (s, 9H);
		1.22-1.28 (m, 6H);
		2.25 (s, 3H);
		3.11 (s, 2H);
		4.19-4.26 (m, 4H);
		7.00-7.02 (m, 1H);
		7.25-7.37 (m, 2H);
		7.74 (1H);
		8.15 (1H),
		9.68 (s, 1H);
		10.61 (1H) ppm.
	INTE65	(DMSO-d6, stored	497.62/	INTT5/
		via K2CO3, primary	498	INTE2
		isomer):
		δ =
		1.09 (s, 9H);
		1.25, (t, 3H);
		2.25 (s, 3H);
		3.11 (s, 2H);
		4.24 (q, 2H);
		4.71 (m, 2H);
		5.24-5.27 (m, 1H);
		5.36-5.40 (m, 1H);
		5.93-6.02 (m, 1H);
		7.01-7.03 (m, 1H);
		7.25-7.37 (m, 2H);
		7.75 (1H);
		8.16 (1H);
		9.69 (s, 1H);
		10.64 (1H) ppm.
	INTE66	(DMSO-d6, stored	533.65/	INTT3/
		via K2CO3, primary	534	INTE1
		isomer):
		δ =
		1.22-1.28 (m, 6H);
		2.37 (s, 3H);
		2.71-2.81 (m, 4H);
		3.20 (s, 2H);
		4.19-4.27 (m, 4H);
		6.97-6.99 (m, 1H);
		7.12-7.30 (m, 7H);
		7.64 (1H);
		8.11 (1H);
		9.50 (s, 1H);
		10.61 (1H) ppm.
	INTE67	(DMSO-d6, stored	545.67/	INTT5/
		via K2CO3, primary	546	INTE2
		isomer):
		δ =
		1.24 (t, 3H);
		2.37 (s, 3H);
		2.71-2.81 (m, 4H);
		3.20 (s, 2H);
		4.25 (q, 4H);
		4.70 (m, 2H);
		5.24-5.27 (m, 1H);
		5.35-5.40 (m, 1H);
		5.93-6.02 (m, 1H);
		6.97-6.99 (m, 1H);
		7.12-7.30 (m, 2H);
		7.64 (1H);
		8.12 (1H);
		9.50 (s, 1H);
		10.64 (1H) ppm.
	INTE68	(DMSO-d6, stored	374.397/	INTT5/
		via K2CO3, primary	375	INTE5
		isomer): δ =
		1.28 (t, 3H);
		4.20 (q, 2H);
		4.72 (d, 2H);
		5.20-5.46 (m, 2H);
		5.84-6.05 (m, 1H);
		6.77 (d, 1H);
		6.98 (d, 1H);
		7.90 (q, 1H);
		8.49 (d, 1H);
		11.26 (s, 1H) ppm.
	INTE69	(DMSO-d6, stored	441.513/	INTT5 +
		via K2CO3, primary	442	INT122/
		isomer): δ =		INTE5
		1.24 (t, 3H);
		3.40 (m, 4H);
		3.68 (m, 4H);
		4.20 (q, 2H);
		4.64 (d, 2H);
		5.14-5.41 (m, 2H);
		5.86-6.00 (m, 1H);
		6.62 (m, 2H);
		7.96 (d, 1H);
		8.46 (s,1H);
		10.42 (s, 1H) ppm.
	INTE70	(DMSO-d6, stored	429.501/	INTT5/
		via K2CO3, primary	430	INTE5
		isomer): δ =
		1.40 (t, 3H);
		3.38 (s, 3H);
		3.42 (m, 2H);
		3.56 (m, 2H);
		4.4 (q, 2H);
		4.78 (d, 2H)
		5.24-5.48 (m, 2H);
		5.86 (m, 1H);
		6.32 (m, 1H);
		7.60 (d, 1H);
		7.76 (d,1H);
		8.00 (d,1H);
		10.42 (s, 1H) ppm.
	INTE71	(DMSO-d6, stored		INTT5/
		via K2CO3, primary		INTE2
		isomer):
		δ =
		1.18 (t, 3H);
		1.67 (m, 4H);
		1.72 (m, 2H);
		2.42-2.50 (m, 6H);
		2.55 (t, 2H);
		4.21 (q, 2H);
		4.67 (d, 2H);
		5.22 (d, 2H);
		5.34 (d, 2H);
		5.87-6.01 (m, 1H);
		6.89 (d, 1H);
		7.08 (d, 1H);
		7.14 (s, 1H);
		7.21 (t, 1H);
		8.18 (s, 1H);
		10.52 (s, 1H) ppm.
	INTE72	(DMSO-d6, stored		INTT5/
		via K2CO3, primary		INTE2
		isomer):
		δ =
		1.20 (t, 3H);
		1.34 (m, 2H);
		1.46 (m, 4H);
		1.70 (m, 2H);
		2.20-2.37 (m, 6H);
		2.53 (t, 2H);
		4.20 (q, 2H);
		4.67 (d, 2H);
		5.22 (d, 2H);
		5.34 (d, 2H);
		5.87-6.01 (m, 1H);
		6.88 (d, 1H);
		7.08 (d, 1H);
		7.12 (s, 1H);
		7.21 (t, 1H);
		8.16 (s, 1H);
		10.45 (s, 1H) ppm.
	INTE73	(DMSO-d6, stored		INTT5/
		via K2CO3, primary		INTE2
		isomer):
		δ =
		1.21 (t, 3H);
		1.69 (m, 2H);
		2.22 (t, 2H);
		2.30 (m, 4H);
		2.53 (t, 2H);
		3.54 (t, 4H);
		4.21 (q, 2H);
		4.67 (d, 2H);
		5.22 (d, 2H);
		5.34 (d, 2H);
		5.88-6.01 (m, 1H);
		6.91 (d, 1H);
		7.08 (d, 1H);
		7.15 (s, 1H);
		7.21 (t, 1H);
		8.18 (m, 1H);
		10.46 (m, 1H) ppm.
	INTE74		454.555/	INTT5 +
		455	INT124/
			INTE5
	INTE75		471.539/	INTT5/
		472	INTE2
	INTE76		484/	INTT5/
		485	INTE1

Intermediate INTE77

4-[2-(3-{[2-[1-Allyloxycarbonyl-1-cyano-meth-(E oder Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenoxy)-acetyl]-piperazine-1-carboxylic acid tert-butyl ester

Dissolve 4.8 g of the compound described under INT77 and 4.4 g of the compound described under INTT5 in ethanol (140 ml) and stir under argon for three hours at 95° C. bath temperature. The condensation, thus arisen, is siphoned off and washed with ethanol. The compound in the title (5.7 g) is obtained in a 67% yield. The raw product is used at the next level without further purification.

¹H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer) δ=1.26 (t, 3H); 1.40 (s, 2H); 3.32 (m, 4H); 3.45 (m, 4H); 4.28 (m, 2H); 4.72 (d, 2H); 4.89 (s, 2H); 5.29 (dd, 1H); 5.40 (dd, 1H); 5.99 (m, 1H); 6.68 (dd, 1H); 6.90 (s, 1H); 6.93 (d, 1H); 7.28 (t, 1H); 8.21 (d, 1H); 10.47 (d, 1H) ppm.

Intermediate INTE78

Cyano-[3-ethyl-4-oxo-5-[1-[3-(2-oxo-2-piperazin-1-yl-ethoxy)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester

Dissolve 2.99 g of the compound described under INTE77 in dichloro-methane (100 ml) and slowly add trifluoro-acetic acid (10 ml) to it. Stir for 2.5 hours under argon at room temperature and then end the reaction through the addition of a 10% watery sodium carbonate solution (approx. 170 ml). Then extract the reaction mixture with dichloro-methane (3×100 ml), wash the unified organic phases with a sodium chloride solution (1×100 ml) and dry following this over sodium sulfate. After distilling off the solvent on the rotation vaporizer, the compound in the title (2 g) is obtained in an 80% yield. The raw product was used at the next level without further purification.

¹H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer) δ=1.23 (m, 3H); 2.68 (m, 2H); 2.71 (m, 2H); 4.25 (m, 2H); 4.73 (m, 2H); 4.82 (s, 2H); 5.29 (dd, 1H); 5.39 (dd, 1H); 5.99 (m, 1H); 6.64 (dd, 1H); 6.88 (s, 1H); 6.91 (d, 1H); 7.27 (t, 1H); 8.22 (s, 1H) ppm.

Intermediate INTE79

[5-[1-{3-[2-(4-Benzyl-piperazin-1-yl)-2-oxo-ethoxy]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid allyl ester

Suspend 2.9 g of the compound described under INTE78 and 0.92 ml benzaldehyde in methanol (240 ml) and add acetic acid (24 ml) and sodium cyanoborhydride (0.7 g) to it at room temperature. Stir the residue at room temperature for 5 hours under argon, neutralize the reaction mixture through the addition of sodium carbonate and siphon off the condensation thus arisen. The compound in the title (2.54 g) is obtained in a 71% yield. The product is used at the next level without further purification.

¹H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer) ¹H-NMR δ=1.29 (m, 3H); 2.32 (m, 2H); 2.41 (m, 2H); 3.43 (m, 4H); 4.26 (m, 2H); 4.72 (d, 2H); 4.86 (s, 2H); 5.29 (d, 1H); 5.40 (d, 1H); 6.00 (m, 1H); 6.68 (dd, 1H); 6.89 (s, 1H); 6.92 (d, 1H); 7.30 (m, 6H); 8.21 (d, 1H); 10.50 (d, 1H) ppm.

4. Synthesis of Acid-Intermediates

Intermediate INTA1

Manufacturing variant 1

Cyano-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid

Pre-place 1.1 g potassium-(tert)-butylate in 50 ml tetrahydrofurane at 0° C. and add 45 μl water. Add 540 mg of the compound described under Intermediate INTEL) and stir for 30 minutes at 0° C., and for 20 hours at room temperature. At 0° C., add 0.25 ml triethylamine and 10.5 ml two molar salt acid (hydrochloric acid) in diethylether and stir at room temperature for an hour. Allow the solvent to condense under high vacuum and use the residue without any further purification.

MW: 412.51; MS (ESI) [M+1]⁺: 413 Manufacturing Variant 2

Dissolve 300 mg of the compound described under INTE2), 80 mg Pd (PPh₃)₄ and 0.6 ml morpholine in 18 ml tetrahydrofurane and stir for 15 hours. After an addition of 40 ml diethylether, filter the solid thus obtained, dry in vacuum and dissolve in 10 ml dimethylformamide. Add the solution to a suspension of 770 mg PL-MIA Resin of the firm Polymer Laboratories GmbH in 5 ml dimethylformamide and stir for 15 hours at room temperature. Filter the reaction mixture and allow the solvent to condense under high vacuum. 280 mg of the compound in the title is obtained as a raw product.

¹H-NMR (DMSO-d6, stored over K₂CO₃): δ=1.20 (t, 3H); 1.88 (m, 4H); 2.50 (m, 4H); 3.09 (m, 2H); 3.20 (m, 2H); 4.20 (q, 2H); 6.93 (d, 1H); 7.04-7.12 (m, 2H); 7.23 (t, 1H); 7.88 (s, 1H); 9.97 (s, 1H) ppm.

Intermediate INTA2

Cyano-[3-ethyl-5-[1-(2-ethylamino-pyridin-4-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid

Dissolve 1.2 g of the compound described under INTE4), 350 mg Pd (PPh₃)₄ and 2.6 ml morpholine in 60 ml tetrahydrofurane and stir for an hour at room temperature. After the addition of 40 ml of hexane, filter the solid obtained, dry in vacuum and dissolve in 20 ml dimethylformamide. Add the solution to a suspension of 6.0 g PL-MIA Resin of the firm Polymer Laboratories GmbH in 30 ml dimethylformamide and stir for 15 hours at room temperature. Filter the reaction mixture and allow the solvent to condense under high vacuum. 970 mg of the compound in the title is obtained as a raw product.

MW: 359.41; MS (ESI) [M+1]⁺: 360

¹H-NMR (DMSO-d6, stored over K₂CO₃): δ=1.11 (t, 3H); 1.22 (t, 3H); 3.23 (m, 2H); 4.22 (q, 2H); 6.25 (s, 1H); 6.42 (d, 1H); 6.54 (s, b, 1H); 7.81 (d, 1H); 7.95 (s, 1H); 10.20 (s, 1H) ppm.

Intermediate INTA3

Cyano-[5-[1-[6-(2,2-dimethyl-propionylamino)-pyridin-2-ylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid

Dissolve 2.2 g of the compound described under INTE5), 560 mg Pd (PPh₃)₄ and 4.2 ml morpholine in 110 ml tetrahydrofurane and stir for an hour at room temperature. After the addition of 50 ml of hexane, filter the excluded solid, dry in vacuum and dissolve in 25 ml dimethylformamide. Add the solution to a suspension of 9.6 g PL-MIA Resin of the firm Polymer Laboratories GmbH in 50 ml dimethylformamide and stir for 15 hours at room temperature. Filter the reaction mixture and allow the solvent to condense under high vacuum. 2.1 g of the compound in the title is obtained as a raw product.

MW: 415.47; MS (ESI) [M+1]⁺: 416

¹H-NMR (DMSO-d6, stored over K₂CO₃): δ=1.15-1.30 (m, 12H); 4.23 (q, 2H); 6.80 (m, 1H); 7.64-7.74 (m, 2H); 8.73 (d, 1H); 9.68 (s, 1H); 10.68 (d, 1H) ppm.

The following compounds are manufactured in addition to the process described above.

			Molecular
			Weight/	Educt/
Example			MS(ESI)	Additional
No.	Structure and name	1H-NMR	[M + 1]+	synthesis
INTA4			MW: 414.49 MS (ESI) [M + 1]+: 415	INTE6/ INTA3
	Cyano-[5-[1-[3-(2,2-dimethyl-
	propionylamino)-phenylamino]-
	oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetic acid
INTA5		(DMSO-d6, stored via K2CO3): δ =1.22(t, 3H); 3.30(s, 2H); 3.68(m, 2H); 4.09(s, 2H); 4.23(q, 2H); 7.01(m, 1H); 7.22-7.32(m, 2H); 7.75(s, 1H); 8.04(d, 1H); 9.71(s, 1H); 10.50(d, 1H) ppm.	MW: 446.48 MS (ESI) [M + 1]+: 447	INTE7/ INTA3
	Cyano-[3-ethyl-5-[1-{3-[2-(2-
	methoxy-ethoxy)-acetylamino]-
	phenylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E
	or Z))-ylidene]-acetic acid
INTA6		(DMSO-d6, stored via K2CO3): δ =1.23(t, 3H); 3.34(s, 3H); 3.51(m, 2H); 3.69(m, 2H); 4.15(s, 2H); 4.22(q, 2H); 6.81(dd, 1H); 7.69-7.78(m, 2H); 7.95(5, 1H); 8.64(d, 1H); 9.98(s, 1H); 10.73(d, 1H) ppm.	MW: 447.47 MS (ESI) [M + 1]+: 448	INTE9/ INTA3
	Cyano-[3-ethyl-5-[1-{6-[2-(2-
	methoxy-ethoxy)-acetylamino]-
	pyridin-2-ylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E
	or Z))-ylidene]-acetic acid
INTA7			444.51 445	INTE21/ INTA3
	Cyano-[3-ethyl-5-[1-[3-(2-
	morpholin-4-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E
	or Z))-ylidene]-acetic acid
INTA8		(DMSO-d6, stored via K2CO3)(selected signals): δ =1.23(t, 3H); 2.71(t, 2H); 3.61(t, 2H); 4.23(q, 2H); 4.68(b, 1H); 6.91(d, 1H); 7.10(d, 1H); 7.16(s, 1H); 7.23(t, 1H); 8.05(d, 1H); 10.23(d, 1H) ppm.	359.41 360	INTE16/ INTA3
	Cyano-[3-ethyl-5-[1-[3-(2-
	hyd roxy-ethyl)-phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA9		(DMSO-d6, stored via K2CO3)(selected signals): δ =1.20(t, 3H); 1.48(s, 9H); 4.20(q, 2H); 6.83(d, 1H); 7.03(d, 1H); 7.18(t, 1H), 7.51(s, 1H); 7.88(d, 1H); 9.40(s, 1H); 10.16(d, 1H) ppm.	430.49 431	INTE17/ INTA3
	[5-[1-(3-tert-
	Butoxycarbonylamino-
	phenylamino)-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	cyano-acetic acid
INTA10			416.46 417	INTE3/ INTA3
	Cyano-[3-ethyl-5-[1-[3-(2-
	hydroxy-2-methyl-
	propionylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA11		1H-NMR(DMSO-d6, 300 MHz)(selected peaks)δ = 1.25(m, 3H); 2.09(s, 3H); 2.58(m, 4H); 2.81 (m, 2H); 3.61(m, 4H); 4.15(m, 2H); 4.26(m, 2H); 6.81 (dd, 1H); 6.92(s, 1H); 7.10(d, 1H); 8.20(d, 1H); 10.35 (d, 1H); 11.08(s, 1H).	MW: 458.536 MS (ESI) [M + 1]+: 459	INTE26/ INTA3
	Cyano-[3-ethyl-5-[1-[4-methyl-3-
	(2-
	Morpholin-4-yl-ethoxy)-
	phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E orZ))-ylidene]-
	acetic acid
INTA12		1H-NMR(DMSO-d6, 300 MHz)(selected peaks)δ = 1.19(m, 3H); 1.47(m, 2H); 1.66(m, 4H); 2.88 (m, 4H); 3.10(m, 2H); 4.12(m, 2H); 4.21(m, 2H); 6.62 (dd, 1H); 6.82(m, 2H); 7.21(m, 1H); 8.00(d, 1H); 10.00 (d, 1H).	MW: 442.537 MS (ESI) [M + 1]+: 443	INTE25/ INTA3
	Cyano-[3-ethyl-4-oxo-5-[1-[3-(2-
	piperidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(E or Z))-
	ylidene]-acetic acid
INTA13		1H-NMR(CDCl3, 300 MHz)(selected peaks)δ =1.23(m, 3H); 2.88 (s, 6H); 4.23(m, 2H); 4.37(m, 2H); 6.73 (dd, 1H); 6.97(m, 2H); 7.30(m, 1H); 8.20(s, 1H).	MW: 402.472 MS (ESI) [M + 1]+: 403	INTE20/ INTA3
	Cyano-[5-[1-[3-(2-
	dimethylainino-ethoxy)-
	phenylamino]-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA14			MW: 428.51 MS (ESI) [M + 1]+: 429	INTE24/ INTA3
	Cyano-[3-ethyl-4-oxo-5-[1-[3-(2-
	pyrrolidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(Z or E))-
	ylidene]-acetic acid
INTA15			MW: 389.39 MS (ESI) [M + 1]+: 390	INTE23/ INTA3
	[5-[1-(3-Carboxymethoxy-
	phenylamino)-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]
	cyano-acetic acid
INTA16			MW: 400,460/ MS (ESI) [M + 1]+: 401	INTE28/ INTA3
	Cyano-[3-ethyl-5-[1-(3-
	isobutyryl-amino-phenylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA17			MW: 386,433/ MS (ESI) [M + 1]+: 387	INTE30/ INTA3
	[5-[-[3-(Acetyl-methyl-amino)-
	phenylamino]-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]
	cyano-acetic acid
INTA18			MW: 415,474/ MS (ESI) [M + 1]+: 416	INTE32/ INTA3
	Cyano-[5-[1-[3-(2-
	dimethylamino-acetylamino)-
	phenylamino]-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA19			MW: 428,514/ MS (ESI) [M + 1]+: 429	INTE34/ INTA3
	Cyano-[5-[1-{3-[(2,2-dimethyl-
	propionyl)-methyl-amino]-
	phenylamino}-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA20			MW: 414,486/ MS (ESI) [M + 1]+: 415	INTE36/ INTA3
	Cyano-[3-ethyl-5-[1-[3-
	(isobutyryl-
	methyl-amino)-phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA21			MW: 388,448/ MS (ESI) [M + 1]+: 389	INTE39/ INTA3
	Cyano-[3-ethyl-5-[1-[3-(2-
	methoxy-
	ethylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]
	acetic acid
INTA22			MW: 429,501/ MS (ESI) [M + 1]+: 430	INTE41/ INTA3
	Cyano-[3-ethyl-5-[1-{3-[2-(ethyl-
	methyl-amino)-acetylamino]-
	phenylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2Z)-
	ylidene]-acetic acid

Intermediate INTA23

[5-[1-{3-[2-(4-Benzyl-piperazin-1-yl)-2-oxo-ethoxy]-phenylamino}-meth-(E/Z)-ylidene]-3ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid

Suspend 2.5 g of the compound described under INTE79 in THF (320 ml) and add to barbituric acid (0.6 g) and Pd(PPh₃)₄ (0.49 g). Stir the reaction mixture overnight, press on the rotary evaporator until a precipitation occurs and extract the resulting condensation. The compound in the title (522 mg) is obtained in a 23 % yield. The product is used at the next level without further purification.

El-MS=548.

The following compounds are manufactured in addition to the process described above.

	+HL,6		Molecular
			Weight/	Educt/
Example			MS(ESI)	Additional
No.	Structure and name	1H-NMR	[M + 1]+	synthesis
A24		(DMSO-d6, stored via K2CO3,selected signals): δ =1.18(t, 3H); 1.58(b, 4H); 2.50(b, 4H); 3.19-3.37(m, 2H); 4.15(q, 2H), 7.13(d, 1H); 7.20(d, 1H); 7.80(t, 1H); 8.40(s,b, 1H); 10.50(s,b, 1H) ppm		INTE49/ INTA3
	Cyano-[5-[1-[6-(1,1-difluoro-2-
	pyrrolidin-1-yl-ethyl)-pyridin-2-
	ylamino]-meth-(E/Z)-ylidene]-3-
	ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetic acid
INTA25			480.63 481	INTE43/ INTA3
	Cyano-[3-ethyl-5-({3-
	[(4aR,8aS)-2-
	(octahydro-isoquinolin-2-yl)-
	ethyl]-phenylamino}-meth-(E/Z)-
	ylidene -4-oxo-thiazolidin-(2-(E
	or Z))-ylidene]-acetic acid
INTA26		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.00(m, 3H); 1.20(m, 3H); 1.72(m, 2H); 2.39(m, 6H); 3.57(m, 2H); 4.20(m, 2H); 4.81(s, 2H); 6.60(dd, 1H); 6.82(5, 1H); 6.88(d, 1H); 7.20(t, 1H); 8.09(d, 1H); 10.29(d, 1H) ppm.	485.57 486	INTE50 INTA23
	Cyano-[3-ethyl-5-[1-{3-[2-(4-
	ethyl-piperazin-1-yl)-2-oxo-
	ethoxy]-phenylamino}-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-
	(2-(E or Z))-ylidene]-acetic acid
INTA27		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.21(t, 3H); 2.22(m, 2H); 2.41(m, 2H); 3.43(m, 4H); 4.19(m, 2H); 4.81(s, 2H); 6.60(dd, 1H); 6.82(s, 1H); 6.88(d, 1H); 7.20(t, 1H); 8.08(d, 1H); 10.29(d, 1H) ppm.	471.54 472	INTE51 INTA23
	Cyano-[3-ethyl-5-[1-{3-[2-(4-
	methyl-piperazin-1-yl)-2-oxo-
	ethoxyl-phenylamino}-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-
	(2-(E or Z))-ylidene]-acetic acid
INTA28			MW: 443,53/ MS (ESI) [M + 1]+: 444	INTE53/ INTA3
	Cyano-[5-[1-[3-(2-diethylamino-
	acetylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(2-(E or Z))
	ylidene]-acetic acid
INTA29			MW: 443,53/ MS (ESI) [M + 1]+: 444	INTE55/ INTA3
	Cyano-[3-ethyl-5-[1-{3-[2-
	(methyl-propyl-amino)-acetyl-
	amino]-phenylamino}-meth-
	(E/Z)-ylidene]-4-oxo-thiazol
	idin-(2-(E or Z))-ylidene]-acetic
	acid
INTA30			MW: 459,53/ MS (ESI) [M + 1]+: 460	INTE59/ INTA3
	Cyano-[3-ethyl-5-[1-(3-{2-[(2-
	methoxy-ethyl)-methyl-amino]-
	acetylamino}-phenylamino)-
	meth-(E/Z)-ylidene]-4-
	oxo-thiazolidin-(2-(E or Z))
	ylidene]-acetic acid
INTA31			MW: 473,55/ MS (ESI) [M + 1]+: 474	INTE61/ INTA3
	Cyano-[3-ethyl-5-[1-(3-{2-[ethyl-
	(2-methoxy-ethyl)-amino]-
	acetylamino}-phenylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA32			MW: 491,57/ MS (ESI) [M + 1]+: 492	INTE63/ INTA3
	[5-[1-{3-[2-(Benzyl-methyl-
	amino)-acetylamino]-phenyl-
	amino}-meth-(E/Z)-ylidene]-3-
	ethyl-4-oxo-thiazo]-idin-(2-(E or
	Z))-ylidene]-cyano-acetic acid
INTA33		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 4.25(q, 2H); 4.51(s, 2H); 5.27(s, 1H); 7.04(d, 1H); 7.18(d, 2H); 7.27-7.34(m, 2H); 8.17(d, 1H); 10.53(d, 1H); 13.03(s, 1H) ppm.		INTE12 INTA23
	Cyano-[3-ethyl-5-[1-(3-
	hydroxymethyl-phenylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetic acid
INTA34		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.22(t, 3H); 1.94(m, 4H); 2.05(m, 2H); 2.54-2.62(m, 6H); 2.70(t, 2H); 4.25(q, 2H); 6.98(d, 1H); 7.10-7.18(m, 2H); 7.32(t, 1H); 7.95(m, 1H); 10.08 (m, 1H); 11.60(m, 1H) ppm.		INTE71 INTA23
	Cyano-[3-ethyl-4-oxo-5-[1-[3-(3-
	pyrrolidin-1-yl-propyl)-
	phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(E or Z))-
	ylidene]-acetic acid
INTA35		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.15(t, 3H); 1.46(m, 2H); 1.62-1.70(m, 4H); 1.94(m, 2H); 2.47-2.61(m, 4H); 2.78(m, 2H); 2.92(m, 2H); 4.15(q, 2H); 6.86(d, 1H); 7.00-7.08(m, 2H); 7.20(t, 1H); 7.86(m, 1H); 9.98(m, 1H); 11.48(m, 1H) ppm.		INTE72 INTA23
	Cyano-[3-ethyl-4-oxo-5-[1-[3-(3-
	piperidin-1-yl-propyl)-
	piperidin-1-yl-propyl)-
	phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(E or Z))-
	ylidene]-acetic acid
INTA36		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.18(t, 3H); 1.71(m,2H); 2.35(t, 2H); 2.40-2.58(m, 6H); 3.52-3.63(m, 4H); 4.18(q, 2H); 6.87(d, 1H); 7.07(d, 1H); 7.13(s, 1H); 7.20(t, 1H); 8.08(d, 1H); 10.29(d, 1H); 11.47(s, 1H) ppm.		INTE73 INTA23
	Cyano-[3-ethyl-5-[1-[3-(3-
	morpholin-4-yl-propyl)-
	phenylainino]-meth-(E/Z)
	ylidene]-4-oxo-thiazolidin-(2-(E
	or Z))-ylidene]-acetic acid
INTA37			444 445	INTE76/ INTA2
	[5-[1-[3-(tert-Butoxycarbonyl-
	methyl-amino)-phenylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(2-(E oder Z))-
	ylidene]-cyano-acetic acid

5. Synthesis of Amides

EXAMPLE 1

2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl )-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(2-hydroxy-1,1-dimethyl-ethyl)-acetamide

Dissolve 170 mg of the raw product described under intermediate INTA1) (approx. 0.42 mmol) in 10 ml dimethylformamide, add 248 mg sodium hydrogencarbonate, 62 μl 2-amino-2-methyl-propane-1-ol, and 200 mg TBTU and stir for 18 hours at room temperature. Add a semi-saturated sodium hydrogencarbonate solution to the reaction mixture and extract with dichlormethane. Wash the organic solution with saturated sodium chloride, dry over sodium sulfate, press and, after purification through chromatography in silica gel, 61 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.30 (t, 3H); 1.36 (s, 6H); 1.74 (m, 4H); 2.54 (m, 4H); 2.69 (m, 2H); 2.79 (m, 2H); 3.43 (d, 2H); 4.27 (q, 2H); 5.27 (t, 1H); 6.74 (s, 1H); 7.00 (d, 1H); 7.18 (d, 1H); 7.25-7.35 (m, 2H); 8.19 (s, 1H); 10.31 (s, 1H) ppm.

EXAMPLE 2

Tetrahydro-pyran-4-carboxylic acid (3-{[2-[1-cyano-1-ethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-amide

Dissolve 42 mg tetrahydropyran-4-carboxylic acid in 10 ml tetrahydrofurane. At 0° C., add 80 μl triethylamine and 42 μl isobutylchloroformate to it. Stir for 30 minutes at room temperature. Then add 100 mg of the compound described under Example 6). Stir for 12 hours at room temperature. Add a semi-saturated sodium hydrogencarbonate solution to the reaction mixture and extract with dichlormethane. Wash the organic solution with saturated sodium chloride, dry over sodium sulfate, press and, after purification through chromatography in silica gel, 49 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

(DMSO-d6, stored via K₂CO₃, primary isomer): δ=1.07 (t, 3H); 1.22 (t, 3H); 1.68 (m, 4H); 2.58 (m, 2H); 3.19 (pentuplet, 2H); 3.39 (m, 1H); 3.90 (m, 1H); 4.21 (q, 2H); 6.90 (s, 1H); 7.12-7.31 (m, 2H); 7.50-7.80 (m, 2H); 8.04 (s, 1H); 9.81-9.99 (s, b, 1H); 10.39 (s, 1H) ppm.

EXAMPLE 3

2-Cyano-N-ethyl-2-[3-ethyl-5-[1-{3-[3-(4-hydroxymethyl-piperidin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide

Dissolve 150 mg of the compound described under Example 19) in 5 ml tetrahydrofurane. Add 0.25 ml triethylamine and 62 mg Piperidin-4-yl-methanol. Stir for 12 hours under re-flow. Add a semi-saturated sodium hydrogencarbonate solution to the reaction mixture and extract with dichlormethane. Wash the organic solution with saturated sodium chloride, dry over sodium sulfate, press and, after purification through chromatography in silica gel, 37 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

(DMSO-d6, stored via K₂CO₃, primary isomer): δ=0.97-1.40 (m, 9H); 1.64 (d, 2H); 1.90 (t, 2H); 2.45 (m, 2H); 2.60 (t, 2H); 2.89 (m, 2H); 3.11-3.29 (m, 4H); 4.21 (q, 2H); 4.49 (t, 1H); 6.92 (s, 1H); 7.13 (d, 1H); 7.24 (t, 1H); 7.56-7.80 (m, 2H); 8.02 (s, 1H); 10.18 (s, 1H); 10.40 (s, 1H) ppm.

EXAMPLE 4

2-Cyano-2-[3-ethyl-5-[1-(3-hydroxymethyl-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-prop-2-ynyl-acetamide

Dissolve 50 mg of the compound described under Intermediate INT9) in 5 ml triethylorthoformiate. Add 148 mg 3-aminobenzyl alcohol and 100 μl triethylorthoformiate. Stir for 3 hours under re-flow. Filter off the excluded product after the cooling of the reaction mixture. After purification through the re-crystallizing of ethanol, 56 mg of the compound in the title is obtained.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.24 (t, 3H); 3.07 (s, b, 1H); 3.92 (m, 2H); 4.23 (q, 2H); 4.49 (d, 2H); 5.25 (t, 1H); 7.00 (d, 1H); 7.13 (d, 1H); 7.21-7.35 (m, 2H); 7.95-8.20 (m, 2H); 10.40 (s, 1H) ppm.

EXAMPLE 5

2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-5-[1-[3-(2-piperidin-1-yl-acetylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide

Dissolve 50 mg of the compound described under Intermediate INTT7) in 10 ml ethanol. Add 140 mg of the compound described under Intermediate INT20) and 100 μL triethylorthoformiate to it. Stir for 3 hours under re-flow. Press the reaction mixture. After purification through the re-crystallizing of ethanol, 26 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.07 (t, 1H); 1.25 (t, 3H); 1.41 (m, 2H); 1.59 (m, 4H); 2.44 (m, 4H); 3.06 (s, 2H); 3.20 (pentuplet, 2H); 4.23 (q, 2H); 6.96 (d, 1H); 7.20-7.33 (m, 2H); 7.60-7.77 (m, 2H); 8.03 (s, 1H); 9.70 (s, 1H); 10.39 (s, 1H) ppm.

EXAMPLE 6

2-[5-[1-(3-Amino-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-ethyl-acetamide

Suspend 7.75 g of the compound manufactured under Example 79) in 120 ml dichlormethane. Add 70 ml trifluoro acetic acid to it. Stir for one hour at room temperature. Press the reaction mixture, add dichlormethane and hexane and press anew. After drying well in vacuum, 11.2 g of the compound in the title is obtained as a trifluoro acetic acid salt. This raw product is used without further purification for the following reactions.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.07 (t, 3H); 1.26 (t, 3H); 3.20 (m, 2H); 4.22 (q, 2H); 6.80 (d, 1H); 7.01 (s, 1H); 7.05 (d, 1H); 7.30 (t, 1H); 7.74 (t, 1H); 8.01 (d, 1H); 9.20 (s, b, 3H); 10.35 (d, 1H) ppm.

EXAMPLE 7

2-[5-[1-[3-(2-Chloro-acetylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-ethyl-acetamide

Suspend approx. 16.9 mmol of the raw product of the compound manufactured under Example 6) (11.2 g) in 500 ml tetrahydrofurane. Add 5.15 ml triethylamine at room temperature and 3.28 g chloro-acetic acid anhydride in portions following this at 15° C. Stir for two hours at room temperature. Add a semi-saturated sodium hydrogencarbonate solution to the reaction mixture and extract with acetic acid ethylester. Wash the organic solution with a saturated sodium chloride solution, dry over sodium sulfate, press and, after purification through re-crystallization from ethanol, 5.26 g of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.09 (t, 3H); 1.26 (t, 3H); 3.21 (pentuplet, 2H); 4.21 (q, 2H); 4.28 (s, 2H); 7.00 (d, 1H); 7.20 (d, 1H); 7.29 (t, 1H); 7.58-7.77 (m, 1H); 8.01 (s, 1H); 10.35 (s, 1H); 10.41 (s, 1H) ppm.

EXAMPLE 8

2-Cyano-N-ethyl-2-[3-ethyl-5-[1-{3-[2-(4-methyl-piperidin-1-yl)-acetylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazol idin-(2-(E or Z))-ylidene]-acetamide

Dissolve 100 mg of the compound described under Example 7) in 5 ml dimethylformamide. Add 0.15 ml triethylamine, 6 mg potassium iodide and 38 μl 14-methylpiperidine to it. Stir for 4 hours at room temperature. Add a semi-saturated sodium hydrogencarbonate solution to the reaction mixture and extract with acetic acid ethylester. Wash the organic solution with saturated sodium chloride, dry over sodium sulfate, press and, after purification through chromatography in silica gel, 62 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=0.91 (d, 3H); 1.08 (t, 3H) 1.14-1.40 (m, 6H); 1.59 (d, 2H); 2.12 (t, 2H); 2.83 (d, 2H); 3.09 (s, 2H); 3.21 (m, 2H); 4.22 (q, 4H); 6.96 (d, 2H); 7.20-7.33 (m, 2H); 7.58-7.78 (m, 2H); 8.04 (s, 1H); 9.69 (s, 1H); 10.40 (s, 1H) ppm.

EXAMPLE 9

2-[5-[1-{3-[2-(4-Acetyl-piperazin-1-yl)-acetylamino]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-ethyl-acetamide

Suspend 94 mg of the compound manufactured under Example 80) in 5 ml dichlormethane. Add 2.5 ml trifluoro-acetic acid to it. Stir for 30 minutes at room temperature. Press the reaction mixture, add dichlormethane and hexane and press anew. After drying well in vacuum, the residue thus obtained is suspended in 5 ml dimethylformamide. Add 50 μL acetic acid, 67 mg sodium hydrogencarbonate and 62 mg TBTU 5A to it. Stir for 12 hours at room temperature. Add a semi-saturated sodium hydrogencarbonate solution to the reaction mixture and extract with acetic acid ethylester. Wash the organic solution with a saturated sodium chloride solution, dry over sodium sulfate, press and, after purification through re-crystallization from ethanol, 48 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.07 (t, 3H); 1.25 (t, 3H) 2.00 (s, 3H); 2.41-2.60 (m, 4H); 3.14-3.28 (m, 4H); 3.50 (m, 4H); 4.22 (q, 2H); 6.98 (m, 1H); 7.21-7.31 (m, 2H); 7.63-7.76 (m, 2H); 8.00 (s, 1H); 9.81 (s, 1H); 10.40 (s, 1H) ppm.

EXAMPLE 10

2-Cyano-N-ethyl-2-[3-ethyl-5-[1-{3-[2-(4-methanesulfonyl-piperazin-1-yl )-acetylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide

Suspend 120 mg of the compound manufactured under Example 80) in 5 ml dichlormethane. Add 2.5 ml trifluoro-acetic acid to it. Stir for 30 minutes at room temperature. Press the reaction mixture, add dichlormethane and hexane and press anew. After drying well in vacuum, the residue thus obtained is suspended in 5 ml tetrahydrofurane. Add 50 μL triethylamine, 20 μL methano-sulfonic acid chloride to it. Stir for 3 hours at room temperature. Add semi-saturated sodium hydrogencarbonate solution to the reaction mixture and extract with acetic acid ethylester. Wash the organic solution with a saturated sodium chloride solution, dry over sodium sulfate, press and, after purification through re-crystallization from ethanol, 46 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.08 (t, 3H); 1.24 (t, 3H) 2.63 (m, 4H); 2.91 (s, 3H); 3.10-3.28 (m, 8H); 4.22 (q, 2H); 6.95 (s, 1H); 7.20-7.30 (m, 2H); 7.56-7.75 (m, 2H); 8.05 (s, 1H); 9.80 (s, 1H); 10.40 (s, 1H) ppm.

EXAMPLE 11

2-Cyano-N-cyanomethyl-2-[3-ethyl-5-[1-[3-(2-hydroxy-acetylamino)-phenylamino]-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide

Dissolve 100 mg of the compound manufactured under Example 95) in 10 ml methanol. Add 1 ml water and 30 mg potassium carbonate to it. Stir for 2 hours at room temperature. Add water to the reaction mixture and extract with acetic acid ethylester. Wash the organic solution with a saturated sodium chloride solution, dry over sodium sulfate, press and, after purification through re-crystallization from ethanol, 72 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.26 (t, 3H); 4.01 (d, 1H); 4.17 (d, 2H); 4.25 (q, 2H); 5.70 (t, 1H); 6.99 (d, 2H); 7.28 (t, 1H); 7.40 (d, 1H); 7.81 (s, 1H); 8.09 (s, 1H); 8.35 (s, 1H); 9.73 (s, 1H); 10.53 (s, 1H) ppm.

EXAMPLE 12

Methanesulfonic acid 2-(3-{[2-[1-cyano-1-(cyanomethyl-carbamoyl )-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-ethyl ester

Dissolve 1.0 g of the compound manufactured under Example 71) in 10 ml dimethylformamide and 200 ml tetrahydrofurane. Add 0.9 ml triethylamine and 0.31 ml methane sulfonic acid chloride to it at −10° C. Stir for 1 hour at room temperature. Add a semi-saturated sodium hydrogencarbonate solution to the reaction mixture and extract with acetic acid ethylester. Wash the organic solution with a saturated sodium chloride solution, dry over sodium sulfate and press. Add dichlormethane to the solid obtained, stir for one hour at room temperature and filter off. 1.0 g of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.26 (t, 3H); 3.00 (t, 2H); 3.11 (s, 3H); 4.17 (m, 2H); 4.24 (q, 2H); 4.45 (t, 2H); 7.01 (d, 1H); 7.19 (d, 1H); 7.25-7.36 (m, 2H); 8.19 (s, 1H); 8.34 (t, 1H); 10.41 (s, 1H) ppm.

EXAMPLE 13

2-Cyano-N-cyanomethyl-2-[3-ethyl-5-[1-[3-(2-iodo-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide

Dissolve 4.5 g of the compound manufactured under Example 12) in 400 ml butanon. Add 1.72 g sodium iodide to it. Stir for 8 hours under re-flow. Add water to the reaction mixture and extract with acetic acid ethylester. 1.6 g of the initial material is re-obtained from the watery phase through filtration. Dry the organic solution over sodium sulfate and press. 3.0 g of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.27 (t, 3H); 3.12 (t, 2H); 3.50 (t, 2H); 4.16 (d, 2H); 4.24 (q, 2H); 6.98 (d, 1H); 7.18 (d, 1H); 7.22-7.34 (m, 2H); 8.20 (d, 1H); 8.35 (t, 1H); 10.41 (d, 1H) ppm. Example 14

2-Cyano-N-cyanomethyl-2-[3-ethyl-5-[1-[3-(2-morpholin-4-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide

Dissolve 120 mg of the compound manufactured under Example 13) in 5 ml dimethylformamide. Add 42 mg morpholine and 65 mg potassium carbonate to it. Stir for 12 hours at room temperature. Add water to the reaction mixture and extract with acetic acid ethylester. Wash the organic solution with saturated sodium chloride, dry over sodium sulfate, press and, after purification through chromatography in silica gel, 40 mg of the compound in the title is obtained as a pH dependent 5-(E/Z)-isomer mixture.

1H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer): δ=1.27 (t, 3H); 2.43 (m, 4H); 2.52 (m, 2H); 2.74 (m, 2H); 3.59 (m, 4H); 4.17 (m, 2H); 4.23 (q, 2H); 6.95 (d, 1H); 7.11 (d, 1H); 7.19-7.30 (m, 2H); 8.18 (s, 1H); 8.32 (s, 1H); 10.39 (s, 1H) ppm.

The following compounds are manufactured according to the process described above.

Ex-			Molecular
am-			Weight/	Educt/
ple			MS(ESI)	Additional
No.	Structure and name	1H-NMR	[M + 1]+	synthesis
15		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.06(t, 3H); 1.23(t, 3H); 1.51-1.91(m, 4H); 2.44(m, 1H); 2.62-2.75(m, 1H); 3.01-3.77(m, 4H); 3.38(m, 2H); 3.54(d, 1H); 4.22(q, 2H); 4.68(t, 1H); 6.97(s, 1H); 7.20-7.32(m, 2H); 7.56-7.78(m, 2H); 8.04(s, 1H); 9.81(s, 1H); 10.40(s, 1H) ppm.	498.61/ 499	7/8
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-{3-
	[2-((S)-2-hydroxymethyl-pyrrolidin-
	1-yl)-acetylamino]-phenylamino}-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
16		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.23(t, 3H); 1.69(s, 4H); 3.20(pentuplet, 2H); 4.21(q, 2H); 7.00(5, 1H); 7.21-7.33(m, 2H); 7.52-7.77(m, 2H); 8.02(5, 1H); 10.03(s, 1H); 10.38(s, 1H) ppm.	450.52/ 451	6/2
	1-Cyano-cyclopropanecarboxylic
	acid(3-{[2-[1-cyano-1-
	ethylcarbamoyl-meth-(E or Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(5-(E/Z))-ylidenemethyl]-amino}-
	phenyl)-amide
17		(CDCl3, stored via K2CO3, primary isomer): δ =1.21(t, 3H); 1.39(t, 3H); 1.85-1.97(m, 4H); 3.30-3.48(m, 2H); 3.89-4.11(m, 2H); 4.37(m, 2H); 4.48(m, 1H); 6.19(m, 1H); 6.80(d, 1H); 7.05(d, 1H); 7.25-7.42(m, 1H); 7.58(d, 1H); 7.70(s, 1H); 8.56(s, 1H); 10.49(d, 1H) ppm.	455.54/ 456	6/2
	Tetrahydro-furan-2-carboxylic acid
	(3-{[2-[1-cyano-1-ethylcarbamoyl-
	meth-(E or Z)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(5-(E/Z))-
	ylidenemethyl]-amino}-phenyl)-
	amide
18		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.93(d, 6H); 1.08(t, 3H); 1.24(t, 3H); 1.93(m, 1H); 3.20(pentuplet, 2H); 3.89(d, 2H); 4.22(q, 2H); 7.39(s, 1H), 7.09(d, 1H); 7.21(t, 1H); 7.49(s, 1H); 7.68(s, 1H); 8.00(s, 1H); 9.68(s, 1H); 10.40(s, 1H) ppm.	457.55/ 458	6/7
	(3-{[2-[1-Cyano-1-ethylcarbamoyl-
	meth-(E or Z)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(5-(E/Z))-
	ylidenemethyl]-amino}-phenyl)-
	carbamic acidisobutyl ester
19		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.24(t, 3H); 3.20(pentuplet, 2H); 4.21(q, 2H); 5.28(m, 1H); 6.27(m, 1H); 6.44(m, 1H); 6.91-7.04(m, 1H); 7.21-7.32(m, 2H); 7.69(m, 1H); 7.77(s, 1H); 8.00(s, 1H); 10.22(s, 1H) ppm.	411.48/ 412	6/2
	N-(3-{[2-[1-Cyano-1-
	ethylcarbamoyl-meth-(E or Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(5-(E/Z))-ylidenemethyl]-amino}-
	phenyl)-acrylamide
20		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.88(t, 3H); 1.08(t, 3H); 1.18-1.38(m, 5H); 1.49(pentuplet, 2H); 3.21(pentuplet, 2H); 3.42(t, 2H); 3.57(t, 2H); 3.68(t, 2H); 4.10(s, 2H); 4.23(q, 2H); 6.99(m, 1H); 7.21-7.32(m, 2H); 7.64-7.78(m, 2H); 8.01(d, 1H); 9.69(s, 1H); 10.40(d, 1H) ppm.	515.63/ 516	6/2
	2-[5-[1-{3-[2-(2-Butoxy-ethoxy)-
	acetylamino]-phenylamino}-meth-
	(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-2-
	cyano-N-ethyl-acetamide
21		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 3.21(pentuplet, 2H); 4.22(q, 2H); 7.04(s, 1H); 7.23-7.35(m, 2H); 7.53-7.67(m, 2H); 8.05(s, 1H); 10.30-11.20(b, 2H) ppm.	453.44/ 454	6/2
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-[3-(2,2,2-trifluoro-
	acetylamino)-phenylamino]-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
22		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.00-1.14(m, 6H); 1.26(t, 3H); 3.32(q, 2H); 3.21(pentuplet, 2H); 4.22(q, 2H); 6.92(d, 1H); 7.14-7.29(m, 2H); 7.61-7.74(m, 2H); 7.99(s, 1H); 9.92(s, 1H); 10.40(s, 1H) ppm.	413.50/ 414	6/2
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-(3-propionylamino-
	phenylamino)-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
23		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.09(t, 3H); 1.24(t, 3H); 2.05(s, 3H); 3.21(pentuplet, 2H); 4.22(q, 2H); 6.94(d, 1H); 7.16(d, 1H); 7.24(t, 1H); 7.60-7.76(m, 2H); 7.99(s, 1H); 10.00(s, 1H); 10.40(s, 1H) ppm.	399.47/ 400	6/2
	2-[5-[1-(3-Acetylamino-
	phenylamino)-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-2-cyano-N-ethyl-
	acetamide
24		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.09(t, 3H); 1.26(t, 3H); 3.21(pentuplet, 2H); 3.39(s, 3H); 4.02(s, 2H); 4.22(q, 2H); 6.98(d, 1H); 7.26(t, 1H); 7.34(d, 1H); 7.71(t, 1H); 7.76(s, 1H); 8.00(d, 1H); 9.82(s, 1H); 10.40(d, 1H) ppm.	429.50/ 430	6/2
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-[3-
	(2-methoxy-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
25		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 2.55(t, 2H); 3.20(pentuplet, 2H); 3.25(s, 3H); 3.62(t, 2H); 4.22(q, 2H); 6.93(d, 1H), 7.19(d, 1H); 7.24(t, 1H); 7.58-7.79(m, 2H); 8.00(s, 1H), 10.00(s, 1H); 10.38(s, 1H) ppm.	443.53/ 444	6/2
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-[3-
	(3-methoxy-propionylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
26		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.24(t, 3H); 1.70(m, 4H); 2.39-2.60(m, 6H); 2.73(t, 2H); 3.20(pentuplet, 2H); 4.23(q, 2H); 6.96(d, 1H); 7.16(d, 1H); 7.25(t, 1H); 7.65-7.77(m, 2H); 7.99(d, 1H); 10.14(s, 1H); 10.39(d, 1H) ppm.	482.60/ 483	19/3
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-[3-(3-pyrrolidin-1-yl-
	propionylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
27		(DMSO-d6, stored via K2CO3, primary isomer): δ =1 .08(t, 3H); 1.27(t, 3H); 1.68(m, 4H); 2.47(m, 4H); 2.64(m, 2H); 2.72(m, 2H); 3.20(pentuplet, 2H); 4.22(q, 2H); 6.92(d, 1H); 7.10(d, 1H); 7.16-7.28(m, 2H); 7.70(t, 1H); 8.09(s, 1H); 10.24(s, 1H) ppm.	439.58/ 440	INTA1/1
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
28		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 1.68(m, 4H); 2.48(m, 4H); 2.62(m, 2H); 2.73(m, 2H); 3.06(s,b, 1H); 3.93(m, 2H); 4.23(q, 2H); 6.93(d, 1H); 7.10(d, 1H); 7.16-7.30(m, 2H); 8.08(t, 1H); 8.12(s, 1H); 10.30(s, 1H) ppm.	449.58/ 450	INTA1/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-pyrrolidin-1-yl-ethyl)-
	phenylamino]-meth-(E/Z)-ylidene]-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
29		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 1.68(m, 4H); 2.50(m, 4H); 2.64(m, 2H); 2.73(m, 2H); 4.17(d, 2H); 4.23(q, 2H); 6.94(d, 1H); 7.10(d, 1H); 7.17-7.31(m, 2H); 8.16(5, 1H); 8.35(s, 1H); 10.38(s, 1H) ppm.	450.56/ 451	INTA1/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-
	ethyl)-phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
30		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 1.70(m, 4H); 2.47(m, 4H); 2.63(m, 2H); 2.74(m, 2H); 3.97(m, 2H); 4.25(q, 2H); 6.95(d, 1H); 7.12(d, 1H); 7.19-7.30(m, 2H); 8.15(5, 1H); 8.21(t, 1H); 10.38(s, 1H) ppm.	493.55/ 494	INTA1/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-pyrrolidin-1-yl-ethyl)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2,2,2-trifluoro-ethyl)-acetamide
31		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.19-1.30(m, 12H); 4.16(d, 2H); 4.24(q, 2H); 6.95(d, 1H); 7.24(t, 1H); 7.37(d, 1H); 7.72(5, 1H); 8.09(s, 1H); 8.32(s, 1H); 9.25(s, 1H); 10.53(s, 1H) ppm.	452.54/ 453	INTA1/1
	2-Cyano-N-cyanomethyl-2-[5-[1-[3-
	(2,2-dimethyl-propionylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
32		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.38(s, 6H); 3.08(s,b, 1H); 3.93(m, 2H); 4.24(q, 2H); 5.76(s, 1H); 6.97(d, 1H); 7.25(t, 1H); 7.43(d, 1H); 7.87(s, 1H); 8.00-8.16(m, 2H); 9.65(s, 1H); 10.42(d, 1H) ppm.	453.52/ 454	INTA10/1
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-
	hydroxy-2-methyl-propionylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-prop-2-ynyl-acetamide
33		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.27(t, 3H); 1.37(s, 6H); 4.17(d, 2H); 4.25(d, 2H); 5.76(s, 1H); 6.98(d, 1H); 7.26(t, 1H); 7.45(d, 1H); 7.38(s, 1H); 8.09(d, 1H); 8.34(t, 1H); 9.66(s, 1H); 10.50(d, 1H) ppm.	454.51/ 455	INTA10/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-[3-(2-hydroxy-2-methyl-
	propionylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
34		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.27(t, 3H); 1.35(s, 6H); 3.95(m, 2H); 4.25(q, 2H); 5.75(s, 1H); 6.08(d, 1H); 7.25(t, 1H); 7.43(d, 1H); 7.88(s, 1H); 8.09(d, 1H); 8.21(t, 1H); 9.65(s, 1H); 10.48(d, 1H) ppm.	497.50/ 498	INTA10/1
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-
	hydroxy-2-methyl-propionylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))
	ylidene]-N-(2,2,2-trifluoro-ethyl)-
	acetamide
35		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.18(t, 3H); 1.25(t, 3H); 1.35(s, 6H); 3.21(pentuplet, 2H); 4.24(q, 2H); 5.75(s, 1H); 6.96(d, 1H); 7.24(t, 1H); 7.42(d, 1H); 7.70(t, 1H); 7.85(s, 1H); 8.03(d, 1H); 9.64(s, 1H); 10.36(d, 1H) ppm.	443.53/ 444	INTA10/1
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-[3-
	(2-hydroxy-2-methyl-
	propionylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
36		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 3.06(m, 1H); 3.31(s, 3H); 3.54(m, 2H); 3.68(m, 2H); 3.93(m, 2H); 4.10(s, 2H); 4.23(q, 2H); 7.01(m, 1H); 7.23-7.34(m, 2H); 7.75(s, 1H); 8.03(d, 1H); 8.10(t, 1H); 9.70(s, 1H); 10.45(d, 1H) ppm.	483.55/ 484	INTA5/1
	2-Cyano-2-[3-ethyl-5-[1-{3-[2-(2-
	methoxy-ethoxy)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-prop-2-ynyl-acetamide
37		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 3.31(s, 3H); 3.54(m, 2H); 3.69(m, 2H); 3.97(m, 2H); 4.10(s, 2H); 4.25(q, 2H); 7.01(m, 1H); 7.22-7.34(m, 2H); 7.76(s, 1H); 8.07(d, 1H); 8.23(t, 1H); 9.71(s, 1H); 10.51(d, 1H) ppm.	527.52/ 528	INTA5/1
	2-Cyano-2-[3-ethyl-5-[1-{3-[2-(2-
	methoxy-ethoxy)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-(2,2,2-trifluoro-ethyl)-
	acetamide
38		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 3.31(s, 3H); 3.54(m, 2H); 3.68(m, 2H); 4.10(5, 2H); 4.18(d, 2H); 4.25(q, 2H); 7.02(m, 1H); 7.23-7.35(m, 2H); 7.75(s, 1H); 8.08(d, 1H); 8.35(t, 1H); 9.71(s, 1H); 10.55(d, 1H) ppm.	484.54/ 485	INTA5/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-{3-[2-(2-methoxy-ethoxy)-
	acetylamino]-phenylamino}-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
39		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.09(t, 3H); 1.18-1.30(m, 12H); 3.21(m, 2H); 4.23(q, 2H); 6.78(dd, 1H); 7.63-7.79(m, 3H); 8.74(s, 1H); 9.68(s, 1H); 10.67(s, 1H) ppm.	442.54/ 443	INTA3/1
	2-Cyano-2-[5-[1-[6-(2 ,2-dimethyl-
	propionylamino)-pyridin-2-ylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	ethyl-acetamide
40		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.19-1.31(m, 12H); 3.08(m, 1H); 3.92(m, 2H); 4.22(q, 2H); 6.78(dd, 1H); 7.65-7.76(m, 2H); 8.14(s, 1H); 8.78(s, 1H); 9.68(s, 1H); 10.75(s, 1H) ppm.	452.54/ 453	INTA3/1
	2-Cyano-2-[5-[1-[6-(2,2-dimethyl-
	propionylamino)-pyridin-2-ylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
41		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.15-1.31(m, 12H); 3.95(m, 2H); 4.22(q, 2H); 6.71(d, 1H); 7.58-7.72(m, 2H); 8.02(s, 1H); 8.88(s, 1H); 9.55(s, 1H); 10.80(s, 1H) ppm.	496.51/ 497	INTA3/1
	2-Cyano-2-[5-[1-[6-(2,2-dimethyl-
	propionylamino)-pyridin-2-ylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2,2,2-trifluoro-ethyl)-acetamide
42		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.19-1.32(m, 12H); 4.18(d, 2H); 4.25(q, 2H); 6.80(d, 1H); 7.65-7.78(m, 2H); 8.40(t, 1H); 8.80(s, 1H); 9.70(s, 1H); 10.81(s, 1H) ppm.	453.52/ 454	INTA3/1
	2-Cyano-N-cyanomethyl-2-[5-[1-[6-
	(2,2-dimethyl-propionylamino)-
	pyridin-2-ylamino]-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(2-(E or Z))-ylidene]-acetamide
43		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 3.21(m, 2H); 3.33(5, 3H); 3.52(m, 2H); 3.69(m, 2H); 4.15(s, 2H); 4.22(q, 2H); 6.79(dd, 1H); 7.64-7.81(m, 3H); 8.67(s, 1H); 9.94(s, 1H); 10.75(s, 1H) ppm.	474.54/ 475	INTA6/1
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-{6-
	[2-(2-methoxy-ethoxy)-
	acetylamino]-pyridin-2-ylamino}-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
44		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 3.09(m, 1H); 3.35(s, 3H); 3.51(m, 2H); 3.69(m, 2H); 3.92(m, 2H); 4.15(s, 2H); 4.22(q, 2H); 6.82(dd, 1H); 7.69-7.81(m, 2H); 8.17(t, 1H); 8.68(s, 1H); 9.99(s, 1H); 10.85(s, 1H) ppm.	484.53/ 485	INTA6/1
	2-Cyano-2-[3-ethyl-5-[1-{6-[2-(2-
	methoxy-ethoxy)-acetylamino]-
	pyridin-2-ylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-prop-2-ynyl-
	acetamide
45		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 3.33(5, 3H); 3.51(m, 2H); 3.69(m, 2H); 3.97(m, 2H); 4.15(s, 2H); 4.24(q, 2H); 6.80(dd, 1H); 7.68-7.82(m, 2H); 8.28(t, 1H); 8.70(s, 1H); 9.99(s, 1H); 10.87(s, 1H) ppm.	528.51/ 529	INTA6/1
	2-Cyano-2-[3-ethyl-5-[1-{6-[2-(2-
	methoxy-ethoxy)-acetylamino]-
	pyridin-2-ylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-(2,2,2-trifluoro-
	ethyl)-acetamide
46		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 3.34(s, 3H); 3.52(m, 2H); 3.69(m, 2H); 4.08-4.32(m, 6H); 6.79(d, 1H); 7.65-7.81(m, 2H); 8.35(s, 1H); 8.73(s, 1H); 9.95(s, 1H); 10.88(s, 1H) ppm.	485.52/ 486	INTA6/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-{6-[2-(2-methoxy-ethoxy)-
	acetylamino]-pyridin-2-ylamino}-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
47		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.99-1.17(m, 6H); 1.25(t, 3H); 3.12-3.29(m, 4H); 4.21(q, 1H); 6.22(s, 1H); 6.38-6.50(m, 2H); 7.75(t, 1H); 7.83(d, 1H); 7.99(d, 1H); 10.20(d, 1H) ppm.	386.48/ 387	INTA2/1
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-(2-
	ethylamino-pyridin-4-ylamino)-
	ineth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
48		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.11(t, 3H); 1.26(t, 3H); 3.07(m, 1H); 3.23(m, 2H); 3.92(m, 2H); 4.22(q, 2H); 6.28(d, 1H); 6.44(dd, 1H); 6.53(t, 1H); 7.84(d, 1H); 8.01(d, 1H); 8.17(t, 1H); 10.30(d, 1H) ppm.	396.47/ 397	INTA2/1
	2-Cyano-2-[3-ethyl-5-[1-(2-
	ethylamino-pyridin-4-ylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
49		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.11(t, 3H); 1.26(t, 3H); 3.22(m, 2H); 3.97(m, 2H); 4.24(q, 2H); 6.24(d, 1H); 6.40-6.50(m, 2H); 7.84(d, 1H); 8.03(s, 1H); 8.27(t, 1H); 10.31(s, 1H) ppm.	440.45/ 441	INTA2/1
	2-Cyano-2-[3-ethyl-5-[1-(2-
	ethylamino-pyridin-4-ylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2,2,2-trifluoro-ethyl)-acetamide
50		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.11(t, 3H); 1.26(t, 3H); 3.22(m, 2H); 4.18(d, 2H); 4.23(q, 2H); 6.26(d, 1H); 6.38-6.51(m, 2H); 7.35(d, 1H); 8.06(d, 1H); 8.40(t, 1H); 10.34(d, 1H) ppm.	397.46/ 398	INTA2/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-(2-ethylamino-pyridin-4-
	ylamino)-meth-(E/Z)-ylidene]-4-
	oxo-thiazolidin-(2-(E orZ))-
	ylidene]-acetamide
51		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 3.21(pentuplet, 2H); 4.23(q, 2H); 4.50(d, 2H); 5.24(t, 1H); 7.00(d, 1H); 7.14(d, 1H); 7.23-7.33(m, 2H); 7.69(t, 1H); 8.08(5, 1H); 10.33(5, 1H) ppm.	372.45/ 373	INTT7/4
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1(3-
	hydroxymethyl-phenylamino)-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
52		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 1.41(m, 2H); 1.59(m, 4H); 2.45(m, 4H); 3.01-3.11(m, 3H); 3.92(m, 2H); 4.24(q, 2H); 7.00(d, 1H); 7.21-7.35(m, 2H); 7.72(s, 1H); 8.00-8.15(m, 2H); 9.71(s, 1H); 10.43(d, 1H) ppm.	492.60/ 493	INTT9 +INT20/5
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-piperidin-1-yl-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
53		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.27(t, 3H); 1.42(m, 2H); 1.58(m, 4H); 2.47(m, 4H); 3.08(s, 2H); 4.17(d, 2H); 4.24(q, 2H); 6.94-7.05(m, 1H); 7.21-7.34(m, 2H); 7.75(s, 1H); 8.09(d, 1H); 8.36(t, 1H); 9.74(5, 1H); 10.52(d, 1H) ppm.	493.59/ 494	INTT10 +INT20/5
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-[3-(2-piperidin-1-yl-
	acetylamino)-phenylamino]-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
54		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.27(t, 3H); 1.41(m, 2H); 1.59(m, 4H); 2.45(m, 4H); 3.08(s, 2H); 3.97(m, 2H); 4.24(q, 2H); 7.00(d, 1H); 7.21-7.34(m, 2H); 7.74(s, 1H), 8.08(s, 1H); 8.21(t, 1H); 9.72(s, 1H); 10.50(s, 1H) ppm.	536.58/ 537	INTT8 +INT20/5
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-piperidin-1-yl-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2,2 ,2-trifluoro-ethyl)-acetamide
55		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 1.77(m, 4H); 2.60(m, 4H); 3.21(pentuplet, 2H); 3.26(s, 2H); 4.23(q, 2H); 6.97(d, 2H); 7.20-7.37(m, 2H); 7.62-7.78(m, 2H); 8.02(s, 1H); 9.76(s, 1H); 10.39(s, 1H) ppm.	468.58/ 469	INTT7 +INT22/5
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-[3-(2-pyrrolidin-1-yl-
	acetylamino)-phenylamino]-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
56		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 1.76(m, 4H); 2.60(m, 4H); 3.05(m, 1H); 3.25(s, 2H); 3.91(m, 2H); 4.23(q, 2H), 6.88(s, 1H); 7.20(t, 1H); 7.29(d, 1H); 7.61(s, 1H); 7.73-8.01(b, 1H); 8.12(s, 1H); 9.70(s, 1H); 10.45(s, 1H) ppm.	478.57/ 479	INTT9 +INT22/5
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-pyrrolidin-1-yl-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
57		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 1.87(m, 4H); 3.02(m, 4H); 3.80(s, 2H); 4.17(d, 2H); 4.24(q, 2H); 6.99-7.09(m, 1H); 7.24-7.38(m, 2H); 7.74(s, 1H); 8.07(d, 1H); 8.36(t, 1H); 10.35(s, 1H); 10.58(d, 1H) ppm.	479.56/ 480	INTT10 +INT22/5
	2-Cyano-N-cyanoinethyl-2-[3-ethyl-
	4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-
	acetylamino)-phenylamino]-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
	Z))-ylidene]-acetamide
58		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 1.75(m, 4H); 2.60(m, 4H); 3.25(s, 2H); 3.96(m, 2H); 4.24(q, 2H); 6.98(d, 1H); 7.21-7.38(m, 2H), 7.75(s, 1H); 8.08(s, 1H); 8.21(t, 1H); 9.78(s, 1H); 10.50(s, 1H) ppm.	522.55/ 523	INTT8 +INT22/5
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-pyrrolidin-1-yl-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2,2,2-trifluoro-ethyl)-acetamide
59		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 2.51(m, 4H); 3.06(m, 1H); 3.13(s, 2H); 3.65(m, 4H); 3.92(m, 2H); 4.24(q, 2H); 6.95(s, 1H); 7.20-7.33(m, 2H); 7.67 Cs, 1H); 7.92-8.15(m, 2H); 9.78(s, 1H); 10.45(s, 1H) ppm.	494.57/ 495	INTT9 +INT24/5
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-
	morpholin-4-yl-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-prop-2-ynyl-acetamide
	ylidene]-N-prop-2-ynyl-acetamide
60		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.27(t, 3H); 2.51(m, 4H); 3.15(s, 2H); 3.64(m, 4H); 4.15(d, 2H); 4.24(q, 2H); 6.96-7.06(m, 1H); 7.23-7.36(m, 2H); 7.74(s, 1H); 8.08(d, 1H); 8.35(t, 1H); 9.81(s, 1H); 10.53(d, 1H) ppm.	495.56/ 496	INTT10 +INT24/5
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-[3-(2-morpholin-4-yl-
	acetylamino)-phenylamino]-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
61		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.27(t, 3H); 2.51(m, 4H); 3.14(s, 2H); 3.64(m, 4H); 3.97(m, 2H); 4.25(q, 2H); 6.95-7.04(m, 1H); 7.22-7.33(m, 2H); 7.73(s, 1H); 8.07(d, 1H); 8.21(t, 1H); 9.80(s, 1H); 10.50(d, 1H) ppm.	538.55/ 539	INTT8 +INT24/5
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-
	morpholin-4-yl-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-(2,2,2-trifluoro-ethyl)-
	acetamide
62		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 2.50(m, 4H); 3.13(s, 2H); 3.20(m, 2H); 3.65(m, 4H); 4.23(q, 2H); 6.91-7.02(m, 1H); 7.20-7.33(m, 2H); 7.63-7.75(m, 2H); 8.01(s, 1H); 9.79(s, 1H); 10.39(s, 1H) ppm.	484.58/ 485	INTT7 +INT24/5
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-[3-
	(2-morpholin-4-yl-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))
	ylidene]-acetamide
63		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.19-1.30(m, 12H); 3.07(m, 1H); 3.92(m, 2H); 4.23(q, 2H); 7.09-7.18(m, 1H); 7.22(t, 1H); 7.51(m, 1H); 8.02(d, 1H); 8.10(t, 1H); 9.08(5, 1H); 10.39(d, 1H) ppm.	469.54/ 470	INTT9 +INT19/5
	2-Cyano-2-[5-[1-[3-(2,2-dimethyl-
	propionylamino)-4-fluoro-
	propionylamino)-4-fluoro-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-prop-2-ynyl-
	acetamide
64		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.16-1.31(m, 12H); 4.17(d, 2H); 4.23(q, 2H); 7.11-7.19(m, 1H); 7.24(t, 1H); 7.03(m, 1H); 8.07(d, 1H); 8.36(t, 1H); 9.09(s, 1H); 10.45(d, 1H) ppm.	470.53/ 471	INTT10 +INT19/5
	2-Cyano-N-cyanomethyl-2-[5-[1-[3-
	(2,2-dimethyl-propionylamino)-4-
	fluoro-phenylamino]-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(2-(E or Z))-ylidene]-acetamide
65		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.17-1.33(m, 12H); 3.97(m, 2H); 4.23(q, 2H); 7.11(s, 1H); 7.21(t, 1H); 7.49(s, 1H); 8.08(s, 1H); 8.13(s, 1H); 9.06(s, 1H); 10.44(s, 1H) ppm.	513.51/ 514	INTT8 +INT19/5
	2-Cyano-2-[5-[1-[3-(2,2-dimethyl-
	propionylamino)-4-fluoro-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-(2,2,2-trifluoro-
	ethyl)-acetamide
66		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.15-1.30(m, 12H); 3.20(pentuplet, 2H); 4.21(q, 2H); 7.08-7.16(m, 1H); 7.21(t, 1H); 7.51(m, 1H); 7.70(t, 1H); 8.00(s, 1H); 9.08(s, 1H); 10.31(s, 1H) ppm.	459.54/ 460	INTT7 +INT19/5
	2-Cyano-2-[5-[1-[3-(2,2-dimethyl-
	propionylamino)-4-fluoro-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-ethyl-acetamide
67		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 2.72(t, 2H); 3.07(m, 1H); 3.62(q, 2H); 3.92(m, 2H); 4.23(q, 2H); 4.65(t, 1H); 6.92(d, 1H); 7.11(d, 1H); 7.17(s, 1H); 7.23(t, 1H); 8.06(s, 1H); 8.12(5, 1H); 10.33(s, 1H) ppm.	396.47/ 397	INTA8/1
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-
	hydroxy-ethyl)-phenylamino]-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-
	(E or Z))-ylidene]-N-prop-2-ynyl-
	acetamide
68		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 3.01(t, 2H); 3.07(m, 1H); 3.12(s, 3H); 3.93(m, 2H); 4.24(q, 2H); 4.43(t, 2H), 7.00(d, 1H); 7.18(d, 1H); 7.23-7.34(m, 2H); 8.09(t, 1H); 8.16(s, 1H); 10.32(s, 1H) ppm.	474.56/ 475	67/12
	Methanesulfonic acid 2-(3-{[2-[1-
	cyano-1-prop-2-ynylcarbamoyl-
	meth-CE or Z)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(5-(E/Z))-
	ylidenemethyl]-amino}-phenyl)-
	ethyl ester
69		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 3.06(m, 1H); 3.13(t, 2H); 3.50(t, 2H); 3.92(m, 2H); 4.21(q, 2H); 6.96(d, 1H); 7.16(d, 1H); 7.20-7.32(m, 2H); 8.08(s,b, 1H); 8.15(s, 1H); 10.31(s, 1H) ppm.	506.37/ 507	68/13
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-iodo-
	ethyl)-phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-prop-2-ynyl-
	Z))-ylidene]-N-prop-2-ynyl-
	acetamide
70		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 1.39(m, 1H); 1.50(m, 4H); 2.30-2.52(m, 6H); 2.72(m, 2H); 3.07(m, 1H); 3.92(m, 2H); 4.24(q, 2H); 6.93(d, 1H); 7.11(d, 1H); 7.17-7.29(m, 2H); 8.04-8.18(m, 2H); 10.30(s,b, 1H) ppm.	463.60/ 646	69/14
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-piperidin-1-yl-ethyl)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
71		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 2.72(t, 2H); 3.61(q, 2H); 4.17(d, 2H); 4.23(q, 2H); 4.65(t, 1H); 6.93(d, 1H); 7.13(d, 1H); 7.19(s, 1H); 7.24(t, 1H); 8.15(5, 1H); 8.32(t, 1H); 10.41(s, 1H) ppm.	397.46/ 398	INTA8/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-[3-(2-hydroxy-ethyl)-
	phenylamino]-meth-(E/Z)-ylidene]-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
72		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 1.39(m, 2H); 1.50(m, 4H); 2.40(m, 4H); 2.49(1, 2H); 2.53(t, 2H); 4.16(d, 2H); 4.25(q, 2H); 6.94(d, 1H); 7.11(d, 1H); 7.16-7.30(m, 2H); 8.16(5, 1H); 8.32(s, 1H); 10.48(s,b, 1H) ppm.	464.59/ 465	13/14
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-[3-(2-piperidin-1-
	ethyl)-phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
73		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.88(d, 3H); 1.02-1.20(m, 2H); 1.20-1.39(m, 4H); 1.57(d, 2H); 1.91(t,2H); 2.40-2.55(m, 2H); 2.71(t, 2H); 2.88(d, 2H); 4.17(m, 2H); 4.23(q, 2H); 6.93(d, 1H); 7.10(d, 1H); 7.26-7.30(m, 2H); 8.18(s, 1H); 8.31(s, 1H); 10.39(s, 1H) ppm.	478.62/ 479	13/14
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-{3-[2-(4-methyl-piperidin-1-yl)-
	ethyl]-phenylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
74		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 2.51-2.67(m, 6H); 2.67-2.81(m, 6H); 4.17(m, 2H); 4.24(q, 2H); 6.93(d, 1H); 7.11(d, 1H); 7.20(s, 1H); 7.24(t, 1H); 8.17(s, 1H); 8.32(s, 1H); 10.39(s, 1H) ppm.	482.63/ 483	13/14
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-[3-(2-thiomorpholin-4-yl-
	ethyl)-phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
75		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 1.85-2.07(m, 4H); 2.50-2.67(m, 6H); 2.75(m, 2H); 4.17(d, 2H); 4.26(q, 2H); 6.93(d, 1H); 7.10(m, 1H); 7.15-7.31(m, 2H), 8.18(s, 1H); 8.28(s,b, 1H); 10.39(s, 1H) ppm.	500.57/ 501	13/14
	2-Cyano-N-cyanomethyl-2-[5-[1-{3-
	[2-(4,4-difluoro-piperidin-1-yl)-
	ethyl]-phenylamino}-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(2-(E or Z))-ylidene]-acetamide
76		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 1.36-1.52(m, 2H); 1.78(d, 2H); 1.99(t, 2H); 2.13-2.36(m, 1H); 2.54(m, 2H); 2.73(m, 2H); 3.01(d, 2H); 4.16(m, 2H); 4.23(q, 2H); 6.92(d, 1H); 7.01-7.30(m, 3H); 8.19(s, 1H); 8.27(s, 1H); 10.40(s, 1H) ppm.	532.59/ 533	13/14
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-{3-[2-(4-trifluoromethyl-
	piperidin-1-yl)-ethyl]-phenylamino}-
	meth-(E/Z)-ylidene]-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
77		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 1.56-1.99(m, 4H); 2.09(t, 2H); 2.56(m, 2H); 2.76(m, 2H); 3.04(d, 2H); 4.13(d, 2H), 4.24(q, 2H); 6.94(d, 1H); 7.01-7.40(m, 8H); 8.10-8.35(m, 2H); 10.40(5, 1H) ppm.	540.69/ 541	13/14
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-{3-[2-(4-phenyl-
	piperidin-1-yl)-ethyl]-phenylamino}-
	meth-(E/Z)-ylidene]-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
78		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 4.17(d, 2H); 4.23(q, 2H); 5.31(d, 1H); 5.90(d, 1H); 6.74(dd, 1H); 7.13-7.26(m, 2H); 7.32(t, 1H); 7.44(s, 1H); 8.20(s, 1H); 8.34(t, 1H); 10.41(s, 1H) ppm.	379.44/ 380	13/14
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-(3-vinyl-phenylamino)-
	meth-(E/Z)-ylidene]-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
79		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.06(t, 3H); 1.23(t, 3H); 1.49(s, 9H); 3.20(m, 2H); 4.22(q, 2H); 6.88(d, 1H); 7.14(d, 1H); 7.20(t, 1H); 7.55(s, 1H); 7.70(t, 1H); 7.99(d, 1H); 9.43(s, 1H); 10.39(d, 1H) ppm.	457.56/ 458	INTA9/1
	(3-{[2-[1-Cyano-1-ethylcarbamoyl-
	meth-(E or Z)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(5-(E/Z))-
	ylidenemethyl]-amino}-phenyl)-
	carbamic acid tert-butyl ester
80		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 1.40(s, 9H); 2.48(m, 4H); 3.17(s, 3H); 3.21(m, 2H); 3.40(m, 4H); 4.23(q, 2H); 6.98(m, 1H); 7.21-7.34(m, 2H); 7.64-7.77(m, 2H); 8.02(s, 1H); 9.80(s, 1H); 10.39(s, 1H) ppm.	583.71/ 584	7/8
	4-[(3-{[2-[1-Cyano-1-
	ethylcarbamoyl-meth-(E or Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(5-(E/Z))-ylidenemethyl]-amino}-
	phenylcarbamoyl)-methyl]-
	piperazine-1-carboxylic acid tert-
	butyl ester
	butyl ester
81		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.00(t, 3H); 1.08(t, 3H); 1.24(t, 3H); 2.31(q, 2H); 2.40-2.60(m, 4H); 3.12-3.28(m, 4H), 3.50(m, 4H); 4.22(q, 2H); 6.98(m, 1H); 7.21-7.33(m, 2H); 7.61-7.76(m, 2H); 8.01(s, 1H); 9.80(s, 1H); 10.39(s, 1H) ppm.	539.66/ 540	80/9
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-{3-[2-(4-propionyl-piperazin-1-
	yl)-acetylamino]-phenylamino}-
	meth-(E/Z)-ylidene]-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
82		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.20(s, 9H); 1.26(t, 3H); 2.42-2.58(m, 4H); 3.17(s, 2H); 3.21(m, 2H); 3.61(m, 4H); 4.22(q, 2H); 6.99(d, 1H); 7.21-7.32(m, 2H); 7.62-7.76(m, 2H); 8.01(s, 1H); 9.80(s, 1H); 10.40(s, 1H) ppm.	567.72/ 568	80/10
	2-Cyano-2-[5-[1-(3-{2-[4-(2,2-
	dimethyl-propionyl)-piperazin-1-yl]-
	acetylamino}-phenylamino)-meth-
	(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	ethyl-acetamide
83		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 2.60(m, 4H); 2.99(m, 4H); 3.15(s, 2H); 3.20(m, 2H); 4.22(q, 2H); 6.92(s, 1H); 7.16-7.28(m, 2H); 7.52-7.82(m, 7H); 8.00(s, 1H); 9.67(s, 1H); 10.36(s, 1H) ppm.	623.76/ 624	80/10
	2-[5-[1-{3-[2-(4-Benzenesulfonyl-
	piperazin-1-yl)-acetylamino]-
	phenylamino}-ineth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-2-cyano-N-ethyl-
	acetamide
84		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.07(t, 3H); 1.24(t, 3H); 2.70(m, 4H); 2.79(m, 4H); 3.17(5, 2H); 3.20(m, 2H); 4.22(q, 2H); 6.97(d, 1H); 7.20-7.34(m, 2H); 7.55-7.77(m, 2H); 8.05(s, 1H); 9.71(s, 1H); 10.39(s, 1H) ppm.	500.65/ 501	7/8
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-[3-(2-thioinorpholin-4-yl-
	acetylamino)-phenylamino]-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
85		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 1.94-2.14(m, 4H); 2.67(m, 4H); 3.12-3.28(m, 4H); 4.22(q, 2H), 6.98(d, 1H); 7.21-7.35(m, 2H); 7.60-7.77(m, 2H); 8.01(s, 1H); 9.79(s, 1H); 10.39(s, 1H) ppm.	518.59/ 519	7/8
	2-Cyano-2-[5-[1-{3-[2-(4,4-difluoro-
	piperidin-1-yl)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-ethyl-acetamide
86		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.08(t, 3H); 1.25(t, 3H); 1.50-1.70(m, 2H); 1.80(d, 2H); 2.12-2.37(m, 3H); 2.95(d, 2H); 3.15(s, 2H); 3.21(m, 2H); 4.22(q, 2H); 6.99(d, 1H); 7.20-7.35(m, 2H); 7.64-7.76(m, 2H); 8.01(d, 1H); 9.73(s, 1H); 10.39(d, 1H) ppm.	550.61/ 551	7/8
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-{3-[2-(4-trifluoromethyl-
	piperidin-1-yl)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
87		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 1.49(s, 9H); 3.06(m, 1H); 3.92(m, 2H); 4.22(q, 2H); 6.89(d, 1H); 7.06(d, 1H); 7.20(t, 1H); 7.55(5, 1H); 7.94-8.13(m, 2H); 9.43(s, 1H); 10.44(5, 1H) ppm.	467.55/ 468	INTA9/1
	(3-{[2-[1-Cyano-1-prop-2-
	ynylcarbainoyl-meth-(E or Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(5-(E/Z))-ylidenemethyl]-amino}-
	phenyl)-carbamic acid tert-butyl
	ester
88		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 3.06(m, 1H); 3.92(m, 2H); 4.23(q, 2H); 6.27(d, 1H); 6.99-7.09(m, 2H); 7.29(t, 1H); 8.04(d, 1H); 8.13(t, 1H); 8.65(b, 3H); 10.40(d, 1H) ppm.	367.43/ 368	87/6
	2-[5-[1-(3-Amino-phenylamino)-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-2-
	cyano-N-prop-2-ynyl-acetamide
89		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 3.08(m, 1H); 3.93(m, 2H); 4.24(q, 2H); 7.17(m, 1H); 7.32-7.40(m, 2H), 7.70(s, 1H); 8.05(s, 1H); 10.50(s, 1H); 11.29(s, 1H) ppm.	463.44/ 464	87/9
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2,2,2-trifluoro-acetylamino)-
	phenyiamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
90		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 3.06(m, 1H); 3.92(m, 2H); 4.15-4.30(m, 4H); 7.02(d, 1H); 7.20(d, 1H); 7.30(t, 1H); 7.68(s, 1H); 7.99-8.15(m, 2H); 10.36(s, 1H); 10.48(s, 1H) ppm.	443.92/ 444	87/9
	2-[5-[1-[3-(2-Chloro-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-2-cyano-N-prop-2-ynyl-
	acetamide
	acetamide
91		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.91(d, 3H); 1.20-1.37(m, 6H); 1.60(d, 2H); 2.13(t, 2H); 2.83(d, 2H); 3.06(m, 1H); 3.09(s, 2H); 3.92(m, 2H); 4.24(q, 2H), 6.99(d, 1H); 7.21-7.35(m, 2H); 7.71(s, 1H); 7.98-8.15(m, 2H); 9.70(s, 1H); 10.45(s, 1H) ppm.	506.63/ 507	90/8
	2-Cyano-2-[3-ethyl-5-[1-{3[2-(4-
	methyl-piperidin-1-yl)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-prop-2-ynyl-acetamide
92		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 2.70(m, 4H); 2.79(m, 4H); 3.08(m, 1H); 3.18(s, 2H); 3.93(m, 2H); 4.24(q, 2H); 6.99(d, 1H); 7.21-7.36(m, 2H); 7.73(5, 1H); 8.00-8.15(m, 2H); 9.74(s, 1H); 10.45(s, 1H) ppm.	510.64/ 511	90/8
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-thiomorpholin-4-yl-acetylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
93		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 1.97-2.13(m, 4H); 2.68(m, 4H); 3.07(m, 1H); 3.24(s, 2H); 3.92(m, 2H); 4.22(q, 2H); 6.99(d, 1H); 7.22-7.36(m, 2H); 7.73(s, 1H); 8.00-8.15(m, 2H); 9.80(s, 1H); 10.47(s, 1H) ppm.	528.59/ 529	90/8
	2-Cyano-2-[5-[1-{3-[2-(4,4-difluoro-
	piperidin-1-yl)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-prop-2-ynyl-
	acetamide
94		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 1.50-1.70(m, 2H); 1.79(d, 2H); 2.13-2.36(m, 3H); 2.95(d, 2H); 3.08(m, 1H); 3.15(s, 2H); 3.92(m, 2H); 4.23(q, 2H); 6.99(d, 1H); 7.20-7.37(m, 2H); 7.71(s, 1H); 7.97-8.19(m, 2H); 9.75(s, 1H); 10.46(s, 1H) ppm.	560.60/ 561	90/8
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-{3-
	[2-(4-trifluoromethyl-piperidin-1-yl)-
	acetylamino]-phenylamino}-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-N-prop-2-ynyl-
	acetamide
95		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.26(t, 3H); 2.13(s, 3H); 4.17(d, 2H); 4.24(q, 2H); 4.66(s, 2H); 7.02(d, 1H); 7.20(d, 1H); 7.30(t, 1H); 7.69(s, 1H); 8.06(d, 1H); 8.35(t, 1H); 10.17(s, 1H); 10.54(d, 1H) ppm.	468.49/ 469	INTT10 +INT27/5
	Acetic acid(3-{[2-[1-cyano-1-
	(cyanomethyl-carbamoyl)-meth-(E
	or Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(5-(E/Z))-ylidenemethyl]-
	amino}-phenylcarbamoyl)-methyl
	ester
96		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 3.31(s, 3H); 4.17(d, 2H); 4.25(q, 2H); 4.88(s, 2H); 7.07(d, 1H); 7.24(d, 1H); 7.31(t, 1H); 7.70(s, 1H); 8.07(s,b, 1H); 8.37(5, 1H); 10.26(s, 1H); 10.57(s, 1H) ppm.	504.55/ 505	11/12
	Methanesulfonic acid(3-{[2-[1-
	cyano-1-(cyanomethyl-carbamoyl)-
	meth-(E or Z)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(5-(E/Z))-
	ylidenemethyl]-amino}-
	phenylcarbamoyl)-methyl ester
97		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 1.30(s, 6H); 3.31(5, 3H); 3.38(d, 2H); 3.55(m, 2H); 3.69(m, 2H); 4.09(s, 2H); 4.21(q, 2H); 5.20(t, 1H); 6.70(s, 1H); 7.01(m, 1H); 7.23-7.32(m, 2H); 7.74(s, 1H); 8.02(d, 1H); 9.70(s, 1H); 10.40(d, 1H) ppm.	517.60/ 518	INTA5/1
	2-Cyano-2-[3-ethyl-5-[1-{3-[2-(2-
	methoxy-ethoxy)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-(2-hydroxy-1,1-dimethyl-
	ethyl)-acetamide
98		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.23(t, 3H); 1.30(s, 6H); 3.32(s, 3H); 3.38(d, 2H); 3.51(m, 2H); 3.68(m, 2H); 4.15(s, 2H); 4.20(q, 2H), 5.71(t, 1H); 6.71(s, 1H); 6.80(d, 1H); 7.69-7.80(m, 2H); 8.69(s, 1H); 9.95(s, 1H); 10.75(5, 1H) ppm.	518.59/ 519	INTA6/1
	2-Cyano-2-[3-ethyl-5-[1-{6-[2-(2-
	methoxy-ethoxy)-acetylamino]-
	pyridin-2-ylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-N-(2-hydroxy-1
	dimethyl-ethyl)-acetamide
99		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.11(t, 3H); 1.24(t, 3H); 1.30(s, 6H); 3.22(m, 2H); 3.28(d, 2H); 4.20(q, 2H); 5.20(t, 1H); 6.23(s, 1H); 6.37-6.49(m, 2H); 6.71(s, 1H); 7.83(d, 1H); 8.00(s, 1H); 10.20(s, 1H) ppm.	430.53/ 431	INTA2/1
	2-Cyano-2-[3-ethyl-5-[1-(2-
	ethylamino-pyridin-4-ylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2-hydroxy-1,1-dimethyl-ethyl)-
	acetamide
100		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.06(t, 3H); 1.25(s, 9H); 1.30(s, 6H); 3.39(d, 2H); 4.21(q, 2H); 5.20(t, 1H); 6.72(s, 1H); 6.79(dd, 1H); 7.65-7.77(m, 2H); 8.55(s, 1H); 9.68(s, 1H); 10.68(s, 1H) ppm.	486.59/ 487	INTA3/1
	2-Cyano-2-[5-[1-[6-(2,2-dimethyl-
	propionylamino)-pyridin-2-ylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2-hydroxy-1,1-dimethyl-ethyl)
	acetamide
101		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.91(d, 3H); 1.15-1.40(m, 6H); 1.60(d, 2H); 2.11(t, 2H); 2.81(d, 2H); 3.09(s, 2H); 4.17(d, 2H); 4.23(q, 2H); 7.00(d, 1H); 7.21-7.35(m, 2H); 7.73(s, 1H); 8.10(s, 1H); 8.34(s, 1H); 9.71(s, 1H); 10.51(s, 1H) ppm.	507.62/ 508	96/8
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-{3-[2-(4-methyl-piperidin-1-yl)-
	acetylamino]-phenylamino}-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
102		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.74-1.02(m, 3H); 1.02-1.35(m, 7H); 1.43-1.88(m, 6H); 1.98(m, 1H); 2.35-2.53(m, 2H); 2.63-3.06(m, 4H); 4.16(d, 2H); 4.24(q, 2H); 6.93(d, 1H); 7.11(d, 1H); 7.18-7.31(m, 2H); 8.17(s, 1H); 8.36(t, 1H); 10.39(s, 1H) ppm.	518.69/ 519	13/14
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-{3-[(4a-(R or S),8a-(R or S))-2-
	(octahydro-isoquinolin-2-yl)-ethyl]-
	phenylamino}-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
103		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.26(m, 3H); 1.71 (m, 4H); 2.79(m, 2H); 3.06(m, 1H); 3.94(m, 2H); 4.10 (m, 2H); 4.28(m, 2H); 6.63(dd, 1H); 6.89(m, 2H); 7.22 (m, 1H); 8.13(m, 2H); 10.28(s, 1H).	465.58/ 466	INTA14/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-pyrrolidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-yiidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
104		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.02(m, 3H); 1.25 (m, 3H); 1.68(m, 4H); 2.79(m, 2H); 3.21(m, 2H); 4.09 (m, 2H); 4.22(m, 2H); 6.62(dd, 1H); 6.88(m, 2H); 7.22 (m, 1H); 7.70(m, 1H); 8.10(s, 1H); 10.18(s, 1H).	455.58/ 456	INTA14/1
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-[3-(2-pyrrolidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
105		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =0.22(m, 2H); 0.40 (m, 2H); 1.02(m, 1H); 1.26(m, 3H); 1.69(m, 4H); 2.79 (m, 2H); 3.03(m, 2H); 4.09(m, 2H); 4.22(m, 2H); 6.62 (dd, 1H); 6.88(m, 2H); 7.24(m, 1H); 7.73(m, 1H); 8.10 (s, 1H); 10.19(s, 1H).	481.62/ 482	INTA14/1
	2-Cyano-N-cyclopropylmethyl-2-[3-
	ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-
	yl-ethoxy)-phenylamino]-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
106		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.23(m, 3H); 1.68 (m, 4H); 2.80(m, 2H); 3.79(m, 2H); 4.09(m, 2H); 4.21 (m, 2H); 5.08(dd, 1H); 5.11(dd, 1H); 5.83(m, 1H); 6.62 (dd, 1H); 6.88(m, 1H); 7.22(m, 1H); 7.98(m, 1H); 8.12 (5, 1H); 10.20(s, 1H).	467.59/ 468	INTA14/1
	N-Allyl-2-cyano-2-[3-ethyl-4-oxo-5-
	[1-[3-(2-pyrrolidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
107		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.27(m, 3H); 1.70 (m, 4H); 2.81(m, 2H); 3.42(m, 1H); 3.50(m, 1H); 4.10 (m, 2H); 4.20(m, 2H); 4.42(m, 1H); 4.54(m, 1H); 6.63 (dd, 1H); 6.88(m, 2H); 7.21(m, 1H); 7.80(m, 1H); 8.12 (s, 1H); 10.22(s, 1H).	473.57/ 474	INTA14/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-pyrrolidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2-fluoro-ethyl)-acetamide
108		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.27(m, 3H); 1.69 (m, 4H); 2.79(m, 2H); 3.58(m, 2H); 4.10(m, 2H); 4.25 (m, 2H); 6.09(tt, 1H); 6.65(dd, 1H); 6.89(m, 2H); 7.24 (m, 1H); 7.97(m, 1H); 8.14(s, 1H); 10.28(s, 1H).	491.56/ 492	INTA14/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[3-
	ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-
	yl-ethoxy)-phenylamino]-meth-
	(E/Z)-ylidene]-hiazolidin-(2-(E or
	Z))-ylidene]-acetamide
109		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.22(m, 3H); 1.70 (m, 4H); 2.81(m, 2H); 3.96(m, 2H); 4.09(m, 2H); 4.22 (m, 2H); 6.66(dd, 1H); 6.88(m, 2H); 7.22(m, 1H); 8.18 (m, 2H); 10.29(s, 1H).	509.55/ 510	INTA14/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-pyrrolidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2,2,2-trifluoro-ethyl)-acetamide
110		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.26(m, 3H); 1.70 (m, 4H); 2.81(m, 2H); 4.09(m, 2H); 4.19(d, 2H); 4.23 (m, 2H); 6.64(dd, 1H); 6.89(m, 2H); 7.25(m, 1H); 8.18 (s, 1H); 8.35(m, 1H); 10.32(s, 1H).	466.56/ 467	INTA14/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-
	ethoxy)-phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
111		1H-NMR(CDCl3, 300 MHz) δ = 1.40 (m, 3H); 2.17(s, 3H); 2.61(m, 4H); 2.87(m, 2H); 3.71 (m, 4H); 3.97(m, 2H); 4.07(m, 2H); 4.35(m, 2H); 6.60 (m, 3H); 7.09(d, 1H); 7.57(m, 1H); 10.50(d, 1H).	MW: 539.58 MS (ESI) [M + 1]+: 540	INTA11/1
	2-Cyano-2-[3-ethyl-5-[1-[4-methyl-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-(2,2,2-trifluoro-ethyl)-
	acetamide
112		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.22(m, 3H); 2.10(s, 3H); 2.72 (m, 2H); 3.58(m, 4H); 4.11(m, 2H); 4.21(m, 2H); 6.05 (tt, 1H); 6.79(dd, 1H); 6.91(s, 1H); 7.08(d, 1H); 7.95 (m, 1H); 8.16(s, 1H); 10.27(s, 1H).	MW: 521.59 MS (ESI) [M + 1]+: 522	INTA11/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[3-
	ethyl-5-[1-[4-(-3-hydroxy-2-
	piperidin-1-yl-ethyl)-phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
113		1H-NMR(CDCl3, 300 MHz) δ = 1.39 (m, 3H); 2.17(s, 3H); 2.58(m, 4H); 2.86(m, 2H); 3.72 2H); 4.07(m, 2H); 4.36(m, 2H); 5.20 (m, 2H); 5.86(m, 1H); 6.27(m, 1H); 6.50(d, 1H); 6.58 (m, 1H); 7.08(d, 1H); 7.56(d, 1H); 10.45(d, 1H).	MW: 497.62 MS (ESI) [M + 1]+: 498	INTA11/1
	2-Cyano-N-(-2-difluoro-ethyl)-2-[3-
	piperidin-1-yl-ethyl)-phenylamino]-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
114		1H-NMR(CDCl3, 300 MHz) (selected peaks) δ =0.19(m, 2H); 0.50(m, 2H); 0.99 (m, 1H); 1.38(m, 2.12(s, 3H); 2.60(m, 4H); 3.17 (m, 2H); 3.70(m, 4H); 4.09(m, 2H); 4.32(m, 2H); 6.30 (m, 1H); 6.60(m, 2H); 7.05(m, 1H); 7.55(d, 1H); 10.42 (d, 1H).	MW: 511.64 MS (ESI) [M + 1]+: 512	INTA11/1
	2-Cyano-N-cyclopropylmethyl-2-[3-
	ethyl-5-[1-[4-methyl-3-(2-
	morpholin-4-yl-ethoxy)-3H);
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
115		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.10(m,3H); 1.22(m, 3H); 2.11 (s, 3H); 2.73(m, 2H); 3.21(m, 2H); 3.60(m, 4H); 4.11 (m, 2H); 4.21(m, 2H); 6.78(dd, 1H); 6.91(d, 1H); 7.08 (d, 1H); 7.68(m, 1H); 8.11(d, 1H); 10.16(d, 1H).	MW: 485.61 MS (ESI) [M + 1]+: 486	INTA11/1
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-[4-
	methyl-3-(2-morpholin-4-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
116		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.26(m, 3H); 2.18(s, 3H); 3.60 (m, 2H); 3.92(m, 4H); 4.11(s, 2H); 4.28(m, 2H); 4.49 (m, 2H); 6.88(dd, 1H); 6.97(5, 1H); 7.13(d, 1H); 8.21 (d, 1H); 10.43(d, 1H); 11.11(s, 1H).	MW: 496.59 MS (ESI) [M + 1]+: 497	INTA11/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-[4-methyl-3-(2-inorpholin-4-yl-
	ethoxy)-phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
117		1H-NMR(CDCl3, 300 MHz) δ = 1.40 (m, 3H); 2.19(s, 3H); 2.28(s, 1H); 2.65(m, 4H); 2.88 (m, 2H); 3.72(m, 4H); 4.15(m, 4H), 4.37(m, 2H); 6.36 (m, 1H); 6.50(d, 1H); 6.11(dd, 1H); 7.09(d, 1H), 7.53 (d, 1H); 10.48(d, 1H).	MW: 495.60 MS (ESI) [M + 1]+: 496	INTA11/1
	2-Cyano-2-[3-ethyl-5-[1-[4-methyl-
	3-(2-morpholin-4-yl-ethoxy)-
	3-(2-morpholin-4-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-prop-2-ynyl-acetamide
118		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.28(m, 3H); 1.38(m, 2H); 1.50 (m, 4H); 2.40(m, 4H); 2.68(m, 2H); 3.92(m, 2H); 4.03 (m, 2H); 4.21(m, 2H); 6.63(dd, 1H); 6.90(m, 2H); 7.24 (m, 1H); 8.20(m, 2H); 10.30(s, 1H).	MW: 523.58 MS (ESI) [M + 1]+: 524	INTA12/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-piperidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2,2,2-trifluoro-ethyl)-acetamide
119		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.29(m, 3H); 1.38(m, 2H); 1.49 (m, 4H); 2.42(m, 4H); 2.68(m, 2H); 3.57(m, 2H); 4.10 (m, 2H); 4.23(m, 2H); 6.08(tt, 1H); 6.62(dd, 1H); 6.98 (m, 2H); 7.22(m, 1H); 7.98(m, 1H); 8.12(s, 1H); 10.27 (s, 1H).	MW: 505.59 MS (ESI) [M + 1]+: 506	INTA12/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[3-
	ethyl-4-oxo-5-[1-[3-(2-piperidin-1-
	yl-ethoxy)-phenylamino]-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
120		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.28(m, 3H); 1.38(m, 2H); 1.50 (m, 4H); 2.42(m, 4H); 2.68(m, 2H); 3.47(m, 1H); 3.54 (m, 1H); 4.09(m, 2H); 4.21(m, 2H); 4.42(m, 1H); 4.59 (m, 1H); 6.63(dd, 1H); 6.89(m, 2H); 7.24(m, 1H); 7.82 (m, 1H); 8.10(s, 1H); 10.22(s, 1H).	MW: 487.60 MS (ESI) [M + 1]+: 488	INTA12/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-piperidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	(2-fluoro-ethyl)-acetamide
121		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.28(m, 3H); 1.39(m, 2H); 1.50 (m, 4H); 2.47(m, 4H); 2.68(m, 2H); 3.80.(m, 2H); 4.09 (m, 2H); 4.25(m, 2H); 5.09(dd, 1H); 5.12(dd, 1H); 5.85 (m, 1H); 6.62(dd, 1H); 6.88(m, 2H); 7.22(m, 1H); 7.85 (m, 1H); 8.10(s, 1H); 10.19(s, 1H).	MW: 481.62 MS (ESI) [M + 1]+: 482	INTA12/1
	N-Allyl-2-cyano-2-[3-ethyl-4-oxo-5-
	[1-[3-(2-piperidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
122		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =0.21(m, 2H); 0.40(m, 2H); 1.00 (m, 1H); 1 .22(m, 3H); 1.38(m, 2H); 1.50(m, 4H); 2.41 (m, 4H); 2.62(m, 2H); 3.04(m, 2H); 4.09(m, 2H); 4.21 (m, 2H); 6.63(dd, 1H); 6.89(m, 2H); 7.22(m, 1H); 7.77 (m, 1H); 8.09(s, 1H); 10.20(s, 1H).	MW: 495.64 MS (ESI) [M + 1]+: 496	INTA12/1
	2-Cyano-N-cyclopropylmethyl-2-[3-
	ethyl-4-oxo-5-[1-[3-(2-piperidin-1-
	yl-ethoxy)-phenylamino]-meth-
	(E/Z)-ylidene]-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
123		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.09(m, 3H); 1.23(m, 3H); 1.39 (m, 2H); 1.49(m, 4H); 2.41(m, 4H); 2.67(m, 2H); 3.21 (m, 2H); 4.09(m, 2H); 4.20(m, 2H); 6.62(dd, 1H); 6.87 (m, 2H); 7.21(m, 1H); 7.70(m, 1H); 8.10(s, 1H); 10.18 (s, 1H).	MW: 469.61 MS (ESI) [M + 1]+: 470	INTA12/1
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-
	5-[1-[3-(2-piperidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
124		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.28(m, 3H); 1.38(m, 2H); 1.49 (m, 4H); 2.44(m, 4H); 2.67(m, 2H); 4.08(m, 2H); 4.15 (d, 2H); 4.21(m, 2H); 6.64(dd, 1H); 6.90(m, 2H); 7.22 (m, 1H); 8.17(s, 1H); 8.38(m, 1H); 10.31(s, 1H).	MW: 480.59 MS (ESI) [M + 1]+: 481	INTA12/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	4-oxo-5-[1-[3-(2-piperidin-1-yl-
	ethoxy)-phenylamino]-meth-(E/Z)-
	ylidene]-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
125		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.25(m, 3H); 1.37(m, 2H); 1.47 (m, 4H); 2.68(m, 2H); 3.07(m, 1H); 3.91(m, 2H); 4.05 (m, 2H); 4.20(m, 2H); 6.64(dd, 1H); 6.89(m, 2H); 7.24 (m, 1H); 8.11(m, 2H); 10.27(s, 1H).	MW: 479.60 MS (ESI) [M + 1]+: 480	INTA12/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-
	(2-piperidin-1-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	thiazolidin-(2-(E or Z))-ylidene]-N-
	prop-2-ynyl-acetamide
126		1H-NMR(CDCl3, 300 MHz) δ = 1.40 (m, 3H); 2.25(m, 1H); 2.34(s, 6H); 2.71(m, 2H); 4.03 (m, 2H); 4.11(m, 2H); 4.38(m, 2H); 6.39(m, 1H); 6.62 (dd, 1H); 6.69(m, 1H); 7.21(d, 1H); 7.56(s, 1H); 10.48 (s, 1H).	MW: 439.54 MS (ESI) [M + 1]+: 440	INTA13/1
	2-Cyano-2-[5-[1-[3-(2-
	dimethylamino-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-N-prop-2-ynyl-acetamide
127		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.21(m, 3H); 2.28(s, 6H); 2.63 (m, 2H); 3.58(m, 2H); 4.05(m, 2H); 4.25(m, 2H); 6.08 (tt, 1H); 6.62(dd, 1H); 6.88(m, 2H); 7.22(m, 1H); 7.99 (m, 1H); 8.13(s, 1H); 10.29(s, 1H).	MW: 465.52 MS (ESI) [M + 1]+: 466	INTA13/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[5-
	[1-[3-(2-dimethylamino-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
128		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.22(m, 3H); 2.25(s, 6H); 2.67 (m, 2H); 3.96(m, 2H); 4.09(m, 2H); 4.26(m, 2H); 6.63 (dd, 1H); 6.90(m, 2H); 7.23(m, 1H); 8.13(s, 1H); 8.22 (m, 1H); 10.30(s, 1H).	MW: 483.51 MS (ESI) [M + 1]+: 486	INTA13/1
	2-Cyano-2-[5-[1-[3-(2-
	dimethylamino-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-N-(2,2,2-trifluoro-ethyl)-
	acetamide
129		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.23(m, 3H); 2.22(s, 6H); 2.61 (m, 2H); 3.79(m, 2H); 4.08(m, 2H); 4.22(m, 2H); 5.08 (dd, 1H); 5.12(dd, 1H); 5.81(m, 1H); 6.63(dd, 1H); 6.89 (m, 2H); 7.22(m, 1H); 7.83(m, 1H); 8.10(5, 1H); 10.20 (s, 1H).	MW: 441.55 MS (ESI) [M + 1]+: 442	INTA13/1
	N-Allyl-2-cyano-2-[5-[1-[3-(2-
	dimethylamino-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
130		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.27(m, 3H); 2.26(s, 6H); 2.62 (m, 2H); 4.07(m, 2H); 4.16(m, 2H); 4.22(m, 2H); 6.63 (dd, 1H); 6.90(m, 2H); 7.25(m, 1H); 8.18(s, 1H); 8.37 (m, 1H); 10.33(s, 1H).	MW: 440.53 MS (ESI) [M + 1]+: 441	INTA13/1
	2-Cyano-N-cyanomethyl-2-[5-[1-[3-
	(2-dimethylamino-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
131		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.26(m, 3H); 2.24(s, 6H); 2.62 1H); 3.51(m, 1H); 4.09(m, 2H); 4.21 (m, 2H); 4.42(m, 2H); 4.58(m, 2H); 6.62(dd, 1H); 6.89 (m, 2H); 7.22(m, 1H); 7.81(m, 1H); 8.11(5, 1H); 10.23 (s, 1H).	MW: 447.53 MS (ESI) [M + 1]+: 448	INTA13/1
	2-Cyano-2-[5-[1-[3-(2-
	dimethylamino-ethoxy)-
	dimethylamino-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-N-(2-fluoro-ethyl)-
	acetamide
132		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =0.21(m, 2H); 0.41(m, 2H); 1.00 (m, 1H); 1 .25(m, 3H); 2.21(s, 6H); 2.61(m, 2H); 3.04 (m, 2H); 4.07(m, 2H); 4.21(m, 2H); 6.62(dd, 1H); 6.88 (m, 2H); 7.22(m, 1H); 7.77(m, 1H); 8.09(s, 1H); 10.19 (s, 1H).	MW: 455.58 MS (ESI) [M + 1]+: 456	INTA13/1
	2-Cyano-N-cyclopropylmethyl-2-[5-
	[1-[3-(2-dimethylamino-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
133		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.05(m, 3H); 1.22(m, 3H); 2.22 (s, 6H); 2.65(m, 2H); 3.21(m, 2H); 4.03(m, 2H); 4.20 (m, 2H); 6.63(dd, 1H); 6.89(m, 2H); 7.21(m, 1H); 7.70 (m, 1H); 8.10(s, 1H); 10.20(s, 1H).	MW: 429.54 MS (ESI) [M + 1]+: 430	INTA13/1
	2-Cyano-2-[5-[1-[3-(2-
	dimethylamino-ethoxy)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-N-ethyl-acetamide
	ylidene]-N-ethyl-acetamide
134		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.29(m, 3H); 2.71(m, 2H); 3.58(m, 4H); 3.95(m, 2H); 4.10(m, 2H); 4.22(m, 2H); 6.65(dd, 1H); 6.90(m, 2H); 7.22(m, 1H); 8.20(m, 2H); 10.31(d, 1H).	525.5/ 526	INTA7/1
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-
	morpholin-4-yl-ethoxy)-
	phenylamino]-meth(E/Z ylidene]-4-
	oxo-thiazolidin-(2Z or E)-ylidene]-
	N-(2,2,2-trifluoro-ethyl)-acetamide
135		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.25(m, 3H); 2.70(m, 2H); 3.60(m, 6H); 4.11(m, 2H); 4.22(m, 2H); 6.08(tt, 1H); 6.64(ddm 1H); 6.89(m, 2H); 7.21(m, 1H); 7.98(m, 1H); 8.12(s, 1H); 10.29(s, 1H).	507.5/ 508	INTA7/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[3-
	ethyl-5-[1-[3-(2-morpholin-4-yl-
	ethoxy)-phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-acetamide
136		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.26(m, 3H); 2.70(m, 2H); 3.48(m, 1H); 3.51(m, 1H); 3.60(m, 4H); 4.11(m, 2H); 4.22(m, 2H); 4.40(m, 1H); 4.58(m, 1H); 6.63(dd, 1H); 6.89(m, 2H); 7.21(m, 1H), 7.81(m, 1H); 8.11(d, 1H); 10.26(d, 1H).	489.5/ 490	INTA7/1
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-
	morpholin-4-yl-
	ethoxy)phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2Z or F)-
	ylidene]-N-(2-fluoro-ethyl)-
	acetamide
137		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.27(m, 3H); 2.70(m, 2H); 3.58(m, 4H); 3.80(m, 2H); 4.11(m, 2H); 4.22(m, 2H); 5.08(dd, 1H); 5.12(dd, 1H); 5.82(m, 1H); 6.63(dd, 1H); 6.88(m, 2H); 7.21(m, 1H); 7.87(m, 1H); 8.10(s, 1H); 10.20(s, 1H).	483.5/ 484	INTA7/1
	N-Allyl-2-cyano-2-[3-ethyl-5-[1-[3-
	(2-morpholin-4-yl-ethoxy)-
	henylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2Z or E)-ylidene]-
	acetamide
138		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =0.21(m, 2H); 0.42(m, 2H); 1.02(m, 1H); 1.27(m, 3H); 2.70(m, 2H); 3.03(m, 2H); 3.61(m, 4H); 4.10(m, 2H); 4.27(m, 2H); 6.66(dd, 1H); 6.88(m, 2H); 7.22(m, 1H); 7.78(m, 1H); 8.11(s, 1H); 10.19(s, 1H).	497.6/ 498	INTA7/1
	2-Cyano-N-cyclopropylmethyl-2-[3-
	ethyl-5-[1-[3-(2-morpholin-4-yl-
	ethoxy)-phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-acetamide
139		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.08(m, 3H); 1.28(m, 3H); 2.70(m, 2H); 3.20(m, 2H); 3.59(m, 4H); 4.11(m, 2H); 4.22(m, 2H); 6.62(dd, 1H); 6.97(m, 2H); 7.23(m, 1H); 7.72(m, 1H); 8.10(s, 1H); 10.20(s, 1H).	471.5/ 472	INTA7/1
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-[3-
	(2-morpholin-4-yl-ethoxy)-
	henylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2Z or E)-ylidene]-
	acetamide
140		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.25(m, 3H); 2.71(m, 2H); 3.60(m, 4H); 4.13(m, 2H); 4.16(m, 2H); 4.21(m, 2H); 6.69(dd, 1H); 6.90(m, 2H), 7.21(m, 1H); 8.18(d, 1H); 8.37(m, 1H); 10.32(d, 1H).	482.5/ 483	INTA7/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-[3-(2-morpholin-4-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-acetamide
141		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.25(m, 3H); 2.71(m, 2H); 3.09(m, 1H); 3.58(m, 4H); 3.93(m, 2H); 4.10(m, 2H); 4.22(m, 2H); 6.63(dd, 1H); 6.89(m, 2H); 7.22(m, 1H); 8.12(m, 2H); 10.27(s, 1H).	481.5/ 482	INTA7/1
	2-Cyano-2-[3-ethyl-5-[1-[3-(2-
	morphlolin-4-yl-ethoxy)-
	phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-N-prop-2-ynyl-acetamide
142		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.18(m,3H); 3.48(m, 2H); 3.69(s, 3H); 4.19(m, 2H); 4.50(s, 2H); 5.98(tt, 1H); 6.60(dd, 1H); 6.83(m, 2H); 7.19(m, 1H); 8.18(s, 1H); 8.40(m, 1H); 10.50(s, 1H).	466.4/ 467	INTA15/1
	(3-{[2-[1-Cyano-1-(2,2-difluoro-
	ethylcarbamoyl)-meth-(Z or E)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(5E/Z)-ylidenemethyl]-amino}-
	phenoxy)-acetic acid methyl ester
143		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.25(m,3H); 3.50(m, 1H); 3.78(s, 3H); 4.23(m, 2H); 4.40(m, 1H); 4.57(m, 3H); 6.70(dd, 1H); 6.93(m, 2H); 7.28(m, 1H); 8.21(5, 1H); 8.32(m, 1H); 10.57(s. 1H).	448.4/ 449	INTA15/1
	(3-{[2-[1-Cyano-1-(2-fluoro-
	ethylcarbainoyl)-meth-(Z or E)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(5E or Z)-ylidenemethyl]-amino}-
	phenoxy)-acetic acid methyl ester
144		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.24(m,3H); 3.79(m, 5H); 4.27(m, 2H); 4.58(s, 2H); 5.07(dd, 1H); 5.11(dd, 1H); 5.81(m, 1H); 6.70(dd, 1H); 6.92(m, 2H); 7.28(m, 1H); 8.22(s, 1H); 8.30(m, 1H); 10.58(s, 1H).	442.4/ 443	INTA15/1
	(3-{[2-[1-Allylcarbamoyl-1-cyano-
	meth-(Z or E)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(5E/Z)-
	ylidenemethyl]-amino}-phenoxy)-
	acetic acid methyl ester
145		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =0.19(m,2H); 0.39(m, 2H); 0.45(m, 1H); 1.21(m, 3H); 3.02(m, 2H); 3.79(s, 3H); 4.25(m, 2H); 4.51(s, 2H); 6.70(dd, 1H); 6.94(m, 2H); 7.29(m, 1H); 8.18(m, 1H); 8.26(s, 1H); 10.58(s, 1H).	456.5/ 457	INTA15/1
	(3-{[2-[1-Cyano-1-
	cyclopropylmethyl-carbamoyl)-eth-
	(Z or E)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(5E/Z)-ylidenemethyl]-
	amino}-phenoxy)-acetic acid
	methyl ester
146		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.02(m,3H); 1.22(m, 3H); 3.18(m, 2H); 3.79(s, 3H); 4.28(m, 2H); 4.50(s, 2H); 6.71(dd, 1H); 6.98(m, 2H); 7.28(m, 1H); 8.11(m, 1H); 8.22(s, 1H); 10.48(s, 1H).	430.4/ 431	INTA15/1
	(3-{[2-[1-Cyano-1-ethylcarbamoyl-
	meth-(Z or E)-ylidene]-3-ethyl-4-
	oxo-thiazolidin-(5E/Z)-
	ylidenemethyl]-amino}-phenoxy)-
	acetic acid methyl ester
147		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.22(m,3H); 3.79(s, 3H); 4.22(m, 4H); 4.68(s, 2H); 6.71(dd, 1H); 6.95(m, 2H); 7.30(m, 1H); 8.22(s, 1H); 8.86(m, 1H); 10.53(s, 1H).	441.4/ 442	INTA15/1
	(3-{[2-[1-Cyano-1-(cyanomethyl-
	carbamoyl)-meth-(Z or E)-ylidene]
	3-ethyl-4-oxo-thiazolidin-(5E/Z)-
	ylidenemethyl]-amino}-phenoxy)-
	acetic acid methyl ester
148		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.24(m, 3H); 3.50(m, 4H); 4.24(m, 2H); 4.40(m, 2H); 4.57(m, 4H); 6.68(dd, 1H); 6.92(m, 2H); 7.28(m, 1H); 7.80(m, 1H); 8.10(s, 1H); 8.32(m, 1H); 10.31(s, 1H).	479.5/ 480	INTA15/1
	2-Cyano-2-[3-ethyl-5-[1-{3-[(2-
	fluoro-ethylcarbamoyl )-methoxy]-
	phenylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2Z or E)-
	ylidene]-N-(2-fluoro-ethyl)-
	acetamide
149		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.28(m,3H); 3.78(m, 4H); 4.26(m, 2H); 4.54(5, 2H); 5.10(m, 4H); 5.81(m, 2H); 6.69(dd, 1H); 6.91(m, 2H); 7.27(m, 1H); 7.88(in 1H); 8.10(d, 1H); 8.30(m, 1H); 10.28(d, 1H).	467.5/ 468	INTA15/1
	N-Allyl-2-[5-[1-(3-
	allylcarbamoylmethoxy-
	phenylamino)-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(2Z or E)-ylidene]-2-cyano-
	acetamide
150		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =0.20(m, 4H); 0.39(m, 4H); 0.97(m, 2H); 1.27(m, 3H); 3.04(m, 4H); 4.21(m, 2H); 4.50(s, 2H); 6.68(dd, 1H); 6.91(m, 2H); 7.22(m, 1H); 7.75(s, 1H); 8.09(s, 1H); 8.16(m, 1H); 10.27(s, 1H).	495.6/ 496	INTA15/1
	2-Cyano-N-cyclopropyl methyl-2-[5-
	[1-{3-[(cyclopropylmethyl-
	carbamoyl)-methoxy]-
	carbamoyl)-methoxy]-
	phenylamino}-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(2Z or E)-ylidene]-acetamide
151		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.09(m, 6H); 1.28(m, 3H); 3.20(m, 4H); 4.21(m, 2H); 4.50(s, 2H); 6.68(dd, 1H); 6.92(m, 2H); 7.27(m, 1H); 7.70(m, 1H); 8.10(d, 1H); 10.26(d, 1H).	443.5/ 444	INTA15/1
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-(3-
	ethylcarbamoylmethoxy-
	phenylamino)-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2Z or E)
	ylidene]-acetamide
152		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.19(m,3H); 4.10(m, 6H); 4.57(s, 2H); 6.60(dd, 1H); 6.88(m, 2H); 7.19(m, 1H); 8.08(s, 1H); 8.26(s, 1H); 8.78(m, 1H); 10.33(s, 1H).	465.4/ 466	INTA15/1
	2-Cyano-N-cyanomethyl-2-[5-[1-{3-
	[(cyanomethyl-carbamoyl)-
	methoxy]-phenylamino}-meth-(E/
	Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2Z or E)-ylidene]-
	acetamide
153		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.28(m,3H); 3.08(m, 1H); 3.13(m, 1H); 3.92(m, 4H); 4.22(m, 2H); 4.55(s, 2H); 6.69(dd, 1H); 6.92(m, 2H); 7.28(m, 1H); 8.11(d, 5, 1H); 8.60(m, 1H); 10.31(s, 1H).	463.5/ 464	INTA15/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-(3-
	prop-2-ynylcarbamoylmethoxy-
	phenylamino)-meth-(E/Z)-
	ylidene]-thiazolidin-(2Z or E)-
	ylidene]-N-prop-2-ynyl-acetamide
154		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.28(m,3H); 3.97(m, 4H); 4.22(m, 2H); 4.63(s, 2H); 6.69(dd, 1H); 6.93(m, 2H); 7.28(m, 1H); 8.20(m, 2H); 8.78(m, 1H); 10.40(s, 1H).	551.4/ 552	INTA15/1
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-{3-
	[(2,2,2-trifluoro-ethylcarbamoyl)-
	methoxy]-phenylamino}-meth-(E/
	Z)-ylidene]-thiazolidin-(2Z or E)-
	ylidene]-N-(2,2,2-trifluoro-ethyl)-
	acetamide
155		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.20(m,3H); 3.47(m, 4H); 4.15(m, 2H); 4.50(s, 2H); 5.97(tm, 2H); 6.60(dd, 1H); 6.82(m, 2H); 7.19(m, 1H); 7.88(s, 1H); 8.03(s, 1H); 8.40(m, 1H); 10.26(s, 1H).	515.4/ 516	INTA15/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[5-
	[1-{3-[(2,2-difluoro-
	ethylcarbamoyl)-methoxy]-
	phenylamino}-meth-(E/Z)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(2Z or E)-ylidene]-acetamide
156		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.19(m,3H); 3.68(s, 3H); 3.89(m, 2H); 4.18(m, 2H); 4.57(s, 2H); 6.60(d, 1H); 6.83(m, 2H); 7.69(m, 1H); 8.15(s, 1H); 8.70(m, 1H); 10.50(s, 1H).	484.4/ 485	INTA15/1
	(3-{[2-[1-Cyano-1-(2,2,2-trifluoro-
	ethylcarbamoyl)-meth-(Z or E)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(5E/Z)-ylidenemethyl]-amino}-
	phenoxy)-acetic acid methyl ester
157		1H-NMR(DMSO- d6, 300 MHz) (selected peaks) δ =1.27(m, 3H); 3.11(m, 1H); 3.79(s, 3H); 3.93(m, 2H); 4.25(m, 2H); 4.58(s, 2H); 6.71(dd, 1H); 6.97(m, 2H); 7.29(m, 1H); 8.22(s, 1H); 8.60(m, 1H); 10.57(s, 1H).	440.4/ 441	INTA15/1
	(3-{[2-[1-Cyano-1-prop-2-
	ynylcarbamoyl-meth-(Z or E)-
	ylidene]-3-ethyl-4-oxo-thiazolidin-
	(5E/Z)-ylidenemethyl]-amino}-
	phenoxy)-acetic acid methyl ester
158		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.05-1.11(m, 9H); 1.24(t, 3H); 2.54-2.61(m, 1H); 3.14-3.23(m, 2H); 4.21(d, 2H); 6.91(d, 1H); 7.18-7.24(m, 2H); 7.67-7.69(m, 2H); 7.96(d, 2H); 9.87(s, 1H); 10.36(d, 1H) ppm.	427.53/ 428	INTA16/1
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-(3-
	isobutyrylamino-phenylamino)-eth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
159		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.11(d, 6H); 1.25(t, 3H); 2.58(m, 1H); 3.94(m, 2H); 4.23(q, 2H); 6.92(d, 1H); 7.18-7.25(m, 2H); 7.70(s, 1H); 8.01(d, 1H); 8.19(t, 1H); 9.87(s, 1H); 10.47(d, 1H) ppm.	481.50/ 482	INTA16/1
	2-Cyano-2-{3-ethyl-5-[1-(3-
	isobutyryl-amino-phenylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	(2,2,2-trifluoro-ethyl)-acetamide
160		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.11(d, 6H); 1.24(t, 3H); 2.53-2.63(m, 1H); 3.05(t,1H); 3.92(dd,2H); 4.22(q, 2H); 6.92(d, 1H); 7.18-7.25(m, 2H); 7.70(s, 1H); 8.80(d, 1H); 8.07(t, 1H); 9.86(s, 1H); 10.42(d, 1H) ppm.	437.52/ 438	INTA16/1
	2-Cyano-2-{3-ethyl-5-[1-(3-
	isobutyryl-amino-phenylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	prop-2-ynyl-acetamide
161		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.11(d, 6H); 1.24(t, 3H); 2.53-2.63(m, 1H); 3.43-3.53(2q, 1H); 4.22(t,1H); 4.40-4.55(2t, 1H); 6.92(d, 1H); 7.18-7.25(m, 2H); 7.69(s, 1H); 7.74(t, 1H); 7.98(1H); 9.86(s, 1H); 10.40(1H) ppm.	445.52/ 446	INTA16/1
	2-Cyano-2-{3-ethyl-5-[1-(3-
	isobutyryl-amino-phenylamino)-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	(2-fluoro-ethyl)-acetamide
162		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.11(d, 6H); 1.25(t, 3H); 2.53-2.63(m, 1H); 4.15(d, 2H); 4.22(q, 2H); 6.94(d, 1H); 7.19-7.26(m, 2H); 7.72(s, 1H); 7.74(t, 1H); 8.03(1H); 9.88(s, 1H); 10.50(1H) ppm.	438.51/ 439	INTA16/1
	2-Cyano-N-cyanomethyl-2-{3-ethyl-
	5-[1-(3-isobutyrylamino-
	phenylamino)-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene}-acetamide
163		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.10(d, 6H); 1.24(t, 3H); 2.54-2.61(m, 1H); 3.52-3.62(m, 2H); 4.22(q, 2H); 5.88-6.18(3t, 1H); 6.91(d, 1H); 7.17-7.24(m, 2H); 7.69(s, 1H); 7.91(t, 1H); 7.98(d, 1H); 9.85(5, 1H); 10.45(1H) ppm.	463.51/ 464	INTA16/1
	2-Cyano-N-(2,2-difluoro-ethyl )-2-
	{3-ethyl-5-[1-(3-isobutyrylamino-
	phenylamino)-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene}-acetamide
164		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.06(t, 3H); 1.25(t, 3H); 1.80(3H); 3.10-3.23(m, 5H); 4.21(q, 2H); 6.96(d, 1H), 7.22(d, 1H); 7.30-7.37(m, 2H); 7.68(t, 1H); 10.40(1H) ppm.	413.50/ 414	INTA17/1
	2-{5-[1-[3-(Acetyl-methyl-amino)-
	phenyl-amino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene}-2-cyano-N-ethyl-
	acetamide
165		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 1.80(3H); 3.14(3H); 3.89-3.98(m, 2H); 4.23(q, 2H); 6.97(d, 1H); 7.22(m, 1H); 7.28-7.36(m, 2H); 8.15-8.21(m, 2H); 10.34(d, 1H) ppm.	467.47/ 468	INTA17/1
	2-{5-[1-[3-(Acetyl-methyl-amino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene}-2-cyano-N-(2,2,2-
	trifluoro-ethyl)-acetamide
166		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 1.80(3H); 3.05(t, 1H); 3.15(3H); 3.90-3.92(m, 2H); 4.18(q, 2H), 6.98(d, 1H); 7.24(m, 1H); 7.33-7.38(m, 2H); 8.10(t, 1H); 8.16(d, 1H); 10.32(d, 1H) ppm.	423.50/ 424	INTA17/1
	2-{5-[1-[3-(Acetyl-methyl-amino)-
	phenyl-amino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene}-2-cyano-N-prop-2-ynyl-
	acetamide
167		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 1.80(3H); 3.15(t, 1H); 3.15(3H); 4.14(d, 2H); 4.22(q, 2H); 6.98(d, 1H); 7.22-7.24(m, 1H); 7.33-7.37(m, 2H); 8.18(d, 1H); 8.33(t, 1H); 10.37(d, 1H) ppm.	424.48/ 425	INTA17/1
	2-{5-[1-[3-(Acetyl-methyl-amino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene}-2-cyano-N-
	cyanomethyl-acetamide
168		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 1.80(3H); 3.15(s, 3H); 3.43-3.53(2q, 2H); 4.22(q, 2H); 4.40-4.55(2t, 2H); 6.97(d, 1H); 7.21-7.37(m, 3H); 7.78(t, 1H); 8.13(1H); 10.23(d, 1H) ppm.	431.49/ 432	INTA17/1
	2-{5-[1-[3-(Acetyl-methyl-amino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene}-2-cyano-N-(2-fluoro-
	ethyl)-acetamide
169		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 1.81(3H); 3.15(s, 3H); 3.50-3.63(m, 2H); 4.23(q, 2H); 5.90-6.20(tt, 1H); 6.99(d, 1H);, 7.23-7.39(m, 3H); 7.95(t, 1H); 8.17(s, 1H); 10.32(d, 1H) ppm.	449.48/ 450	INTA17/1
	2-{5-[1-[3-(Acetyl-methyl-amino)-
	phenyl-amino]-meth-(E/Z)-ylidene]
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene}-2-cyano-N-(2,2-
	difluoro-ethyl)-acetamide
170		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.06(t, 3H); 1.24(t, 3H); 2.28(s, 2H); 3.07(s, 2H); 3.20(p, 2H); 4.21(q, 2H); 6.94(d, 1H); 7.20-7.31(m, 2H); 7.68(t, 1H); 7.74(s, 1H), 7.99(d, 1H); 9.76(s, 1H); 10.35(d, 1H) ppm.	442.54/ 443	INTA18/1
	2-Cyano-2-{5-[1-[3-(2-dimethyl-
	amino-acetylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	ethyl-acetamide
171		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 2.28(s, 6H); 3.07(s, 2H); 3.79-3.98(m, 4H); 4.23(q, 2H); 6.80(t, 1H); 6.96(m, 1H); 7.22-7.32(m, 2H); 7.76(5, 1H); 8.05(d, 1H); 8.19(t, 1H); 9.77(s, 1H); 10.47(d, 1H) ppm.	496.52/ 497	INTA18/1
	2-Cyano-2-{5-[1-[3-(2-dimethyl-
	amino-acetylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	(2,2,2-trifluoro-ethyl)-acetamide
172		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 2.28(s, 6H); 3.05(t, 1H); 3.07(s, 2H); 3.91-3.93(m, 2H); 4.22(q, 2H); 6.96(d, 1H); 7.22-7.33(m, 2H); 7.76(s, 1H); 8.03(d, 1H); 8.08(t, 1H); 9.77(s, 1H); 10.43(d, 1H) ppm.	452.54/ 453	INTA18/1
	2-Cyano-2-{5-[1-[3-(2-dimethyl-
	amino-acetylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	prop-2-ynyl-acetamdie
173		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.25(t, 3H); 2.28(s, 6H); 3.07(s, 2H); 4.14-4.16(m, 2H); 4.23(q, 2H); 6.97(d, 1H); 7.23-7.33(m, 2H); 7.77(s, 1H); 8.07(d, 1H); 8.33(t, 1H); 9.78(1H); 10.51(1H) ppm.	453.53/ 454	INTA18/1
	2-Cyano-N-cyanomethyl-2-{5-[1-[3-
	(2-dimethylamino-acetylamino)
	phenylamino]-meth-(E/Z)-ylidene]-
	3-ethyl-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene}-acetamide
174		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 2.27(s, 6H); 3.06(s, 2H); 3.43-3.53(2q, 2H); 4.22(q, 2H); 4.40-4.55(2t, 2H); 6.93-6.95(m, 1H); 7.20-7.31(m, 2H); 7.74-7.78(m, 2H), 8.01(d, 1H); 9.75(s, 1H); 10.38(d, 1H) ppm.	460.53/ 461	INTA18/1
	2-Cyano-2-{5-[1-[3-(2-dimethyl-
	amino-acetylamino)-phenylamino]-
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	(2-fluoro-ethyl)-acetamide
175		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 2.27(s, 6H); 3.06(s, 2H); 3.52-3.62(m, 2H); 4.22(q, 2H); 5.89-6.19(3t, 1H); 6.94(d, 1H); 7.20-7.31(m, 2H); 7.37(1H); 7.91(1H); 8.04(1H); 9.75(s, 1H); 10.44(s, 1H) ppm.	478.52/ 479	INTA18/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-
	{5-[1-[3-(2-dimethylamino-
	acetylamino)-phenylamino]-meth-
	(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-
	acetamide
176		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.99(s, 9H); 1.07(t, 3H); 1.24(t, 3H); 3.10(s, 3H); 3.17-3.23(m, 2H); 4.22(q, 2H); 6.97(d, 1H); 7.27-7.38(m, 2H); 7.70(t, 1H), 8.11(s,1H); 10.26(s, 1H) ppm.	455.58/ 456	INTA19/1
	2-Cyano-2-[5-[1-{3-[(2,2-dimethyl-
	propionyl)-methyl-amino]-phenyl-
	amino}-meth-(E/Z)-ylidene]-3-ethyl-
	4-oxo-thiazolidin-(2-(E or Z))
	ylidene]-N-ethyl-acetamide
177		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.99(s, 9H); 1.25(t, 3H); 3.10(s, 3H); 3.90-3.99(m, 2H); 4.23(q, 2H); 6.99(d, 1H); 7.28-7.41(m, 3H); 8.17(d, 1H); 8.23(t, 1H); 10.37(d, 1H) ppm.	509.55/ 510	INTA19/1
	2-Cyano-2-[5-[1-{3-[(2,2-dimethyl-
	propionyl)-methyl-amino]-phenyl-
	amino}-meth-(E/Z)-ylidene]-3-ethyl-
	4-oxo-thiazolidin-(2-(E or Z))
	ylidene]-N-(2,2,2-trifluoro-ethyl)-
	acetamide
178		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.00(s, 9H); 1.24(t, 3H); 3.06(t, 1H); 3.10(s, 3H); 3.91-3.93(m, 2H); 4.22(q, 2H); 6.98(d, 1H); 7.28-7.41(m, 3H); 8.14(d, 1H); 10.32(d, 1H) ppm.	465.58/ 466	INTA19/1
	2-Cyano-2-[5-[1-{3-[(2,2-dimethyl-
	propionyl)-methyl-amino]-phenyl-
	amino}-meth-(E/Z)-ylidene]-3-ethyl-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-prop-2-ynyl-acetamide
179		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.00(s, 9H); 1.26(t, 3H); 3.12(s, 3H); 4.16(d, 2H); 4.24(q, 2H); 7.00(d, 1H); 7.30-7.43(m, 3H); 8.19(d, 1H); 8.37(t, 1H); 10.41(d, 1H) ppm.	466.56/ 467	INTA19/1
	2-Cyano-2-[5-[1-{3-[(2,2-dimethyl-
	propionyl)-methyl-amino]-phenyl-
	amino}-meth-(E/Z)-ylidene]-3-ethyl-
	4-oxo-thiazolidin-(2-(E or Z))
	ylidene]-N-prop-2-ynyl-acetamide
180		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.99(s, 9H); 1.24(t, 3H); 3.09(s, 3H); 3.42-3.52(2q, 2H); 4.21(q, 2H); 4.41(t, 1H); 4.53(t, 1H); 6.95(d, 1H); 7.24-7.36(m, 3H); 7.78(d, 1H); 8.12(s, 1H); 10.29(s, 1H) ppm.	473.57/ 474	INTA19/1
	2-Cyano-2-[5-[1-{3-[(2,2-dimethyl-
	propionyl)-methyl-amino]-phenyl-
	amino}-meth-(E/Z)-ylidene]-3-ethyl-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-(2,2-trifluoro-ethyl)-
	acetamide
181		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.01(s, 9H); 1.26(t, 3H); 3.09(s, 3H); 3.51-3.61(m, 2H); 4.21(q, 2H); 5.86-6.16(3t, 1H); 6.94(d, 1H); 7.23-7.37(m, 3H); 7.94(t, 1H); 8.12(1H); 10.26(1H) ppm.	491.56/ 492	INTA19/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[5-
	[1-{3-[(2,2-dimethyl-propionyl)-
	methyl-amino]-phenylamino}-meth-
	(E/Z)-ylidene]-3-ethyl-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]-
	acetamide
182		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.93(d, 6H); 1.07(t, 3H); 1.24(t, 3H); 2.47(m, 1H); 3.13(s, 3H); 3.17-3.23(m, 2H); 4.20(q, 2H); 6.98(d, 1H); 7.27-7.32(m, 2H); 7.39(t, 1H); 7.72(t, 1H); 8.13(d,1H); 10.27(d, 1H) ppm.	441.56/ 442	INTA20/1
	2-Cyano-N-ethyl-2-{3-ethyl-5-[1-[3-
	(isobutyryl-methyl-amino)-phenyl-
	amino]-meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-
	acetamide
183		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.93(d, 6H); 1.25(t, 3H); 2.47(m, H); 3.13(s, 3H); 3.90-3.99(m, 2H); 4.23(q, 2H); 6.99(d, 1H); 7.28-7.43(m, 3H); 8.20-8.23(m, 2H); 10.38(1H) ppm.	495.53/ 469	INTA20/1
	2-Cyano-2-{[3-ethyl-5-[1-[3-
	(isobutyryl-methyl-amino)-phenyl-
	amino]-meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	(2,2,2-trifluoro-ethyl)-acetamide
184		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.93(d, 6H); 1.24(t, 3H); 2.47(m,H); 3.06(t,H); 3.14(s, 3H); 3.91-3.93(m, 2H); 4.22(q, 2H); 6.98(d, 1H); 7.28-7.33(m, 2H); 7.39(t, 1H); 8.16(1H); 10.33(1H) ppm.	451.51/ 452	INTA20/1
	2-Cyano-2-{3-ethyl-5-[1-[3-
	(isobutyryl-methyl-amino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene}-N-prop-2-ynyl-acetamide
	ylidene}-N-prop-2-ynyl-acetamide
185		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.93(d, 6H); 1.25(t, 3H); 2.47(m,H); 3.14(s, 3H); 4.15(d, 2H); 4.23(q, 2H); 6.99(d, 1H); 7.28-7.30(m, 1H); 7.34-7.41(m, 2H); 8.20(1H); 8.36(t, 1H); 10.40(1H) ppm.	452.54/ 453	INTA20/1
	2-Cyano-N-cyanomethyl-2-{3-ethyl-
	5-[1-[3-(isobutyryl-methyl-amino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
186		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.93(d, 6H); 1.24(t, 3H); 2.47(m,H); 3.13(s, 3H); 3.44-3.54(2q, 2H); 4.22(q, 2H); (t, 1H); 4.54(t, 1H); 6.97(d, 1H); 7.25-7.31(m, 2H); 7.37(t, 1H); 7.79(t, 1H); 8.13(t, 1H); 10.28(1H) ppm.	459.55/ 460	INTA20/1
	2-Cyano-2-{3-ethyl-5-[1-{3-
	(isobutyryl-methyl-amino)-phenyl-
	amino]-meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-N-
	(2-fluoro-ethyl)-acetamide
187		(DMSO-d6, stored via K2CO3, primary isomer): δ =0.93(d, 6H); 1.24(t, 3H); 2.47(m,H); 3.13(s, 3H); 3.53-3.62(m, 2H); 4.23(q, 2H); 5.90-6.20(tt, 1H); 6.90(d, 1H); 7.27-7.33(m, 2H); 7.39(t, 1H); 7.98(t, 1H); 8.18(1H); 10.37(1H) ppm.	477.54/ 478	INTA20/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-
	{3-ethyl-5-[1-[3-(isobutyryl-methyl-
	amino)-phenylamino]-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene}-acetamide
188		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.06(t, 3H); 1.23(t, 3H); 3.19(q, 2H); 3.28(s, 3H); 3.47(t, 2H); 4.21(q, 2H); 5.78(t, 1H); 6.30-6.32(dd, 1H); 6.41-6.44(dd, 1H); 6.49(t, 1H); 7.00(t, 1H); 7.68(t, 1H); 7.98(d, 1H); 10.13(d, 1H) ppm.	415.52/ 416	INTA21/1
	2-Cyano-N-ethyl-2-{3-ethyl-5-[1-[3-
	(2-methoxy-ethylamino)-phenyl-
	amino]-meth-(E/Z)-ylidene]-4-oxo-
	amino]-meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene}-
	acetamide
189		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 3.19(q, 2H); 3.28(s, 3H); 3.47(t, 2H); 4.14(d, 2H); 4.22(q, 2H); 5.78(t, 1H); 6.31-6.33(dd, 1H); 6.42-6.45(dd, 1H); 6.49(1H); 7.01(t, 1H); 8.05(s, 1H); 8.29(1H); 10.27(s, 1H) ppm.	426.50/ 427	INTA21/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-[3-(2-methoxy-ethylamino)-
	phenylamino]-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-acetamide
190		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 3.19(q, 2H); 3.28(s, 3H); 3.47(t, 2H); 3.53-3.63(m, 2H); 4.22(q, 2H); 5.78(t, 1H); 5.90-6.20(tt, 1H); 6.31-6.33(dd, 1H); 6.42-6.44(dd, 1H); 6.49(t, 1H); 7.01(t, 1H); 7.92(t, 1H); 8.02(d,1H); 10.22(d, 1H) ppm.	451.50/ 452	INTA21/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[3-
	ethyl-5-[1-[3-(2-methoxy-
	ethylamino)-phenylamino]-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
191		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.24(t, 3H); 3.18(q, 2H); 3.28(s, 3H); 3.43-3.53(m, 4H); 3.53-3.63(m, 2H); 4.22(q, 2H); 4.42(t, 1H); 4.54(t, 1H); 5.77(t, 1H); 6.30-6.33(dd, 1H); 6.41-6.44(dd, 1H); 6.49(1H); 7.00(t, 1H); 7.76(t, 1H); 8.00(d,1H); 10.16(d, 1H) ppm.	433.51/ 434	INTA21/1
	2-Cyano-2-3-ethyl-5-[1-[3-(2-
	methoxy-ethylamino)-
	phenylamino]-meth-(E/Z)-ylidene]
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-(2-fluoro-ethyl)-
	acetamide
192		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.02-1.08(m, 6H); 1.23(t, 3H); 2.28(s, 3H); 2.51(q, 2H); 3.11(s, 2H); 3.16-3.23(m, 2H), 4.21(q, 2H); 6.93-6.96(m, 1H); 7.21-7.31(m, 2H); 7.68(t, 1H); 7.73(1H); 8.00(d, 1H); 9.71(s, 1H); 10.35(d, 1H) ppm.	456.57/ 457	INTA22/1
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-{3-
	[2-(ethyl-methyl-amino)-acetyl-
	amino]-phenylamino}-meth-(E/Z)-
	ylidene]-4-oxo-thiazolidin-(2-(E or
	Z))-ylidene]-acetamide
193		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.04(t, 3H); 1.25(t, 3H); 2.27(s, 3H); 2.51(m, 2H); 3.11(s, 2H); 3.90-3.98(m, 2H); 4.23(q, 2H); 6.96(d, 1H); 7.22-7.32(m, 2H); 7.74(s, 1H); 8.07(1H); 8.19(1H); 9.71(s, 1H); 10.46(1H) ppm.	510.54/ 511	INTA22/1
	2-Cyano-2-13-ethyl-5-[1-{3-[2-
	(ethyl-methyl-amino)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-(2,2,2-trifluoro-ethyl)-
	acetamide
194		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.04(t, 3H); 1.24(t, 3H); 2.28(s, 3H); 2.51(q, 2H); 3.12(s, 2H); 3.91-3.92(dd, 2H); 4.22(q, 2H); 6.95-6.97(m, 1H); 7.22-7.31(m, 2H); 7.73(s, 1H); 8.03(d, 2H); 8.07(t, 1H); 9.72(s, 1H); 10.41(d, 1H) ppm.	466.57/ 467	INTA22/1
	2-Cyano-2-[3-ethyl-5-[1-{3-[2-
	(ethyl-methyl-amino)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]-
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-prop-2-ynyl-acetamide
195		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.04(t, 3H); 1.25(t, 3H); 2.28(s, 3H); 2.51(m, 2H); 3.12(s, 2H); 4.15(d, 2H); 4.23(q, 2H); 6.96-6.98(m, 1H); 7.22-7.32(m, 2H); 7.75(1H); 8.07(d, 2H); 8.33(t, 1H); 9.72(1H); 10.50(d, 1H) ppm.	467.55/ 468	INTA22/1
	2-Cyano-N-cyanomethyl-2-[3-ethyl-
	5-[1-{3-[2-(ethyl-methyl-amino)-
	acetylamino]-phenylamino}-meth-
	acetylamino]-phenylamino}-meth-
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-
	(E or Z))-ylidene]-acetamide
196		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.04(t, 3H); 1.25(t, 3H); 2.28(s, 3H); 2.51(m, 2H); 3.11(s,2H); 3.54-3.62(m, 2H); 4.23(q, 2H); 5.90-6.20(tt, 1H); 6.95-6.97(m, 1H); 7.22-7.32(m, 2H); 7.74(s, 1H); 7.95(t, 1H); 8.05(d, 1H); 9.71(s,1H); 10.44(d, 1H) ppm.	492.55/ 493	INTA22/1
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[3-
	ethyl-5-[1-{3-[2-(ethyl-methyl-
	amino)-acetylamino]-phenylamino}-
	meth-(E/Z)-ylidene]-4-oxo-
	thiazolidin-(2-(E or Z))-ylidene]
	acetamide
197		(DMSO-d6, stored via K2CO3, primary isomer): δ =1.04(t, 3H); 1,254(t, 3H); 2.28(s, 3H); 2.51(m, 2H); 3.12(s, 2H); 3.43-3.53(2q, 2H); 4.22(q, 2H); 4.42(t, 1H); 4.54(t, 1H); 6.94-6.96(m, 1H); 7.21-7.31(m, 2H); 7.73(s, 1H), 7.79(t, 1H); 8.02(d, 1H); 9.71(s,1H); 10.40(d, 1H) ppm.	474.56/ 475	INTA22/1
	2-Cyano-2-13-ethyl-5-[1-{3-[2-
	(ethyl-methyl-amino)-acetylamino]-
	phenylamino}-meth-(E/Z)-ylidene]
	4-oxo-thiazolidin-(2-(E or Z))-
	ylidene]-N-(2-fluoro-ethyl)-
	acetamide

EXAMPLE 198

Acetic acid (3-{[2-[1-cyano-1-prop-2-ynylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenylcarbamoyl)-methyl ester

Dissolve 2.5 g of the compound described under Intermediate INTE44 in 160 ml tetrahydrofurane, add 1.66 g N,N-dimethyl barbituric acid and 614 mg Pd(PPh₃)₄ to it and stir for two hours at room temperature. Following this 3.68 ml triethylamine, add 1.09 ml propargylamine and 5.12 g TBTU and stir for a further 15 hours at room temperature. Add 250 ml acetic acid ethylester and wash once again with 100 ml water. Dry the organic phase over sodium sulfate. After purification through re-crystallization from dichlormethane and additional re-crystallization from ethanol, 1.68 g of the compound in the title is obtained.

¹H-NMR (DMSO-d6, stored over K₂CO₃, primary isomer):

δ=1.25 (t, 3H); 2.14 (s, 3H); 3.07 (t, 1H); 3.88-4.00 (m, 2H); 4.24 (q, 2H); 4.66 (s, 2H); 7.02 (d, 1H); 7.20 (d, 1H); 7.29 (t, 1H); 7.67 (s, 1H); 8.02 (d, 1H); 8.11 (t, 1H); 10.16 (s, 1H); 10.46 (d, 1H) ppm.

EXAMPLE 199

2-Cyano-2-[3-ethyl-5-[1-[3-(2-hydroxy-acetylamino)-phenylamino]-meth-(E/Z)-ylidene]-4-oxo-thiazol idin-(2-(E or Z))-ylidene]-N-prop-2-ynyl-acetamide

Dissolve 2.6 g of the compound described under Example 198 in 80 ml dimethylformamide and add 40 ml methanol and 40 ml water to it. Add 1.15 g of potassium carbonate and stir for two hours at room temperature. Add 1000 ml acetic acid ethylester, the organic phase is separated and washed thrice with 75 ml of a semi-saturated sodium chloride solution each time. Dry the organic phase over sodium sulfate. 2.19 g of the compound in the title is obtained.

(DMSO-d6, stored via K₂CO₃, primary isomer): δ=1.21 (t, 3H); 3.02 (b, 1H); 3.83-3.93 (m, 2H); 3.96 (d, 2H); 4.19 (q, 2H); 5.67 (t, 1H); 6.94 (d, 1H); 7.22 (t, 1H); 7.35 (d, 1H); 7.77 (s, 1H); 7.94-8.12 (m, 2H); 9.70 (s, 1H); 10.40 (d, b, 1H) ppm.

EXAMPLE 200

Methanesulfonic acid (3-{[2-[1-cyano-1-prop-2-ynylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenylcarbamoyl)-methyl ester

Dissolve 2.18 g of the compound described under Example 199 in 18 ml dimethylformamide and add 320 ml tetrahydrofurane to it. At 0° C., add 1.78 ml triethylamine and 0.60 ml metansulfonic acid chloride and stir for one hour at room temperature. Add 500 ml acetic acid ethylester and 200 ml water, separate the organic phase and wash thrice with 75 ml of a semi-saturated sodium chloride solution each time. Dry the organic phase over sodium sulfate. After purification through a stirring out of the solids with dichlormethane, 2.02 g of the compound in the title is obtained.

(DMSO-d6, stored via K₂CO3, primary isomer):

δ=1.24 (t, 3H); 3.06 (b, 1H); 3.31 (s, 3H); 3.86-3.99 (m, 2H); 4.22 (q, 2H); 4.85 (s, 2H); 7.04 (d, 1H); 7.22 (d, 1H); 7.30 (t, 1H); 7.68 (s, 1H); 8.03 (d, 1H); 8.10 (t, 1H); 10.24 (s, 1H); 10.47 (d, b, 1H) ppm.

EXAMPLE 201

2-cyano-N-cyanomethyl-2-[5-[1-{3-[2-(4,4-difluoro-piperidin -1-yl)-acetylamino]-4-fluoro-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-( 2-(E or Z))-ylidene]-acetamide

Suspend 60 mg of the compound described under INTT10 in 3 ml 1-propanol, add 138 mg of the compound described under INT62 and 0.16 ml trietylorthoformiate to it. Stir for 4 hours at 140° C. in a bomb tube. Allow the reaction mixture to gradually cool at room temperature and stir for 15 hours at room temperature. Filter off the excluded solids and wash successively with ethanol and diethylether. After purification through filtration through silica gel and subsequent re-crystallization from ethanol, 106 mg of the compound in the title are obtained.

(DMSO-d6, stored via K₂CO₃, primary isomer): δ=1.20 (t, 3H); 1.83-2.10 (m, 4H); 2.66 (m, 4H); 3.26 (s, 2H); 4.11 (d, 2H); 4.19 (q, 2H); 6.95-7.12 (m, 1H); 7.22 (t, 1H); 7.93 (s, b, 1H); 8.02 (s, 1H); 8.27 (s, b, 1H); 9.62 (s, 1H); 10.50 (s, b, 1H) ppm.

EXAMPLE 202

2-[5-[1-(3-Amino-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-(2,2,2-trifluoro-ethyl)-acetamide

Suspend 1.6 g of the compound described under Example 204 in 40 ml dichlormethane. Add 24 ml trifluoro-acetic acid to it and stir for one hour at room temperature. Press reaction mixture, add dichlormethane and hexane and press anew. After drying well in vacuum, 1.7 g of the compound in the title is obtained in the form of trifluoro acetic acid salt. This raw product is used without further purification for the following reactions.

EXAMPLE 203

2-[5-[1-[3-(2-chloro-acetylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-(2,2,2-trifluoro-ethyl)-acetamide

Dissolve 3.1 mmol of the trifluoro-acetic acid salts of the compound described under Example 202 in 45 ml tetrahydrofurane. At 0° C., add 0.64 ml pyridine and 0.60 mg chloro-acetic acid anhydride and stir for 30 minutes at room temperature. Add 200 ml acetic acid ethylester and 100 ml water, separate the organic phase and dry over sodium sulfate. After purification through the re-crystallizing of ethanol, 1.12 g of the compound in the title is obtained.

(DMSO-d6, stored via K₂CO₃, primary isomer): δ=1.27 (t, 3H); 3.98 (m, 2H); 4.19-4.31 (m, 4H); 7.04 (d, 1H); 7.22 (d, 1H); 7.31 (t, 1H); 7.70 (s, 1H); 8.06 (b, 1H); 8.21 (b, 1H); 10.40 (s, 1H); 10.54 (s, b, 1H) ppm.

EXAMPLE 204

N-Allyl-2-[5-[1-{3-[2-(4-benzyl-piperazin-1-yl)-2-oxo-ethoxy]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-acetamide

Dissolve 95 mg of the compound described under INTA23 in 3 ml DMF and add HATU (194 mg) as well as allylamine (34 μl). Stir the reaction residue at room temperature under argon over night, diluted with water (approx. 20 ml), made alkaline through the addition of a sodium carbonate solution and extracted with acetic ester (3×10 ml). Dry the unified organic phases over sodium sulfate and distill the solvent on a rotary evaporator Purify the raw product chromatographically on the Flashmaster. The compound in the title (45 mg) is obtained in a 45 % yield.

¹H-NMR (CDCl₃, primary isomer): δ=1.39 (m, 3H); 2.49 (m, 4H); 3.61 (m, 4H); 3.69 (m, 2H); 3.97 (m, 2H); 4.38 (m, 2H); 4.80 (s, 2H); 5.21 (m, 2H); 5.88 (m, 1H); 6.38 (t, 1H); 6.58 (m, 3H); 7.12 (t, 1H); 7.50 (m, 2H); 7.68 (m, 1H); 8.00 (d, 1H); 8.65 (d, 1H); 10.40 (d, 1H) ppm.

The following compounds are manufactured according to the process described above.

			Molec-
			ular	Educt/
			Weight/	Addi-
Ex-			MS	tional
ample			(ESI)	syn-
no.	Structure and name	1H-NMR	[M + 1]+	thesis
205		(DMSO-d6, stored via K2CO3, primary isomer):		INTA9/1
	(3-{[2-[1-Cyano-1-(2,2,2-trifluoro-	δ =
	ethylcarbamoyl)-meth-(E or Z)-	1.25(t, 3H); 1.49(s, 9H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	3.97(m, 2H); 4.25(q, 2H);
	(5-(E/Z))-ylidenemethyl]-amino}-	6.90(d, 1H); 7.07(d, 1H);
	phenyl)-carbamic acid tert-butyl	7.21(t, 1H); 7.57(s, 1H);
	ester	8.03(b, 1H); 8.22(b, 1H);
		9.45(s, 1H); 10.50(s, b, 1H)
		ppm
206		(DMSO-d6, stored via K2CO3, primary isomer):		INTT11/ INT54/5
	2-Cyano-N-(2,2-difluoro-ethyl)-2-[3-	δ =
	ethyl-5-[1-[3-(1-hydroxy-2-piperidin-	1.21(t, 3H);
	1-yl-ethyl)-phenylamino]-meth-	1.27-1.56(m, 6H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.27-2.42(m, 6H);
	(E or Z))-ylidene]-acetamide	3.45-3.63(m, 2H);
		4.20(q, 2H); 4.65(s, b, 1H);
		4.95(s, b, 1H); 6.02(tt, 1H);
		6.99(d, 1H); 7.10(d, 1H);
		7.17-7.33(m, 2H);
		7.90(s, b, 1H); 8.09(s, 1H);
		10.37(s, b, 1H)
		ppm
207		(DMSO-d6, stored via K2CO3, primary isomer):		INTT7/ INT54/5
	2-Cyano-N-ethyl-2-[3-ethyl-5-[1-[3-	δ =
	(1-hydroxy-2-piperidin-1-yl-ethyl)-	1.03(t, 3H); 1.20(t, 3H);
	phenylamino]-meth-(E/Z)-ylidene]-	1.27-1.54(m, 6H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.23-2.44(m, 6H);
	ylidene]-acetamide	3.16(m, 2H); 4.18(q, 2H);
		4.62-4.66(m, 1H); 4.94(s, b, 1H);
		6.98(d, 1H); 7.08(d, 1H);
		7.17-7.33(m, 2H);
		7.62(s, b, 1H);
		8.05(s, 1H); 10.27(s, b, 1H)
		ppm
208		(DMSO-d6, stored via K2CO3, primary isomer):		INTT10/ INT54/5
	2-Cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-[3-(1-hydroxy-2-piperidin-1-yl-	1.21(t, 3H);
	ethyl)-phenylamino]-meth-(E/Z)-	1.28-1.56(m, 6H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	2.24-2.43(m, 6H);
	Z))-ylidene]-acetainide	4.12(d, 2H); 4.19(q, 2H);
		4.65(s, b, 1H); 4.95(s, b, 1H);
		7.00(d, 1H); 7.13(d, 1H);
		7.17-7.33(m, 2H);
		8.11(s, 1H); 8.28(s, b, 1H);
		10.41(s, b, 1H)
		ppm
209		(DMSO-d6, stored via K2CO3, primary isomer):		INTT9/ INT54/5
	2-Cyano-2-[3-ethyl-5-[1-[3-(1-	δ =
	hydroxy-2-piperidin-1-yl-ethyl)-	1.20(t, 3H);
	phenylamino]-meth-(E/Z)-ylidene]-	1.27-1.54(m, 6H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.24-2.44(m, 6H);
	ylidene]-N-prop-2-ynyl-acetamide	3.02(m, 1H); 3.88(m, 2H);
		4.19(q, 2H); 4.65(s, b, 1H);
		4.94(s, b, 1H); 6.99(d, 1H);
		7.10(d, 1H);
		7.16-7.32(m, 2H);
		7.95-8.14(m, 2H);
		10.33(s, b, 1H);
		ppm
210		(DMSO-d6, stored via K2CO3, primary isomer):		INTA24/1
	2-Cyano-2-[3-ethyl-5-[1-{3-	δ =
	[(4aR, 8aS)-2-(octahydro-	0.70-1.30(m, 16H);
	isoquinolin-2-yl)-ethyl]-	1.40-1.71(m, 6H);
	phenylamino}-meth-(E/Z)-ylidene]-	1.88(t, 1H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.35-2.50(m, 2H);
	ylidene]-N-(2-hydroxy-1,1-dimethyl-	2.60-2.71(m, 1H);
	ethyl)-acetamide	2.75(d, 1H); 2.88(d, 1H);
		3.33(d, 2H); 4.16(q, 2H);
		5.14(t, 1H); 6.60(s, b, 1H);
		6.86(d, 1H);
		6.97-7.23(m, 3H);
		8.09(s, 1H); 10.20(s, b, 1H)
		ppm
211		(DMSO-d6, stored via K2CO3, primary isomer):		69/14
	2-Cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	methyl-piperidin-1-yl)-ethyl]-	0.84(d, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	0.99-1.36(m, 6H);
	4-oxo-thiazolidin-(2-(E or Z))-	1.53(d, 2H); 1.88(t, 2H);
	ylidene]-N-prop-2-ynyl-acetamide	2.35-2.50(m, 2H);
		2.60-2.71(m, 2H);
		2.78-2.90(m, 2H);
		3.00(b, 1H);
		3.82-3.92(m, 2H);
		4.19(q, 2H); 6.82(d, 1H);
		6.95(d, 1H); 7.02(s, 1H);
		7.14(t, 1H); 7.74(s, b, 1H);
		8.13(s, 1H); 10.24(s, b, 1H)
		ppm
212		(DMSO-d6, stored via K2CO3, primary isomer):		69/14
	2-Cyano-2-[3-ethyl-4-oxo-5-[1-{3-	δ =
	[2-(4-phenyl-piperidin-1-yl)-ethyl]-	1.21(t, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	1.53-1.76(m, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	2.02(t, 2H);
	prop-2-ynyl-acetamide	2.38-2.58(m, 3H);
		2.71(t, 2H);
		2.95-3.07(m, 3H);
		3.83-3.93(m, 2H);
		4.20(q, 2H); 6.91(d, 1H);
		7.03-7.30(m, 8H);
		8.05(s, b, 1H); 8.11(s, 1H);
		10.29(s, b, 1H)
		ppm
213		(DMSO-d6, the chief isomer, stored over K2CO3):		69/14
	2-cyano-2-[5-[1-{3-[2-(4,4-difluoro-	δ =
	piperidin-1-yl)-ethyl]-phenylamino}-	1.21(t, 3H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	1.80-2.00(m, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	2.40-2.61(m, 6H);
	prop-2-ynyl-acetamide	2.70(t, 2H); 3.02(b, 1H);
		3.83-3.92(m, 2H);
		4.20(q, 2H); 6.90(d, 1H);
		7.00-7.28(m, 3H);
		7.91-8.17(m, 2H);
		10.30(s, b, 1H)
		ppm.
214		(DMSO-d6, the chief isomer, stored over K2CO3):		69/14
	2-cyano-2-[3-ethyl-4-oxo-5-[1-{3-[2-	δ =
	(4-trifluoromethyl-piperidin-1-yl)-	1.20(t, 3H);
	ethyl]-phenylamino}-meth-(E/Z)-	1.30-1.49(m, 2H);
	ylidene]-thiazolidin-(2-(E orZ))-	1.73(d, 2H); 1.95(t, 2H);
	ylidene]-N-prop-2-ynyl-acetamide	2.10-2.32(m, 1H);
		2.45-2.57(m, 2H);
		2.62-2.75(m, 2H);
		2.91-3.05(m, 3H);
		3.83-3.94(m, 2H);
		4.19(q, 2H); 6.87(d, 1H);
		7.01(d, 1H); 7.09(s, 1H);
		7.18(t, 1H); 7.87(s, b, 1H);
		8.11(s, 1H);
		10.26(s, b, 1H) ppm.
215		(DMSO-d6, the chief isomer, stored over K2CO3):		69/14
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	methyl-piperazin-1-yl)-ethyl]-	1.21(t, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	2.40-3.10(m, b 15H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.02(b, 1H);
	ylidene]-N-prop-2-ynyl-acetamide	3.83-3.96(m, 2H);
		4.20(q, 2H); 6.92(d, 1H);
		7.09(d, 1H);
		7.15-7.29(m, 2H);
		8.00-8.15(m, 2H);
		10.27(d, 1H)
		ppm.
216		(DMSO-d6, the chief isomer, stored over K2CO3):		69/14
	2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(2-	δ =
	thiomorpholin-4-yl-ethyl)-	1.22(t, 3H);
	phenylamino]-meth-(E/Z)-ylidene]-	2.50-2.66(m, 6H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	2.66-2.80(m, 6H);
	prop-2-ynyl-acetamide	3.03(m, 1H);
		3.87-3.98(m, 2H);
		4.22(q, 2H); 6.90(d, 1H);
		7.05(d, 1H); 7.13(s, 1H);
		7.21(t, 1H); 7.96(s, b, 1H);
		8.11(s, 1H);
		10.30(s, b, 1H)
		ppm.
217		(DMSO-d6, the chief isomer, stored over K2CO3):		69/14
	2-[5-[1-{3-[2-(4-benzyl-piperidin-1-	δ =
	yl)-ethyl]-phenylamino}-meth-(E/Z)-	1.20(t, 3H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	1.32-1.56(m, 3H);
	(2-(E or Z))-ylidene]-2-cyano-N-	1.83(t, 2H);
	prop-2-ynyl-acetamide	2.35-2.50(m, 4H);
		2.65(t, 2H);
		2.80-2.90(m, 2H);
		3.00(m, 1H);
		3.83-3.93(m, 2H);
		4.20(q, 2H); 6.87(d, 1H);
		6.98-7.30(m, 8H);
		7.99(s, b, 1H); 8.09(s, 1H);
		10.24(s, b, 1H)
		ppm.
218		(DMSO-d6, the chief isomer, stored over K2CO3):		69/14 or INTA24/1
	2-cyano-2-[3-ethyl-5-({3-	δ =
	[(4aR, 8aS)-2-(octahydro-	0.70-1.00(m, 3H);
	isoquinolin-2-yl)-ethyl]-	1.00-1.30(m, 7H);
	phenylainino}-meth-(E/Z)-ylidene]-	1.40-1.70(m, 6H);
	4-oxo-thiazolidin-(2-(E or Z))-	1.90(t, 1H);
	ylidene]-N-prop-2-ynyl-acetamide	2.37-2.50(m, 2H);
		2.61-2.95(m, 4H);
		3.00(b, 1H);
		3.85-3.93(m, 2H);
		4.20(q, 2H); 6.89(d, 1H);
		7.06(d, 1H); 7.15(s, b, 1H);
		7.20(t, 1H); 8.00(s, b, 1H);
		8.09(s, 1H);
		10.25(s, b, 1H)
		ppm.
219		(DMSO-d6, the chief isomer, stored over K2CO3):		69/14
	2-cyano-2-[3-ethyl-5-[1-[3-(2-	δ =
	morpholin-4-yl-ethyl)-	1.25(t, 3H);
	phenylamino]-meth-(E/Z)-ylidene]-	2.36-2.60(m, 6H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.73(t, 2H); 3.05(b, 1H);
	ylidene]-N-prop-2-ynyl-acetamide	3.52-3.63(m, 4H);
		3.89-3.98(m, 2H);
		4.22(q, 2H); 6.92(d, 1H);
		7.09(d, 1H); 7.19(s, b, 1H);
		7.22(t, 1H); 8.01(s, b, 1H);
		8.13(s, 1H);
		10.30(s, b, 1H)
		ppm.
220		(DMSO-d6, the chief isomer, stored over K2CO3):		13/14
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[2-(4-hydroxy-piperidin-1-	1.22(t, 3H);
	yl)-ethyl]-phenylamino}-meth-(E/Z)-	1.31-1.53(m, b, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	1.64-1.82(m, b, 2H);
	Z))-ylidene]-acetamide	1.98-2.28(m, b, 2H);
		2.38-2.66(m, b, 2H);
		2.66-2.96(m, b, 4H);
		3.50(b, 1H); 4.17(d, 2H);
		4.25(q, 2H); 6.61(b, 1H);
		6.95(d, 1H); 7.12(d, 1H);
		7.21(s, b, 1H); 7.26(t, 1H);
		8.18(s, b, 1H); 8.35(t, 1H);
		10.40(s, b, 1H)
		ppm.
221		(DMSO-d6, the chief isomer, stored over K2CO3):		13/14
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[2-(4-methyl-piperazin-1-yl)-	1.26(t, 3H); 2.16(s, 3H);
	ethyl]-phenylamino}-meth-(E/Z)-	2.21-2.60(m, 10H);
	ylidenel]-4-oxo-thiazolidin-(2-(E or	2.71(t, 2H); 4.18(d, 2H);
	Z))-ylidene]-acetamide	4.24(q, 2H);
		7.11(d, 1H); 7.21(s, b, 1H);
		7.24(t, 1H); 8.16(s, b, 1H);
		8.35(t, 1H);
		10.39(s, b, 1H)
		ppm.
222		(DMSO-d6, the chief isomer, stored over K2CO3):		13/14
	2-[5-[1-{3-[2-(4-benzoyl-piperidin-1-	δ =
	yl)-ethyl]-phenylamino}-meth-(E/Z)-	1.21(t, 3H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	1.48-1.88(m, 4H);
	(2-(E or Z))-ylidene]-2-cyano-N-	2.14(t, 2H);
	cyanomethyl-acetamide	2.45-2.60(m, 2H);
		2.65-2.80(m, 2H);
		2.90-3.07(m, 2H);
		3.30-3.48(m, 1H);
		4.11(d, 2H); 4.22(q, 2H);
		6.74-7.25(m, 4H);
		7.47-7.70(m, 3H);
		7.90-8.06(m, 3H);
		8.23(s, b, 1H);
		10.40(s, b, 1H)
		ppm.
223		(DMSO-d6, the chief isomer, stored over K2CO3):		13/14
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[(4aS, 8aS)-2-(octahydro-	1.10-1.80(m, 17H);
	isoquinolin-2-yl)-ethyl]-	2.00-2.22(m, 2H);
	phenylamino}-meth-(E/Z)-ylidene]-	2.40-2.60(m, 2H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.70(t, 2H); 4.16(d, 2H);
	ylidene]-acetamide	4.24(q, 2H); 6.93(d, 1H);
		7.10(d, 1H); 7.19(s, b, 1H);
		7.22(t, 1H); 8.16(s, 1H);
		8.30(s, b, 1H);
		10.40(s, b, 1H)
		ppm.
224		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT11/ INT60/201
	2-cyano-N-(2,2-difluoro-ethyl)-2-[3-	δ =
	ethyl-5-[1-[4-fluoro-3-(2-morpholin-	1.20(t, 3H); 2.51(b, 4H);
	4-yl-acetylamino)-phenylamino]-	3.16(s, 2H);
	4-yl-acetylamino)-phenylamino]-	3.40-3.70(m, 6H);
	meth-(E/Z)-ylidene]-4-oxo-	4.19(q, 2H); 6.02(tt, 1H);
	thiazolidin-(2-(E or Z))-ylidene]-	6.95-7.10(m, 1H);
	acetamide	7.22(t, 1H);
		7.82-8.11(m, 3H);
		9.62(s, 1H); 10.44(s, b, 1H)
		ppm.
225		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT8/ INT60/201
	2-cyano-2-[3-ethyl-5-[1-[4-fluoro-3-	δ =
	(2-morpholin-4-yl-acetylamino)-	1.21(t, 3H); 2.51(b, 4H);
	phenylamino]-meth-(E/Z)-ylidene]-	3.16(s, 2H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.60(b, 4H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	3.81-3.99(m, 2H);
	acetamide	4.19(q, 2H);
		6.95-7.11(m, 1H);
		7.22(t, 1H); 8.00(b, 2H);
		8.16(s, b, 1H);
		9.63(s, 1H);
		10.47(s, b, 1H); ppm.
226		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT9/ INT60/201
	2-cyano-2-[3-ethyl-5-[1-[4-fluoro-3-	δ =
	(2-morpholin-4-yl-acetylamino)-	1.20(t, 3H); 2.51(b, 4H);
	phenylamino]-meth-(E/Z)-ylidene]-	2.97-3.07(m, 1H);
	phenylamino]-meth-(E/Z)-ylidene]-	3.16(s, 2H); 3.60(b, 4H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.80-3.95(m, 2H);
	ylidene]-N-prop-2-ynyl-acetamide	4.18(q, 2H);
		6.96-7.12(m, 1H);
		7.22(t, 1H);
		7.85-8.20(m, 3H);
		9.62(s, 1H);
		10.42(s, b, 1H)
		ppm.
227		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT10/ INT60/201
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-[4-fluoro-3-(2-morpholin-4-yl-	1.20(t, 3H); 2.51(b, 4H);
	acetylamino)-phenylamino]-meth-	3.16(s, 2H); 3.60(b, 4H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.60(b, 4H); 4.12(d, 2H);
	(E or Z))-ylidene]-acetamide	4.19(q, 2H);
		6.97-7.12(m, 1H);
		7.23(t, 1H); 8.00(b, 2H);
		8.29(s, b, 1H); 9.63(s, 1H);
		10.49(s, b, 1H)
		ppm.
228		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT7/ INT60/201
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-[4-	δ =
	fluoro-3-(2-morpholin-4-yl-	1.03(t, 3H); 1.19(t, 3H);
	fluoro-3-(2-morpholin-4-yl-	2.51(b, 4H);
	acetylamino)-phenylamino]-meth-	3.07-3.23(m, 4H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.60(b, 4H); 4.18(q, 2H);
	(E or Z))-ylidene]-acetamide	6.90-7.15(m, 1H);
		7.21(t, 1H);
		7.64(s, b, 1H);
		7.70-8.10(m, 2H);
		9.62(s, 1H);
		10.36(s, b, 1H)
		ppm.
229		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT9/ INT62/201
	2-cyano-2-[5-[1-{3-[2-(4,4-difluoro-	δ =
	piperidin-1-yl)-acetylamino]-4-	1.17(t, 3H);
	fluoro-phenylamino}-meth-(E/Z)-	1.85-2.11(m, 4H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	2.57-2.76(m, 4H);
	(2-(E or Z))-ylidene]-N-prop-2-ynyl-	2.99(b, 1H); 3.24(s, 2H);
	acetamide	3.75-3.95(m, 2H);
		4.17(q, 2H); 6.88(b, 1H);
		7.13(t, 1H); 7.74(m, b, 2H);
		8.08(s, 1H); 9.54(s, 1H);
		10.42(s, 1H)
		ppm.
230		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT8/ INT62/201
	2-cyano-2-[5-[1-{3-[2-(4,4-difluoro-	δ =
	piperidin-1-yl)-acetylamino]-4-	1.21(t, 3H);
	fluoro-phenylamino}-meth-(E/Z)-	1.85-2.09(m, 4H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	2.56-2.75(m, 4H);
	(2-(E or Z))-ylidene]-N-(2,2,2-	3.26(s, 2H);
	trifluoro-ethyl)-acetamide	3.85-3.95(m, 2H);
		4.19(q, 2H); 7.05(b, 1H);
		7.21(t, 1H); 7.93(b, 1H);
		8.01(s, 1H); 8.14(b, 1H);
		9.61(s, 1H);
		10.47(s, 1H)
		ppm.
231		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT11/ INT62/201
	2-cyano-N-(2,2-difluoro-ethyl)-2-[5-	δ =
	[1-{3-[2-(4,4-difluoro-piperidin-1-yl)-	1.20(t, 3H);
	acetylamino]-4-fluoro-	1.85-2.12(m, 4H);
	phenylamino}-meth-(E/Z)-ylidene]-	2.57-2.73(m, 4H);
	3-ethyl-4-oxo-thiazolidin-(2-(E or	3.26(s, 2H);
	Z))-ylidene]-acetamide	3.42-3.65(m, 2H);
		4.19(q, 2H); 6.02(tt, 1H);
		6.95-7.20(b, 1H);
		7.21(t, 1H);
		7.75-8.07(m, 3H);
		9.61(s, 1H);
		10.44(s, b, 1H)
		ppm.
232		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT7/ INT62/201
	2-cyano-2-[5-[1-{3-[2-(4,4-difluoro-	δ =
	piperidin-1-yl)-acetylamino]-4-	1.02(t, 3H); 1.19(t, 3H);
	fluoro-phenylamino}-meth-(E/Z)-	1.87-2.10(m, 4H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	2.58-2.75(m, 4H);
	(2-(E orZ))-ylidene]-N-ethyl-	3.16(m, 2H); 3.25(s, 2H);
	acetamide	4.17(q, 2H); 7.01(b, 1H);
		7.19(t, 1H); 7.56(b, 1H);
		7.87(b, 1H); 7.96(s, 1H);
		9.60(s, 1H); 10.35(s, 1H)
		ppm.
233		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT12/ INT62/201
	2-cyano-2-[5-[1-{3-[2-(4,4-difluoro-	δ =
	piperidin-1-yl)-acetylamino]-4-	1.22(t, 3H); 1.29(s, 6H);
	fluoro-phenylamino}-meth-(E/Z)-	1.89-2.12(m, 4H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	2.62-2.76(m, 4H);
	(2-(E or Z))-ylidene]-N-(2-hydroxy-	3.29(s, 2H); 3.37(d, 2H);
	1,1-dimethyl-ethyl)-acetamide	4.19(q, 2H); 5.18(t, 1H);
		6.63(s, b, 1H); 7.05(s, b, 1H);
		7.23(t, 1H); 7.93(s, b, 1H);
		8.01(s, 1H); 9.64(s, 1H);
		10.39(s, b, 1H)
		ppm.
234		(DMSO-d6, the chief isomer, stored over K2CO3):		200/8
	2-cyano-2-[3-ethyl-5-[1-[3-(2-	δ =
	imidazol-1-yl-acetylamino)-	1.20(t, 3H);
	phenylamino]-meth-(E/Z)-ylidene]-	2.96-3.08(m, 1H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.82-3.94(m, 2H);
	ylidene]-N-prop-2-ynyl-acetamide	4.18(q, 2H); 4.87(s, 2H);
		6.86(s, 1H); 6.96(d, 1H);
		7.10-7.19(m, 2H);
		7.25(t, 1H); 7.60(s, b, 2H);
		7.98(s, 1H); 8.03(s, b, 1H);
		10.33(s, 1H);
		10.41(s, b, 1H)
		ppm.
235		(DMSO-d6, the chief isomer, stored over K2CO3):		200/8
	2-[5-[1-[3-(2-benzoimidazol-1-yl-	δ =
	acetylamino)-phenylamino]-meth-	1.19(t, 3H); 3.01(b, 1H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	3.82-3.93(m, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	4.17(q, 2H); 5.15(s, 2H);
	cyano-N-prop-2-ynyl-acetamide	6.95(s, b, 1H);
		7.12-7.33(m, 4H);
		7.51(d, 1H); 7.58(s, b, 1H);
		7.64(d, 1H); 7.99(b, 2H);
		8.20(s, 1H); 10.40(s, 1H);
		10.48(s, 1H)
		ppm.
236		(DMSO-d6, the chief isomer, stored over K2CO3):		200/8
	2-cyano-2-[3-ethyl-4-oxo-5-[1-{3-[2-	δ =
	(4-phenyl-piperidin-1-yl)-	1.20(t, 3H);
	acetylamino]-phenylamino}-meth-	1.63-1.87(m, 4H);
	(E/Z)-ylidene]-thiazolidin-(2-(E or	2.16-2.34(m, 2H);
	Z))-ylidene]-N-prop-2-ynyl-	2.45-2.55(m, 1H);
	acetamide	2.95(d, 2H); 3.01(b, 1H);
		3.12(s, 2H);
		3.81-3.95(m, 2H);
		4.19(q, 2H); 6.94(d, 1H);
		7.09-7.37(m, 7H);
		7.69(s, b, 1H);
		7.86-8.11(m, 2H);
		9.72(s, 1H);
		10.39(s, b, 1H)
		ppm.
237		(DMSO-d6, the chief isomer, stored over K2CO3):		203/8
	2-[5-[1-{3-[2-(4-benzyl-piperidin-1-	δ =
	yl)-acetylamino]-phenylamino}-	1.15-1.41(m, 5H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	1.41-1.65(m, 3H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	2.09(t, 2H);
	cyano-N-(2,2,2-trifluoro-ethyl)-	2.49-2.60(m, 2H);
	acetamide	2.85(d, 2H); 3.06(s, 2H);
		3.87-4.14(m, 2H);
		4.25(q, 2H); 6.92(d, 1H);
		7.12-7.35(m, 7H);
		7.61(s, b, 1H);
		8.02(s, b, 1H);
		8.11(s, 1H); 9.64(s, 1H);
		10.50(s, 1H)
		ppm.
238		(DMSO-d6, the chief isomer, stored over K2CO3):		203/8
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	methyl-piperidin-1-yl)-acetylamino]-	0.91(d, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	1.16-1.42(m, 6H);
	4-oxo-thiazolidin-(2-(E or Z))-	1.52-1.55(m, 2H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	2.03-2.20(m, 2H);
	acetamide	2.83(d, 2H); 3.09(s, 2H);
		3.88-4.05(m, 2H);
		4.26(q, 2H); 7.00(d, 1H);
		7.22-7.38(m, 2H);
		7.71(s, 1H); 8.09(s, 1H);
		8.20(s, b, 1H); 9.71(s, 1H);
		10.50(s, b, 1H)
		ppm.
239		(DMSO-d6, the chief isomer, stored over K2CO3):		203/8
	2-cyano-2-[5-[1-{3-[2-(4,4-difluoro-	δ =
	piperidin-1-yl)-acetylamino]-	1.21(t, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	1.91-2.10(m, 4H);
	3-ethyl-4-oxo-thiazolidin-(2-(E or	2.63(b, 4H);
	Z))-ylidene]-N-(2,2,2-trifluoro-	3.20(s, 2H);
	ethyl)-acetamide	3.84-4.00(m, 2H);
		4.21(q, 2H); 6.96(d, 1H);
		7.20-7.32(m, 2H);
		7.71(s, 1H); 8.05(d, 1H);
		8.20(t, 1H); 9.79(s, 1H);
		10.50(d, 1H)
		ppm.
240		(DMSO-d6, the chief isomer, stored over K2CO3):		203/8
	2-cyano-2-[3-ethyl-4-oxo-5-[1-{3-[2-	δ =
	(4-trifluoromethyl-piperidin-1-yl)-	1.21(t, 3H);
	acetylamino]-phenylamino}-meth-	1.49-1.63(m, 2H);
	(E/Z)-ylidene]-thiazolidin-(2-(E or	1.75(d, 2H);
	Z))-ylidene]-N-(2,2,2-trifluoro-	2.10-2.31(m, 2H);
	ethyl)-acetamide	2.90(d, 2H); 3.11(s, 2H);
		3.85-3.98(m, 2H);
		4.21(q, 2H); 6.97(d, 1H);
		7.19-7.32(m, 2H);
		7.70(s, 1H); 8.03(s, b, 1H);
		8.19(t, 1H); 9.71(s, 1H);
		10.50(s, b, 1H)
		ppm.
241		(DMSO-d6, the chief isomer, stored over K2CO3):		203/8
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	hydroxymethyl-piperidin-1-yl)-	1.13-1.40(m, 6H);
	acetylamino]-phenylamino}-meth-	1.65(d, 2H); 2.11(t, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.87(d, 2H); 3.10(s, 2H);
	(E or Z))-ylidene]-N-(2,2,2-trifluoro-	3.28(t, 2H);
	ethyl)-acetamide	3.88-4.04(m, 2H);
		4.25(q, 2H); 4.45(t, 1H);
		6.96(d, 1H);
		7.20-7.36(m, 2H);
		7.70(s, b, 1H);
		8.12(b, 2H); 9.71(s, 1H);
		10.50(s, 1H)
		ppm.
242		(DMSO-d6, the chief isomer, stored over K2CO3):		203/8
	2-cyano-2-[3-ethyl-4-oxo-5-[1-{3-[2-	δ =
	(4-phenyl-piperidin-1-yl)-	1.21(t, 3H);
	acetylamino]-phenylamino}-meth-	1.69-1.91(m, 4H);
	(E/Z)-ylidene]-thiazolidin-(2-(E or	2.20-2.35(m, 2H);
	Z))-ylidene]-N-(2,2,2-trifluoro-	2.44-2.60(m, 1H);
	ethyl)-acetamide	2.99(d, 2H); 3.15(s, 2H);
		3.85-4.02(m, 2H);
		4.23(q, 2H); 6.81(s, b, 1H);
		7.12-7.68(m, 9H);
		8.23(s, b, 1H);
		9.65(s, b, 1H);
		10.50(s, 1H)
		ppm.
243		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	4-oxo-5-[1-[3-(2-thiomorpholin-4-yl-	1.25(t, 3H);
	acetylamino)-phenylamino]-meth-	2.62-2.87(m, 8H);
	(E/Z)-ylidene]-thiazolidin-(2-(E or	3.17(s, 2H); 4.16(d, 2H);
	Z))-ylidene]-acetamide	4.23(q, 2H); 6.93(b, 1H);
		7.19-7.37(m, 2H);
		7.64(s, b, 1H);
		8.02-8.37(m, 2H);
		9.70(s, 1H);
		10.52(s, b, 1H)
		ppm.
244		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-[5-[1 -{3-	δ =
	[2-(4,4-difluoro-piperidin-1-yl)-	1.26(t, 3H);
	acetylamino]-phenylamino}-meth-	1.93-2.16(m, 4H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	2.60-2.74(m, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-	3.24(s, 2H); 4.17(d, 2H);
	acetamide	4.25(q, 2H); 6.99(d, 1H);
		7.20-7.40(m, 2H);
		7.72(s, 1H); 8.09(s, 1H);
		8.31(s, b, 1H);
		9.80(s, 1H);
		10.53(s, b, 1H)
		ppm.
245		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	4-oxo-5-[1-{3-[2-(4-trifluoromethyl-	1.25(t, 3H);
	piperidin-1-yl)-acetylamino]-	1.50-1.70(m, 2H);
	phenylamino}-meth-(E/Z)-ylidene]-	1.80(d, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-	2.11-2.39(m, 3H);
	acetamide	2.95(d, 2H); 3.16(s, 2H);
		4.17(d, 2H); 4.23(q, 2H);
		7.00(d, 1H);
		7.21-7.38(m, 2H);
		7.73(s, 1H); 8.09(s, 1H);
		8.34(t, 1H); 9.77(s, 1H);
		10.52(s, b, 1H)
		ppm.
246		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-[5-[1-{3-[2-(4-benzyl-piperidin-1-	δ =
	yl)-acetylamino]-phenylamino}-	1.17-1.41(m, 5H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	1.41-1.63(m, 3H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	2.08(t, 2H);
	cyano-N-cyanomethyl-acetamide	2.42-2.60(m, 2H);
		2.83(d, 2H); 3.08(s, 2H);
		4.17(d, 2H); 4.23(q, 2H);
		6.99(d, 1H);
		7.11-7.36(m, 7H);
		7.72(s, 1H); 8.08(s, b, 1H);
		8.34(t, 1H); 9.70(s, 1H);
		10.51(s, b, 1H)
		ppm.
247		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-[5-[1-{3-[2-(4-Benzoyl-piperidin-	δ =
	1-yl)-acetylamino]-phenylamino}-	1.24(t, 3H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	1.63-1.87(m, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	2.26-2.43(m, 2H);
	cyano-N-cyanomethyl-acetamide	2.85-3.00(m, 2H);
		3.17(s, 2H);
		3.36-3.50(m, 1H);
		4.17(d, 2H); 4.23(q, 2H);
		7.00(d, 1H);
		7.21-7.40(m, 2H);
		7.56(t, 2H); 7.65(t, 1H);
		7.75(s, 1H); 7.99(d, 2H);
		8.10(s, 1H); 8.32(s, b, 1H);
		9.77(s, 1H);
		10.51(s, b, 1H)
		ppm.
248		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-(3-ethyl-	δ =
	5-{[3-((4aS, 8aS)-2-octahydro-	1.15-2.05(m, 15H);
	isoquinolin-2-yl-acetylamino)-	2.15-2.38(m, 2H);
	phenylamino]-meth-(E/Z)-ylidene}-	2.48-2.65(m, 2H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.90-3.20(m, 2H);
	ylidene)-acetamide	4.16(d, 2H); 4.24(q, 2H);
		7.01(d, 1H);
		7.20-7.34(m, 2H);
		7.73(s, 1H); 8.08(s, b, 1H);
		8.34(t, 1H); 9.62(s, 1H);
		10.52(s, b, 1H)
		ppm.
249		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-(3-ethyl-	δ =
	5-{[3-((4aR, 8aS)-2-octahydro-	0.75-1.13(m, 3H);
	isoquinolin-2-yl-acetylamino)-	1.10-1.41(m, 7H);
	phenylamino]-meth-(E/Z)-ylidene}-	1.41-1.75(m, 5H);
	4-oxo-thiazolidin-(2-(E or Z))-	1.80(t, 1H);
	ylidene)-acetamide	2.07-2.23(m, 1H);
		2.72(d, 1H); 2.88(d, 1H);
		3.10(s, 2H); 4.17(d, 2H);
		4.24(q, 2H); 7.00(d, 1H);
		7.20-7.35(m, 2H);
		7.72(s, 1H); 8.10(s, b, 1H);
		8.34(t, 1H); 9.72(s, 1H);
		10.52(s, b, 1H)
		ppm.
250		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[2-(4-methyl-piperazin-1-yl)-	1.25(t, 3H);
	acetylamino]-phenylamino}-meth-	2.18(s, 3H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.30-2.55(m, 8H);
	(E or Z))-ylidene]-acetamide	3.12(s, 2H); 4.18(d, 2H);
		4.25(q, 2H); 6.99(d, 1H);
		7.20-7.36(m, 2H);
		7.71(s, 1H); 8.10(s, 1H);
		8.34(s, b, 1H); 9.75(s, 1H);
		10.51(s, b, 1H)
		ppm.
251		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[2-(4-hydroxy-piperidin-1-	1.14-1.40(m, 6H);
	yl)-ethyl]-phenylamino}-meth-(E/Z)-	1.65(d, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	2.10(t, 2H); 2.85(d, 2H);
	Z))-ylidene]-acetamide	3.10(s, 2H); 3.26(t, 2H);
		4.16(d, 2H); 4.24(q, 2H);
		4.44(t, 1H); 7.00(d, 1H);
		7.21-7.36(m, 2H);
		7.72(s, 1H); 8.08(s, b, 1H);
		8.33(t, 1H); 9.71(s, 1H);
		10.52(s, b, 1H)
		ppm.
252		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[2-(4-hydroxymethyl-	1.21(t, 3H);
	piperidin-1-yl)-acetylamino]-	1.64-1.82(m, 4H);
	phenylamino}-meth-(E/Z)-ylidene]-	2.18-2.32(m, 2H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.47-2.57(m, 1H);
	ylidene]-acetamide	2.94(d, 2H); 3.13(s, 2H);
		4.12(d, 2H); 4.21(q, 2H);
		6.97(d, 1H);
		7.10-7.34(m, 7H);
		7.74(s, 1H); 8.05(s, b, 1H);
		8.31(t, 1H); 9.73(s, 1H);
		10.50(s, b, 1H)
		ppm.
253		(DMSO-d6, the chief isomer, stored over K2CO3):		96/8
	2-cyano-N-cyanomethyl-2-[5-[1-{3-	δ =
	[2-(4-cyano-4-phenyl-piperidin-1-	1.25(t, 3H);
	yl)-acetylamino]-phenylamino}-	2.08-2.29(m, 4H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	2.55-2.69(m, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-	3.04(d, 2H); 3.27(s, 2H);
	acetamide	4.17(d, 2H); 4.24(q, 2H);
		7.00(d, 1H);
		7.21-7.53(m, 5H);
		7.59(d, 2H); 7.77(s, 1H);
		8.08(s, b, 1H); 8.35(t, 1H);
		9.81(s, 1H);
		10.54(s, b, 1H)
		ppm.
254		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT8 +INT67/201
	2-[5-[1-[5-bromo-4-((R)-1-	δ =
	hydroxymethyl-2-methyl-	0.97(d, 3H); 1.01(d, 3H);
	propylamino)-pyrimidin-2-ylamino]-	1.32(t, 3H); 2.07(m, 1H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	3.67(m, 2H); 4.03(m, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	4.10(m, 1H); 4.30(q, 2H);
	cyano-N-(2,2,2-trifluoro-ethyl)-	4.86(s, b, 1H); 6.60(s, b, 1H);
	acetamide	8.25(s, 1H); 8.35(s, b, 1H);
		8.62(s, b, 1H);
		11.09(s, b, 1H)
		ppm.
255		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT10 +INT67/201
	2-[5-[1-[5-bromo-4-((R)-1-	δ =
	hydroxymethyl-2-methyl-	0.90(d, 3H); 0.96(d, 3H);
	propylamino)-pyrimidin-2-ylamino]-	1.26(t, 3H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	1.94-2.04(m, 1H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	3.55-3.69(m, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	4.05(m, 1H); 4.18(d, 2H);
	cyano-N-cyanomethyl-acetamide	4.23(q, 2H); 4.79(t, 1H);
		6.55(d, 1H); 8.19(s, 1H);
		8.41(t, 1H); 8.57(s, b, 1H);
		11.04(s, b, 1H)
		ppm.
256		(DMSO-d6, the chief isomer, stored over K2CO3):		INTT7 +INT67/201
	2-[5-[1-[5-bromo-4-((R)-1-	δ =
	hydroxymethyl-2-methyl-	0.88(d, 3H); 0.92(d, 3H);
	propylamino)-pyrimidin-2-ylamino]-	1.06(t, 3H); 1.23(t, 3H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	1.90-2.01(m, 1H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.12-3.22(m, 2H);
	cyano-N-ethyl-acetamide	3.51-3.66(m, 2H);
		4.03(m, 1H); 4.20(q, 2H);
		4.77(t, 1H); 6.50(s, b, 1H);
		7.75(s, b, 1H); 8.15(s, 1H);
		8.50(s, 1H);
		10.90(s, 1H)
		ppm.
257		(DMSO-d6, the chief isomer, stored over K2CO3):		INTA23/1
	2-cyano-2-[5-[1-[6-(1,1-difluoro-2-	δ =
	pyrrolidin-1-yl-ethyl)-pyridin-2-	1.03(t, 3H); 1.21(t, 3H);
	ylamino]-meth-(E/Z)-ylidene]-3-	1.57(b, 4H); 2.50(b, 4H);
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-	3.10-3.35(m, 4H);
	ylidene]-N-ethyl-acetamide	4.18(q, 2H); 7.15(d, 1H);
		7.28(d, 1H); 7.76(t, 1H);
		7.85(t, 1H); 8.55(d, 1H);
		10.46(d, 1H)
		ppm.
258		(DMSO-d6, the chief isomer, stored over K2CO3):		INTA23/1
	2-cyano-2-[5-[1-[6-(1,1-difluoro-2-	δ =
	pyrrolidin-1-yl-ethyl)-pyridin-2-	1.22(t, 3H); 1.57(b, 4H);
	ylamino]-meth-(E/Z)-ylidene]-3	2.50(b, 4H);
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-	3.20-3.32(m, 2H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	3.85-3.99(m, 2H);
	acetamide	4.20(q, 2H); 7.15(d, 1H);
		7.30(d, 1H); 7.86(t, 1H);
		8.27(t, 1H); 8.61(s, b, 1H);
		10.97(s, b, 1H)
		ppm.
259		(DMSO-d6, the chief isomer, stored over K2CO3):		INTA23/1
	2-cyano-N-cyanomethyl-2-[5-[1-[6-	δ =
	(1,1-difluoro-2-pyrrolidin-1-yl-ethyl)-	1.22(t, 3H); 1.58(b, 4H);
	pyridin-2-ylamino]-meth-(E/Z)-	2.52(b, 4H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	3.20-3.35(m, 2H);
	(2-(E or Z))-ylidene]-acetamide	4.13(d, 2H); 4.20(q, 2H);
		7.27(d, 1H); 7.31(d, 1H);
		7.88(t, 1H); 8.41(t, 1H);
		8.61(s, b, 1H);
		11.00(s, b, 1H)
		ppm.
260		(DMSO-d6, the chief isomer, stored over K2CO3):		INTA23/1
	2-cyano-2-[5-[1-[6-(1,1-difluoro-2-	δ =
	pyrrolidin-1-yl-ethyl)-pyridin-2-	1.21(t, 3H); 1.57(b, 4H);
	ylamino]-meth-(E/Z)-ylidene]-3-	2.50(b, 4H); 3.03(b, 1H);
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-	3.16-3.36(m, 2H);
	ylidene]-N-prop-2-ynyl-acetamide	3.83-3.95(m, 2H);
		4.19(q, 2H); 7.15(d, 1H);
		7.29(d, 1H); 7.85(t, 1H);
		8.16(t, 1H); 8.58(d, 1H);
		10.92(d, 1H)
		ppm.
261		(Methanol):	538.60/539	INTT8/ INT85/5
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	methyl-piperazin-1-yl)-ethoxy]-	1.30(m, 3H); 2.71(s, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	2.88(m, 6H, wide);
	4-oxo-thiazolidin-(2-(E or Z))-	3.10(m, 4H); 3.99(m, 2H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	4.18(m, 2H); 4.33(m, 2H);
	acetamide	6.70(dd, 1H); 6.80(m, 2H);
		7.28(t, 1H);
		8.19(s, 1H) ppm.
262		(DMSO-d6, the chief isomer, stored over K2CO3):	537.61/538	INTT8/ INT87/5
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	methyl-piperidin-1-yl)-ethoxy]-	0.85(d, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	1.19(m, 6H, wide);
	4-oxo-thiazolidin-(2-(E or Z))-	3.16(m, 2H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	2.00(m, 2H);
	acetamide	2.63(m, 2H);
		2.88(m, 2H); 3.90(m, 2H);
		4.07(m, 2H); 4.22(m, 2H);
		6.61(dd, 1H); 6.88(m, 2H);
		7.20(t, 1H); 8.12(m, 2H);
		10.25(d, 1H) ppm.
263		(DMSO-d6, the chief isomer, stored over K2CO3):	537.61/538	INTT8/ INT89/5
	2-[5-[1-[3-(2-azepan-1-yl-ethoxy)-	δ =
	phenylamino]-meth-(E/Z)-ylidene]-	1.22(m, 3H); 1.52(m, 8H);
	3-ethyl-4-oxo-thiazolidin-(2-(E or	2.65(m, 4H); 2.82(m, 2H);
	Z))-lidene]-2-cyano-N-(2,2,2-	3.90(m, 2H); 4.01(m, 2H);
	trifluoro-ethyl)-acetamide	4.20(m, 2H); 6.61(dd, 1H);
		6.83(m, 2H); 7.19(m, 1H);
		8.08(s, 1H); 8.16(t, 1H);
		10.29(s, 1H) ppm.
264		(DMSO-d6, the chief isomer, stored over K2CO3):	523.62/524	INTA26/204
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[2-(4-ethyl-piperazin-1-yl)-2-	0.98(t, 3H); 1.20(m, 3H);
	oxo-ethoxy]-phenylamino}-meth-	2.31(m, 6H); 3.40(m, 4H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	4.12(d, 2H); 4.20(m, 2H);
	(E or Z))-ylidene]-acetamide	4.80(s, 2H); 6.60(dd, 2H);
		6.81(d, 1H); 6.88(dd, 1H);
		7.20(t, 1H); 8.10(s, 1H);
		8.29(t, 1H);
		10.21(s, 1H) ppm.
265		(DMSO-d6, the chief isomer, stored over K2CO3):	548.62/549	INTA26/204
	2-cyano-N-(2,2-difluoro-ethyl)-2-[3-	δ =
	ethyl-5-[1-{3-[2-(4-ethyl-piperazin-	0.99(t, 3H); 1.21(t, 3H);
	1-yl)-2-oxo-ethoxy]-phenylamino}-	2.30(m, 6H); 3.55(m, 2H);
	meth-(E/Z)-ylidene]-4-oxo-	4.20(m, 2H); 4.79(s, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-	6.03(tt, 1H); 6.58(dd, 1H);
	acetamide	6.81(m, 2H); 7.19(t, 1H);
		7.80(m, 1H); 8.10(s, 1H);
		9.95(s, 1H) ppm.
266		(DMSO-d6, the chief isomer, stored over K2CO3):	522.63/523	INTA26/204
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	ethyl-piperazin-1-yl)-2-oxo-ethoxy]-	0.99(t, 3H); 1.21(t, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	2.31(m, 6H); 3.41(m, 4H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.89(m, 2H); 4.17(m, 2H);
	ylidene]-N-prop-2-ynyl-acetamide	4.79(s, 2H); 6.57(dd, 1H);
		6.83(m, 2H); 7.20(t, 1H);
		8.07(m, 1H);
		10.20(s, 1H) ppm.
267		(DMSO-d6, the chief isomer, stored over K2CO3):	566.61/567	INTA26/204
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	ethyl-piperazin-1-yl)-2-oxo-ethoxy]-	0.99(t, 3H); 1.23(m, 3H);
	phenylamino}-meth-(E/Z)-ylidene]-	2.31(m, 6H); 3.41(m, 4H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.90(m, 2H); 4.20(m, 2H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	4.79(s, 2H); 6.57(dd, 1H);
	acetamide	6.80(s, 1H); 6.83(d, 1H);
		7.21(t, 1H); 8.09(m, 2H);
		10.10(s, 1H) ppm.
268		(DMSO-d6, the chief isomer, stored over K2CO3):	510.62/511	INTA27/204
	N-Allyl-2-cyano-2-[3-ethyl-5-[1-{3-	δ =
	[2-(4-methyl-piperazin-1-yl)-2-oxo-	1.21(t, 3H); 2.18(s, 3H);
	ethoxy]-phenylamino}-meth-(E/Z)-	2.21(m, 2H); 2.30(m, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	3.42(m, 4H); 4.20(m, 2H);
	Z))-ylidene]-acetamide	4.81(s, 2H); 5.09(m, 2H);
		5.81(m, 1H); 6.60(dd, 1H);
		6.80(s, 1H); 6.88(d, 1H);
		7.20(d, 1H); 7.83(t, 1H);
		8.08(d, 1H);
		10.20(d, 1H) ppm.
269		(DMSO-d6, the chief isomer, stored over K2CO3):	509.59/510	INTA27/204
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[2-(4-methyl-piperazin-1-yl)-	1.20(t, 3H); 2.18(s, 3H);
	2-oxo-ethoxy]-phenylamino}-meth-	2.21(m, 2H); 2.40(m, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.39(m, 4H); 4.12(d, 2H);
	(E or Z))-ylidene]-acetamide	4.20(m, 2H); 4.80(s, 2H);
		6.58(dd, 1H); 6.82(s, 1H);
		6.87(d, 1H); 7.21(t, 1H);
		8.10(s, 1H); 8.31(t, 1H);
		10.30(s, 1H) ppm.
270		(DMSO-d6, the chief isomer, stored over K2CO3):	534.59/535	INTA27/204
	2-cyano-N-(2,2-difluoro-ethyl)-2-[3-	δ =
	ethyl-5-[1-{3-[2-(4-methyl-iperazin-	1.20(t, 3H); 2.18(s, 3H);
	1-yl)-2-oxo-ethoxy]-phenylamino}-	2.21(m, 2H); 2.32(m, 2H);
	meth-(E/Z)-ylidene]-4-oxo-	3.40(m, 4H); 3.52(m, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-	4.20(m, 2H); 4.79(s, 2H);
	acetamide	6.03(tt, 1H); 6.59(dd, 1H);
		6.81(s, 1H); 6.86(d, 1H);
		7.19(t, 1H); 7.92(m, 1H);
		8.08(m, 1H);
		10.31(d, 1H) ppm.
271		(DMSO-d6, the chief isomer, stored over K2CO3):	508.60/509	INTA27/204
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	methyl-piperazin-1-yl)-2-oxo-	1.21(t, 3H); 2.19(s, 3H);
	ethoxy]-phenylamino}-meth-(E/Z)-	2.22(m, 2H); 2.31(m, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	3.02(m, 1H); 3.39(m, 4H);
	Z))-ylidene]-N-prop-2-ynyl-	3.88(m, 2H); 4.20(m, 2H);
	acetamide	4.80(s, 2H); 6.58(dd, 1H);
		6.80(s, 1H); 6.83(d, 1H);
		7.19(t, 3H); 8.08(s, 2H);
		10.25(s, 1H) ppm.
272		(DMSO-d6, the chief isomer, stored over K2CO3):	552.58/553	INTA27/204
	2-cyano-2-[3-ethyl-5-[1-{3-[2-(4-	δ =
	methyl-piperazin-1-yl)-2-oxo-	1.22(t, 3H); 2.18(s, 3H);
	ethoxy]-phenylamino}-meth-(E/Z)-	2.22(m, 2H); 2.31(m, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	3.41(m, 4H); 3.91(m, 2H);
	Z))-ylidene]-N-(2,2,2-trifluoro-	4.20(m, 2H); 4.80(s, 2H);
	ethyl)-acetamide	6.61(dd, 1H); 6.80(s, 1H);
		6.88(d, 1H); 7.21(t, 1H);
		8.10(s, 1H); 8.18(m, 1H);
		10.21(s, 1H) ppm.
273		(DMSO-d6, the chief isomer, stored over K2CO3):	585.69/586	INTA23/204
	2-[5-[1-{3-[2-(4-benzyl-piperazin-1-	δ =
	yl)-2-oxo-ethoxy]-phenylamino}-	1.21(t, 3H); 2.30(m, 2H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	2.39(m, 2H); 3.41(m, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.49(s, 2H); 4.11(d, 2H);
	cyano-N-cyanomethyl-acetamide	4.20(m, 2H); 4.79(s, 2H);
		6.60(dd, 1H); 6.80(s, 1H);
		6.85(d, 1H); 7.21(t, 1H);
		7.29(m, 5H); 8.09(s, 1H);
		8.31(t, 1H);
		10.30(s, 1H) ppm.
274		(DMSO-d6, the chief isomer, stored over K2CO3):	610.69/611	INTA23/204
	2-[5-[1-{3-[2-(4-benzyl-piperazin-1-	δ =
	yl)-2-oxo-ethoxy]-phenylamino}-	1.21(t, 3H); 2.29(m, 2H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	2.49(m, 2H); 3.42(m, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.48(s, 2H); 3.57(m, 2H),
	cyano-N-(2,2-difluoro-ethyl)-	4.20(m, 2H); 4.80(s, 2H);
	acetamide	6.02(tt, 1H); 6.48(dd, 1H);
		6.80(s, 1H); 6.86(d, 1H);
		7.20(t, 1H); 7.29(m, 5H);
		7.92(t, 1H); 8.08(d, 1H);
		10.27(d, 1H) ppm.
275		(DMSO-d6, the chief isomer, stored over K2CO3):	584.70/585	INTA23/204
	2-[5-[1-{3-[2-(4-benzyl-piperazin-1-	δ =
	yl)-2-oxo-ethoxy]-phenylamino}-	1.21(t, 3H); 2.28(m, 2H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	2.39(m, 2H); 3.02(m, 1H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.47(m, 4H); 3.49(s, 2H);
	cyano-N-prop-2-ynyl-acetamide	3.90(m, 2H); 4.20(m, 2H);
		4.79(s, 2H); 6.58(dd, 1H);
		6.80(s, 1H); 6.86(d, 1H);
		7.18(t, 1H); 7.29(m, 5H);
		8.07(m, 2H);
		10.21(d, 1H) ppm.
276		(DMSO-d6, the chief isomer, stored over K2CO3):	628.68/629	INTA23/204
	2-[5-[1-{3-[2-(4-benzyl-piperazin-1-	δ =
	yl)-2-oxo-ethoxy]-phenylamino}-	1.41(m, 3H); 3.08(m, 4H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	3.66(m, 4H); 3.80(m, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	4.00(m, 2H); 4.38(m, 2H);
	cyano-N-(2,2,2-trifluoro-ethyl)-	4.74(s, 2H); 6.65(m, 4H);
	acetamide	7.33(m, 4H); 7.62(m, 2H);
		8.07(d, 1H);
		10.50(d, 1H) ppm.
277		(DMSO-d6, the chief isomer, stored over K2CO3):	470.60/471	INTA28/1
	2-cyano-2-[5-[1-[3-(2-diethylamino-	δ =
	acetylamino)-phenylamino]-meth-	1.02(t, 6H); 1.07(t, 3H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	1.24(t, 3H); 2.60(q, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	3.15(s, 2H);
	ethyl-acetamide	3.16-3.23(m, 2H);
		4.22(q, 2H);
		6.95-6.97(m, 1H);
		7.22-7.32(m, 2H);
		7.69(t, 1H); 7.72(1H);
		8.02(1H); 9.68(s, 1H);
		10.35(1H) ppm.
278		(DMSO-d6, the chief isomer, stored over K2CO3):	524.57/525	INTA28/1
	2-cyano-2-[5-[1-[3-(2-diethyl-	δ =
	amino-acetylamino)-phenylamino]-	1.02(t, 6H); 1.24(t, 3H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	2.60(q, 4H); 3.15(s, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	3.90-3.99(m, 2H);
	(2,2,2-trifluoro-ethyl)-acetamide	4.23(q, 2H);
		6.97-6.99(m, 1H);
		7.23-7.33(m, 2H);
		7.74(s, 1H); 8.08(1H);
		8.20(t, 1H); 9.69(s, 1H);
		10.74(1H) ppm.
279		(DMSO-d6, the chief isomer, stored over K2CO3):	506.58/507	INTA28/1
	2-cyano-2-[5-[1-[3-(2-diethyl-	δ =
	amino-acetylamino)-phenylamino]-	1.02(t, 6H); 1.25(t, 3H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	2.60(q, 4H); 3.15(s, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	3.58(tt, 2H); 4.23(q, 2H);
	(2,2-difluoro-ethyl)-acetamide	6.05(tt, 1H);
		6.97-6.99(m, 1H);
		7.23-7.30(m, 2H);
		7.74(s, 1H); 7.95(t, 1H);
		8.05-8.07(1H);
		9.70(s, 1H);
		10.43-10.46(1H) ppm.
280		(DMSO-d6, the chief isomer, stored over K2CO3):	488.59/489	INTA28/1
	2-cyano-2-[5-[1-[3-(2-diethyl-	δ =
	amino-acetylamino)-phenylamino]-	1.02(t, 6H); 1.24(t, 3H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	2.60(q, 4H); 3.15(s, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	3.44-3.54(2q, 2H);
	(2-fluoro-ethyl)-acetamide	4.22(q, 2H);
		4.42(t, 1H); 4.54(t, 1H)
		6.05(tt, 1H);
		6.96-6.98(m, 1H);
		7.23-7.32(m, 2H);
		7.73(s, 1H); 7.78(t, 1H);
		8.03-8.06(1H);
		9.70(s, 1H);
		10.39-10.42(1H)
		ppm.
281		(DMSO-d6, the chief isomer, stored over K2CO3):	481.58/459	INTA28/1
	2-cyano-N-cyanomethyl-2-[5-[1-[3-	δ =
	(2-diethylamino-acetylamino)-	1.02(t, 6H); 1.25(t, 3H);
	phenylamino]-meth-(E/Z)-ylidene]-	2.60(q, 4H);
	3-ethyl-4-oxo-thiazolidin-(2 (E or	3.15(s, 2H);
	Z))-ylidene]-acetamide	3.44-3.54(2q, 2H);
		4.15(d, 2H); 4.22(q, 1H);
		6.98-7.00(m, 1H);
		7.23-7.34(m, 2H);
		7.75(s, 1H);
		8.07-8.10(1H);
		8.34(t, 1H);
		9.70(s, 1H);
		10.49-10.52(1H)
		ppm.
282		(DMSO-d6, the chief isomer, stored over K2CO3):	470.60/471	INTA29/1
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-{3-	δ =
	[2-(methyl-propyl-amino)-acetyl-	0.87(t, 3H); 1.07(t, 3H);
	amino]-phenylamino}-meth-(E/Z)-	1.24(t, 3H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	1.43-1.53(m, 2H);
	Z))-ylidene]-acetamide	2.29(s, 3H); 2.39(t, 2H);
	Z))-ylidene]-acetamide	3.12(s, 2H);
		3.16-3.23(m, 2H);
		4.21(q, 2H);
		6.95-6.97(m, 1H);
		7.22-7.29(m, 2H);
		7.68(t, 1H); 7.72(1H);
		8.01(1H); 9.68(s, 1H);
		10.37(1H) ppm.
283		(DMSO-d6, the chief isomer, stored over K2CO3):	524.57/525	INTA29/1
	2-cyano-2-[3-ethyl-5-[1-{3-[2-	δ =
	(methyl-propyl-amino)-acetyl-	0.88(t, 3H); 1.25(t, 3H);
	amino]-phenylamino}-meth-(E/Z)-	1.43-1.52(m, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	2.29(s, 3H); 2.40(t, 2H);
	Z))-ylidene]-N-(2,2,2-tri	3.12(s, 2H);
	fluoro-ethyl)-acetamide	3.90-3.99(m, 2H);
		4.23(q, 2H);
		6.97-6.99(m, 1H);
		7.23-7.30(m, 2H);
		7.75(s, 1H);
		8.05-8.07(1H);
		8.20(t, 1H); 9.69(s, 1H);
		10.47-10.49(1H)
		ppm.
284		(DMSO-d6, the chief isomer, stored over K2CO3):	506.58/507	INTA29/1
	2-cyano-2-[3-ethyl-5-[1-{3-[2-	δ =
	(methyl-propyl-amino)-acetyl-	0.88(t, 3H); 1.25(t, 3H);
	amino]-phenylamino}-meth-(E/Z)-	1.43-1.52(m, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	2.29(s, 3H); 2.39(t, 2H);
	Z))-ylidene]-N-(2,2-difluoro-ethyl)-	3.12(s, 2H); 3.58(tt, 2H);
	acetamide	4.23(q, 2H); 6.05(tt, 1H);
		6.96-6.98(m, 1H);
		7.23-7.29(m, 2H);
		7.74(s, 1H); 7.95(t, 1H);
		8.05(1H); 9.68(s, 1H);
		10.45(1H) ppm.
285		(DMSO-d6, the chief isomer, stored over K2CO3):	488.59/489	INTA29/1
	2-cyano-2-[3-ethyl-5-[1-{3-[2-	δ =
	(methyl-propyl-amino)-acetyl-	0.88(t, 3H); 1.25(t, 3H);
	amino]-phenylamino}-meth-(E/Z)-	1.43-1.52(m, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	2.29(s, 3H); 2.40(t, 2H);
	Z))-ylidene]-N-(2-fluoro-ethyl)-	3.12(s, 2H);
	acetamide	3.44-3.54(2q, 2H);
		4.23(q, 2H);
		4.41-4.55(2t, 2H);
		6.96-6.98(m, 1H);
		7.22-7.29(m, 2H);
		7.74(s, 1H); 7.80(t, 1H);
		8.01-8.04(1H);
		9.69(s, 1H);
		10.40-10.43(1H)
		ppm.
286		(DMSO-d6, the chief isomer, stored over K2CO3):	480.59/481	INTA29/1
	2-cyano-2-[3-ethyl-5-[1-{3-[2-
	(methyl-propyl-amino)-acetyl-	0.88(t, 3H); 1.24(t, 3H);
	amino]-phenylamino}-meth-(E/Z)	1.42-1.52(m, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	2.29(s, 3H); 2.40(t, 2H);
	Z))-ylidene]-N-prop-2-ynyl-	3.06(m, 1H); 3.12(s, 2H);
	acetamide	3.91-3.93(m, 2H);
		4.22(q, 2H);
		6.96-6.98(m, 1H);
		7.23-7.29(m, 2H);
		7.74(s, 1H);
		8.05-8.08(1H);
		8.01-8.04(m, 2H);
		9.68(s, 1H);
		10.44(1H) ppm.
287		(DMSO-d6, the chief isomer, stored over K2CO3):	481.58/459	INTA29/1
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-{3-[2-(methyl-propyl-amino)-	0.88(t, 3H); 1.25(t, 3H);
	5-[1-{3-[2-(methyl-propyl-amino)-	1.43-1.52(m, 2H);
	acetylamino]-phenylamino}-meth-	2.29(s, 3H); 2.40(t, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.12(s, 2H); 4.15(d, 2H);
	(E or Z))-ylidene]-acet-amide	4.23(q, 2H);
		6.97-6.99(m, 1H);
		7.23-7.30(m, 2H);
		7.75(s, 1H);
		8.08(1H);
		8.34(t, 1H);
		9.69(s, 1H);
		10.51(1H) ppm.
288		(DMSO-d6, the chief isomer, stored over K2CO3):	486.60/487	INTA30/1
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-(3-	δ =
	{2-[(2-methoxy-ethyl)-methyl-	1.07(t, 3H); 1.24(t, 3H);
	amino]-acetylamino}-phenyl-	1.45-1.50(m, 2H);
	amino)-meth-(E/Z)-ylidene]-4-oxo-	2.36(s, 3H); 2.64(t, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-	3.17-3.23(m, 4H);
	acetamide	3.27(s, 3H); 3.46(t, 1H);
		4.21(q, 2H);
		6.96-6.98(m, 1H);
		7.20-7.28(m, 2H);
		7.68-7.71(m, 2H);
		8.00(d, 1H);
		9.74(s, 1H);
		10.36-10.39(s, 1H)
		ppm.
289		(DMSO-d6, the chief isomer, stored over K2CO3):	540.57/541	INTA30/1
	2-cyano-2-[3-ethyl-5-[1-(3-{2-[(2-	δ =
	methoxy-ethyl)-methyl-amino]-	1.25(t, 3H);
	acetylamino}-phenylamino)-meth-	1.45-1.50(m, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.35(s, 3H); 2.64(t, 2H);
	(E or Z))-ylidene]-N-(2,2,2-trifluoro-	3.18(s, 2H); 3.27(s, 3H);
	ethyl)-acetamide	3.46(t, 2H);
		3.90-3.99(m, 2H);
		4.23(q, 2H);
		6.97-6.99(m, 1H);
		7.21-7.30(m, 2H);
		7.73(s, 1H);
		8.05-8.07(1H);
		8.22(t, 1H); 9.75(s, 1H);
		10.49-10.51(s, 1H)
		ppm.
290		(DMSO-d6, the chief isomer, stored over K2CO3):	506.58/507	INTA30/1
	2-cyano-2-[3-ethyl-5-[1-(3-{2-[(2-	δ =
	methoxy-ethyl)-methyl-amino]-	1.25(t, 3H); 2.35(s, 3H);
	acetylamino}-phenylamino)-meth-	2.64(t, 2H); 3.18(s, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.27(s, 3H); 3.46(t, 2H);
	(E or Z))-ylidene]-N-(2,2-difluoro-	3.53-3.63(tt, 2H);
	ethyl)-acetamide	4.30(q, 2H);
		5.90-6.20(tt, 1H);
		6.97-6.99(m, 1H);
		7.21-7.30(m, 2H);
		7.73(s, 1H); 7.96(t, 1H);
		8.03-8.05(1H);
		9.75(s, 1H);
		10.46-10.49(1H)
		ppm.
291		(DMSO-d6, the chief isomer, stored over K2CO3):	488.59/489	INTA30/1
	2-cyano-2-[3-ethyl-5-[1-(3-{2-[(2-	δ =
	methoxy-ethyl)-methyl-amino]-	1.23(t, 3H); 2.34(s, 3H);
	acetylamino}-phenylamino)-meth-	2.62(t, 2H); 3.16(s, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.25(s, 3H);
	(E or Z))-ylidene]-N-(2-fluoro-ethyl)-	3.43-3.52(m, 2H);
	acetamide	4.21(q, 2H); 4.41(t, 1H);
		4.53(t 1H);
		6.94-6.96(m, 1H);
		7.19-7.28(m, 2H);
		7.70(s, 1H); 7.78(t, 1H);
		8.01(1H); 9.73(s, 1H);
		10.42(1H) ppm.
292		(DMSO-d6, the chief isomer, stored over K2CO3):	496.59/497	INTA30/1
	2-cyano-2-[3-ethyl-5-[1-(3-{2-[(2-	δ =
	methoxy-ethyl)-methyl-amino]-	1.24(t, 3H); 2.36(s, 3H);
	acetylamino}-phenylamino)-meth-	2.64(t, 2H); 3.06(m, 1H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.18(s, 2H); 3.27(s, 3H);
	(E or Z))-ylidene]-N-prop-2-ynyl-	3.46(t, 2H);
	acetamide	3.91-3.93(m, 2H);
		4.22(q, 2H);
		6.96-6.98(m, 1H);
		7.21-7.30(m, 2H);
		7.72(s, 1H);
		8.02-8.05(1H);
		8.10(t, 1H); 9.74(s, 1H);
		10.43-10.46(1H)
		ppm.
293		(DMSO-d6, the chief isomer, stored over K2CO3):	497.58/498	INTA30/1
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-(3-{2-[(2-methoxy-ethyl)-	1.25(t, 3H); 2.36(s, 3H);
	methyl-amino]-acetylamino}-	2.64(t, 2H); 3.18(s, 2H);
	phenylamino)-meth-(E/Z)-ylidene]-	3.27(s, 3H); 4.15(d, 2H);
	4-oxo-thiazolidin-(2-(E or Z))-	4.22(q, 2H);
	ylidene]-acetamide	6.98-7.00(m, 1H);
		7.21-7.31(m, 2H);
		7.74(s, 1H);
		8.05-8.08(1H);
		8.34(t, 1H);
		9.75(s, 1H);
		10.51-10.54(1H)
		ppm.
294		(DMSO-d6, the chief isomer, stored over K2CO3):	500.62/501	INTA31/1
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-(3-	δ =
	{2-[ethyl-(2-methoxy-ethyl)-amino]-	1.01(t, 3H); 1.07(t, 3H);
	acetylamino}-phenylamino)-meth-	1.24(t, 3H); 2.66(q, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.72(t, 2H);
	(E or Z))-ylidene]-acetamide	3.17-3.23(m, 5H);
		3.26(s, 2H); 3.44(t, 2H);
		4.21(q, 2H);
		6.96-6.98(m, 1H);
		7.20-7.31(m, 2H);
		7.70(m, 2H);
		7.99-8.03(1H);
		9.77(s, 1H);
		10.37-10.40(1H)
		ppm.
295		(DMSO-d6, the chief isomer, stored over K2CO3):	554.60/555	INTA31/1
	2-cyano-2-[3-ethyl-5-[1-(3-{2-	δ =
	[ethyl-(2-methoxy-ethyl)-amino]-	1.01(t, 3H); 1.25(t, 3H);
	acetylamino}-phenylamino)-meth-	2.66(q, 2H); 2.72(t, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.21(s, 2H); 3.26(s, 3H);
	(E or Z))-ylidene]-N-(2,2,2-trifluoro-	3.43(t, 2H);
	ethyl)-acetamide	3.90-3.93(m, 2H);
		4.23(q, 2H);
		6.97-6.99(m, 1H);
		7.20-7.31(m, 2H);
		7.70(m, 1H); 8.07(1H);
		8.19(1H); 9.77(s, 1H);
		10.50(1H) ppm.
296		(DMSO-d6, the chief isomer, stored over K2CO3):	536.61/537	INTA31/1
	2-cyano-2-[3-ethyl-5-[1-(3-{2-
	[ethyl-(2-methoxy-ethyl)-amino]-	1.01(t, 3H); 1.24(t, 3H);
	acetylamino}-phenylamino)-meth-	2.66(q, 2H); 2.72(t, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.21(s, 2H); 3.26(s, 3H);
	(E or Z))-ylidene]-N-(2,2-difluoro-	3.44(t, 2H);
	ethyl)-acetamide	3.53-3.63(tt, 2H);
		4.22(q, 2H);
		5.90-6.20(tt, 1H);
		6.97-6.99(m, 1H);
		7.20-7.31(m, 2H);
		7.70(m, 1H); 7.94(m, 1H);
		8.05(1H); 9.77(s, 1H);
		10.48(1H) ppm.
297		(DMSO-d6, the chief isomer, stored over K2CO3):	518.61/519	INTA31/1
	2-cyano-2-[3-ethyl-5-[1-(3-{2-	δ =
	[ethyl-(2-methoxy-ethyl)-amino]-	1.01(t, 3H); 1.24(t, 3H);
	acetylamino}-phenylamino)-meth-	2.66(q, 2H); 2.72(t, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.21(s, 2H); 3.26(s, 3H);
	(E or Z))-ylidene]-N-(2-fluoro-ethyl)-	3.42-3.54(m, 4H);
	acetamide	4.22(q, 2H); 4.26(t, 1H);
		4.54(t, 1H);
		6.97-6.99(m, 1H);
		7.20-7.31(m, 2H);
		7.70(m, 1H); 7.80(t, 1H);
		8.01-8.05(1H);
		9.77(s, 1H);
		10.40-10.44(1H)
		ppm.
298		(DMSO-d6, the chief isomer, stored over K2CO3):	510.62/511	INTA31/1
	2-cyano-2-[3-ethyl-5-[1-(3-{2-	δ =
	[ethyl-(2-methoxy-ethyl)-amino]-	1.01(t, 3H); 1.24(t, 3H);
	acetylamino}-phenylamino)-meth-	2.66(q, 2H); 2.72(t, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.06(m, 1H); 3.21(s, 2H);
	(E or Z))-ylidene]-N-	3.26(s, 3H); 3.44(t, 3H);
	prop-2-ynyl-acetamide	3.91-3.93(m, 2H);
		4.22(q, 2H);
		6.97-6.99(m, 1H);
		7.20-7.31(m, 2H);
		7.71(m, 1H);
		8.02-8.06(1H);
		8.09(t, 1H); 9.78(s, 1H);
		10.43-10.46(1H)
		ppm.
299		(DMSO-d6, the chief isomer, stored over K2CO3):	511.61/512	INTA31/1
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-(3-{2-[ethyl-(2-methoxy-ethyl)-	1.20(t, 3H); 1.25(t, 3H);
	amino]-acetylamino}-phenyl-	2.66(q, 2H); 2.72(t, 2H);
	amino)-meth-(E/Z)-ylidene]-4-oxo-	3.21(s, 2H); 3.26(s, 3H);
	thiazolidin-(2-(E or Z))-ylidene]-	3.44(t, 3H); 4.15(d, 2H);
	acetamide	4.22(q, 2H);
		6.98-7.00(m, 1H);
		7.21-7.32(m, 2H);
		7.71(m, 1H); 8.08(1H);
		8.33(1H); 9.78(s, 1H);
		10.53(1H) ppm.
300		(DMSO-d6, the chief isomer, stored over K2CO3):	518.64/519	INTA32/1
	2-[5-[1-{3-[2-(benzyl-methyl-amino)-	δ =
	acetylamino]-phenylamino}-meth-	1.07(t, 3H); 1.24(t, 3H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	2.27(s, 3H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.13-3.23(m, 4H);
	cyano-N-ethyl-acetamide	3.65(s, 2H); 4.22(q, 4H);
		6.98-7.00(m, 1H);
		7.22-7.40(m, 7H);
		7.69(t, 1H); 7.74(1H);
		8.02(1H); 9.80(s, 1H);
		10.37-10.39(1H)
		ppm.
301		(DMSO-d6, the chief isomer, stored over K2CO3):	572.61/573	INTA32/1
	2-[5-[1-{3-[2-(benzyl-methyl-amino)-
	acetylamino]-phenylamino}-meth-	1.25(t, 3H); 2.26(s, 3H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	3.18(s, 4H); 3.65(s, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.90-3.99(m, 2H);
	cyano-N-(2,2,2-trifluoro-ethyl)-	4.23(q, 2H)
	acetamide	6.96-6.98(m, 1H);
		7.23-7.40(m, 7H);
		7.75(1H); 8.08(1H);
		8.20(1H); 9.80(s, 1H);
		10.51(1H) ppm.
302		(DMSO-d6, the chief isomer, stored over K2CO3):	554.62/555	INTA32/1
	2-[5-[1-{3-[2-(benzyl-methyl-amino)-	δ =
	acetylamino]-phenylamino}-meth-	1.25(t, 3H); 2.27(s, 3H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	3.18(s, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.53-3.65(m, 4H);
	cyano-N-(2,2-difluoro-ethyl)-	3.90-3.99(m, 2H);
	acetamide	4.23(q, 2H)
		5.90-6.20(tt, 1H);
		6.96-6.98(m, 1H);
		7.23-7.40(m, 7H);
		7.75(1H); 7.95(t, 1H);
		8.04-8.06(1H);
		9.80(s, 1H);
		10.46-10.48(1H)
		ppm.
303		(DMSO-d6, the chief isomer, stored over K2CO3):	536.63/537	INTA32/1
	2-[5-[1-{3-[2-(Benzyl-methyl-amino)-	δ =
	acetylamino]-phenylamino}-meth-	1.25(t, 3H); 2.27(s, 3H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	3.18(s, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.44-3.54(m, 2H);
	cyano-N-(2-fluoro-ethyl)-acetamide	3.65(s, 2H); 4.23(q, 2H);
		4.42(t, 1H); 4.54(t, 1H);
		6.96-6.98(m, 1H);
		7.23-7.40(m, 7H);
		7.74(1H); 7.79(t, 1H);
		8.02-8.04(1H);
		9.79(s, 1H);
		10.41-10.43(1H)
		ppm.
304		(DMSO-d6, the chief isomer, stored over K2CO3):	528.64/529	INTA32/1
	2-[5-[1-{3-[2-(Benzyl-methyl-amino)-	δ =
	acetylamino]-phenylamino}-meth-	1.25(t, 3H); 2.27(s, 3H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	3.06(m, 1H); 3.18(s, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.65(s, 2H);
	cyano-N-prop-2-ynyl-acetamide	3.91-3.93(m, 2H);
		4.22(q, 4H);
		6.96-6.98(m, 1H);
		7.23-7.40(m, 7H);
		7.75(1H);
		8.03-8.10(m, 2H);
		9.79(s, 1H);
		10.43-10.45(1H)
		ppm.
305		(DMSO-d6, the chief isomer, stored over K2CO3):	529.63/530	INTA32/1
	2-[5-[1-{3-[2-(benzyl-methyl-amino)-	δ =
	acetylamino]-phenylamino}-meth-	1.25(t, 3H); 2.27(s, 3H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	3.19(s, 2H); 3.65(s, 2H);
	(E/Z)-ylidene]-3-ethyl-4-oxo-	4.15(d, 2H); 4.23(q, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	6.97-6.99(m, 1H);
	cyano-N-cyanomethyl-acetamide	7.24-7.40(m, 7H);
		7.76(1H); 8.08(1H);
		8.33(t, 1H); 9.80(s, 1H);
		10.52(1H) ppm.
306		(DMSO-d6, the chief isomer, stored over K2CO3):	443.53/444	7/8
	2-cyano-2-[5-[1-[6-(2-dimethyl-	1.07(t, 3H);
	amino-acetylamino)-pyridin-2-	1.24(t, 3H); 2.30 (s, 6H);
	ylamino]-meth-(E/Z)-ylidene]-3-	3.13(s, 2H);
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-	3.16-3.23(m, 2H);
	ylidene]-N-ethyl-acetamide	4.21(q, 2H);
		6.77-6.79(m, 1H);
		7.69-7.76(m, 3H);
		8.59(1H); 9.88(s, 1H);
		10.72(1H) ppm.
307		(DMSO-d6, the chief isomer, stored over K2CO3):	457.56/458	7/8
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-{6-	1.02-1.08(2t, 6H);
	[2-(ethyl-methyl-amino)-acetyl-	1.24(t, 3H); 2.30(s, 3H);
	amino]-pyridin-2-ylamino}-meth-	2.53(q, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.18-3.28(m, 4H);
	(E or Z))-ylidene]-acetamide	4.21(q, 2H);
	(E or Z))-ylidene]-acetamide	6.77-6.79(m, 1H);
		7.69-7.76(m, 3H);
		8.58(1H); 9.85(s, 1H);
		10.73(1H) ppm.
308		(DMSO-d6, the chief isomer, stored over K2CO3):	471.59/472	7/8
	2-cyano-2-[5-[1-[6-(2-diethyl-	1.02(t, 6H); 1.07(t, 3H);
	amino-acetylamino)-pyridin-2-	1.24(t, 3H); 2.63(q, 4H);
	ylamino]-meth-(E/Z)-ylidene]-3-	3.17-3.23(m, 4H);
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-	4.21(q, 2H);
	ylidene]-N-ethyl-acetamide	6.78-6.80(m, 1H);
		7.69-7.78(m, 3H);
		8.54-8.56(1H);
		9.84(s, 1H);
		10.72-10.74(1H)
		ppm.
309		(DMSO-d6, the chief isomer, stored over K2CO3):	471.59/472	7/8
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-{6-	δ =
	[2-(methyl-propyl-amino)-acetyl-	0.91(t, 3H); 1.07(t, 3H);
	amino]-pyridin-2-ylamino}-meth-	1.24(t, 3H); 1.47(q, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.31(s, 3H); 2.42(t, 2H);
	(E or Z))-ylidene]-acetamide	3.18-3.28(m, 4H);
		4.21(q, 2H);
		6.77-6.79(m, 1H);
		7.69-7.77(m, 3H);
		8.57(1H); 9.85(s, 1H);
		10.71(1H) ppm.
310		(DMSO-d6, the chief isomer, stored over K2CO3):	471.59/472	7/8
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-{6-	δ =
	[2-(isopropyl-methyl-amino)-acetyl-	1.02(d, 6H); 1.07(t, 3H);
	amino]-pyridin-2-ylamino}-meth-	1.24(t, 3H); 2.27(s, 3H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.87-2.94(m, 1H);
	(E or Z))-ylidene]-acetamide	3.15-3.23(m, 4H);
		4.21(q, 2H);
		6.78-6.80(m, 1H);
		7.70-7.76(m, 3H);
		8.55(1H); 9.79(s, 1H);
		10.73(1H) ppm.
311		(DMSO-d6, the chief isomer, stored over K2CO3):	485.61/486	7/8
	2-[5-[1-{6-[2-(tert-butyl-methyl-am	δ =
	ino)-acetylamino]-pyridin-2-yl-	1.07(t, 3H); 1.09(s, 9H);
	amino}-meth-(E/Z)-ylidene]-3-ethyl-	1.24(t, 3H); 2.28(s, 3H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.17-3.23(m, 4H);
	ylidene]-2-cyano-N-ethyl-	4.21(q, 2H);
	acetamide	6.78-6.80(m, 1H);
		7.70-7.73(m, 3H);
		8.54(1H); 9.82(s, 1H);
		10.74(1H) ppm.
312		(DMSO-d6, the chief isomer, stored over K2CO3):	487.58/488	7/8
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-(6-	δ =
	{2-[(2-methoxy-ethyl)-methyl-	1.07(t, 3H); 1.24(t, 3H);
	amino]-acetylamino}-pyridin-2-	2.37(s, 3H); 2.66(t, 2H);
	ylamino)-meth-(E/Z)-ylidene]-4-	3.17-3.23(m, 4H);
	oxo-thiazolidin-(2-(E or Z))-	3.27(s, 3H); 3.44(t, 2H);
	ylidene]-acetamide	4.21(q, 2H);
		6.77-6.79(m, 1H);
		7.69-7.78(m, 3H);
		8.60(1H); 9.94(s, 1H);
		10.72(1H) ppm.
313		(DMSO-d6, the chief isomer, stored over K2CO3):	501.61/502	7/8
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-(6-	δ =
	{2-[ethyl-(2-methoxy-ethyl)-amino]-	1.00(t, 3H); 1.07(t, 3H);
	acetylamino}-pyridin-2-ylamino)-	1.24(t, 3H);
	meth-(E/Z)-ylidene]-4-oxo-	2.69-2.75(m, 4H);
	thiazolidin-(2-(E orZ))-ylidene]-	3.17-3.23(m, 4H);
	acetamide	3.29(s, 3H); 3.42(t, 2H);
		4.21(q, 2H);
		6.77-6.79(m, 1H);
		7.69-7.78(m, 3H);
		8.58-8.61(1H);
		9.97(s, 1H);
		10.70-10.73(1H)
		ppm.
314		(DMSO-d6, the chief isomer, stored over K2CO3):	519.63/520	7/8
	2-[5-[1-{6-[2-(benzyl-methyl-amino)-	δ =
	acetylamino]-pyridin-2-ylamino}-	1.07(t, 3H); 1.26(t, 3H);
	meth-(E/Z)-ylidene]-3-ethyl-4-oxo-	2.27(s, 3H);
	thiazolidin-(2-(E or Z))-ylidene]-2-	3.17-3.24(m, 2H);
	cyano-N-ethyl-acetamide	3.28(s, 2H); 3.65(s, 2H);
		4.23(q, 2H);
		6.78-6.80(m, 1H);
		7.23-7.28(m, 1H);
		7.36-7.38(m, 5H);
		7.69-7.77(m, 3H);
		8.64(1H);
		10.04(1H) ppm.
315		(DMSO-d6, the chief isomer, stored over K2CO3):	533.66/534	7/8
	2-cyano-N-ethyl-2-[3-ethyl-5-[1-{6-	δ =
	[2-(methyl-phenethyl-amino)-	1.07(t, 3H); 1.26(t, 3H);
	acetylamino]-pyridin-2-ylamino}-	2.37(s, 3H);
	meth-(E/Z)-ylidene]-4-oxo-	2.73-2.79(m, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-	3.17-3.25(m, 4H);
	acetamide	4.23(q, 2H);
		6.77-6.79(m, 1H);
		7.12(t, 1H);
		7.22-7.28(m, 4H);
		7.67-7.77(m, 3H);
		8.56(s, 1H); 9.60(s, 1H);
		10.65(1H) ppm.
316		(DMSO-d6, the chief isomer, stored over K2CO3):	497.50/498	7/8
	2-cyano-2-[5-[1-[6-(2-dimethyl-	δ =
	amino-acetylamino)-pyridin-2-	1.26(t, 3H); 2.30(s, 6H);
	ylamino]-meth-(E/Z)-ylidene]-3-	3.13(s, 2H);
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-	3.91-4.00(m, 2H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	4.23(q, 2H);
	acetamide	6.77-6.79(m, 1H);
		7.70-7.76(m, 2H);
		8.26-8.29(1H);
		8.64(1H); 9.91(s, 1H);
		10.84(1H) ppm.
317		(DMSO-d6, the chief isomer, stored over K2CO3):	525.56/526	7/8
	2-cyano-2-[5-[1-[6-(2-diethyl-	δ =
	amino-acetylamino)-pyridin-2-	1.02(t, 6H); 1.26(t, 3H);
	ylamino]-meth-(E/Z)-ylidene]-3-	2.62(q, 4H); 3.22(s, 2H);
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-	3.91-3.99(m, 2H);
	ylidene]-N-(2,2,2-tri-fluoro-ethyl)-	4.23(q, 2H);
	acetamide	6.78-6.80(m, 1H);
		7.71-7.76(m, 2H);
		8.27(t, 1H); 8.60(1H);
		9.86(s, 1H);
		10.84(1H) ppm.
318		(DMSO-d6, the chief isomer, stored over K2CO3):	525.56/526	7/8
	2-cyano-2-[3-ethyl-5-[1-{6-[2-	δ =
	(methyl-propyl-amino)-acetyl-	0.91(t, 3H); 1.26(t, 3H);
	amino]-pyridin-2-ylamino}-meth-	1.47(q, 2H); 2.31(s, 3H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.43(t, 2H); 3.18(s, 2H);
	(E or Z))-ylidene]-N-(2,2,2-trifluoro-	3.91-3.99(m, 2H);
	ethyl)-acetamide	4.23(q, 2H);
		6.77-6.79(m, 1H);
		7.70-7.77(m, 2H);
		8.26(t, 1H);
		8.61-8.63(1H);
		9.88(s, 1H);
		10.81-10.83(1H)
		ppm.
319		(DMSO-d6, the chief isomer, stored over K2CO3):	525.56/526	7/8
	2-cyano-2-[3-ethyl-5-[1-{6-[2-(iso-	δ =
	propyl-methyl-amino)-acetyl-	1.02(d, 6H); 1.26(t, 3H);
	amino]-pyridin-2-ylamino}-meth-	2.27(s, 3H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	2.88-2.94(m, 1H);
	(E or Z))-ylidene]-N-(2,2,2-trifluoro-	3.16(s, 2H);
	(E or Z))-ylidene]-N-(2,2,2-trifluoro-	3.91-3.99(m, 2H);
	ethyl)-acetamide	4.23(q, 2H);
		6.78-6.80(m, 1H);
		7.70-7.78(m, 2H);
		8.27(t, 1H); 8.60(1H);
		9.81(s, 1H);
		10.84(1H) ppm.
320		(DMSO-d6, the chief isomer, stored over K2CO3):	539.58/540	7/8
	2-[5-[1-{6-[2-(tert-butyl-methyl-	δ =
	amino)-acetylamino]-pyridin-2-yl-	1.09(s, 9H); 1.26(t, 3H);
	amino}-meth-(E/Z)-ylidene]-3-ethyl-	2.29(s, 3H); 3.18(s, 2H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.91-3.99(m, 2H);
	ylidene]-2-cyano-N-(2,2,2-trifluoro-	4.23(q, 2H);
	ethyl)-acetamide	6.79-6.81(m, 1H);
		7.71-7.79(m, 2H);
		8.26(t, 1H);
		8.58-8.60(1H);
		9.84(s, 1H);
		10.82-10.84(1H)
		ppm.
321		(DMSO-d6, the chief isomer, stored over K2CO3):	541.56/542	7/8
	2-cyano-2-[3-ethyl-5-[1-(6-{2-[(2-	δ =
	methoxy-ethyl)-methyl-amino]-	1.25(t, 3H); 2.38(s, 3H);
	acetylamino}-pyridin-2-ylamino)-	2.66(t, 2H); 3.23(s, 2H);
	meth-(E/Z)-ylidene]-4-oxo-	3.29(s, 3H); 3.44(t, 2H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	3.91-3.99(m, 2H);
	(2,2,2-trifluoro-ethyl)-acetamide	4.23(q, 2H);
		6.77-6.79(m, 1H);
		7.70-7.79(m, 3H);
		8.27(t, 1H);
		8.63-8.66(1H);
		9.96(s, 1H);
		10.81-10.84(1H)
		ppm.
322		(DMSO-d6, the chief isomer, stored over K2CO3):	555.58/556	7/8
	2-cyano-2-[3-ethyl-5-[1-(6-{2-	δ =
	[ethyl-(2-methoxy-ethyl)-amino]-	1.00(t, 3H); 1.26(t, 3H);
	acetyl-amino}-pyridin-2-ylamino)-	2.69-2.75(m, 4H);
	meth-(E/Z)-ylidene]-4-oxo-	3.26(s, 2H); 3.30(s, 3H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	3.42(t, 2H);
	(2,2,2-trifluoro-ethyl)-acetamide	3.91-3.99(m, 2H);
		4.23(q, 2H);
		6.77-6.79(m, 1H);
		7.70-7.80(m, 2H);
		8.27(t, 1H);
		8.63-8.66(1H);
		9.99(s, 1H);
		10.81-10.84(1H)
		ppm.
323		(DMSO-d6, the chief isomer, stored over K2CO3):	573.60/574	7/8
	2-[5-[1-{6-[2-(benzyl-methyl-	δ =
	amino)-acetylamino]-pyridin-2-yl-	1.27(t, 3H); 2.27(s, 3H);
	amino}-meth-(E/Z)-ylidene]-3-ethyl-	3.28(s, 2H); 3.65(s, 2H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.91-4.00(m, 2H);
	ylidene]-2-cyano-N-(2,2,2-tri-fluoro-	4.25(q, 2H);
	ethyl)-acetamide	6.78-6.80(m, 1H);
		7.23-7.29(m, 1H);
		7.36-7.38(m, 4H);
		7.70-7.76(m, 2H);
		8.27(t, 1H);
		8.67-8.70(1H);
		10.05(1H);
		10.81-10.84(1H)
		ppm.
324		(DMSO-d6, the chief isomer, stored over K2CO3):	587.63/588	7/8
	2-cyano-2-[3-ethyl-5-[1-{6-[2-	δ =
	(methyl-phenethyl-amino)-acetyl-	1.27(t, 3H); 2.37(s, 3H);
	amino]-pyridin-2-ylamino}-meth-	2.74-2.79(m, 4H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	3.25(s, 2H);
	(E or Z))-ylidene]-N-(2,2,2-tri-	3.91-4.00(m, 2H);
	fluoro-ethyl)-acetamide	4.25(q, 2H);
		6.77-6.79(m, 1H);
		7.12(t, 1H);
		7.22-7.28(m, 4H);
		7.68-7.74(m, 2H);
		8.26(t, 1H);
		8.58-8.62(1H);
		9.61(s, 1H);
		10.78-10.81(1H)
		ppm.
325	2-cyano-N-cyanomethyl-2-[3-ethyl- 5-[1-[6-(2-methoxy-ethylamino)- pyridin-2-ylamino]-meth-(E/Z)- ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide		427.48/428	INTT10/ INT83/5
326	2-cyano-2-[3-ethyl-5-[1-[6-(2- methoxy-ethylamino)-pyridin-2- ylamino]-meth-(E/Z)-ylidene]-4- oxo-thiazolidin-(2-(E or Z))- ylidene]-N-(2,2,2-trifluoro-ethyl)- acetamide		470.47/471	INTT8/ INT83/5
327	2-cyano-2-[3-ethyl-5-[1-[6-(2- methoxy-ethylamino)-pyridin-2- ylamino]-meth-(E/Z)-ylidene]-4- oxo-thiazolidin-(2-(E or Z))- ylidene]-N-prop-2-ynyl-acetamide		426.501/427	INTT9/ INT83/5
328	2-cyano-N-ethyl-2-[3-ethyl-5-[1-[6- (2-methoxy-ethylamino)-pyridin-2- ylamino]-meth-(E/Z)-ylidene]-4- oxo-thiazolidin-(2-(E or Z))- ylidene]-acetamide		416.506/417	INTT7/ INT83/5
329	2-cyano-N-(2,2-difluoro-ethyl)-2-[3- ethyl-5-[1-[6-(2-methoxy- ethylamino)-pyridin-2-ylamino]- meth-(E/Z)-ylidene]-4-oxo- thiazolidin-(2-(E or Z))-ylidene]- acetamide		452.486/453	INTT11/ INT83/5
330	2-cyano-2-[5-[1-[6-(2- dimethylamino-ethylamino)-pyridin- 2-ylamino]-meth-(E/Z)-ylidene]-3- ethyl-4-oxo-thiazolidin-(2-(E or Z))- ylidene]-N-prop-2-ynyl-acetamide		439.543/440	INTT9/ INT120/5
331	2-cyano-N-cyanomethyl-2-[5-[1-[6- (2-dimethylamino-ethylamino)- pyridin-2-ylamino]-meth-(E/Z)- ylidene]-3-ethyl-4-oxo-thiazolidin- ylidene]-3-ethyl-4-oxo-thiazolidin- (2-(E or Z))-ylidene]-acetamide		440.531/441	INTT10/ INT120/5
332	2-cyano-2-[3-ethyl-5-[1-(6- morpholin-4-yl-pyridin-2-ylamino)- meth-(E/Z)-ylidene]-4-oxo- thiazolidin-(2-(E or Z))-ylidene]-N- prop-2-ynyl-acetamide		438.512/439	INTT9/ INT116/5
333	2-cyano-N-ethyl-2-[3-ethyl-5-[1-(6- morpholin-4-yl-pyridin-2-ylamino)- meth-(E/Z)-ylidene]-4-oxo- thiazolidin-(2-(E or Z))-ylidene]- acetamide		428.517/429	INTT7/ INT116/5
334	2-cyano-N-(2,2-difluoro-ethyl)-2-[3- ethyl-5-[1-(6-morpholin-4-yl-pyridin- 2-ylamino)-meth-(E/Z)-ylidene]-4- oxo-thiazolidin-(2-(E or Z))- ylidene]-acetamide		464.498/465	INTT11/ INT116/5
335	2-cyano-2-[3-ethyl-5-[1-(6- morpholin-4-yl-pyridin-2-ylamino)- meth-(E/Z)-ylidene]-4-oxo- thiazolidin-(2-(E or Z))-ylidene]-N- (2,2,2-trifluoro-ethyl)-acetamide		482.488/483	INTT8/ INT116/5
336	2-cyano-N-cyanomethyl-2-[3-ethyl- 5-[1-(6-morpholin-4-yl-pyridin-2- ylamino)-meth-(E/Z)-ylidene]-4-xo- thiazolidin-(2-(E or Z))-ylidene]- acetamide		439.499 440	INTT10/ INT116/5
337	2-cyano-N-cyanomethyl-2-[3-ethyl- 5-[1-(2-morpholin-4-yl-pyridin-4- ylamino)-meth-(E/Z)-ylidene]-4- oxo-thiazolidin-(2-(E or Z))- ylidene]-acetamide		439.499/440	INTE69/198
338		(DMSO-d6, the chief isomer, stored over K2CO3):		INTA33/1
	2-cyano-2-[3-ethyl-5-[1-(3-	δ =
	hydroxymethyl-phenylamino)-meth-	1.27(t, 3H); 3.95(m, 2H);
	(E/Z)-ylidene]-4-oxo-thiazolidin-(2-	4.24(q, 2H); 4.50(d, 2H);
	(E or Z))-ylidene]-N-(2,2,2-trifluoro-	5.27(t, 1H); 7.01(d, 1H);
	ethyl)-acetamide	7.16(d, 1H);
		7.26-7.32(m, 2H);
		8.08-8.24(m, 2H);
		10.47(s, 1H) ppm.
339		(DMSO-D6, the chief isomer, stored over K2C03):		INTA33/1
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-(3-hydroxymethyl-	1.27(t, 3H); 4.17(d, 2H);
	phenylamino)-meth-(E/Z)-ylidene]-	4.24(q, 2H); 4.50(d, 2H);
	4-oxo-thiazolidin-(2-(E or Z))-	5.26(t, 1H); 7.02(d, 1H);
	ylidene]-acetamide	7.16(d, 1H);
		7.25-7.33(m, 2H);
		8.16(s, 1H); 8.32(s, 1H);
		10.49(s, 1H) ppm.
340		(DMSO-D6, the chief isomer, stored over K2C03):		338/12 und 8
	2-cyano-2-[3-ethyl-5-[1-(3-	δ =
	morpholin-4-ylmethyl-	1.23(t, 3H); 2.33(s, 4H);
	phenylamino)-meth-(E/Z)-ylidene]-	3.42(s, 2H); 3.54(m, 4H);
	4-oxo-thiazolidin-(2-(E or Z))-	3.93(m, 2H); 4.20(q, 2H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	6.98(d, 1H); 7.16(d, 1H);
	acetamide	7.20-7.28(m, 2H);
		8.10(s, 1H); 8.17(s, 1H);
		10.40(s, 1H) ppm.
341		(DMSO-D6, the chief isomer, stored over K2C03):		338/12 und 8
	2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(4-	δ =
	trifluoromethyl-piperidin-1-	1.23(t, 3H); 1.44(m, 2H);
	ylmethyl)-phenylamino]-meth-	1.75(d, 2H); 1.94(t, 2H);
	(E/Z)-ylidene]-thiazolidin-(2-(E or	2.23(m, 1H); 2.87(d, 2H);
	Z))-ylidene]-N-(2,2,2-trifluoro-	3.43(s, 2H); 3.93(m, 2H);
	ethyl)-acetamide	4.20(q, 2H); 6.97(d, 1H);
		7.17(d, 1H);
		7.20-7.27(m, 2H);
		8.09(d, 1H); 8.19(t, 1H);
		10.40(d, 1H) ppm.
342		(DMSO-D6, the chief isomer, stored over K2C03):		4/12 und 8
	2-cyano-2-[3-ethyl-5-[1-(3-	δ =
	morpholin-4-ylmethyl-	1.21(t, 3H); 2.34(s, 4H);
	phenylamino)-meth-(E/Z)-	3.02(s, 1H); 3.40(s, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	3.56(m, 4H); 3.89(m, 2H);
	Z))-ylidene]-N-prop-2-ynyl-	4.19(q, 2H); 6.97(d, 1H);
	acetamide	7.17(d, 1H);
		7.20-7.28(m, 2H);
		8.08(m, 2H);
		10.36(d, 1H) ppm.
343		(DMSO-D6, the chief isomer, stored over K2C03):		4/12 und 8
	2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(4-	δ =
	trifluoromethyl-piperidin-1-	1.20(t, 3H); 1.42(m, 2H);
	ylmethyl)-phenylamino]-meth-	1.74(d, 2H); 1.93(t, 2H);
	(E/Z)-ylidene]-thiazolidin-(2-(E or	2.23(m, 1H); 2.85(d, 2H);
	Z))-ylidene]-N-prop-2-ynyl-	3.02(s, 1H); 3.42(s, 2H);
	acetamide	3.89(m, 2H); 4.20(q, 2H);
		6.96(d, 1H); 7.16(d, 1H);
		7.22-7.27(m, 2H);
		8.07(m, 2H);
		10.34(d, 1H) ppm.
344		(DMSO-D6, the chief isomer, stored over K2C03):		339/12 und 8
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-(3-morpholin-4-ylmethyl-	1.22(t, 3H); 2.35(s, 4H);
	phenylamino)-meth-(E/Z)-ylidene]-	3.45(s, 2H); 3.57(m, 4H);
	4-oxo-thiazolidin-(2-(E or Z))-	4.14(d, 2H); 4.20(q, 2H);
	ylidene]-acetamide	6.98(d, 1H); 7.17(d, 1H);
		7.23-7.28(m, 2H);
		8.10(m, 1H); 8.32(t, 1H);
		10.43(s, 1H) ppm.
345		(DMSO-D6, the chief isomer, stored over K2C03):		339/12 und 8
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	4-oxo-5-[1-[3-(4-trifluoromethyl-	1.21(t, 3H); 1.44(m, 2H);
	piperidin-1-ylmethyl)-phenylamino]-	1.76(d, 2H); 1.94(t, 2H);
	meth-(E/Z)-ylidene]-thiazolidin-(2-	2.25(m, 1H); 2.87(d, 2H);
	(E or Z))-ylidene]-acetamide	3.45(s, 2H); 4.13(d, 2H);
		4.20(q, 2H); 6.97(d, 1H);
		7.16(d, 1H);
		7.22-7.28(m, 2H);
		8.12(m, 1H); 8.32(t, 1H);
		10.43(m, 1H) ppm.
346		(DMSO-D6, the chief isomer, stored over K2C03):		339/12 und 8
	2-cyano-N-cyanomethyl-2-[5-[1-[3-	δ =
	(4,4-difluoro-piperidin-1-ylmethyl)-p	1.21(t, 3H); 1.93(m, 4H);
	henylamino]-meth-(E/Z)-ylidene]-3-	2.48(m, 4H); 3.49(s, 2H);
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-	4.12(d, 2H); 4.20(q, 2H);
	ylidene]-acetamide	6.98(d, 1H); 7.17(d, 1H);
		7.24-7.29(m, 2H);
		8.10(d, 1H); 8.31(t, 1H);
		10.42(d, 1H) ppm.
347		(DMSO-D6, the chief isomer, stored over K2C03):		339/12 und 8
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	4-oxo-5-[1-(3-thiomorpholin-4-	1.21(t, 3H); 2.58(m, 8H);
	ylmethyl-phenylamino)-meth-(E/Z)-	3.46(s, 2H); 4.12(d, 2H);
	ylidene]-thiazolidin-(2-(E or Z))-	4.20(q, 2H); 6.96(d, 1H);
	ylidene]-acetamide	7.17(d, 1H);
		7.21-7.29(m, 2H);
		8.11(d, 1H); 8.32(t, 1H);
		10.41(d, 1H) ppm.
348		(DMSO-D6, the chief isomer, stored over K2C03):		INTA34/1
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-prop	1.20(t, 3H); 1.64(m, 4H);
	yl)-phenylamino]-meth-(E/Z)-	1.72(m, 2H); 2.42(m, 6H);
	ylidene]-thiazolidin-(2-(E or Z))-	2.57(t, 2H); 4.11(d, 2H);
	ylidene]-acetamide	4.20(q, 2H); 6.89(d, 1H);
		7.06-7.24(m, 3H);
		8.12(s, 1H); 8.31(t, 1H);
		10.40(s, 1H) ppm.
349		(DMSO-D6, the chief isomer, stored over K2C03):		INTA35/1
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	4-oxo-5-[1-[3-(3-piperidin-1-yl-	1.20(t, 3H); 1.33(m, 2H);
	propyl)-phenylamino]-meth-(E/Z)-	1.45(m, 4H); 1.68(m, 2H);
	ylidene]-thiazolidin-(2-(E or Z))-	2.19(t, 2H); 2.26(m, 4H);
	ylidene]-acetamide	2.53(t, 2H); 4.12(d, 2H);
		4.20(q, 2H); 6.88(d, 1H);
		7.07(d, 1H); 7.13(s, 1H);
		7.20(t, 1H); 8.12(s, 1H);
		8.28(m, 1H);
		10.32(s, 1H) ppm.
350		(DMSO-D6, the chief isomer, stored over K2C03):		INTA36/1
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-[3-(3-morpholin-4-yl-propyl)-	1.21(t, 3H); 1.70(m, 2H);
	phenylamino]-meth-(E/Z)-ylidene]-	2.23(t, 2H); 2.29(m, 4H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.55(t, 2H); 3.54(t, 4H);
	ylidene]-acetamide	4.12(d, 2H); 4.20(q, 2H);
		6.88(d, 1H); 7.08(d, 1H);
		7.14(s, 1H); 7.20(t, 1H);
		8.11(s, 1H); 8.29(t, 1H);
		10.32(s, 1H) ppm.
351		(DMSO-D6, the chief isomer, stored over K2C03):		INTA34/1
	2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-	δ =
	pyrrolidin-1-yl-propyl)-phenylamin	1.21(t, 3H); 1.63(m, 4H);
	o]-meth-(E/Z)-ylidene]-thiazolidin-	1.69(m, 2H);
	(2-(E or Z))-ylidene]-N-(2,2,2-	2.32-2.40(m, 6H);
	trifluoro-ethy	2.56(t, 2H); 3.92(m, 2H);
	l)-acetamide	4.21(q, 2H); 6.88(d, 1H);
		7.08(d, 1H); 7.13(s, 1H);
		7.20(t, 1H); 8.12(s, 1H);
		8.15(t, 1H);
		10.38(s, 1H) ppm.
352		(DMSO-D6, the chief isomer, stored over K2C03):		INTA36/1
	2-cyano-2-[3-ethyl-5-[1-[3-(3-	δ =
	morpholin-4-yl-propyl)-	1.20(t, 3H); 1.68(m, 2H);
	phenylamino]-meth-(E/Z)-ylidene]-	2.27(t, 2H); 2.32(m, 4H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.55(t, 2H); 3.53(t, 4H);
	ylidene]-N-(2,2,2-trifluoro-ethyl)-	3.92(m, 2H); 4.20(q, 2H);
	acetamide	6.88(d, 1H);
		7.05-7.23(m, 3H);
		8.11(s, 1H); 8.17(m, 1H);
		10.32(m, 1H) ppm.
353		(DMSO-D6, the chief isomer, stored over K2C03):		INTA34/1
	2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-	δ =
	pyrrolidin-1-yl-propyl)-phenylamin	1.20(t, 3H); 1.62(m, 4H);
	o]-meth-(E/Z)-ylidene]-thiazolidin-	1.68(m, 2H);
	(2Z)-ylidene]-N-prop-2-ynyl-	2.32-2.40(m, 6H);
	acetamide	2.54(t, 2H); 3.01(s, 1H);
		3.88(m, 2H); 4.19(q, 2H);
		6.87(d, 1H); 7.06(d, 1H);
		7.12(s, 1H); 7.20(t, 1H);
		8.04-8.13(m, 2H);
		10.28(s, 1H) ppm.
354		(DMSO-D6, the chief isomer, stored over K2C03):		INTA35/1
	2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-	δ =
	piperidin-1-yl-propyl)-phenylamino	1.20(t, 3H); 1.32(m, 2H);
	]-meth-(E/Z)-ylidene]-thiazolidin-	1.43(m, 4H); 1.68(m, 2H);
	(2Z)-ylidene]-N-prop-2-ynyl-	2.20(t, 2H); 2.27(m, 4H);
	acetamide	2.52(t, 2H); 3.01(s, 1H);
		3.88(m, 2H); 4.20(q, 2H);
		6.87(d, 1H); 7.06(d, 1H),
		7.12(s, 1H); 7.20(t, 1H);
		8.03-8.11(m, 2H);
		10.26(s, 1H) ppm.
355		(DMSO-D6, the chief isomer, stored over K2C03):		INTA36/1
	2-cyano-2-[3-ethyl-5-[1-[3-(3-	δ =
	morpholin-4-yl-propyl)-	1.20(t, 3H); 1.68(m, 2H);
	phenylamino]-meth-(E/Z)-ylidene]-	2.22(t, 2H); 2.28(m, 4H);
	4-oxo-thiazolidin-(2-(E or Z))-	2.54(t, 2H); 3.01(s, 1H);
	ylidene]-N-prop-2-ynyl-acetamide	3.52(t, 4H); 3.88(m, 2H);
		4.19(q, 2H); 6.87(d, 1H);
		7.06(d, 1H); 7.13(s, 1H);
		7.19(t, 1H);
		8.02-8.10(m, 2H);
		10.25(m, 1H) ppm.
356		(DMSO-D6, the chief isomer, stored over K2C03):		INTT10/ INT95/5
	2-cyano-N-cyanomethyl-2-[5-[1-{3-	δ =
	[3-(4,4-difluoro-piperidin-1-yl)-prop	1.22(t, 3H); 1.71(m, 2H);
	yl]-phenylamino}-meth-(E/Z)-	1.92(m, 4H); 2.31(t, 2H);
	ylidene]-3-ethyl-4-oxo-thiazolidin-	2.42(m, 4H); 2.55(t, 2H);
	(2-(E or Z))-ylidene]-acetamide	4.12(d, 2H); 4.20(q, 2H);
		6.88(d, 1H); 7.07(d, 1H);
		7.13(s, 1H); 7.20(t, 1H);
		8.12(s, 1H); 8.30(t, 1H);
		10.34(s, 1H) ppm.
357		(DMSO-D6, the chief isomer, stored over K2C03):		INTT10/ INT94/5
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	4-oxo-5-[1-[3-(3-thiomorpholin-4-yl-	1.20(t, 3H); 1.68(m, 2H);
	propyl)-phenylamino]-meth-(E/Z)-	2.28(t, 2H);
	ylidene]-thiazolidin-(2-(E or Z))-	2.45-2.57(m, 10H);
	ylidene]-acetamide	4.12(d, 2H); 4.20(q, 2H);
	ylidene]-acetamide	6.87(d, 1H); 7.06(d, 1H);
		7.12(s, 1H); 7.20(t, 1H);
		8.12(s, 1H); 8.28(m, 1H);
		10.37(m, 1H) ppm.
358		(DMSO-D6, the primary isomer, store over K2C03):	452.542/453	INTT10/ INT118/5
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-[6-(4-methyl-piperazin-1-yl)-	1.25(t, 3H); 2.82(s, 3H);
	pyridin-2-ylamino]-meth-(E/Z)-	3.75(m, 2H); 4.12(d, 2H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	4.18(m, 4H); 4.26(m, 4H);
	Z))-ylidene]-acetamide	6.41(d, 2H); 6.62(d, 1H);
		7.51(t, 1H); 8.62(d, 1H);
		10.86(s, 1H) ppm.
359		(DMSO-D6, the primary isomer, store over K2C03):	438.512/439	INTE69/198
	2-cyano-2-[3-ethyl-5-[1-(2-	δ =
	morpholin-4-yl-pyridin-4-ylamino)-	1.23(t, 3H); 3.03(m, 1H);
	meth-(E/Z)-ylidene]-4-oxo-	3.40(m, 4H); 3.63(m, 4H);
	thiazolidin-(2-(E or Z))-ylidene]-N-	3.89(m, 2H); 4.21(q, 2H);
	prop-2-ynyl-acetamide	6.66(m, 2H); 7.92(d, 1H);
		8.13(t, 1H); 8.23(d, 1H);
		10.25(s, 1H) ppm.
360		(DMSO-D6, the primary isomer, store over K2C03):	452.542/453	INTE74/198
	2-cyano-N-cyanomethyl-2-[3-ethyl-	δ =
	5-[1-[2-(4-methyl-piperazin-1-yl)-	1.19(t, 3H); 3.31(s, 3H);
	pyridin-4-ylamino]-meth-(E/Z)-	3.41(m, 4H); 3.71(m, 4H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	4.11(m, 2H); 4.21(m, 2H);
	Z))-ylidene]-acetamide	6.63(m, 2H); 7.92(d, 1H);
		8.23(d, 1H); 8.33(t, 1H);
		10.35(d, 1H) ppm.
361		(DMSO-D6, the primary isomer, store over K2C03):	477.540/478	INTE74/198
	2-cyano-N-(2,2-difluoro-ethyl)-2-[3-	δ =
	ethyl-5-[1-[2-(4-methyl-piperazin-1-	1.26(t, 3H); 3.31(s, 3H);
	yl)-pyridin-4-ylamino]-meth-(E/Z)-	3.45(m, 4H); 3.71(m, 4H);
	ylidene]-4-oxo-thiazolidin-(2-(E or	4.13(m, 2H); 4.21(m, 2H);
	Z))-ylidene]-acetamide	6.61(m, 2H); 7.97(d, 1H);
		8.23(d, 1H); 8.33(t, 1H);
		10.35(d, 1H) ppm.
362	2-cyano-N-cyanomethyl-2-[3-ethyl- 5-[1-[2-(2-methoxy-ethylamino)- pyridin-4-ylamino]-meth-(E/Z)- ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide		427.488/428	INTE70/198
363	2-cyano-N-cyanomethyl-2-[5-[1- [3,5-difluoro-6-(2-methoxy- ethylamino)-pyridin-2-ylamino]- meth-(E/Z)-ylidene]-3-ethyl-4-oxo- thiazolidin-(2-(E or Z))-ylidene]- acetamide		463.469/464	INTT10/ INT114/5
364	(6-{[2-[1-Cyano-1-ethylcarbamoyl- meth-(Z)-ylidene]-3-ethyl-4-oxo- thiazolidin-(5-(E/Z))-ylidenemethyl]- amino}-pyridin-(2-(E oder Z))-yl)- carbamic acid tert-butyl ester		458.543/459	INTE75/198
365	2-[5-[1-(6-Amino-pyridin-2- ylamino)-meth-(E/Z)-ylidene]-3- ethyl-4-oxo-thiazolidin-(2-(E oder Z))-ylidene]-2-cyano-N-ethyl- acetamide		358.425/359	364/6
366	2-[5-[1-[6-(2-Chloro-acetylamino)- pyridin-2-ylamino]-meth-(E/Z)- ylidene]-3-ethyl-4-oxo-thiazolidin- (2-(E oder Z))-ylidene]-2-cyano-N- ethyl-acetamide		434.908/435	365/203
367			512.514/513	INTE75/198
368			412.396/413	364/6
369			488.879/489	365/203

EXAMPLE 370

(3-{[2-[1-cyano-1-(2,2,2-trifluoro-ethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-carbamic acid tert-butyl ester

2.6 g trifluoroethylamine, 8.4 g TBTU and 3.6 ml triethylamine are added to a solution of intermediate INTA37 in DMF (360ml). The reaction mixture is stirred at ambient temperature for 12 hours. The solvent is distilled off and the raw product obtained mixed with a mixture of acetic acid ethyl ester and total NaHCO₃ solution and extracted. The united organic phases are dried over sodium sulfate and the solvent is distilled on the rotary evaporator. The raw product is chromatographically purified. 7.9 g of title compound is obtained.

MW: 511; MS (ESI) [M+1]⁺: 512

EXAMPLE 371

(3-{[2-[1-cyano-1-prop-2-ynylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-carbamic acid tert-butyl ester

1.3 ml propargylamine 6.2 g TBTU and 2.7 ml triethylamine are added to a solution of intermediate INTA37 in DMF (285mi). The reaction mixture is stirred at ambient temperature for 12 hours. The solvent is distilled off and the raw product obtained mixed with a mixture of acetic acid ethyl ester and total NaHCO₃ solution and extracted. The united organic phases are dried over sodium sulfate and the solvent is distilled off on the rotary evaporator. The raw product is chromatographically purified. 7.9 g of title compound is obtained.

MW: 467; MS (ESI) [M+1]⁺: 468

Example 372

2-cyano-2-[3-ethyl-5-[1-(3-methylamino-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-(2,2,2-trifluoro-ethyl)-acetamide

7.9 of the compound described under Example 370 is suspended in 175 ml dichloromethane. 19 ml trifluoroacetic acid is added. It is then stirred for 2.5 hours at ambient temperature. The reaction mixture is carefully admixed into 400 ml of cooled 1 M NaOH solution. It is then mixed and extracted with dichloromethane and acetic acid ethyl ester. The organic phase is dried over Na₂SO₄. 7 g of the title compound is obtained as trifluoroacetic acetic acid salt. That raw product is used without further purification for the next reactions.

EXAMPLE 373

2-cyano-2-[3-ethyl-5-[1-(3-methylamino-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-prop-2-ynyl-acetamide

5.8 g of the compound described under Example 371 is suspended in 140 ml dichloromethane. 15.4 ml trifluoroacetic acid is added. It is then stirred for 4 hours at ambient temperature. The reaction mixture is carefully admixed into 300 ml of cooled 1 M NaOH solution. It is then mixed and extracted with dichloromethane and acetic acid ethyl ester. The organic phase is dried over Na₂SO₄. 3 g of the title compound is obtained as trifluoroacetic acetic acid salt. That raw product is used without further purification for the next reactions.

EXAMPLE 374

2-[5-[1-f3-[(2-chloro-acetyl)-methyl-amino]-phenylamino-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-(2,2,2-trifluoro-ethyl)-acetamide

0.71 mmol of the trifluoroacetic acid salt of the compound described under Example 372 is suspended in 9 ml tetrahydrofurane. After adding 113 μl pyridine and 157 mg chloroacetic acid anhydride it is stirred for 2.5 h at ambient temperature. 20 ml acetic acid ethyl ester and 10 ml total sodium hydrogen carbonate solution are added, the organic phase is separated off and dried over sodium sulfate. 0.4 g of the title compound is obtained.

MW: 501; MS (ESI) [M+1]⁺: 502

EXAMPLE 375

2-[5-[1-{3-[(2-chloro-acetyl)-methyl-amino]-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-prop-2-ynyl-acetamide

8 mmol of the trifluoroacetic acid salt of the compound described under Example 373 is suspended in 50 ml tetrahydrofurane. After adding 1.3 μl pyridine and 2 g chloroacetic acid anhydride dissolved in 50 ml THF it is stirred for 4h at ambient temperature. 200 ml acetic acid ethyl ester and 100 total sodium hydrogen carbonate solution are added, the organic phase is separated off and dried over sodium sulfate. 3.1 g of the title compound is obtained.

MW: 457; MS (ESI) [M+1]⁺: 458

Parallel Synthesis Method 1 (PSM 1):

EXAMPLE 376

2-cyano-2-[5-[1-[3-(2-2,3-dihydro-benzo[1,4]oxazin-4-yl-acetylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-prop-2-ynyl-acetamide

In an argon atmosphere a solution of 67 mg (0.15 mmol) 2-[5-[1-[3-(2-Chloro-acetylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E oder Z))-ylidene]-2-cyano-N-prop-2-ynyl-acetamide and 6.5 mg (0.04 mmol) potassium iodide in 1.5 ml DMF a solution of 270 mg (0.38 mmol) 3,4-Dihydro-2H-benzo[1,4]oxazine were added in 0.5 ml DMF was added. After the addition of 170 μL (1.22 mmol) triethlyamin, the mixture was stirred at room temperature for 12 hours.

The reaction mixture was separated from the solvent. The raw product so obtained was purified by HPLC. 5.1 mg (9%) of the desired product was isolated.

HPLC-MS (analytic) of the purified product

(Detection: UV=254 nM; Column: Purospher STAR RP18e, 125×4 mm, 5μ (Merck KgGa, Darmstadt); Liquid: A: H₂O/0.1% TFA, B: CH₃CN/0.1% TFA, Gradient: 5 to 95% B in 10 min.; Flow rate: 1 ml/min):

Retention time of the product=9.25 min.; MS of the product: m/z=560 ([M+H]⁺)

Parallel Synthesis Method 2 (PSM 2):

EXAMPLE 377

2-Cyano-N-cyanomethyl-2-[3-ethyl-5-[1-3-[2-(2-methyl-pyrrolidin-1-yl)-acetylamino]-phenylamino}-meth-(E/Z)-ylidene]4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide

In an argon atmosphere a solution of 76 mg (0.15 mmol) Methanesulfonic acid (3-{[2-[1-cyano-1-(cyanomethyl-carbamoyl)-meth-(E oder Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenylcarbamoyl)-methyl ester and 6.5 mg (0.04 mmol) potassium iodide in 1.5 ml DMF a solution of 278 mg (0.37 mmol) 3,4-Dihydro-2H-benzo[1,4]oxazine in 0.5 ml DMF is added. After the addition of 213 μL (1.22 mmol) diisopropylethylamin, the mixture was stirred at room temperature for 12 hours. The reaction mixture was separated from the solvent.

The raw product so obtained was purified by HPLC. 30 mg (37%) of the desired product was isolated.

HPLC-MS (analytic) of the purified product

(Detection: UV=254 nM; Column: Purospher STAR RP18e, 125×4 mm, 5μ (Merck KgGa, Darmstadt); Liquid: A: H₂O/0.1% TFA, B: CH₃CN/0.1% TFA, Gradient: 5 to 95% B in 10 min.; Flow rate: 1 ml/min):

Retention time of the product=9.09 min.; MS of the product: m/z=548 ([M+H]⁺)

		Reten-
Ex-		tion
ample		time	MW	MW
no.	Structure	[min]	calc.	found	Method
378		9.7	516	517	PSM 1
379		7.12	510	511	PSM 1
380		10.15	530	531	PSM 1
381		6.68	498	499	PSM 1
382		9.3	522	523	PSM 1
383		9.68	518	519	PSM 1
384		9.7	534	535	PSM 1
385		9.36	534	535	PSM 1
386		7.33	532	533	PSM 1
387		9.49	522	523	PSM 1
388		9.35	532	533	PSM 1
389		6.42	512	513	PSM 1
390		9.25	504	505	PSM 1
391		5.97	497	498	PSM 1
392		6.37	500	501	PSM 1
393		6.94	518	519	PSM 1
394		9.61	526	527	PSM 1
395		6.87	520	521	PSM 1
396		9.9	540	541	PSM 1
397		9.33	532	533	PSM 1
398		9.44	528	529	PSM 1
399		5.81	521	522	PSM 1
400		9.42	546	547	PSM 1
401		9.32	532	533	PSM 1
402		9.27	514	515	PSM 1
403		6.04	507	508	PSM 1
404		6.47	510	511	PSM 1
405		6.98	528	529	PSM 1
406		9.32	527	528	PSM 2
407		6.73	521	522	PSM 2
408		6.8	521	522	PSM 2
409		9.65	541	542	PSM 2
410		6.55	509	510	PSM 2
411		9.0	533	534	PSM 2
412		9.0	529	530	PSM 2
413		6.01	509	510	PSM 2
414		5.68	522	523	PSM 2
415		9.2	545	546	PSM 2
416		8.94	545	546	PSM 2
417		7.18	543	544	PSM 2
418		9.09	533	534	PSM 2
419		6.72	539	540	PSM 2
420		6.27	516	517	PSM 2
421		6.95	509	510	PSM 2
422		6.48	497	498	PSM 2
423		6.4	523	524	PSM 2
424		8.8	515	516	PSM 2
425		5.92	508	509	PSM 2
426		5.92	494	495	PSM 2
427		6.37	511	512	PSM 2
428		6.66	529	530	PSM 2
429		0.0	604	605	PSM 2
430		8.44	498	499	PSM 1
431		8.89	516	517	PSM 1
432		7.28	514	515	PSM 1
433		6.37	468	469	PSM 1
434		6.45	494	495	PSM 1
435		5.75	479	480	PSM 1
436		5.92	465	466	PSM 1
437		6.52	482	483	PSM 1
438		5.97	507	508	PSM 1
439		7.72	575	576	PSM 1
440		8.77	540	541	PSM 2
441		7.02	534	535	PSM 2
442		7.12	534	535	PSM 2
443		9.7	554	555	PSM 2
444		7.44	522	523	PSM 2
445		8.82	546	547	PSM 2
446		8.64	542	543	PSM 2
447		6.75	524	525	PSM 2
448		8.9	558	559	PSM 2
449		7.94	558	559	PSM 2
450		7.27	556	557	PSM 2
451		9.2	546	547	PSM 2
452		6.89	552	553	PSM 2
453		9.22	556	557	PSM 2
454		7.1	522	523	PSM 2
455		6.83	542	543	PSM 2
456		6.53	492	493	PSM 2
457		6.24	508	509	PSM 2
458		6.67	536	537	PSM 2
459		6.59	524	525	PSM 2
460		6.65	506	507	PSM 2
461		7.05	554	555	PSM 2
462		8.62	528	529	PSM 2
463		6.84	520	521	PSM 2
464		7.43	583	584	PSM 2
465		5.74	521	522	PSM 2
466		7.33	613	614	PSM 2
467		7.96	611	612	PSM 2
468		7.5	601	602	PSM 2
469		7.49	601	602	PSM 2
470		6.53	524	525	PSM 2
471		6.77	542	543	PSM 2
472		6.29	549	550	PSM 2
473		7.24	613	614	PSM 2
474		6.77	522	523	PSM 2
475		9.37	584	585	PSM 2
476		7.43	578	579	PSM 2
477		7.49	578	579	PSM 2
478		10.2	598	599	PSM 2
479		9.32	590	591	PSM 2
480		9.13	586	587	PSM 2
481		6.44	593	594	PSM 2
482		7.1	568	569	PSM 2
483		6.05	579	580	PSM 2
484		9.5	602	603	PSM 2
485		9.12	604	605	PSM 2
486		9.32	602	603	PSM 2
487		7.66	600	601	PSM 2
488		9.72	590	591	PSM 2
489		7.28	596	597	PSM 2
490		9.71	600	601	PSM 2
491		7.49	566	567	PSM 2
492		7.25	586	587	PSM 2
493		6.92	554	555	PSM 2
494		6.65	552	553	PSM 2
495		7.08	580	581	PSM 2
496		7.02	568	569	PSM 2
497		7.06	550	551	PSM 2
498		9.12	572	573	PSM 2
499		7.26	564	565	PSM 2
500		7.77	627	628	PSM 2
501		6.09	565	566	PSM 2
502		7.74	657	658	PSM 2
503		6.45	565	566	PSM 2
504		6.51	551	552	PSM 2
505		7.18	568	569	PSM 2
506		7.07	586	587	PSM 2
507		6.74	593	594	PSM 2
508		8.04	661	662	PSM 2
509		6.51	508	509	PSM 2
510		9.89	570	571	PSM 2
511		7.09	564	565	PSM 2
512		9.6	576	577	PSM 2
513		9.97	572	573	PSM 2
514		9.94	579	580	PSM 2
515		5.96	552	553	PSM 2
516		9.69	590	591	PSM 2
517		7.21	586	587	PSM 2
518		7.18	559	560	PSM 2
519		6.63	580	581	PSM 2
520		6.43	552	553	PSM 2
521		6.86	554	555	PSM 2
522		6.89	572	573	PSM 2
523		9.61	568	569	PSM 2
524		6.95	540	541	PSM 2
525		6.31	558	559	PSM 2
526		6.86	613	614	PSM 2
527		7.33	551	552	PSM 2
528		6.48	647	648	PSM 2
529		7.89	647	648	PSM 2
530		0.0	509	510	PSM 2
531		10.48	571	572	PSM 2
532		7.47	565	566	PSM 2
533		7.74	565	566	PSM 2
534		10.63	585	586	PSM 2
535		7.21	553	554	PSM 2
536		10.44	577	578	PSM 2
537		10.86	573	574	PSM 2
538		6.5	580	581	PSM 2
539		6.14	566	567	PSM 2
540		10.05	591	592	PSM 2
541		10.31	589	590	PSM 2
542		7.79	587	588	PSM 2
543		10.04	587	588	PSM 2
544		7.61	553	554	PSM 2
545		7.18	573	574	PSM 2
546		7.26	541	542	PSM 2
547		6.74	539	540	PSM 2
548		7.06	567	568	PSM 2
549		6.93	555	556	PSM 2
550		7.01	537	538	PSM 2
551		7.61	585	586	PSM 2
552		9.95	559	560	PSM 2
553		7.23	551	552	PSM 2
554		0.0	614	615	PSM 2
555		6.54	552	553	PSM 2
556		6.67	538	539	PSM 2
557		7.09	555	556	PSM 2
558		7.48	573	574	PSM 2
559		6.65	580	581	PSM 2
560		7.76	644	645	PSM 2
561		6.28	455	456	PSM 2
562		10.01	517	518	PSM 2
563		3.37	511	512	PSM 2
564		7.24	511	512	PSM 2
565		10.38	531	532	PSM 2
566		6.01	526	527	PSM 2
567		6.32	499	500	PSM 2
568		5.68	512	513	PSM 2
569		5.66	512	513	PSM 2
570		9.96	535	536	PSM 2
571		9.92	537	538	PSM 2
572		9.58	535	536	PSM 2
573		7.36	533	534	PSM 2
574		10.06	523	524	PSM 2
575		7.04	529	530	PSM 2
576		9.64	533	534	PSM 2
577		7.22	499	500	PSM 2
578		6.88	519	520	PSM 2
579		6.71	487	488	PSM 2
580		6.33	469	470	PSM 2
581		6.22	485	486	PSM 2
582		6.69	513	514	PSM 2
583		6.56	501	502	PSM 2
584		6.48	483	484	PSM 2
585		7.19	531	532	PSM 2
586		9.81	505	506	PSM 2
587		7.33	560	561	PSM 2
588		7.41	590	591	PSM 2
589		8.03	588	589	PSM 2
590		7.43	578	579	PSM 2
591		7.46	590	591	PSM 2
592		7.57	578	579	PSM 2
593		6.0	498	499	PSM 2
594		6.1	484	485	PSM 2
595		6.57	501	502	PSM 2
596		7.07	519	520	PSM 2
597		7.8	594	595	PSM 2
598		7.26	590	591	PSM 2

6. Other amides

In analogous fashion the following compounds can be created:

TABLE
Amides (2)
Example Structure
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670

EXAMPLES

The following examples describe the biological effects of the invented compounds:

PLK Enzyme-Assay

Recombinant human Plk-1 (6×His) was purified from insect cells (Hi5) infected with a baculovirus.

10 ng (recombinant created, purified) PLK enzyme is incubated for 90 minutes at room temperature with biotin casein and 33P-γ-ATP as a sub-stratum in a volume of 15 μl in 384 well Greiner Small Volume Microtiterplates (final concentration in buffer: 660 ng/ ml PLK; 0.7 μM Casein, 0.5 μM ATP incl. 400 nCi/ml 33P-γ-ATP; 10 mM MgCl2, 1 mM MnCl2; 0.01% NP40; 1 mM DTT, Protease inhibitors; 0.1 mM Na2VO3 in 50 mM HEPES pH 7.5). At the end of the reaction a 5 μl stop solution (500 μM ATP; 500 mM EDTA; 1% triton ×100; 100 mg/ ml streptavidin coated SPA Beads in PBS) was added. After the microtiter plate is closed with foil, the beads are sedimented through centrifugation (10 min., 1500 rpm). The fixing of the 33P-γ-ATP in casein was set as a measure of the enzyme activity by β-Counting. The measure of inhibitor activity was referenced against a control solution (=unrestricted enzyme activity=0% inhibition) and the average value of several deposits that contained 300 μM Wortmannin (=fully restricted enzyme activity=100% inhibition).

Test substances were introduced in various concentrations (0 μM, and in the range of 0.01-30 μM). The final concentration of the dimethylsulfoxide solvent in all concentrations amounted to 1.5%.

Proliferation Assay

Cultivated human MaTu breast tumor cells were spread on plates to a thickness of 5000 cells per measuring point in a 96-hole multititerplate in 200 μl of the appropriate growth medium. After 24 hours the cells of one plate (the zero-point plate) were stained with crystal violet (see below), while the medium of the other plates was replaced by fresh culture medium (200 μl), to which was added the test substances in various concentrations (0 μM and in the range of 0.01 to 30 μm; the final concentration of the dimethylsulfoxide solvent was 0.5%). The cells were incubated for 4 days in the presence of the test substances. The cell proliferation was determined by the staining of the cells with crystal violet. The cells were fixed by the addition of 20 μl per measuring point of an 11% glutaraldehyde solution for 15 minutes at room temperature. After the fixed cells were washed three times with water, the plates were dried at room temperature. The cells were stained by the addition of 100 μl per measuring point of a 0.1% crystal violet solution (pH set at pH3 through the addition of acetic acid). After the fixed cells were washed three times with water, the plates were dried at room temperature. The coloring was dissolved by the addition of 100 μl per measuring point of a 10% acetic acid solution. Extinction was determined photometrically at a wave length of 595 nm. The percentage change of the cell growth was calculated by normalizing the measured values at the extinction value of the zero-point plate (=0%) and the extinction of the untreated cells (0 μM) (=100%).

The results of the PLK-1 enzyme assay and of the proliferation assay are shown in the table 1.

			Inhibition of
			tumor cell
			proliferation
		Inhibition	(MaTu)
Example no.	Structure	PLK-1 IC50 [nM]	IC50 [μM]
55		150	0.78
30		16	0.2
127		24	0.33
126		22	0.59
41		20	0.83
63		100	0.65

TABLE 2
Comparison with Current State of Technology
			Inhibition of
			tumor cell
			proliferation
		Inhibition	(MaTu)
Example no.	Structure	PLK-1 IC50 [nM]	IC50 [μM]
30		16	0.2
Comparison 527 from PCT/EP2004/ 012242		100	2.8
127		24	0.33
Comparison 310 from PCT/EP2004/ 012242		74	5.6
126		22	0.59
Comparison 307 from PCT/EP2004/ 012242		71	1.7

TABLE 3
Comparison with Current State of Technology
			Inhibition of
			tumor cell
			proliferation
		Inhibition	(MaTu)
Example no.	Structure	PLK-1 IC50 [nM]	IC50 [μM]
41		20	0.83
Comparison 326 from PCT/EP2004/ 012242		73	1.6
63		100	0.65
Comparison 323 from PCT/EP2004/ 012242		140	2.5

From Table 1 it can be seen that the present invented compounds of general formula 1 inhibit PLK. Furthermore the expert can see from Tables 2 and 3 that the present invented substances are also better than the current state of technology.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.

The entire disclosures of all applications, patents and publications, cited herein and of corresponding German application No. 102004061503.9, filed Dec. 15, 2004 and U.S. Provisional Application Ser. No. 60/637,777, filed Dec. 22, 2004, are incorporated by reference herein.

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

1. Compounds of general formula I

2. Compounds of general formula 1, according to claim 1, in which the meaning is as follows: T1, T2 and T3 stand independently of one another for —CH═ or —N═R3 stands for K, L, or M, X stands for halogen, hydroxy or for the —OR6, —NR10R11 group or for C2-C10-heterocycloalkyl, in which the heterocycloalkyl in the ring contains at least one atom, equal or different, from the following group of nitrogen, oxygen, or sulfur and may also be made up of one or more —(CO)—, —(C═S)— or —SO2— groups in the ring, and may be contained in one or more double bonds in the ring, and the ring itself may be substituted C1-C3-alkyl substituted once or several times, equal or different, substituted with cyano, halogen, hydroxy, aryl or with the —(CO)—R5, —NR12R13 group or substituted once or several times, equal or different, with halogen, hydroxy or C1-C3-alkylthio, in which the aryl itself may be substituted once or several times, equal or different, with cyano, halogen or C1-C3-alkoxy, L stands for the group —O—R7, —(CH2)n—(CO)—NH—R8 or —O—(CH2)n—(CO)—O—R8, R9 stands for C1-C5-alkyl, C2-C4-alkenyl, cyclopropyl or C2-C10-heterocycloalkyl substituted once or several times, equal or different, with C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, C2-C10-heterocycloalkyl, cyano, cyclopropyl, halogen, hydroxy or with the —NR10R11, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—R14 group, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself may be substituted once or several times, equal or different, with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group or substituted once or several times, equal or different, with halogen, hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-Alkyl, in which the aryl itself may once or several times, equal or different, substituted with halogen or C1-C3-alkoxy, R16 stands for hydrogen or for C2-C4-alkenyl, cyclopropyl or C2-C10-heterocycloalkyl substituted once or several times, equal or different, with C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, C2-C10-heterocycloalkyl, cyano, cyclopropyl, halogen, hydroxy or with the —NR10R11, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—R14 group, or for C1-C4-alkyl substituted once or several times, equal or different, with C1-C4-alkoxy, cyano, cyclopropyl, halogen, hydroxy or with the —NR10R11, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—R14 group, or stands for methyl substituted once or several times, equal or different, with C2-C10-heterocycloalkyl, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself may be substituted C1-C3-alkyl substituted once or several times, equal or different, with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group, or once or several times, equal or different, with halogen, hydroxy, C1-C3-alkylthio or phenyl in which the aryl itself once or several times, equal or different, may be substituted with halogen or C1-C3-alkoxy, or stands for C1-C4-alkyl substituted once or several times, equal or different, with C2-C10-heterocycloalkyl, or stands for C2-C4-alkyl substituted once or several times, equal or different, with C1-C4-alkoxy-C1-C4-alkoxy, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself may be substituted once or several times, equal or different, with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group, or once or several times, equal or different, with halogen, hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, in which the aryl itself may once or several times, equal or different may be substituted with halogen or C1-C3-alkoxy, and as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

3. Compounds of general formula 1, according to claim 1, in which the meaning is as follows: R7 stands for C1-C3-alkyl substituted once or several times, equal or different, with —NR12R13 or C2-C10-heterocycloalkyl, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, R9 stands for C1-C5-alkyl, C2-C4-alkenyl, cyclopropyl or C2-C10-heterocycloalkyl substituted if need be once or several times, equal or different, with C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, C2-C10-heterocycloalkyl, cyano, cyclopropyl, halogen, hydroxy or with the —NR10R11, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—R12 groups, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and if may contain one or more double bonds in the ring, and the ring itself may be substituted if need be once or several times, equal or different, with halogen, cyano, hydroxy, phenyl, which itself may be substituted with if need be once or several times, equal or different, with halogen or C1-C3-alkoxy, or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group, or once or several times, equal or different, with halogen, hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, R10 and R11 stand for independent of one another C1-C5-alkyl, C2-C10-heterocycloalkyl, aryl or heteroaryl substituted if need be once or several times, equal or different, with halogen, C1-C3-alkyl, C1-C3-alkoxy, substituted C1-C5-alkyl, C2-C10-heterocycloalkyl, aryl or heteroaryl, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and if may contain one or more double bonds in the ring, R14 stands for C1-C3-alkyl or for phenyl, and n stands for 1-4, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

4. Compounds of general formula 1, according to claim 1, in which the meaning is as follows: R1 stands for methyl, ethyl, isopropyl or cyclopropyl substituted if need be once or several times, equal or different, with halogen, R2 stands for methyl, ethyl, allyl, property or at least hydroexyethyl substituted once with methyl and substituted if need be once or several times, equal or different, with cyano, cyclopropyl, ethinyl or halogen, X stands for halogen, hydroxy or for the —OR6, —NR10R11 group or for azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, or tetrahydrochinolinyl, in which pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves can be substituted if need be once or several times, equal or different, with halogen, hydroxy, phenyl, which itself can be substituted if need be once or several times, equal or different, with halogen or C1-C3-alkoxy, or can be substituted if need be once or several times, equal or different, with the —(CO)—R5, —NR12R13 group or substituted if need be once or several times, equal or different with cyano, halogen, hydroxy or C1-C3-alkylthio substituted C1-C3-Alkyl, R4 stands for hydrogen, cyano or halogen or for methyl substituted if need be once or several times, equal or different, with halogen, R5 stands for methyl, ethyl, tert.-butyl, phenyl or —NH2, R6 stands for —SO2-Methyl, R7 stands for C1-C3-alkyl substituted if need be once or several times, equal or different, with —N(C1-C3-alkyl )2, pyrrolidinyl, morpholinyl, or piperidinyl R8 stands for methyl, ethyl, allyl or propargyl substituted if need be once or several times, equal or different, with cyano, cyclopropyl or halogen, R9 stands for methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl, or tetrahydrofuranyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl, substituted if need be once or several times, equal or different, with C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl, cyano, cyclopropyl, halogen, hydroxy or with the —NR10R11, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—C1-C3-alkyl group, in which pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, benzopyrrolidinyl, tetrahydrochinolinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, tetrahydrotriazolthionyl, morpholinyl, tetrahydroisochinolinyl, octahydroisochinolinyl themselves may be substituted if need be once or several times, equal or different, with halogen, hydroxy, phenyl or C1-C3-Alkoxy, or with the —(CO)—R5, —(CO)—O—R5, —(SO2)—R14, —N(CH3)2 group, or substituted if need be once or several times, equal or different with halogen, hydroxy, methylthio, or phenyl substituted methyl or ethyl, R10 and R11 stand independent of one another for C1-C5-alkyl, pyrrolidinyl, phenyl or pyridinyl substituted if need be once or several times, equal or different, with halogen, C1-C3-alkyl or C1-C3-alkoxy, R12 and R13 stand independent of one another for hydrogen or for methyl, ethyl, or isopropyl, R14 stands for C1-C4-alkyl or for phenyl, and n stands for 1 or 2, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

5. Compounds of general formula 1, according to claim 1, in which the meaning is as follows: U stands for —CH═, —CF═, —C(CH3)═ or —N═, R1 stands for methyl, ethyl, isopropyl or cyclopropyl substituted if need be once or several times, equal or different, with fluorine, R2 stands for methyl, ethyl, allyl, propargyl or at least hydroxyethyl substituted at least once with methyl, substituted if need be once or several times, equal or different, with cyano, cyclopropyl, ethinyl or fluorine, K stands for methyl, ethyl or ethenyl substituted if need be once or several times, equal or different with X, X stands for halogen, hydroxy or for the —O—SO2-methyl group or for pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, in which methyl can be substituted if need be once or several times, equal or different, with pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, itself substituted if need be once or several times, equal or different with halogen, hydroxy, phenyl or with methyl substituted if need be once or several times, equal or different with halogen, L stands for the group —O—R7, —O—(CH2)n—(CO)—NH—R8 or —O—(CH2)n —(CO)—O—R8, M stands for the group —NH—R9, —NH—(CO)—OH, —NH—(CO)—O—R9 or —NR12—(CO)—R16, R7 stands for ethyl substituted if need be once or several times, equal or different with —N(C1-C3-alkyl)2, pyrrolidinyl, morpholinyl or piperidinyl, R8 stands for methyl, ethyl, allyl or propargyl substituted if need be once or several times, equal or different with cyano, cyclopropyl or fluorine R9 stands for methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl substituted if need be once or several times, equal or different, with C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, cyano, cyclopropyl, halogen, hydroxy or with the —N(C1-C3-alkyl)2, —O—(CO)—(C1-C3-alkyl) or —O—(SO2)-C1-C3-alkyl-group, in which pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl can themselves be substituted if need be once or several times, equal or different, with halogen or with the —(CO)—C1-C4-alkyl, —(CO)—O—C1-C4-alkyl, —(SO2)-C1-C3-alkyl, —(SO2)-phenyl, —N(C1-C3-alkyl)2 group, or substituted if need be once or several times, equal or different, with halogen, hydroxy or C1-C3-alkylthio substituted methyl or ethyl, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

6. Compounds of general formula 1, according to claim 1, in which the meaning is as follows: R1 stands for ethyl, X stands for iodine, hydroxy or for the —O—SO2-methyl group or for pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl, in which pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl or octahydroisochinolinyl can themselves be substituted if need be once or several times, equal or different, with halogen, hydroxy, phenyl or methyl substituted if need be once or several times, equal or different, with halogen, R7 stands for ethyl substituted if need be once or several times, equal or different with —N(CH3)2, pyrrolidinyl, morpholinyl or piperidinyl, R9 stands for methyl, ethyl, isopropyl, isobutyl, tert.-butyl, ethenyl, cyclopropyl, tetrahydropyranyl or tetrahydrofuranyl, substituted if need be once or several times, equal or different, with methoxy, ethoxy, butoxy-ethoxy, methoxy-ethoxy, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, cyano, cyclopropyl, chlorine, fluorine, hydroxy or the —N(CH3)2, —N(CH3)(C2H5), —O—(CO)—(CH3) or —O—(SO2)-methyl group, in which pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl can themselves be substituted if need be once or several times, equal or different, with fluorine, or with the —(CO)—CH3, —(CO)—C2H5, —(CO)—C(CH3)3, —CO)—O—C(CH3)3, —(SO2)—CH3, —(SO2)-phenyl, —N(CH3)2 group, or can be substituted if need be once or several times, equal or different, with fluorine, hydroxy, or methylthio substituted methyl or ethyl, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

7. Compounds of general formula 1, according to claim 1, in which the meaning is as follows: R16 stands for C2-C10-heterocycloalkyl substituted methyl substituted if need be once or several times, equal or different, with C1-C4-alkoxy, cyano, cyclopropyl, halogen, hydroxy or with the —NR10R11, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—R14 substituted C1-C4-alkyl group, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself may be substituted if need be once or several times, equal or different, with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group or may be substituted with C1-C3-alkoxy which itself may be substituted if need be once or several times, equal or different, with halogen, hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, in which the aryl itself can be substituted if need be once or several times, equal or different, with halogen or C1-C3-alkoxy, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

8. Compounds of general formula 1, according to claim 7, R16 stands for C1-C4-alkyl substituted if need be once or several times, equal or different, with the —NR10R11 group, or methyl substituted if need be once or several times, equal or different, with C2-C10-heterocycloalkyl, in which in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself may be substituted if need be once or several times, equal or different, with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group, or substituted if need be once or several times, equal or different with halogen, hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, in which the aryl itself can be substituted if need be once or several times, equal or different with halogen or C1-C3-alkoxy, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

9. Compounds of general formula 1, according to claim 1, in which the meaning is as follows: K stands for C1-C3-alkyl substituted if need be once or several times, equal or different, with P or C2-C4-alkenyl substituted if need be once or several times, equal or different, with X, P stands for the —OR6, —NR18R19, C2-C5-heterocycloalkyl group or for C6-C10heterocycloalkyl, in which the C2-C5-heterocycloalkyl and the C6-C10heterocycloalkyl in the ring contain at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring of C2-C5-Heterocycloalkyl itself is substituted once or several times, equal or different, with cyano, halogen, hydroxy, aryl or with the —(CO)—R5 group or substituted once or several times, equal or different, with halogen or C1-C3-Alkylthio substituted C1-C3-alkyl, in which the aryl itself can be substituted if need be once or several times, equal or different, with cyano, halogen or C1-C3-alkoxy, and the ring of the C6-C10-heterocycloalkyl itself can be substituted if need be once or several times, equal or different, with cyano, halogen, hydroxy, aryl or with the —(CO)—R5, —NR12R13 group or substituted if need be once or several times, equal or different, with halogen, hydroxy or C1-C3-alkylthio substituted C1-C3-alkyl, in which the aryl itself can be substituted if need be once or several times, equal or different, with cyano, halogen or C1-C3-alkoxy, L stands for the group —O—R7, —O—(CH2)n—(CO)—NH—R17, —(O)—(CH2)n—(CO)—R15 or —O—(CH2)n—(CO)—O—R8, R7 stands for C1-C3-Alkyl substituted if need be once or several times, equal or different, with C6-C10-Heterocycloalkyl, in which the C6-C10 Heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself can be substituted if need be once or several times, equal or different, with halogen, aryl or once or several times, equal or different, with halogen substituted C1-C3-Alkyl, or stands for C1-C3-alkyl substituted once or several times, equal or different, with C2-C5-heterocycloalkyl, in which the C2-C5-heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself is substituted if need be once or several times, equal or different, with halogen, aryl, or substituted once or several times, equal or different, with halogen substituted C1-C3-alkyl, R16 stands for hydrogen, C2-C4-alkenyl, cyclopropyl, C2-C5-heterocycloalkyl or C6-C10-heterocycloalkyl or methyl substituted with heteroaryl or for C1-C4-alkyl, C2-C4-alkenyl, cyclopropyl, C2-C5-heterocycloalkyl or C6-C10-heterocycloalkyl substituted once or several times, equal or different, with C1-C4-alkoxy, C2-C5-heterocycloalkyl, C6-C10-heterocycloalkyl, cyano, cyclopropyl or the —NR18R19, —O—(CO)—R5, —SO2)—R14 or —O—(SO2)—R14 group, in which the C2-C5-heterocycloalkyl and the C6-C10-heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring of C2-C5-heterocycloalkyl itself is substituted once or several times, equal or different, with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14 group, or substituted once or several times, equal or different, with halogen, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, in which the aryl itself can be substituted once or several times, equal or different, with halogen, C1-C3-alkyl or C1-C3-alkoxy, R17 stands for C1-C3-alkyl substituted once or several times, equal or different, with halogen or cyano, or if need be substituted once or several times, equal or different, with halogen, cyclopropyl or cyano substituted C3-C4-alkenyl or C3-C4-alkinyl, R18 und R19 stands for independent of one another C1-C5-alkyl, C2-C10-heterocycloalkyl, aryl, —(CH2)n-aryl or heteroaryl if need be substituted once or several times, equal or different, with halogen, C1-C3-alkyl, C1-C3-alkoxy, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, in which either R18 or R19 stands for C2-C10-heterocycloalkyl, —(CH2)n-aryl, or a heteroaryl, or for a C2-C10-heterocycloalkyl, —(CH2)n-aryl or heteroaryl if need be substituted once or several times, equal or different, with halogen, C1-C3-alkyl, C1-C3-alkoxy, or stands for a C1-C5-alkyl substituted once or several times, equal or different, with C1-C3-alkoxy, or for an aryl substituted once or several times, equal or different, with C1-C3-alkyl, C1-C3-alkoxy, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)—or —SO2— groups in the ring and may contain one or more double bonds in the ring, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

10. Compounds of general formula I, according to claim 9, in which the meaning is as follows: in which T1, T2 and T3 stand independently of one another for —CH═ or —N═R3 stands for K, L, or M, P stands for the —OR6, —NR18R19, C2-C5-heterocycloalkyl group or for C6-C10heterocycloalkyl, in which the C2-C5-heterocycloalkyl and the C6-C10heterocycloalkyl in the ring contain at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring of the C2-C5-heterocycloalkyl itself is substituted once or several times, equal or different, with cyano, halogen, hydroxy, aryl or with the —(CO)—R5 group or substituted once or several times, equal or different, with halogen or C1-C3-Alkylthio substituted C1-C3-alkyl, in which the aryl itself may be substituted if need be once or several times, equal or different, with cyano, halogen or C1-C3-alkoxy, L stands for the —O—R7, —O—(CH2)n—(CO)—NH—R17 or —O—(CH2)n—(CO)—O—R8 group, R9 stands for C1-C4-alkyl, C2-C4-alkenyl, cyclopropyl or C2-C10-heterocycloalkyl, substituted if need be once or several times, equal or different, with C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, C2-C10-heterocycloalkyl, cyano, cyclopropyl, halogen, hydroxy or with the —NR10R11, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—R14 group, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself if need be once or several times, equal or different can be substituted with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group or if need be once or several times, equal or different, can be substituted with halogen, hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, in which the aryl itself can be substituted if need be once or several times, equal or different, with halogen or C1-C3-alkoxy, R16 stands for hydrogen, C2-C4-alkenyl, cyclopropyl, C2-C5-heterocycloalkyl or C6-C10-heterocycloalkyl or for C1-C4-alkyl, C2-C4-alkenyl, cyclopropyl, C2-C5-heterocycloalkyl or C6-C10-Heterocycloalkyl substituted once or several times, equal or different, with C1-C4-alkoxy, C2-C5-heterocycloalkyl, C6-C10-heterocycloalkyl, cyano, cyclopropyl or with the —NR18R19, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—R14 substituted C1-C4-Alkyl group, in which the C2-C5-heterocycloalkyl and the C6-C10-heterocycloalkyl in the ring contain at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring of the C2-C5-heterocycloalkyl itself is substituted once or several times, equal or different, with halogen, cyano, hydroxy, aryl or with the —CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group, or is substituted once or several times, equal or different, with halogen,hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, in which the aryl itself if need be once or several times, equal or different, can be substituted with halogen or C1-C3-alkoxy, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

11. Compounds of general formula I, according to claim 1, in which R3 stands for K, or L, K stands for C1-C3-alkyl substituted be once or several times, equal or different, with X, in which the C1-C3-Alkyl can be substituted if need by once or several times, equal or different, with hydroxy or halogen, X stands for NR10R11 or for C2-C10-heterocycloalkyl, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself if need be once or several times, equal or different, can be substituted with cyano, halogen, hydroxy, aryl or with the —(CO)—R5, —NR12R13 group or substituted with if need be once or several times, equal or different, halogen, hydroxy or C1-C3-alkylthio substituted C1-C3-alkyl, in which the aryl itself can be substituted if need be once or several times, equal or different, with cyano, halogen or C1-C3-alkoxy, stands for the —O—R7 group, R7 stands for C1-C3-alkyl substituted once or several times, equal or different, with —NR12R13 or C2-C10-heterocycloalkyl, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself if need be once or several times, equal or different, can be substituted with halogen, aryl or substituted if need be once or several times, equal or different, with halogen substituted C1-C3-Alkyl, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

12. Compounds of general formula I, according to claim 11, in which the meaning is as follows: X stands for —N(C1-C3-Alkyl )2 or for azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl or tetrahydrochinolinyl, in which azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, octahydroisochinolinyl, benzopyrrolidinyl, piperazinyl, tetrahydrooxazolyl, piperazinonyl, tetrahydrothiazolyl, tetrahydroimidazolonyl, benzomorpholinyl, triazinthionyl, tetrahydroisochinolinyl, tetrahydrochinolinyl themselves may be substituted if need be once or several times, equal or different, with halogen, hydroxy, phenyl, that itself may be substituted if need be once or several times, equal or different, with halogen or C1-C3-alkoxy, or with the —(CO)—R5 group or substituted once or several times, equal or different, with cyano, halogen or C1-C3-alkylthio substituted C1-C3-alkyl. R7 stands for C1-C3-alkyl substituted once or several times, equal or different, with —N(C1-C3-Alkyl )2 or C2-C10-heterocycloalkyl, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

13. Compounds of general formula 1, according to claim 1, in which the meaning is as follows: R3 stands for M, M stands for the —NR12—(CO)—R16 group, R16 stands for methyl substituted if need be once or several times, equal or different, with C1-C4-alkoxy, C2-C10-heterocycloalkyl, heteroaryl, cyano, cyclopropyl, halogen, hydroxy or with the —NR10R11, —O—(CO)—R5, —(SO2)—R14 or —O—(SO2)—R14 group, in which the methyl itself can be substituted if need be once or several times, equal or different, with C1 to C3-alkyl, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)—, —(C═S)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself if need be once or several times, equal or different, can be substituted with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, NR2R13 group or can be substituted if need be once or several times, equal or different, with halogen, hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, in which the aryl itself if need be once or several times, equal or different, can be substituted with halogen, C1-C3-alkyl or C1-C3-alkoxy, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

14. Compounds of general formula I, according to claim 13, in which the meaning is as follows: R16 stands for methyl substituted once or several times, equal or different, with C2-C10-heterocycloalkyl, heteroaryl or with the —NR10R11 group, in which the methyl itself can be substituted if need be once or several times, equal or different, with C1 to C3-alkyl, in which the heterocycloalkyl in the ring contains at least one atom equal or different, of the following group of nitrogen, oxygen, or sulfur and may be made up of one or more —(CO)— or —SO2— groups in the ring and may contain one or more double bonds in the ring, and the ring itself if need be once or several times, equal or different, can be substituted with halogen, cyano, hydroxy, aryl or with the —(CO)—R5, —(CO)—O—R12, —(SO2)—R14, —NR12R13 group or can be substituted if need be once or several times, equal or different, with halogen, hydroxy, C1-C3-alkylthio or phenyl substituted C1-C3-alkyl, in which the aryl itself if need be once or several times, equal or different, can be substituted with halogen, C1-C3-alkyl or C1-C3-alkoxy, as well as their solvents, hydrates, diastereomers, enantiomers, and salts.

15. Compounds of the general formulas II or IV

16. Compounds of general formula II according to claim 15 with the following formulas: 2-cyano-N-ethyl-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide, 2-cyano-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-(2,2,2-trifluoro-ethyl)-acetamide, 2-cyano-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-prop-2-ynyl-acetamide or 2-cyano-N-cyanomethyl-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide 2-cyano-N-(2,2-difluoro-ethyl)-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide 2-cyano-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-(2-hydroxy-1,1-dimethyl-ethyl)-acetamide 2-cyano-2-[3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-(2-fluoro-ethyl)-acetamide as well as their solvents, hydrates, diastereomers, enantiomers, and salts as intermediate products for the creation of the compounds of general formula (I).

17. Compounds of the general formulas (II) or (IV) according to claim 15 or compounds according to claim 16 for use as intermediate products for the creation of compounds of general formula (I).

18. Compounds of the general formulas (II) or (IV) according to claim 15 or compounds according to claim 16 for use as intermediate products for the creation of compounds of general formula (D).

19. Medications that contain at least one compound in accordance with claim 1.

20. The use of the compounds of general formula I, according to claim 1, for the creation of a medication.

21. Compounds according to claim 1 or medications with appropriate materials for formulation and delivery.

22. The process for creation of compounds of general formula I, in which compounds of general formula II and compounds of general formula III,

23. A process under claim 22, in which for the creation of compounds of general formula II, compounds of general formula V,